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PREFACE 
This third Public Health Status and Forecasts (PHSF) report again contains a great deal
of up-to-date information about Dutch public health and care. Hence, it is a valuable
document for policy-makers and provides a solid foundation for new policies while also
creating an opportunity to evaluate current policy affecting public health and care. In
addition, as far as possible, it enables policies to be ‘evidence-based’. The Minister for
Health, Welfare and Sport has ultimate responsibility for the policies concerning public
health and health care. Accordingly, in 1999 this PHSF report was commissioned by the
then minister. In fact, it provides a valuable source of inspiration for others than the
Ministry of Health, Welfare and Sport as well. Local government councils, other min-
istries and the various parties in the health care sector may also benefit from the PHSF
report when drawing up their policies. I therefore strongly recommend that all such bod-
ies should read this report.
Dutch health policy is facing considerable challenges. There are an increasing number
of healthy elderly people whereas the young are tending to display unhealthy behaviour.
It is difficult to create a broad basis for effective prevention when the current emphasis
is on individual interests and choices. The health care sector’s limited capacity, a limited
budget and an increase in both the demand for care and the growing potential of medical
technology place increasing demands on an effective harmonization of supply and
demand. European regulations exert a growing influence on all aspects of prevention
and care. Good information will assist an efficient decision-making process for all these
areas. 
The timeliness of this report, when basing policy on information, is reflected by the fact
that this PHSF report will be followed by a government policy document on prevention.
The latter document will draw to a great extent on the information contained in this
report. This is the essence of the policy cycle. Decisions are formulated on the basis of
both factual information and socio-political points of interest. Subsequently, informa-
tion is collected to determine the extent to which these policy intentions have been
achieved, especially those that involve quantitative goals. 
Even more than its predecessor from 1997, this 2002 PHSF report consists of a brief
summary and builds on a further analysis of work that has been previously published
either in book form or on the Internet. Implicitly, the title ‘Health On Course?’ also
refers to related Web publications: the ‘National Compass on Public Health’
(www.nationaalkompas.nl) and the ‘National Atlas of Public Health’ (www.zorgatlas.nl).
We can use the Compass and Atlas to find out whether we are in fact on course! Apart
from these Web publications, a great deal of basic information has been derived from a
series of PHSF thematic reports, which have been published over the last two years.
The PHSF team has produced all these reports through close collaboration with many
well-known researchers and specialized institutes throughout the Netherlands. In all,
well over 300 people have contributed their expertise. While compiling the ‘Health on
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Course?’ report, the PHSF team was supported by a National Scientific Advisory Com-
mittee and a Supervisory Committee consisting of representatives of the Ministry of
Health, Welfare and Sport. The involvement of so many individuals has made the PHSF
report a truly national undertaking. I would like to offer all of them my sincere thanks
for their efforts. 
Clémence Ross-van Dorp,
State Secretary for Health, Welfare and Sport
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KEY MESSAGES 
The Health on Course? report presents new data and insights about public health, care
and prevention in the Netherlands. It simultaneously examines the past, present and
future, and draws comparisons both at home and abroad. These insights may support the
Ministry of Health, Welfare and Sport in the development of a medium and long-term
vision for health and care. This information is also important for other players in the
Netherlands: the public health inspectorate, local government councils, other ministries,
patients and consumers, prevention and health care providers, health insurers, and
health research and research programming organizations. Here we present the major
findings and dilemmas, along with their significance for the parties involved. 
Major findings 
We in the Netherlands are living and staying healthy for longer
Since 1980, male life expectancy has increased by 3.1 years while female life expectan-
cy has grown by 1.4 years. From birth, we can now expect an average life span of,
respectively, 75.5 and 80.6 years. The years that have been added over the last decade
are generally spent in good health. Statistics Netherlands predicts that life expectancy
will increase even more over the next 20 years.
• This increase is mainly due to fewer deaths from coronary heart disease and stroke. In
addition, fewer men are dying of lung cancer.
• The major cause of death is still coronary heart disease. Along with mental ill health
and chronic lung diseases, this disorder also causes the greatest loss of quality of life.
• Around the year 2000, both men and women experienced roughly the same number of
healthy years: 61 years are spent in self perceived good health, more than 70 without
disabilities, and 68 in good mental health. Consequently, the number of subsequent
unhealthy years is considerably higher for women than for men.
• Considering that neither the incidence nor the duration of chronic disorders has
decreased, certain health care provisions, such as medical devices and pharmaceuti-
cals, seem to have effectively improved the social participation of the chronically ill.
Yet the Netherlands drops toward the European average
However, the Netherlands is falling behind in the EU. Male life expectancy is increasing
less rapidly than in most EU countries. The increase in the life expectancy of women is
actually stagnating to such an extent that we are now below the EU average.
• Male mortality from lung cancer is still one of the highest in the EU. Female mortality
is increasing more rapidly than the European average. Ever more women are also
dying from chronic lung diseases (COPD). Smoking is the main cause of both lung
cancer and COPD.
• The Netherlands has comparatively high infant and perinatal mortality rates. This also
applies to mortality from breast cancer, although this has recently fallen.
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• If we assume the most favourable mortality rates in the EU for 14 major causes of
death, Dutch life expectancy could still be improved by six years for men and four
years for women. However, we would lose four years if we were to have the most
adverse rates in the EU for these causes of death.
There are also persistent differences in health
Health is unequally divided across the Netherlands. There are considerable differences
in health between the rich and the poor, and from one neighbourhood to another. There
is no indication that these differences have decreased over the last five years.
• Men with the lowest level of education live 5.0 years less than their most highly edu-
cated counterparts. For women, this difference is 2.6 years. Moreover, men and
women with the highest level of education live on average ten years longer without
disabilities. In terms of the number of years spent in self-perceived good health, the
difference is 16 years for men and 14 years for women.
• Comparing regions or neighbourhoods also reveals similar differences in health.
Poorer health in deprived areas is frequently linked to an accumulation of adverse
environmental factors, both social and physical, combined with an unhealthy lifestyle.
• Trends in inequalities in health cannot be reliably established on the basis of the avail-
able data. However, there is no indication of a decrease in the existing differences in
health.
Unhealthy behaviour is the major cause of stagnating health
Unhealthy behaviour is the major cause of the stagnating life expectancy of Dutch
adults. Over the last few years, women have acquired many of men’s unhealthy behav-
iour patterns. But adverse trends in unhealthy behaviour are also particularly prevalent
amongst the young and can be regarded as long-term investments in ‘bad health’. By
contrast, the elderly have adopted a healthier lifestyle. Environmental factors also con-
tribute to the Netherlands’ total burden of disease. There is no indication that stagnating
life expectancies are linked to problems within the health care sector.
• There are particularly worrying trends among young people, involving smoking, the
excessive use of alcohol, not eating enough fruit and vegetables, and taking insuffi-
cient exercise. In addition, there is a growing incidence of serious overweight in ever
younger age groups.
• The Netherlands scores badly in Europe in terms of smoking and the excessive use of
alcohol. By contrast, we do relatively well as far as physical activity is concerned. If
we Dutch were to achieve Europe’s most favourable level for known risk factors, we
would in theory add another 1.4 years to male life expectancy while females would
gain 1.2 years.
• A considerable proportion of the total annual mortality (140,000 deaths in 2000) in the
Netherlands is linked to unhealthy behaviour and could therefore be theoretically
avoided. The major factors are: smoking (around 15% of deaths each year), the exces-
sive consumption of saturated fat (5%), not eating enough vegetables and fruit (5%), a
lack of exercise (6%), high blood pressure (6%) and serious overweight (6%). Rough
estimates indicate that the contribution of environmental factors to the Netherlands’
total burden of disease does not exceed 5%.
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• A considerable proportion of Dutch health care use can be attributed to an unhealthy
lifestyle, overweight and high blood pressure. The costs involved amount to between 5
and 9% of total health care expenditure.
• Access to Dutch health care has been placed under pressure over the past years by, for
instance, waiting times and waiting lists. There is no indication that this is in any way
linked to the stagnation in the growth of life expectancy, which is mainly due to
adverse developments in lifestyle.
A new approach to prevention can turn the tide
Prevention, particularly by promoting a healthy lifestyle, could result in considerable
health gains. A modern approach is based on a stimulating environment and an integrat-
ed method within existing ‘settings’ rather than by solely placing the emphasis on influ-
encing behaviour. This could occur by making a healthy lifestyle an obvious part of
socio-cultural life: at school, during sport and recreation, at work, in neighbourhoods
and in traffic. Moreover, prevention demands a durable vision, and long-term attention
and investment. Much could also be gained if prevention were to acquire a more explic-
it role in the provision of care.
• Along with the Ministry of Health, Welfare and Sport, other government sectors, and
public and private bodies can also contribute to the development of better health. Fac-
tual information, price incentives, clarity about ‘healthy’ and ‘unhealthy’ products,
and the organization of both the workplace and the built environment could entice the
citizen into making healthy choices and avoiding unhealthy behaviour. Here, preven-
tive interventions are more effective when supported by legislation and regulations.
• Prevention is more likely to succeed when it involves an approach that is specifically
geared towards the particular target group and is based on a long-term vision involv-
ing constant support.
• Prevention programs are too rarely evaluated, and successful local initiatives should
be more frequently copied at a national level.
• The clear inclusion of prevention within the health care sector would benefit both pub-
lic health and the sector’s efficiency. This is often obstructed by the sector’s system of
budgeting and the lack of financial incentives, for instance, and by other organization-
al aspects along with the pressure of work. Medical training generally places insuffi-
cient emphasis on prevention.
More care and different care are needed in the future
In the future, a growing and more elderly population will result in a considerable
increase in the number of disease cases, particularly those involving chronic disorders.
If the trend of the last few years continues, the total volume of Dutch health care will
have to expand by 2.4% each year until 2006 just to maintain its present level. There
must also be an additional shift from cure to care. Over the next few years, the elimina-
tion of waiting lists and other obstacles will require an estimated further investment of
at least 0.6% each year for four years.
• Dutch society spent 36 billion euros on health care in 1999, which was 9.6% of the
gross domestic product. Most of this was for cure facilities such as hospitals (29%),
pharmaceuticals (10%) and GPs (3%). Caring for the elderly, the chronically ill and
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the handicapped (care facilities) accounted for more than 36% of all expenditure. Less
than 4% was spent on prevention, half of which involved occupational health care.
This does not cover prevention as included in the provision of care.
• The elderly use more care than do young people. This also accelerates from the age of
sixty onwards and applies to both men and women.
• In the future, half of the requisite extra growth in volume will be due to population
growth and an ageing society; the other half will be caused by advances in medical
technology and by the consumer’s changing demand for care.
• There are already considerable waiting times and capacity deficits in the nursing care
sector. The extra resources that have been made available in recent years have resulted
in a higher level of production. However, recent trends show that as yet most sectors
have not experienced any decrease in waiting lists.
• Health care use in the Netherlands is average when compared with that of neighbour-
ing countries. This applies to the volume of health care, to its share of the gross
domestic product and to the average health expenditure per capita. Over the past few
decades, the growth in per capita health expenditure has been less than that of our
immediate neighbours.
Care is not only a question of quantity but also of quality
In the future, it will not only be a matter of more care but also of high quality care. High
quality care means care that is effective, safe and available to everyone. Care could
become both more effective and safer if ‘best practices’ and standards were to be
applied effectively, and if the lessons learned in trial projects were to be broadly imple-
mented. Trial projects could, for instance, involve safer or more integrated care. Such
qualitative improvements could also reduce costs. Obstacles to the implementation of
these improvements are generally of an organizational or financial nature.
• The prompt application of new and effective medical technology and the reduction of
unnecessary inter-doctor variations could result in health gains. However, evaluation
of the effectiveness and safety in actual practice is still necessary and involves both
‘medical technology assessment’ and ‘post-marketing surveillance’.
• Integrated care - optimizing the patient’s journey through the care circuit - could result
in health gains, in creating a more patient-specific approach and in a more targeted use
of resources.
• Research in the United States and Australia has shown that adverse effects of medical
treatment may lead to a considerable loss of health involving a decrease in life
expectancy of 6 to 12 months. As yet there has been no Dutch research in this area, but
the situation in the Netherlands is unlikely to be significantly different. Trial projects
have shown that focused alertness can greatly reduce the incidence of certain specific
health risks in care such as decubitus ulcers and wound infections.
• There are no indications in the Netherlands of socio-economic differences in access to
necessary care. However, those with lower educational levels seem to make less ade-
quate use of care, for example when they have a chronic disease.
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Prevention not only better, but also frequently cheaper
The costs of each additional, healthy year of life gained through interventions can vary
considerably from one area of prevention and health care to another. Some interventions
reduce expenses while others cost more than one hundred thousand euros for each addi-
tional, healthy year of life. Preventive interventions can result in a considerable health
gain, and often at little expense. So prevention is not only better than cure, it is also fre-
quently more efficient. It pays to invest in prevention, particularly in the long term.
However, this is not simply a matter of health gains per invested euro, it is also about
solidarity and access to cure and care.
• Preventive measures at the beginning of the disease chain, such as the neonatal heel
prick, vaccinations or traffic regulations, are often more efficient than interventions at
the end of the chain, such as lung transplantation. The general desire for a high level of
individual protection also has as a result that sometimes expensive environmental
measures are taken.
• However, apart from the cost-effectiveness and efficiency of interventions, there is
also the issue of solidarity and of each Dutch citizen’s legitimate right to protection,
cure and care. Nonetheless, making the relation between costs and health gains more
explicit could create greater transparency in the decision-making process.
There are certain gaps in the provision of information
An effective and constant flow of information is the basis of monitoring, analysis and
reporting, as presented by the PHSF reports. Since the 1997 PHSF report, the flow of
information has improved in certain areas, but deteriorated in others. There are still
some major problem areas:
• Many data collections lack continuity, fail to represent the country as a whole or allow
insufficient opportunity for regional differentiation.
• Registration and research do not draw sufficiently on information about socio-eco-
nomic status, ethnicity, domestic situations and other relevant characteristics such as
the severity of a disease or the quality of life.
• Care registration is too fragmented and frequently fails to include diagnostic data or to
assign a unique number to each patient. This makes it impossible to monitor a given
course of care at the level of individual patients.
• Various data collections (including those from the public domain) are compiled and
stored by private bodies, as a result of which access to this information is becoming
increasingly difficult or even totally impossible.
• Data about the quality, effectiveness, safety and accessibility of prevention and health
care is extremely incomplete.
• There is an increasing need for international ‘benchmarking’. Various schemes for
measuring ‘health system performance assessment’ are being developed but the inter-
national comparability of data still leaves much to be desired.
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The findings’ significance for the various players
Central government must invest in prevention to reverse the stagnation in
health
Investment in prevention is vital if we are to break through the stagnation in the devel-
opment of our health. The government will have to achieve this by creating a coherent
policy framework and a long-term vision for health. Therefore, it must continue to invest
in existing preventive facilities, and must strongly encourage the development, evalua-
tion and national implementation of new, preventive interventions. Here, the focus of
attention needs to be directed at strengthening prevention within the health care system
as well as intersectoral policy.
• The 2002 PHSF report provided the government with leads for developing national
priorities for collective prevention. The government could subsequently link quantita-
tive objectives to these priorities in consultation with the other players. This creates the
opportunity to monitor the policy’s progress empirically. In addition, national objec-
tives may stimulate and inspire the other players to develop and implement their own
policy plans.
• The government must continue to invest in existing preventive facilities so as to sus-
tain the existing level of health gain. This entails keeping the existing system of pre-
ventive facilities up to standard, which also involves their inspection and mainte-
nance.
• The national implementation of new and effective interventions must be promoted.
This could occur through the distribution of information about these interventions in
dialogue with the other players, the creation of collaborative alliances and the structur-
al financing of national implementation.
• The government must continue to invest in research into the development, effective-
ness, implementation and evaluation of preventive interventions so as to broaden the
prevention policy’s basis.
• The implementation of effective prevention activities within the health care system
must be promoted by, for instance, eliminating organizational and financial obstacles
or by stimulating care providers and health insurers.
• The government could encourage health-oriented, intersectoral policy at a departmen-
tal level by making agreements about common goals within the various policy fields.
Here, opportunities include the major cities policy (Ministry of the Interior and King-
dom Relations), sport (the Ministry of Health, Welfare and Sport), schools (Ministry
of Education, Culture and Science), employment (Ministry of Social Affairs and
Employment), traffic safety (Ministry of Transport, Public Works and Water Manage-
ment), and housing and the environment (Ministry of Housing, Spatial Planning and
the Environment).
• The government could encourage structural co-operation between local government
councils and local representatives of health care providers, health insurers, and con-
sumer and patients’ organizations. 
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Local-level prevention players should combine forces 
The actual implementation of collective prevention largely occurs at local level. Coun-
cils and municipal medical and health services are important local players in co-opera-
tion with the local representatives of the care providers, the health insurers and the
requesters of care. They should combine forces and work together on formulating and
developing a local prevention policy with common, local priorities and policy objec-
tives. A national public health policy framework could inspire the local players and pro-
vide guidance for drawing up local public health reports and for formulating local
objectives.
• Within the national policy framework, local players could promote the development,
implementation and evaluation of new interventions within the local setting. They
could also stimulate the implementation of effective interventions, which have been
adjusted to reflect the local circumstances.
• Local forms of intersectoral co-operation must be strengthened. Here, national agree-
ments could be developed at departmental level, and local initiatives elsewhere could
serve as a source of inspiration for all the players including the national government.
• The local players must jointly examine how effective preventive interventions could
be included in the basic responsibilities of the relevant care providers. They must also
reinforce the development of new preventive interventions within the health care 
system.
• There must be joint investment in a two-way risk communication system between the
government and the citizen which also refers to the citizen’s own responsibility. Con-
sumer and patients’ organizations could make a major contribution to a balanced
approach to risks and their perception. 
More care, different care and better care are both necessary and feasible
The 2002 PHSF report was neither willing nor able to deal with the full scope of the
health care sector. It examines care primarily in terms of attainable health gain. Here,
the key words are ‘accessibility’, ‘effectiveness’, ‘safety’, ‘costs’ and ‘efficiency’. More
and different care will be needed in the future, and this is mainly due to a growing and
increasingly elderly population. Moreover, there are still many opportunities to improve
the quality of care.
More care and different care could be achieved by: 
• Keeping the annual increase in the Dutch health care budget in step with demographic
changes, advances in medical technology and other autonomous developments. An
annual increase of at least 2.4 to 3% would appear to be needed until 2006. This can be
partly justified by the budget’s interrupted growth in the 1990s.
• Solving the capacity deficits by expanding medical training in combination with a
long-term vision for developing the capacity of the medical professions.
• Making the necessary shift of investments from cure to care within the required total
increase.
Better care could be achieved by:
• The explicit inclusion of health objectives when formulating preconditions for a new
health care system. These could include health gain, promoting quality of life and
reducing inequality in health.
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• Increasing the quality of care by encouraging the use of standards and guidelines
while retaining the flexibility needed for modernizing the health care system.
• Eliminating financial and organizational obstacles that needlessly block the adoption
of effective forms of health care modernization, integrated care and new technology.
• Examining whether, within a patient-specific orientation, a boundary could be defined
for the ‘medically unjustified’ demand for care.
• Extra investment in the availability and, particularly, in the tailoring of care for weak-
er social groups.
• Encouraging the development of methods for institutions and care providers that mea-
sure health outcomes or relevant process parameters. These indicators could be used
for improving internal quality, for the external assessment of quality by care market
consumers and insurers, and to achieve accountability to both society and parliament.
Dilemmas in prevention and care
The analysis of prevention and care in the Netherlands reveals a number of dilemmas
that sometimes seem to obstruct rational policy choices. Some dilemmas have existed
for quite some time while others will only reach practical significance in the future. It is
important to stimulate a political and social debate on these issues in order to achieve
the right social balance for these dilemmas.
• Prevention is a long-term undertaking. Investments generally require time to yield
health dividends, and this often occurs gradually and in an imperceptible manner. This
means that prevention may suffer in a political arena where short-term problems are
fighting for priority.
• The citizen demands maximum safety from the government at all costs yet rejects any
restriction on his freedom to, for instance, subject his health to considerable risks.
Hence, policy-makers are confronted with the difficult choice of whether to opt for the
collective interest of public health or to respect the individual’s freedom of choice.
Here, a related dilemma concerns the contradiction between the collective interests of
public health and the private economic interests of, for instance the drinks and tobacco
industries.
• Experts and the public frequently fail to agree about the potential, nature, extent and
control of health risks. The public tends to ignore the risk experts’ estimates. Hence,
the government faces the dilemma of whether to deal with these risks rationally on the
basis of ‘scientific’ estimates of potential risk, damage and the cost effectiveness of
safety measures, or to consider the public’s legitimate experience of those risks as
based on a range of values and norms.
• Investing in preventive measures aimed at avoiding or delaying disease often yields a
higher level of health gain than the care provided during the later phases of the disease
process. Here, prevention is better than cure and the health gain is frequently obtained
in a cheaper way. This in turns leads to a dilemma between the efficient use of limited
resources and every Dutch person’s right to the best possible care.
• The basic premise of demand-oriented care and the ‘right to care’ runs counter to an
imperative financial framework, whereby care provision is limited. However, a budget
ceiling always exists even within an ample financial framework. Improving the func-
tioning of this ‘imperfect’ care market also entails a considerable number of dilem-
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mas: should solidarity be sacrificed for efficiency through, for instance, individual
insurance contributions? Should the basic insurance policy be extended or will people
have to opt for additional coverage? Could a useful distinction be made between ‘evi-
dence-based’ medicine and problems that have been ‘unjustly medicalized’?
• Endeavouring to maintain standards in health care raises its quality but, in theory, this
could also hamper timely modernization and impede a patient-oriented approach.
• Developments in genetics provide us with greater insight into our personal risk and
treatment profile. This means that in the future we will be able to apply both preven-
tion and treatment increasingly effectively. However, these developments also entail
all manner of moral and ethical dilemmas. This is primarily because the diagnostic
potential is increasing far more rapidly than the possibilities for treatment. How do we
deal with the right not to know which diseases we may develop later on if, as yet, there
is no prospect of a cure? How should we treat a technology that produces more dis-
eases and diagnoses them at an earlier stage, yet does not yield any significant health
gain? Should the often-pricey pharmaceuticals that compensate for an individual’s
unhealthy lifestyle be a collective financial burden?
• Some argue in favour of measuring the quality or performance of health care so as to
increase its quality and make the options of both consumers and insurers more trans-
parent. To what extent should we support the public disclosure of this information? Do
we want to use quality measurement to create league tables and rogues galleries? Or
should we use it as a lesson for the improvement of quality? 
Opportunities to create a more effective flow of information
An effective and constant flow of information is essential for creating the basis of an
‘evidence-based policy’. Hence, the government must develop a long-term vision for its
information and research policies, which it must also direct.
• The government must clearly indicate the health and care subjects that need to be reg-
ularly supplied with data. The monitoring of quantitative policy objectives could be a
part of this process.
• The government could agree on the characteristics and working structure of data collec-
tions in consultation with other parties. Central direction enables efficiency gains to be
made by improving the co-ordination between data collections. The government must
also ensure that private interests do not obstruct access to relevant data collections.
• The government should promote local-level collection of data concerning local needs,
in good co-ordination with the existing needs at national level.
• The government must forcefully pursue the development and funding of national pub-
lic health and health care research programs.
• The government could provide an extra stimulus for the on-going development of
frameworks and indicators for measuring performance and risks in care and preven-
tion. This will eventually create more effective possibilities for ‘benchmarking’ at the
meso-level (between institutions) and at the macro-level (between countries).
• The government could encourage the Netherlands to become more deeply involved in
the efforts of European and other international institutions to make data from different
countries more readily comparable. One way in which this could be achieved is to
encourage Dutch researchers to make an active contribution to the design and imple-
mentation of the European public health programme.
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1 THE 2002 DUTCH PUBLIC HEALTH
STATUS AND FORECASTS REPORT:
A NATIONAL UNDERTAKING 
The new Public Health Status and Forecasts report 
How healthy are the Dutch, both now and in the future? Are there major differences
between population groups, regions or neighbourhoods? As a country, how do we com-
pare with our neighbours and what can we conclude from this? What have all our efforts
concerning prevention and care actually achieved, also in terms of the constantly
increasing costs? Will health care remain affordable for our rapidly ageing population
while our doctors are also becoming more competent? These are the kind of questions
that are discussed in the 2002 Dutch Public Health Status and Forecasts report (PHSF
2002. 
The third edition of the PHSF report has a new structure. The information and analyses
are divided into three sections so as to relate more efficiently to the various users’ needs: 
1. Basic detailed information is available on the following websites: the National Com-
pass on Public Health (www.nationaalkompas.nl), the National Atlas of Public
Health (www.zorgatlas.nl) and the ‘Cost of Illness’ site (www.costofillness.nl).
2. The PHSF thematic reports mainly provide information about specific, medium-
term government policies. 
3. This ‘Health on Course?’ report outlines the current views and is primarily intended
to support policy development, both national and local, over a longer period of time. 
New in this PHSF report is also an emphasis on making comparisons. Figures are espe-
cially interesting in terms of developments over time and of differences between popu-
lation groups, regions or countries. These differences show what has already been
achieved and where new opportunities exist. Moreover, the geographic perspective is
linked with two important trends: on the one hand, the increasing focus of national poli-
cy on the international context (the EU, the other OECD countries and the World Health
Organization) and, on the other hand, on the progressive decentralization of responsibil-
ities by re-assigning them to lower government institutions. 
The PHSF’s role
Judging by the broadly-based use of the two previous editions, the Public Health Status
and Forecasts reports have acquired a clear role in the provision of information. These
reports support the Ministry of Health, Welfare and Sport in the evaluation of its on-
going policy and by providing direction in the preparation of new policies for the com-
ing years. However, there are other players in the field of public health who also use the
PHSF’s information: consumers or those with a demand for care, providers of care and
prevention, insurers, government health authorities and the lower government institu-
tions. In addition, the PHSF reports are frequently used as a standard reference work in
university-level education and in the prioritising and programming of academic
research. (See also: text block 1.1). 
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Text block 1.1: Ten years of Public Health Status and Forecasts reports
As the co-ordinating institution, the National Insti-
tute of Public Health and the Environment (RIVM)
published in 1993 the first Public Health Status
and Forecasts report 1950-2010. This rather bulky
publication followed the example of successful
Dutch environmental surveys such as ‘Concern
for Tomorrow’ (‘Zorgen voor Morgen’). Many
researchers, registration holders and policy-mak-
ers contributed to this report. Therefore, as a
whole, the PHSF reports are the product of a
national effort that emphasizes a complete and
quantitative description of the status of Dutch
public health and the most important factors that
determine it. Here, the findings concerning shifts
in the healthy life expectancies of both men and
women, the most important causes of death and
illness, and the potential for prevention through
lifestyle changes are expressed in a somewhat
abstract way and have probably provided inspira-
tion instead of having directly supported concrete
policy. Nonetheless, partly due to gaps highlight-
ed by the 1993 PHSF report, research was under-
taken to determine the incidence of psychiatric
disorders in the general population (NEMESIS). 
The second PHSF report was published in 1997 as
a brief summary of a series of report sections. It
was more focused on concrete policy issues, and
provided a solid prognosis of the annual increase
in health care costs. Accordingly, it was used to
adjust the fairly low estimates included in the
government agreements of the day. Well-docu-
mented proof of the considerable differential in
health between urban and rural areas, and
between different neighbourhoods and regions
undoubtedly helped socio-economic health varia-
tions to acquire a higher priority on the political
agenda. The PHSF finding that young people in
particular are increasingly opting for unhealthy
behaviour was included in the prevention policy
and subsequently combated with a combination of
information and legislation, which focused on
tobacco and alcohol. Unfortunately, the PHSF rec-
ommendation that resources be made available
for the evaluation of local preventative programs
was never taken up. 
In the present layout, the PHSF consist of three
parts: 
1. Websites (www.nationaalkompas.nl, 
www.zorgatlas.nl and www.costofillness. nl)
that provide a wide range of up-to-date infor-
mation about health and health care; 
2. Thematic reports about specific subjects, which
are intended for short and medium-term policy
development. These thematic reports are linked
via policy advice groups to the policy develop-
ments of the relevant ministries and, in particu-
lar, those of the Ministry of Health, Welfare and
Sport. Various thematic reports have now pub-
lished in this series: ‘Health in the Cities’
(‘Gezondheid in de grote steden’), ‘Mother and
child care within reach’ (‘Ouder- en kindzorg
binnen bereik’), ‘Medicines and Medical
Devices’ (‘Geneesmiddelen en medische hulp-
middelen’), ‘Time for Healthy Living’ (‘Tijd voor
gezond gedrag’), ‘Cost of Illness in the Nether-
lands’ (‘Kosten van Ziekten in Nederland’) and
‘Regional variations in the use of pharmaceuti-
cals’ (‘Slikken in Nederland; Regionale variaties
in geneesmiddelengebruik’). Their findings are
often even more specifically geared towards
policy development;
3. The ‘Health on Course?’ summary report that
focuses on medium and long-term policy. 
It is difficult to say to what extent the PHSF’s find-
ings have influenced policy. Policy development is
based on an accumulation of information and dis-
cussion generated by the academic and scientific
worlds with obvious contributions from the social
sector, such as professional groups, patients’
organizations and political bodies. A number of
government papers specifically refer to PHSF
information, as was the case with the govern-
ment’s plan to include health explicitly in its urban
policy as a result of the ‘Health in the Cities’ the-
matic report and other documents. The PHSF
reports’ influence is clearly demonstrated by their
use as a standard reference work in university-
level education, and in the prioritizing of research
(such as the Netherlands Organisation for Health
Research and Development). It was partly due to
the 1997 PHSF report that the Second Dutch
National Survey of General Practice (‘Tweede
Nationale Studie’) was set up to examine the inci-
dence and prevalence of diseases by monitoring
by GPs’ practices. Scientific publications also fre-
quently refer to the PHSF reports when dealing
with public health in the Netherlands. There are
also numerous references to the PHSF reports in
the policy documents of the Ministry of Health,
Welfare and Sport and in those of related organi-
zations such as the Royal Dutch Medical Associa-
tion (KNMG), the Netherlands Mental Health care
Association (GGZ-NL), the Netherlands Institute
for Health Promotion and Disease Prevention
(NIGZ), the Netherlands Institute for Care and
Welfare (NIZW) and the Dutch Municipal medical
and health services (GGD). 
Over the years, the PHSF reports have incorporat-
ed a large body of information concerning the web
of Dutch health information, in which they have
Historical gains
More than 150 years of public hygiene and health care have resulted in an unprecedent-
ed improvement in Dutch public heath. Children born today have a life expectancy of
almost 80 years with more than 60 of them spent in good health. The average life
expectancy in the middle of the 19th century was at most 38 years and those years were
full of illness and disability. We all know that we owe this miracle to inspired hygienists,
a combination of engineers and doctors, who advocated the construction of sewers, the
system of provision of drinking water and decent housing. Moreover, medical care
became increasingly important throughout the 20th century. Vaccination and the use of
antibiotics have added many years of healthy life. In addition, our increasing prosperity,
improved working conditions, eating patterns, domestic comfort and an extensive sys-
tem of health protection have also contributed considerably.
The control of environmental factors has virtually eliminated early death through infec-
tious diseases. Society’s modernization has also led to a greatly reduced birth rate. This
‘health transition’ is ultimately the cause of the West’s ageing population. The emphasis
on collective prevention has shifted away from the physical environment and towards
unhealthy behaviour as being the cause of many chronic diseases. This has also lead to
increasing research into the relation between behaviour and the social and physical
environments.
Life expectancy will continue to increase over the coming decades. A major factor here
is our increased ability to tackle a third group of disease determinants, namely genetic
factors. Hence, knowledge of individual genetic traits will result in lifestyle advice that
is tailored to the individual. The most important challenges for the next few years are to
ensure the preservation of what has already been achieved and that the extra years are
spent in reasonable health. 
Since the 1980s, a major focus of interest has been the distribution of health across the
population. Even in an egalitarian country such as the Netherlands, there are consider-
able differences in health between the various population groups. These differences are
linked to socio-economic factors such as income and education, and to behavioural dif-
ferences. From a geographical perspective, we see these differences reflected in the
below average health of residents of deprived areas or in differences between urban and
rural communities. Moreover, health differences between population groups indicate
that there is still much to be achieved. 
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(continue text block 1.1)
now assumed a central position. This has in turn
led to the people behind these reports becoming
increasingly involved with international activities.
The ECHI (European Community Health Indica-
tors) Project was the clearest example of this.
Here, all the countries of the European Union
attempted to draw up a common, comparable and
policy-relevant set of health indicators. These
activities also increased the PHSF’s focus on
international comparisons. 
Finally, the Dutch Ministry of Health, Welfare and
Sport’s new ‘Prevention Policy Memorandum’
(‘Nota Preventiebeleid’), which is soon to be pub-
lished, draws extensively on the updated informa-
tion and analysis that was collected for the 2002
PHSF report. 
Growing care
Today’s health care strongly emphasizes quality of life, and reducing and postponing
social restrictions associated with chronic disorders of the elderly. On average, the
health of the Dutch scores reasonably well when compared with their foreign counter-
parts, while health care costs remain average. Should we therefore be happy with our
efficient health system? Unfortunately not entirely. Persistent waiting lists, high work-
loads and major shortages of staff illustrate growing levels of friction in the health care
sector. Demographic and social developments place the health system under consider-
able pressure. An increasingly elderly society, fewer young people, individualization,
more assertive and better-informed citizens, internationalization, increased prosperity
and rapidly-progressing medical technology seem to disturb the relation between supply
and demand still further. Not only will the demand for health care increase and change,
but the quality and diversity of its supply will also grow considerably. 
Moreover, we have now reached a situation of diminishing returns (Council for Public
Health and Health Care (RVZ), 2001a). Each year, we spend many billions on our health
system (almost 10% of the gross domestic product) and this budget is growing steadily.
Moreover, we will never again achieve the enormous health gains that we once did with
relatively simple interventions in the domestic environment. 
Health remains just as precious to us as ever, and we are continually widening our inter-
pretation of this concept. For many years now, it has no longer been a question of a tan-
gible absence of disease and infirmity but, in the spirit of the World Health Organiza-
tion’s well-known definition, of ‘complete physical, mental and social well-being’. This
also means that, in theory, there is virtually no limit to the appropriation of resources,
and that the efficiency of the health system plays an increasingly important role (Sarac-
ci, 1997). In view of this, the definition of health has been limited in first instance to the
absence of physical and psychological symptoms that can be recognized and named by
a physician (Netherlands Scientific Council for Government Policy (WRR), 1997). 
Gradually, concepts such as ‘efficiency’, ‘freedom of choice’ and ‘market forces’ have
gained importance and new dilemmas have developed. Are we sacrificing some solidar-
ity in the interests of extra efficiency? Must we extend the standard health care package
or should you be willing to pay for additional insurance for extras? For that matter, it is
striking that this discussion focuses on money, staff, organization and the health care
provided. The repercussions for public health are generally not considered. If efficiency
comes to play a more pivotal part then, ultimately, the ability to measure achievements
will also become more important. 
The players
The rapid changes outlined here require timely and adequate information about the state
of public health, and developments within it. Such information is not only for the gov-
ernment but also for a large number of other parties. Who are the players in the field of
our health system and what are their primary information needs? 
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In the health care field, the players are mostly described as the requesters of care, the
providers of care, and health care funders or insurers. These groups have their own sec-
tor and professional organizations. The government (Ministry of Health, Welfare and
Sport, the Public Health supervisory service and lower government institutions) is also
present on the field. It is right at the heart of things, maintaining or adjusting the rules.
Complicated relations exist between the players, and roles are sometimes switched (fig-
ure 1.1). Hence, the requester of care is the patient so far as the provider of care is con-
cerned, but is the policy holder vis-à-vis the health care funder. The carer is not only a
professional carer but also an entrepreneur. Ultimately, as the financier of care, the
health care funder is also the insurer of the requester of care. This complicated triangu-
lar relationship makes it difficult to operate the health system. Moreover, there is an
increasing pressure to alter roles and to direct through demand rather than through sup-
ply, and to improve the health system’s efficiency. Hence, the requester of care is
expected to be better informed, more emancipated and to act as an actual consumer
complete with, for instance, his or her individual budget. The provider of care must
focus more on his or her clients, and must place greater emphasis on efficiency and safe-
ty. The health care funders are expected to provide greater direction. They could stimu-
late competition between the providers of care by purchasing the best care for the lowest
possible prices. The government must ultimately play a more distant role. All these par-
ties need information concerning public health and care, so as to develop their policies
(Westerhout, 2000). 
Roles in the broad domain of prevention are more subtly divided than they are in care.
The protection of health has traditionally been a constitutional task for the government.
The maintenance of rules and laws concerning the safety of food, goods, homes and
buildings, work, traffic and the environment is controlled by the Public Health supervi-
sory service and by other inspectorates. In terms of prevention, the role of the Ministry
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Figure 1.1: The players in the health care field (Source: Van der Maas & Mackenbach, 1999).
of Health, Welfare and Sport is to provide directives, to stimulate and to create the right
conditions. It is assisted in this task by a series of advisory councils. However, other
departments dealing with social affairs, employment, managing the environment, hous-
ing, traffic and justice contribute just as much to public health through their intersectoral
policy. Municipal councils, frequently through their municipal medical and health ser-
vices, bear responsibility for the realization, continuity and cohesion of collective pre-
vention and for gearing it to curative care. 
Prevention is ‘provided’, among others, by municipal medical and health services, child
health centres, and outpatients’ clinics for STD’s along with organizations that primarily
focus on care. A series of private institutions, which are also involved with prevention,
collect and distribute information about responsible lifestyles and disease prevention.
This diverse group includes institutions such as Dutch traffic safety organisations and
anti-cancer charities. Prevention is also promoted in the workplace, at school, in neigh-
bourhoods, during sporting activities, and in medical and paramedical practice. This
work is carried out by a range of professionals who provide health information, advice,
screening and vaccinations, and who modify the working environment, both physically
and psycho-socially.
Policy-relevant information by answering seven questions
Over the past few years, the policy agendas of the Ministry of Health, Welfare and Sport
have reflected the motto: ‘care for people in a healthy society’. The policy aims at ‘pro-
moting a general state of health, promoting healthy behaviour, eliminating or diminish-
ing the factors that threaten health and, wherever possible, protecting against harmful
exposures. Life expectancy and the quality of life are the policy’s primary premisses. 
The agendas of the Ministry of Health, Welfare and Sport provide citizens with the
prospect of ‘timely care and services for which they are insured and to which they are
entitled’ (VWS, 2001, 2002a). Here, the key concepts are ‘risk solidarity’ and ‘accessi-
bility’. Every Dutch person must be able to insure himself against the cost of illness and
care, no matter the individual risk involved given a particular age, socio-economic sta-
tus or state of health. It should also be pointed out that all this must be available at an
acceptable price. It is anticipated that this will ultimately entail a radical overhaul of the
entire Dutch health care system. 
In the latest yearly report on health care, (‘Zorgnota’; VWS, 2002a), the Balkenende
government, which took office in July, gives further emphasis to the citizen’s right to
care throughout the year. Hence, financial and organizational barriers must be eliminat-
ed and counterproductive incentives should disappear. The providers of care become
care entrepreneurs who are stimulated by health care insurers and care consumers to
provide greater, timely and higher-quality care. The insurers provide directions, super-
vized by the government. It is striking that the Balkenende government is endeavouring
to take an extremely positive view of our ageing society, rather than simply seeing it as
an unfortunate expense. Investing in health contributes substantially to the population’s
welfare and is therefore worthwhile. 
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The outlined objectives have already been laid out in the most recent public health poli-
cy memorandum, ‘Healthy and Well’ (Nota: ‘Gezond en Wel’; VWS, 1995), and in a
series of memoranda for specific areas. The two main current Dutch health policy objec-
tives can be summarized as follows: 
Maintaining and improving public health. 
There are three points of special interest here: 
• preventing avoidable disease and mortality;
• reducing differences in health between socio-economic groups;
• preserving quality of life (particularly for those with chronic diseases).
Cure and care for people with diseases and handicaps. 
Both the cure and the care should be: 
• of high quality (effective, safe and appropriate); 
• available to everyone when needed;
• provided at an acceptable price. 
This PHSF report aims to illustrate the current state of these two core objectives and
how they may develop in the future. Therefore, using the basic model of public health as
its guiding principle, the contents of this 2002 PHSF report have been structured around
the following seven questions. The questions are colour-coded according to this model’s
blocks (text block 1.2). 
1. How is our health? What are the most important public health problems and how are
they developing? How do we compare with other countries in the European Union? Are
there striking health differences in the Netherlands between the various population
groups, neighbourhoods or regions? 
2. What factors determine our health? What are the obvious causes of health problems
(such as behaviour or environment) and what are the trends? How do we compare with
the rest of the European Union? Are there environmental or social differences in these
factors in the Netherlands? 
3. What is the significance of prevention and care for our health? Are there geographi-
cal or inter-institutional differences in the Netherlands? Are prevention and care as
effective as they could be, in the light of contemporary scientific evidence? Is this effec-
tiveness adversely affected by problems in the health care system? 
4. How much care is used, for what and by whom? Which health problems entail the
greatest costs? Do we spend more or less than other EU countries? Are there regional
differences in the use of care and what is their significance? 
5. Are the profits and costs in balance? How much health does a euro buy? Is prevention
always cheaper than cure?
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6. What will the future bring? How and to what degree will the expected socio-demo-
graphic developments and advances in medical technology influence our health? 
And finally: 
7. What does this information mean in terms of health policy? Where are the opportuni-
ties for health gains? What are the dilemmas of the future? What is the most important
information for guiding the various players?
Looking from different angles
Let us once again review the contents of the PHSF report from the different players’ per-
spectives: which of the questions discussed are relevant for which target group? 
Considering its responsibility, the national government has an interest in answers to all
these questions. Where are the shortcomings in our health status, what are their causes
and where are the opportunities for improvement amongst the Dutch as a whole, specif-
ic Dutch groups or even individuals? What are the trends? What do prevention and care
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Text block 1.2: The basic conceptual model of the 2002 PHSF report.
As with previous PHSF reports, we use a concep-
tual framework to structure the information and to
deal with it systematically (figure 1.2). It focuses
on our health status along with the determining
factors (determinants). This health status can be
described in terms of the prevalence of disorders,
and how this influences social participation and
quality of life, or in terms of causes of death or
composite measures such as healthy life
expectancy. Personal characteristics including
age, gender, hereditary predisposition or over-
weight greatly influence our health. Other deter-
minants concern lifestyle, and the social or physi-
cal environment. Current policy around 2002
places great emphasis on our lifestyle, eating pat-
terns and bad habits, such as smoking and the
excessive use of alcohol. The social and physical
domains cover issues such as education, profes-
sion or income, exposure to harmful substances,
radiation or pathogens in the workplace, and the
domestic environment and our food. 
Health policy should maintain everyone’s health
and, as far as possible, improve it through pre-
vention and care. Prevention primarily focuses on
the determinants: reducing exposure to factors
that damage health through health protection or
by influencing behaviour. Prevention also includes
the early detection and treatment of disease. Care
focuses on health problems that have already
been identified. Here, it may involve either a cure
or primarily care (where there is no prospect of a
cure). Finally, another major factor is health care
use. Health care use naturally depends on health
status, but is also inevitably linked to supply. Care
is formally provided in the various sectors of our
health system (such as a hospital or nursing
home), but also on an informal level by the imme-
diate family, friends or neighbours. Health policy
influences health status, health care use and
determinants of health, and is, in turn, influenced
by them. This dynamic system is affected by
autonomous demographic, macro-economic,
sociocultural developments and by advances in
medical technology. 
Health status
Determinants
Health policy
Autonomous
developments
Healthcare use
Figure 1.2: The basic conceptual model of the
PHSF reports (Source: Ruwaard & Kramers,
1997).
achieve and where are the opportunities for integrating both areas? What incurs the
major costs? Are these costs acceptable? What do we exactly mean by efficiency? The
next government report on prevention policy (‘Nota Preventiebeleid’), which will
appear shortly, will make extensive use of the information that has been collected in this
2002 PHSF report. 
Lower government institutions, primarily municipal councils, will be mainly interested
in the question of benchmarking, in how their residents’ health compares with the rest of
the Netherlands, and how the situation varies from neighbourhood to neighbourhood.
An understanding of the relation between health, behaviour, quality of the social and
physical environment, health care use and provision can help local government councils
to develop an integrated, intersectoral approach to deprivation involving neighbour-
hoods, schools, sports clubs, neighbourhood associations and medical professionals. 
Health care funders can profit from insights into present and future patterns of disease,
given the developments in demography, the trends in behaviour and the quality of both
the domestic and working environments. Will there be major shifts in the demand for
care and what would the financial consequences be? What is the situation in terms of the
health gains of prevention and care? This may be a matter not only of the quality of care
and the accessibility of care facilities but also of a customer-friendly attitude. Can the
health gains be increased by integrating prevention into care? An increased directing
role for health care funders also requires more opportunities for monitoring health care
achievements with the help of a transparent and valid set of indicators. Moreover, a
comparison with achievements in other countries creates insight into opportunities for
improvement. 
The developments in lifestyle and patterns of disease are naturally also important for the
providers of care, in relation to the expected demand for care and the opportunities for
integrating prevention into care. They too will be involved with making reliable mea-
surements of achievements, both medical and organizational, in relation to both funding
and the requester of care. Insight into the chain of care also benefits the provider of care.
What is the significance of the various parts of the chain both in terms of time and cost?
Insight into the lifestyles of groups of citizens, the quality of the physical and social
environment, and successful, local experimental prevention schemes may also benefit
‘prevention providers’ such as municipal medical and health services. 
Those in need of care benefit from insights into the determinants of health, particularly
behaviour, but also from insights into the health related quality of their domestic and
working environments. This equally applies to non-governmental organizations (con-
sumer’s representatives) in the case of specific diseases (i.e. cancer or diabetes mellitus)
or specific causes (smoking or environmental pollution) when organizing campaigns.
People that are demanding care currently seem to believe that ‘access to information’
and ‘the right provider attitude’ are the most important aspects. However, as consumers,
they also have an interest in information about the outcomes of medical interventions. 
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What is the structure of the 2002 PHSF report?
Chapter 2 consists of the facts and analyses covering the first five questions from the
above series of seven. One question is discussed per section. This chapter continues the
theme of the 1997 PHSF report with a description of the most important developments
in the field of public health. 
In chapter 3, these facts and analyses are placed in a future perspective, as based on
socio-demographic and medical-technological prospects. This chapter concentrates on
the sixth question in the above-mentioned series. 
Chapter 4 charts the consequences for policy. The most important dilemmas for health
policy are identified, on the basis of the diagnosis (chapter 2) and of quantitative and
qualitative forecasts (chapter 3). This also takes account of the perspectives of various
players and the changing division of roles. The fourth chapter also discusses the need
for and optimalization of the provision of information. Finally, chapter 4 also indicates
how the status of public health and the achievements of the health system may be coher-
ently described and monitored with the help of well-chosen indicators. 
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2 HEALTH AND CARE IN THE NETHERLANDS:
SIGNIFICANT TRENDS AND SALIENT DIF-
FERENCES
This chapter presents facts, interrelationships and analyses concerned with health status,
the underlying determining factors, health care and prevention. We identify the areas
that have recently been the subject of marked trends and the areas that show clear
regional or international differences. This chapter also describes the health differences
that exist between socio-economic groups and ethnic groups in the Netherlands. Such
trends and differences clarify what has been achieved so far, and help to identify oppor-
tunities for further improvement.
The information in this chapter is arranged in accordance with the PHSF conceptual
model (figure 1.2), based on the following questions:
2.1 What is the state of affairs with regard to our health?
2.2 What factors determine our health?
2.3 What do prevention and care mean for our health?
2.4 How much health care is used, what is it used for and by whom?
2.5 Are the benefits and costs in balance?
Each section briefly presents several core data items, together with more detailed exam-
ples. Each of sections 2.1, 2.2 and 2.4 looks at the following topics: current national sit-
uation, historical trends, position of the Netherlands relative to other European coun-
tries, regional differences, and differences between sections of the population.
Additional material on underlying studies, further details and references to data sources
and research is available in the National Compass on Public Health (www.natio-
naalkompas.nl), the National Atlas of Public Health (www.zorgatlas.nl) and the ‘Cost of
Illness’ site (www.costofillness.nl). We have kept the number of references to these
websites to a minimum in this report in the interest of readability. However, the websites
mentioned have special hyperlinks to take the readers of ‘Health on course’ directly to
the corresponding background information (mostly in Dutch, however).
2.1 What is the state of affairs with regard to our
health?
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Dutch health would appear to be developing in the right direction
We are living longer and we are healthier than ever, which is borne out by numerous
facts, for example that the life expectancy of Dutch men in 2000 has increased to 75.5
years, and that of women to 80.6 years. This increase is mainly attributable to the sus-
tained decline in mortality from coronary heart disease and stroke. Furthermore, the
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declining mortality from lung cancer in men is contributing to a rise in life expectancy,
under the influence of both a healthier lifestyle and improved health care.
Healthy life expectancy also increased in the 1990s, by an amount equal to or greater
than the increase in life expectancy. The years that have been gained are therefore
enjoyed in good health, especially for men. Women are living ever longer free of dis-
abilities and in good mental health, but, conversely, shorter in terms of good self-per-
ceived health.
Nonetheless, our ill health is a major burden on both the individual and society
The burden of ill health consists of more than the cost of health care alone, as it also
entails premature mortality, a loss of quality of life for patients and people in their
environment, diminished social participation and work incapacity.
The major causes of death are coronary heart disease, stroke and lung cancer. What is
more, many years of life are lost to mortality from breast cancer and suicide. Mental
disorders (depression, anxiety disorders and alcohol dependence), coronary heart dis-
ease and chronic obstructive pulmonary disease (COPD) are the main conditions associ-
ated with a decline in quality of life.
People with chronic diseases and impairments are to a lesser extent taking part in a
wide range of social activities. Their degree of participation in labour is also lower,
especially among patients with cardiovascular and musculoskeletal diseases. The major-
ity of work incapacity is attributable to mental disorders and musculoskeletal disorders.
Furthermore, there are ample reasons for us to be concerned about our health
Our health is not only a burden, but also gives cause for concern. The Netherlands is
lagging behind other EU countries. Men’s life expectancy is increasing at a slower rate
than in most EU countries, and women’s is stagnating to such an extent that we have
now fallen below the EU average. The mortality from lung cancer in men is still one of
the highest in the EU, and in women it is increasing faster than the EU average. The
death rate from chronic obstructive pulmonary disease (COPD) among women is
increasing relative to other member states. The mortality from breast cancer in the
Netherlands also remains obstinately high by international standards. Depression, anxi-
ety disorders and diabetes mellitus are also on the increase, but in these cases the main
reason is better recognition by physicians and patients.
Another cause for concern is that health is distributed unequally in the Netherlands,
with considerable differences between rich and poor, city and countryside, indigenous
Dutch and members of ethnic minorities. The least educated men live 5.0 years less
than the best educated. The corresponding difference for women is 2.6 years. Further-
more, the most highly educated men and women remain free of disabilities for an aver-
age of almost 10 years longer. The difference in the number years that people feel
healthy is as much as 16 years for men and 14 years for women. There are also similarly
large differences between regions, with residents of deprived areas in the major cities
being the worst off on average. Finally, life expectancy varies greatly between groups
of different ethnic origin.
2.1.1 Life expectancy and health
How long do we live, and how many years of our lives do we enjoy in good health? Are
we living ever longer, and remaining healthy ever longer? How does the situation in the
Netherlands compare with other EU countries? And are there any striking differences in
life expectancy and health in the Netherlands between regions or population groups?
This section presents core information on the life expectancy and health of the Dutch
population. Section 2.1.2 elaborates this picture by discussing specific diseases and dis-
orders that cause ill health, and by answering questions such as ‘What are the most sig-
nificant causes of death?’, ‘What are the common diseases and disorders?’, ‘Which con-
tribute most to a decline in quality of life, to work incapacity and to the total burden of
disease?’, ‘Which diseases have shown a marked increase or decrease in prevalence?’,
‘How large are the differences between socio-demographic groups, or between
regions?’ and ‘Are there any significant differences with other EU countries?’. The
answers to all these questions helps us to form a view of both health and ill health in the
Netherlands.
The health status of the population can be described by referring to various different
indicators. Text block 2.1 sets out the indicators that we use in this report and how they
relate to each other.
Women live an average of five years longer than men, but the difference is
becoming smaller
In 2000, life expectancy at birth was 75.5 years for men and 80.6 years for women,
which is a difference of more than five years. At 65 years of age, the difference in life
expectancy between men and women is still almost four years (table 2.1). Men have a
higher rate of mortality at any age, but the difference is especially large between 60 and
80 years of age, by a factor of almost two.
Between 1980 and 2000, life expectancy increased by 3.1 years for men and 1.4 years
for women. The rising life expectancy among men coincides with the declining mortali-
ty from significant causes of death such as coronary heart disease, stroke and lung can-
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Text block 2.1: A systematic look at health status
The health status of the population of the Nether-
lands is described with reference to four types of
indicators (figure 2.1): diseases and disorders;
functioning and quality of life; mortality; (ill)
health plus life expectancy. These indicators are
not entirely independent; for example, diseases
can lead to a reduction in functioning and quality
of life, and to a rise in mortality. The (ill) health
and life expectancy indicator combines disease
prevalence, quality of life and mortality in a single
measure at population level.
Health status indicators
Functioning and quality of life
Mortality
(Ill)health and life expectancy
Diseases and disorders
Determinants
Figure 2.1: The conceptual model of PHSF; elaborat-
ed for the block ‘Health status’ (Source: Ruwaard &
Kramers, 1997).
cer. For women, the increase in life expectancy has been stagnating since the late 1980s,
mainly as a result of the past increase in the number of women starting to smoke. For
example, there has been a consequential rise in mortality from lung cancer and COPD in
women (see also section 2.1.2). The effect of this stagnation is a constant erosion of the
difference in life expectancy between men and women.
Healthy life expectancy is almost equal for men and women
Healthy life expectancy is an indication of the proportion of life expectancy that is
enjoyed in good health. Healthy life expectancy is a measure that combines the length
and quality of life (for definitions of life expectancy and healthy life expectancy see text
block 2.2). This report presents the following three types of healthy life expectancy: as
determined by self-perceived health, by having physical impairments (disability) and by
mental health.
For each of these three types, healthy life expectancy is almost equal for men and
women. For instance, life expectancy in good self-perceived health is 61.3 years for
men and 60.8 years for women, which, although not a large difference, does mean that
women live almost 20 years in ill health and men ‘only’ 14 years.
Moreover, at 65 years of age, the years that women outlive men will be spent almost
completely in ill health (table 2.1). It should be noted that this ill health is for the most
part ‘minor ill health’ (figure 2.2), which is also true of the years with disability and the
years in mental ill health (Perenboom et al., 2002).
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Table 2.1: Life expectancy and healthy life expectancy of the Dutch population in 2000, at birth and at 65
years of age (Sources: see text block 2.2).
Men Women
At birth:
Life expectancy 75.5 80.6
Healthy life expectancy
• life expectancy in good self-perceived health 61.3 60.8
• disability-free life expectancy 70.2 70.6
• life expectancy in good mental health 67.4 68.1
65 years of age:
Life expectancy 15.3 19.2
Healthy life expectancy
• life expectancy in good self-perceived health 9.3 9.9
• disability-free life expectancy 12.1 12.8
• life expectancy in good mental health 14.0 16.4
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Figure 2.2: Survival curve for Dutch men and women in 2000. The area between the lines repre-
sents the number of years of self-perceived good health, or, conversely, of minor, moderate and
major ill health (Sources: see text block 2.2).
Text block 2.2: What is healthy life expectancy?
What is life expectancy?
Life expectancy indicates how many years people
can expect to live, on the assumption that the
current age-specific mortality probabilities
remain constant. For the purposes of this report,
life expectancy is calculated on the basis of the
mortality probabilities in 2000. 
What is healthy life expectancy?
Healthy life expectancy is the number of years
that one may expect to live in good health. It is
thus a combined measure of the length and quali-
ty of life. The quality of life is determined by three
health indicators, each of which yields a particu-
lar type of healthy life expectancy: 
• Life expectancy in good self-perceived health;
• Life expectancy without disability;
• Life expectancy in good mental health. 
In the case of life expectancy in good self-per-
ceived health, the number of ‘healthy’ years is
determined on the basis of the percentage of indi-
viduals answering ‘good’ or ‘very good’ to a
question about self-perceived health. Those who
answered ‘fair’, ‘sometimes good and sometimes
bad’ or ‘bad’, on the other hand, are classified as
‘unhealthy’. In this connection, the response ‘fair’
is taken to correspond to slight ill health, ‘some-
times good and sometimes bad’ to medium ill
health and ‘bad’ to severe ill health.
Life expectancy without disability is calculated
with the aid of data on long-term physical impair-
ment in ten activities in the fields of hearing,
sight, mobility and activities of daily living (ADL).
Individuals are classified as suffering from a dis-
ability if they state that they are unable to carry
out one or more of these activities, or can only
carry them out with great difficulty. 
The determination of expectancy of life in good
mental health makes use of the Affect Balance
Scale, which considers five negative feelings
(loneliness, unrest, boredom, depression and dis-
tress). The number of years of ‘ill health’ is deter-
mined on the basis of the percentage of individu-
als suffering from one or more of these five
feelings often or very often. 
Sources used
The mortality and life expectancy data were
derived from the CBS-StatLine (CBS = Statistics
The healthy life expectancy of men is increasing, while the trend for
women is unclear
Life expectancy is increasing, but the question is whether people actually live longer in
good health. This is indeed the case for men, who have seen an increase in total life
expectancy in the past decade accompanied by an increase in healthy life expectancy
(table 2.2). The increase in life expectancy in good self-perceived health and in good
mental health is approximately as large as the increase in total life expectancy, which
means that the years gained are enjoyed in good health. Disability-free life expectancy
is increasing even more than life expectancy.
The findings are contradictory for women: life expectancy in good self-perceived health
is decreasing, while life expectancy in good mental health, and especially disability-free
life expectancy, are increasing (Perenboom et al., 2002).
There is no less disease, but there is less disability
The number of years that people live with disabilities has therefore decreased sharply
(compression of morbidity), with an especially steep decline in mobility and hearing
impairments among the elderly. However, there are no indications that musculoskeletal
diseases or hearing impairments are declining. In general, the number of years that peo-
ple live with disease would actually appear to have increased, as can be seen in an
analysis that included fourteen self-reported chronic diseases (Perenboom et al., 2002).
Apparently, therefore, people are becoming better able to cope with the physical impair-
ments of their disease or disorder, which could be related to the increased use of medical
devices such as rollator walkers (walking frames) and hearing aids. As in most western
countries, a pattern seems to be emerging of a decrease in impairments, or at least of
their severity (Robine et al., 2002).
In contrast to disability-free life expectancy, life expectancy in ‘good self-perceived
health’ has increased less than total life expectancy (men), or has even decreased
(women). The number of unhealthy years has therefore increased, especially for women
(expansion of morbidity). It is unclear where the discrepancy in the trends between the
different measures of health originates. One possible factor is that self-perceived health
is a subjective measure, which involves both objective health and increasing expecta-
tions of an individual’s own health.
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(continue text block 2.2)
Netherlands).
Information about the health of individuals living
on their own comes from the Statistics Nether-
lands’ continuous survey (called ‘Gezondheidsen-
quête’ (Health Survey) up to and including May
1996, and the ‘POLS gezondheid en arbeid’ sur-
vey (Keeping a finger on the pulse in health and
work) from 1997 onwards). Data on the elderly in
nursing and care homes was taken from surveys
on elderly people in institutions (Ouderen In
Instellingen) (OII-2000 and earlier versions). The
data on healthy life expectancy was processed by
TNO-PG (Prevention and Health department of
the Netherlands Organization for Applied Scientif-
ic Research) (Perenboom et al., 2002; Mulder et
al., 2002; Van Herten et al., 2002)
Life expectancy in the Netherlands is rising more slowly than the EU aver-
age
What is the position of the Netherlands in comparison with other European countries in
terms of life expectancy? The life expectancy of Dutch men at birth is rising less rapidly
than the EU average (figure 2.3). Nonetheless, the Netherlands still occupies a relatively
favourable position in terms of life expectancy at birth for men. However, this is no
longer the case for the remaining life expectancy at a greater age. In other words, Dutch
men suffer relatively high mortality at an advanced age. In comparison with other Euro-
pean countries, a relatively large number of elderly Dutch men die from lung cancer,
COPD, pneumonia and prostate cancer.
The life expectancy of Dutch women continues to lag even further behind the EU aver-
age than that of men (figure 2.3). Their life expectancy is stagnating at all ages and has
now fallen below the EU average. A similar development can be seen only in Denmark,
where the effect is even more marked.
The stagnation women’s life expectancy is mainly a consequence of 
smoking
One obvious candidate for the cause of the relatively unfavourable developments in life
expectancy is the most significant cause of death in the Netherlands, coronary heart dis-
ease. However, the associated trend fails to explain the stagnating life expectancy, since
mortality from coronary heart disease is developing favourably, both for men and
women. The decline in mortality that took place in the Netherlands between 1980 and
1993 was even one of the most pronounced in Europe.
Mortality from smoking-related diseases is a major element in the unfavourable trend
for women. For instance, the increase in mortality from lung cancer among Dutch
women in the period from 1980 to 1993 was the highest in Europe, at over 85% (La Vec-
chia et al., 1998). The incidence of lung cancer in Dutch women now exceeds the Euro-
pean average. The mortality from COPD, breast cancer and colorectal cancer among
Dutch women is also higher than in other European countries (Van der Wilk et al.,
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Table 2.2: Change a in life expectancy and healthy life expectancy of the Dutch population (in years), in the
period from 1980 to 2000 (Sources: see text block 2.2).
Men Women
Change in total life expectancy 
from 1980-2000 +3.1 +1.4
from 1983-2000 b +2.7 +1.1
from 1989-2000 c +1.8 +0.6
Change in life expectancy in good self-perceived health 1983-2000 +2.4 -1.2
Change in disability-free life expectancy 1989-2000 +5.8 +5.5
Change in life expectancy in good mental health 1989-2000 +1.9 +2.8
a) the changes are based on regression coefficients and are all statistically significant.
b) self-perceived health was first measured in 1983.
c) disability (physical impairments) and mental health were first measured in 1989.
2001). More information on international mortality differences according to cause of
death can be found in section 2.1.2.
A difference of almost ten years in healthy life expectancy between regions
Geographical life expectancy differences exist not only within Europe, but also within
the Netherlands. For instance, life expectancy is relatively low in South-Limburg, the
northeast of the Netherlands and the major cities (text block 2.3). People in several
regions in the west (including Amstelland - De Meerlanden and Delfland) attain the
greatest average age. The maximum differences in life expectancy between these
municipal medical and health service regions (GGD-regions) are 3.2 years for men and
2.5 years for women. The regional differences in healthy life expectancy (on the basis of
self-perceived health) rise to almost ten years (Mulder et al., 2002). For instance, people
in the major cities, South Limburg and the northeast enjoy relatively few healthy years
(55-58 years), while people in several regions in the west of the country, the Veluwe and
North and Central Drenthe enjoy approximately 65 years of good self-perceived health
(figure 2.4). This is true for both men and women. The regions with many low socio-
economic status residents have a particularly modest life expectancy. Indeed, there are
striking similarities between the regional pattern of healthy life expectancy and that of
socio-economic status (figure 2.4).
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Figure 2.3: Life expectancy trends for men and women in various EU countries in the period
from 1970 to 2000. As well as the Netherlands and the EU average (EU-15), the most and least
favourable countries are shown (Source: WHO-HFA, 2002).
Less well educated men live an average of five years less than highly 
educated men
The difference in life expectancy of men with only an elementary school education and
men with a higher vocational or academic education is almost five years. The respective
life expectancies are 73.1 and 78.0 years. For women the difference is 2.6 years: women
with only an elementary school education live 79.5 years on average, while highly edu-
cated women live 82.1 years on average (figure 2.5). A difference of five years in life
expectancy is large. It is as large as the total difference in life expectancy of men and
women. In order to find a life expectancy for men that is five years less than their cur-
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Figure 2.4: The regional spread of healthy life expectancy (HLE) in the period from 1995 to
1999 and socio-economic status (SES) in the Netherlands in 1995 (education, occupation and
income) (Sources: see text block 2.2; Knol, 1998).
Text block 2.3: People who live in deprived neighbourhoods are less healthy
The lower level of health in cities can be mainly
ascribed to the situation in the deprived urban
areas, which are subject to multiple health prob-
lems. For example, the probability of dying before
the age of 65 is 50% higher in a deprived area
than in a prosperous neighbourhood. The reasons
for this are largely related to the socio-demo-
graphic make-up of the neighbourhoods. A rela-
tively large proportion of the people who live in
deprived areas have a low socio-economic status
and/or are immigrants, and both these groups are
associated with poorer health. It is clear that the
mechanisms that give rise to socio-economic dif-
ferences in health also play a role in the differ-
ences in health observed within the big cities.
Relevant factors here include material and imma-
terial living conditions, lifestyle factors and the
accessibility and quality of health care (Van der
Lucht & Verkleij, 2001).
rent life expectancy, we have to go back approximately thirty years. The difference in
life expectancy between people with a low and a high educational level differs from that
reported in PHSF 1997. It was calculated then that the difference in life expectancy
between the lowest and the highest Social Economic Status (SES) group was 3.5 years
for both men and women. This finding was based partly on Swedish research results.
The new figures are based on four longitudinal Dutch studies (ERGO, LASA, PPHV,
GLOBE) (Van Herten et al., 2002).
There are also socio-economic differences in healthy life expectancy
Socio-economic differences exist not only for life expectancy, but also for healthy life
expectancy, and the difference between people of a low and a high educational level is
then even larger: less well educated men and women then live 9.9 and 8.6 fewer years,
respectively, in good health (in other words: without disability). For instance, men with
only an elementary school education live on average for 64 years without disability, and
9 years with disability (figure 2.5). Their total life expectancy, 73 years, is even lower
than the disability-free life expectancy of more highly educated men (higher vocational
or academic education), who live on average for 74 years without disability, but ‘only’
four years with disabilities. Another measure for healthy life expectancy, self-perceived
health, shows even greater differences, with less well educated men and women then
having 15.8 and 14.0 fewer healthy years, respectively.
Socio-economic differences in health are not becoming any smaller
The differences in healthy life expectancy are greater than was stated in PHSF 1997. It
is difficult to establish trends in health differences on the basis of the data available.
Currently, four educational levels are distinguished as opposed to three: the highest edu-
cational level has been divided in two to increase the homogeneity within a class.
Nonetheless, the differences would not appear to be declining. This is evident in analy-
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Figure 2.5: Life expectancy and disability-free life expectancy according to educational level for
Dutch men and women, 1995-1999 (Sources: see text block 2.2).
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ses of trends in socio-economic differences on the basis of self-reported health, as mea-
sured since the early 1980s in various Statistics Netherlands (CBS) surveys (Konings-
Dalstra et al., 2000). These data indicate at most that the health differences are stabiliz-
ing. The inequality in self-perceived health and the presence of two or more chronic
diseases has even increased. The main increase is in income-related differences, more so
than those related to educational level. This is possibly connected with the slower
progress being made by the poorest groups in the Netherlands in well-being and living
conditions (including material living conditions) (Konings-Dalstra et al., 2000).
The life expectancy of ethnic minority groups is not always shorter
It is often assumed that ethnic minority population groups also have a lower life
expectancy, in particular because of their less favourable socio-economic status. How-
ever, this assumption is not entirely consistent with the available data, which actually
show a high mortality rate among the young (and very young) members of ethnic
minorities and, conversely, a more favourable mortality rate among the older members
of ethnic minorities (Hoogenboezem & Israëls, 1990; Wild & McKeigue, 1997; Razum
et al., 1998; Abraido Lanza et al., 1999; Weitoft et al., 1999). Among the possible expla-
nations for the lower mortality among older members of ethnic minorities in the Nether-
lands are selective remigration and the fact that immigrants form a healthy, selected
group from the country of origin (Uitenbroek et al., 2001). Differences in lifestyle or
genetic factors may also play a role. Moreover, there are considerable health differences
between the various ethnic minority population groups (text block 2.4).
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Text block 2.4: Differences in life expectancy by country of origin
Life expectancy at birth depends on the country of
origin, among other things. Appreciable differ-
ences may exist between one country and anoth-
er. For example, men of Moroccan origin live on
average more than 3.5 years longer than Dutch
men, while men of Turkish and Surinamese origin
have a life expectancy which is on average about
1.5 years less than for Dutch males. Men from the
Dutch Antilles and Aruba have nearly the same life
expectancy as Dutch men. Moroccan women live
on average nearly a year longer, and Surinamese
women nearly 1.5 years less long, than Dutch
women. The life expectancies for women of Turk-
ish and Antillean or Aruban origin are roughly
equal to those for women of Dutch origin.
In general, mortality among migrant groups is rel-
atively high in lower age groups and relatively low
in higher age groups. The age at which the
expected mortality becomes less than that for
individuals of Dutch origin depends strongly on
country of origin and gender. For example,
Moroccan men up to 30 years old have a higher
risk of mortality while above 40 they have a lower
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Figure 2.6: Life expectancy among Dutch residents
from different countries of origin, in the period
from 1995 to 2000 (Source: Statistics Netherlands
(CBS) mortality and population statistics).
2.1.2 Mortality, disease and quality of life
The previous section discussed the (healthy) life expectancy of the population of the
Netherlands. This section considers the question of which diseases and disorders are
responsible to a significant degree for the years people spend in poor health, on the basis
of a variety of health measures (text block 2.5). It should be noted that we use the terms
diseases and disorders here to refer only to the 53 diseases and disorders selected for
PHSF (unless stated otherwise). By identifying which diseases and disorders are chiefly
responsible for our ‘ill health’, we also identify opportunities for prevention and care.
Coronary heart disease, stroke and lung cancer are the major causes of
death
The total number of deaths in the Netherlands in 2000 amounted to more than 140,000
people. Cardiovascular diseases and lung problems were the top five major causes of
death. Most men die of coronary heart disease (9,900 deaths) and lung cancer (6,300
deaths), and most women of coronary heart disease (7,500 deaths) and stroke (7,200
deaths) (table 2.3 and appendix 1). As well as differences between men and women,
there are also differences between the various age groups (text block 2.6).
Coronary heart disease, lung cancer and stroke head the list of the major causes of death
for both mortality and the number of years of life lost (text block 2.5). However, the
other diseases and disorders in the top five mortality list are pneumonia and COPD,
while those in the top five for the number of years of life lost are breast cancer and sui-
cide (table 2.3 and appendix 1). In comparison with PHSF 1997, pneumonia is a new
entrant in the top five major causes of death, replacing chronic heart failure. In the list of
diseases and disorders that are responsible for most of the years of life lost, chronic
heart failure has been replaced by suicide.
The most common ailments are neck and back problems, hearing impair-
ments and anxiety disorders
It is important to know not only what people die from, but also what they suffer from.
The most frequently occurring diseases (prevalence) in the Netherlands according to an
epidemiological population survey are neck and back problems, hearing impairments
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risk of mortality, while Surinamese men up to 75
years of age have a higher expected mortality. In
this study, migrants are defined according to their
own country of origin and that of both parents;
the results thus relate to first- and second-gener-
ation migrant groups combined. The data on older
individuals (aged 75 years or older) of Turkish,
Moroccan, Antillean and Aruban origin should be
treated with some caution in view of the small
size of these groups. The expected mortalities for
migrant groups aged less than 75 years are, how-
ever, based on such large populations that con-
clusions about relative mortality rates can be
drawn with confidence. 
(Authors: V Bos, JP Mackenbach and AE Kunst from
Erasmus MC, University Medical Centre Rotterdam and
IM Keij-Deerenberg from Statistics Netherlands Voor-
burg. Based on unpublished studies.)
and anxiety disorders (table 2.3 and appendix 1). It is difficult to say whether these are
actually the most frequently occurring disorders, because data is not available from the
population survey for all 53 diseases and disorders. Data from care registrations also
show that coronary heart disease, visual impairments, asthma and diabetes mellitus
occur very frequently, and they put hearing impairments at the top of the list of fre-
quently occurring diseases for both men and women. For men, coronary heart disease is
in second place, whereas for women it is osteo-arthritis. The diseases with the most new
cases per year in the Netherlands (incidence) are infections of the upper respiratory tract
(including the common cold), domestic accidents, and neck and back problems (table
2.3 and appendix 1).
In order to obtain the most complete picture possible, we used both a variety of care reg-
istrations and epidemiological population surveys as sources, recognizing that there is
often a discrepancy between these two types of sources.
Much quality of life is lost as a result of mental disorders
The prevalence and incidence figures shed light on the occurrence of diseases and disor-
ders, but they say nothing about their consequences in terms of quality of life. It is
important to gain an insight into this aspect because some diseases have far-reaching
consequences for people’s performance and quality of life, while the consequences of
other diseases are less serious. The impact of diseases on quality of life can be measured
in years lived with disability (YLD) (text block 2.5), which is a measure not only of the
number of years spent in disease, but also the severity of the disease or disorder. Disor-
ders such as neck and back problems, hearing impairments and contact eczema do not
appear in the top five when severity is taken into account. The main conditions associat-
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Table 2.3: The major diseases and disorders in the Netherlands in 2000, according to mortality, years of life
lost, prevalence, incidence, loss in quality of life, and disability-adjusted life-years (DALY) (Sources: see text
block 2.5). For a more extensive overview of the ranking of diseases and disorders, see appendix 1.
Rank- Cause of death Largest number Highest Highest Most loss Highest loss
ing with most lost years prevalence a incidence b in quality of DALYs
mortality of life of life
1 Coronary Coronary Neck and Infections of Anxiety Coronary 
heart disease heart disease back problems the upper disorders heart disease
respiratory tract
2 Stroke Lung cancer Hearing Private Depression Anxiety
disorders accidents disorders
3 Lung cancer Stroke Anxiety Neck and Coronary Stroke
disorders back problems heart disease
4 Pneumonia Breast cancer Contact  Acute urinary Dependence COPD
eczema tract infections on alcohol
5 COPD Suicide Knee or Pneumonia COPD Dependence
osteo-arthritis and acute  on alcohol
of the hip bronchi(oli)tis
a) ranking based on population surveys.
b) ranking based on care registrations.
ed with a loss in quality of life are mental disorders, coronary heart disease and COPD
(table 2.3 and appendix 1). For men, alcohol dependence is at the top, followed by coro-
nary heart disease and anxiety disorders. For women, anxiety disorders, depression and
osteo-arthritis occupy the top three.
Different ages have different diseases that lead to a significant loss of quality of life (text
block 2.6).
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Text block 2.5: Different measures of health give different insights
There are different ways of measuring people’s
health. The ones used in this chapter are summa-
rized below. 
Mortality and years of life lost
The most traditional measure of health is mortali-
ty, i.e. the number of people dying of a particular
disease. A second measure, based on mortality
statistics, is the number of years of life lost; age
at the time of death is also taken into account in
the calculation of this measure. Years of life lost
is thus the number of years an individual dying of
a particular complaint still had to live according to
his or her life expectancy at that time. Hence, an
individual who dies young loses more years of
life. Mortality data was derived from Statistics
Netherlands’ (CBS) mortality statistics. 
Prevalence and incidence
The prevalence of a particular disease is the num-
ber of individuals who have that disease at a par-
ticular moment in time (the point prevalence) or
in a particular period (e.g. the annual prevalence).
The incidence is the number of new cases of the
disease in question or the number of new individ-
uals with this disease in a particular period.
Unless otherwise indicated, the point prevalence
and the annual incidence are given in this report.
Prevalence and incidence data were derived from
various sets of primary care records: the Contin-
ue Morbiditeitsregistratie Nijmegen (KUN)
(Nijmegen Continuous Morbidity Registration),
the Continue Morbiditeitsregistratie Peilstations
Nederland (Nivel) (Continuous Morbidity Regis-
tration for Sampling Stations in the Netherlands,
maintained by Nivel), the Transitieproject (UvA)
(Transition Project, maintained by the University
of Amsterdam), the Registratienet Huisartsprak-
tijken Limburg (UM) (Registration Network for
Primary Care practices in Limburg, maintained by
the University of Limburg, Maastricht), the Regis-
tratie Netwerk Universitaire Huisartspraktijken
Leiden en Omstreken (UL) (Registration Network
for University Primary Care practices in Leiden
and environment, maintained by the University of
Leiden) and the Tweede Nationale Studie naar
ziekten en verrichtingen in de huisartspraktijk
(Nivel/RIVM) (Second Dutch National Survey on
General Practice, undertaken jointly by Nivel and
RIVM). Use has also been made of records specif-
ic to certain diseases such as the Nederlandse
Kankerregistratie (Dutch Cancer Registration Sys-
tem), records from institutions such as nursing
homes, and epidemiological population studies
(such as NEMESIS and the ERGO study). For an
overview of the sources used per disease, see the
Nationaal Kompas Volksgezondheid (Dutch
National Compass on Public Health: www.natio-
naalkompas.nl).
Loss of quality of life expressed as years lived
with disability 
The number of years lived with disability is calcu-
lated by multiplying the prevalence of the disease
in question (or the incidence multiplied by the
duration) by a weighting factor indicating the
severity of the disease. This weighting factor,
which is determined by a panel of experts, per-
mits comparison of the years lived with disability
for various diseases and also allows years lived
with disability to be compared with years lost by
death. If, for example, a disease has a weighting
factor of 0.5, this means that a year lived with this
disability is regarded as equivalent to six months
lost by premature death. Uncertainties still
remain, however, about certain aspects of the
estimation of years lived with disability. This is
particularly true of the relationship between the
weighting factor and the prevalence of the dis-
ease. It is of crucial importance that the descrip-
tion of the disease for which a weighting factor
has been determined agrees with the description
of the disease for which the prevalence is known.
Mild, highly prevalent diseases are associated
with the greatest uncertainties. 
DALY combines information on mortality, morbid-
ity and quality of life
The burden of disease for the population as a
whole is expressed in DALYs (‘Disability-Adjusted
Life-Years’) - a concept developed by the WHO.
The DALY is the sum of the years of life lost and
the years lived with disability. It may be noted that
the calculation of the DALY is associated with the
same limitations as that of the years lived with
disability.
The high burden of disease is chiefly attributable to coronary heart dis-
ease, anxiety disorders and stroke
Years lived with disability (YLD) therefore say something about both the prevalence
and the severity of diseases. DALYs go further by taking account of the fact that some
diseases lead to premature mortality (text block 2.5). Of the diseases studied here, coro-
nary heart disease, anxiety disorders, stroke and COPD cause the most burden of dis-
ease (table 2.3 and appendix 1). The loss of DALYs through coronary heart disease,
stroke and COPD arises from a loss of both years of life and quality of life, whereas for
anxiety disorders only the loss of quality of life is involved. It may appear strange at
first sight that anxiety disorders are responsible for so much loss of health. However, it
is significant here that anxiety disorders have a powerful impact on cognitive and emo-
tional performance, and because they therefore affect the more complex and higher
human capacities, they are a significant threat to quality of life (Ormel et al., 1994). Fur-
thermore, these disorders occur relatively often. There are some differences in the dis-
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Text block 2.6: A closer look at different age groups
Disease and the burden of disease can vary from
one age group to another. The main differences
between age groups are summarized below. 
Mortality
Each age group has characteristic causes of
death. In the 0-14 year age group, these are peri-
natal disorders, congenital abnormalities (in par-
ticular of the cardiovascular and nervous sys-
tems), domestic and traffic accidents and cancer.
In the 15-24 year age group, they are traffic acci-
dents, suicide, cancer (in particular lymphomas,
leukaemia and brain cancer), diseases of the ner-
vous system (in particular epilepsy and muscular
dystrophy), murder and manslaughter. The main
causes of death in the 25-44 year age group are
suicide and coronary heart disease, while in the
45-74 year age group they are coronary heart dis-
ease, lung cancer, other heart diseases (in partic-
ular chronic heart failure and cardiac arrest),
stroke, COPD, cancer of the colon and rectum and
breast cancer. Additional important causes of
death in the 75+ year age group are pneumonia
and dementia. 
Loss of quality of life
In children (0-14 years), asthma (and COPD),
intellectual disability, traffic accidents and respi-
ratory tract infections account for a large part of
the years lived with disability (referred to as ‘loss
of quality of life’ from now on). In young people
(15-24 years) and young adults (25-44 years),
alcohol dependence, depression and anxiety dis-
orders account for more than half of the loss of
quality of life. Coronary heart disease, osteo-
arthritis and COPD are added to this list in the 45-
65 year age group. The elderly tend to suffer
somewhat less from mental disorders: loss of
quality of life in this age group is largely due to
coronary heart disease, osteo-arthritis, visual
impairment, stroke and COPD. It may be noted
that these results apply to the 53 diseases select-
ed for the PHSF. This means that no cancers that
occur especially in children are included in the
overall loss of quality of life. The picture would be
different if all diseases and complaints would
have been taken into consideration.
Burden of disease expressed in DALYs
Eleven percent of the overall burden of disease in
the Netherlands is found in children and young
people (0-24 years), 45% in adults (25-64 years)
and 44% in the elderly (65+ years). The main fac-
tors contributing to the burden of disease in chil-
dren (0-14 years) are injuries due to (traffic) acci-
dents, asthma and COPD, congenital
abnormalities and intellectual disability. The rele-
vant factors in young people (15-24 years) and
young adults (25-44 years) are depression, anxi-
ety disorders, alcohol dependence and suicide,
though traffic accidents also continue to play an
important role. The burden of disease above 44
years is mainly due to coronary heart disease,
lung cancer and COPD; mental disorders also
remain important in this age group, however. The
elderly are also affected by stroke, COPD, demen-
tia, osteo-arthritis and diabetes mellitus. As in the
case of the loss of quality of life (see above),
these data only refer to the 53 diseases selected
for the PHSF.
eases responsible for the greatest burden of disease for men and women: in the case of
men, the greatest DALY loss is through coronary heart disease, followed by alcohol
dependence and COPD, whereas for women, the top three are anxiety disorders, coro-
nary heart disease and depression. For different ages, different diseases are associated
with a high burden of disease (text block 2.6).
Having a disease and disabilities hinders social participation
Diseases, disorders and impairments have consequences for mortality and quality of
life. One of the determinants of quality of life is the degree of participation in social and
public activities. In general, people with impairments (involving some combination of
hearing, walking and vision) have more participation problems than people with a dis-
ease (such as asthma or COPD, a cardiac abnormality or stroke). People with impair-
ments therefore devote less of their leisure time to social contacts and going out. They
also take less part in sport and visit cultural or recreational facilities less often, which is
a result not only of their poorer state of health, but also of transport problems and the
less than perfect accessibility of buildings (SCP reports on the disabled: De Klerk, 2000,
2002). Unfortunately, no information is available concerning the extent to which certain
diseases and impairments lead to participation problems. A better understanding of this
entire issue is needed (text block 2.7).
Chronic diseases and disability give rise to lower labour participation
The labour participation of those suffering from a disease is also lower than that of those
who are free of disease, and this is especially true of people with a chronic disorder. Of
all 15 to 65-year-olds, 61% work; of the chronically ill, 52% have a paid job of 12 hours
or more. The participation is particularly low among those with heart disease, the after-
effects of a stroke and musculoskeletal disorders. Conversely, asthma sufferers, for
example, work virtually the same hours as those who are free of chronic disease. The
associated impairments have an even stronger influence than the nature of the disease
itself: of those with physical impairments, 38% work. Those with physical impairments
who also work are likely to have a part-time job and a less senior position than disability-
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Text block 2.7: More insight into social participation is desirable
The results concerning social participation are
based on reports on the disabled published by the
Social and Cultural Planning Office (SCP). The
2000 report dealt with the participation of dis-
abled individuals in the work process and their
financial position, while the 2002 report also cov-
ers other aspects of social participation such as
free time and care. The category ‘disabled’
includes people with chronic diseases as well as
those with physical and mental disability. Howev-
er, the SCP makes no distinction between the vari-
ous forms of complaints or impairments. Addi-
tional studies are needed to give insight into the
extent to which different complaints and impair-
ments contribute to disability. This is particularly
important in the interests of effective prevention.
Future studies will be able to make use of a new
classification of functioning and participation, as
described in the International Classification of
Functioning, Disability and Health (ICF) published
by the WHO (WHO, 2001a). Use of this classifica-
tion will promote uniformity of terminology in the
various studies, and the comparability of their
results. A further aim for the future is a better
understanding of trends in the field of social par-
ticipation. An initial analysis of Statistics Nether-
lands’ data yields encouraging results: the social
participation of elderly individuals with disabilities
has improved over the past decade (Perenboom,
1999).
free working people. This diminished participation in the labour process means that
people with chronic disorders and/or disabilities have a lower income. In addition, they
have higher disease-related expenses. Furthermore, people with a chronic disease or
impairment more often draw a social benefit, such as a work incapacity benefit (De
Klerk, 2000, 2002; Rijken et al., 2001).
Mental disorders are the major cause of work incapacity among young
people
Which diseases and disorders lead most to work incapacity? This can be deduced from
work incapacity benefits records, which reveal that in the year 2000 one quarter (25.5%)
of current benefits [Work Incapacity Benefits (WAO), Work Incapacity Benefits for
Self-Employed Persons (WAZ) and Work Incapacity Benefits for Persons with an Early
Handicap (WAJONG); in total 952,000] were paid to people who had been declared
unfit for work because of musculoskeletal disorders (figure 2.7). One third (33.8%)
became unfit for work because of a mental disorder, 5.0% because of cardiovascular
diseases and 5.6% because of acute physical injuries. Mental disorders are responsible
for more than half of the work incapacity among younger people (up to 35 years of age).
Older disabled people more often become unfit to work as a result of musculoskeletal
diseases.
The major changes in the pattern of disease
We described in the sections above how often diseases and disorders occur and what the
consequences are. However, it is also important to know which diseases and disorders
have increased or decreased in incidence, and where changes have occurred in the mor-
tality trends. We derived data on trends from various registrations, such as the Nether-
lands Tuberculosis Register, the Netherlands Medical Registration System (LMR), the
Dutch Cancer Registration System (NKR) and the cause of death statistics of Statistics
Netherlands (CBS). As a source of trend data from general practitioner registrations, we
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Figure 2.7: Percentage of the total number of disability benefits in the Netherlands according to
diagnostic groups and age in 2000 (Source: National Institute for Social Insurance (LISV, 2001).
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also used the Nijmegen Continuous Morbidity Registrations, which have been main-
tained in the same way for some considerable time and cover a large number of diseases
and disorders. Table 2.4 includes the diseases and disorders that have exhibited the
greatest changes in the past ten years in terms of an absolute increase or decrease. A
number of readily explainable developments in the pattern of disease are given below.
As well as diseases exhibiting large, absolute changes some diseases have increased or
decreased sharply in percentage terms, and they are usually the less frequently occurring
ones, which tends to mask the changes. Some examples are prostate cancer (60%
increase) and basal cell carcinoma (55% increase). Sometimes, marked changes are also
visible within certain age groups or for certain diagnoses within a disease group. One
example is acute bronchiolitis in children from birth to four years of age (an almost
300% increase in the number of hospital admissions between 1992 and 1999). More
information on trends in certain age groups or for specific diagnoses within disease
groups can be found in the National Compass on Public Health. The description of the
trends also mentions aspects of lifestyle, care and prevention, which are covered in
greater detail in sections 2.2 and 2.3.
Health problems aggravated by changing behaviour
The increase in health problems in the Netherlands is partly the consequence of chang-
ing behaviour, a clear example of which is the increasing mortality from lung cancer
among women. This trend reflects the developments in smoking habits of women in the
1970s. The same is true of COPD, a chronic obstruction of the respiratory tract, and
another major cause of death: the fact that women started to smoke more in the past led
to a marked increase in the prevalence and mortality figures in the 1990s. This also part-
ly explains the unfavourable trend in the life expectancy of Dutch women in comparison
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Table 2.4: Ranking of diseases in the Netherlands on the basis of the largest, statistically significant,
changes in the period from 1990 to 2000.a
Prevalence Incidence Mortality
Fastest increase Asthma (m,f) b Cystitis (f) Pneumonia (m,f)
Cataract (m,f) Domestic accidents (m/f) Lung cancer (f)
Diabetes mellitus (m) Depression (f) COPD (f)
COPD (f) Diabetes mellitus (f) Oesophageal cancer (m)
Osteoporosis (f) Anxiety disorders (m,f) Sepsis (m,f)
Fastest decline Neck and back problems (m) Upper respiratory tract Coronary heart disease (m,f)
infections (m)
Congenital abnormalities Gastrointestinal tract Lung cancer (m)
cardiovascular system (m/f) infections (m) Stroke (m,f)
Parkinson’s disease (f) Sports injuries (m/f) Stomach cancer (m,f)
Gastric ulcer (f) Lung cancer (m) AIDS (m)
Stomach cancer (m,f)
a) the results were obtained using linear regression analysis on age-corrected data for the incidence, prevalence and mor-
tality of the 53 disease (groups) selected for PHSF. The diseases with the sharpest rise or fall are at the top.
b) m=men; f=women; m/f=figure only available for the total of men and women.
with other European countries (figure 2.3). Another effect of changing behaviour, but in
a completely different area, has been the increasing number of domestic accidents
(‘injuries in and around the house’). Domestic accidents are now high in the top five dis-
orders with the highest incidence. The increase is probably attributable to the fact that
people have more leisure time, which they use for ever more active pursuits. The num-
ber of healthy, active elderly people is also increasing. It goes without saying that
besides the undesirable effects mentioned here, physical activity also has many
favourable effects on health (see section 2.2).
Favourable developments attributable to changes in behaviour and 
prevention
However, changing behaviour can also lead to positive developments for health. For
instance, the incidence of and mortality from lung cancer is decreasing rapidly, as a
result of the fact that men are smoking less. This decline in mortality started in the early
1980s. The sharp decrease in the number of sports injuries, as recorded by hospital
emergency departments, is also connected with changes in behaviour. Among the possi-
ble explanations are the declining frequency of sport participation (the percentage of
those who participate in sports who do so each week) and the growing popularity of
individual, unorganized sports such as swimming, cycling and walking, which are asso-
ciated with a smaller probability of injury than organized team sports.
Furthermore, the number of cases of mortality from stomach cancer has been declining
for several decades. This is probably connected with the replacement of pickling as a
means of preserving food in favour of refrigeration in the second half of the twentieth
century, in view of the fact that the previously high salt intake would have increased the
chance of stomach cancer. Moreover, Helicobacter pylori, a bacterium that is involved
in the development of stomach cancer, is becoming less common. Finally, there is also a
visible decline in the number of children being born with a congenital abnormality of
the cardiovascular system. It is plausible that the increasing use of folic acid and, to a
smaller extent, prenatal investigation (followed by termination of pregnancy) have also
made a contribution. The intake of folic acid prevents not only neural tube defects, but
also abnormalities of the cardiovascular system (Cornel et al., 2002).
The declining mortality from major causes of death through improved
treatment
Another favourable trend is the declining mortality through improved treatment. For
instance, the mortality from coronary heart disease, the most significant cause of death
in the Netherlands, has decreased sharply. The mortality from myocardial infarction has
shown a particularly marked decrease. Alongside a more healthy lifestyle, improved
care plays an important role: both the treatment of hypercholesterolemia and high blood
pressure, and hospital care have improved. The marked decrease in mortality from
stroke is also attributable to the above mentioned factors. A striking new development
since 1996 is that the number of hospital admissions for the chronic forms of coronary
heart disease, such as old myocardial infarction, angina pectoris and chronic heart fail-
ure, appear to have stopped increasing. In the past, this increase had existed as a side-
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effect of the improved survival rates from myocardial infarction. Finally, the incidence
of and mortality from AIDS are also declining, which is attributable to a combination of
antiviral agents that have been in general use since 1996. As a result, HIV infection
leads less frequently or much later to AIDS. The number of HIV infections is probably
not decreasing, although no satisfactory registrations are kept. This suspicion is based
on the finding that the number of cases of sexually transmitted diseases (STD) increased
sharply in 2001 compared with 2000 (Van de Laar et al., 2001).
Some trends reflect changes in diagnostics and demand for care
Certain diseases appear to show a trend, while in reality the increase or decrease must be
attributed to changes in diagnostics and demand for care. Anxiety disorders and depres-
sion, which are common and sometimes major disorders, have been recorded more fre-
quently by general practitioners in recent years. It is unlikely that any ‘real’ increase
(trend) is involved here. Other factors whose relevance is beyond doubt are the
improved ability of general practitioners to recognize the disorders, the enhanced thera-
peutic possibilities and the introduction of standards. Currently, it is often the case that
those with mental problems also seek professional help at an earlier stage. The sharp
increase in diabetes mellitus is also partly attributable to an increased alertness to symp-
toms on the part of general practitioners and patients themselves. On the other hand,
there has been a decrease in the number of hospital admissions for diabetes mellitus.
Complications associated with diabetes mellitus apparently occur less often, possibly
because of better treatment in primary health care and outpatient clinics. The sharp
decrease in the number of recorded upper respiratory tract infections (especially the
common cold and acute nasal sinusitis) ultimately reflects only a change in the demand
for care, and not a true decrease in incidence. The decreasing demand for care is con-
nected with the fact that the costs of certain pharmaceuticals, such as nose drops, have
not been covered by insurance since 1994 (Van de Lisdonk et al., 1999).
Mortality from lung cancer in the Netherlands is high in comparison with
other EU countries
Besides comparisons based on time, comparisons between countries are also relevant.
How does the mortality in the Netherlands compare with that in other countries? For
two of the three major causes of death in the Netherlands, the average mortality rate is
approximately equal to the European Union average (in the case of heart disease) or
below it (in the case of stroke). However, the mortality from lung cancer among Dutch
men is the highest in the European Union, especially among elderly men. Indeed, the
mortality from lung cancer among Dutch men older than seventy is three to four times
as high as among Swedish men of the same age (figure 2.8) (Van der Wilk et al., 2001).
In all countries, mortality from lung cancer among women is much lower than it is
among men, and it shows marked variation - by a factor of five - within the EU. Danish
women have the highest and Spanish and Portuguese women the lowest mortality from
lung cancer. The mortality from lung cancer among Dutch women is moving relentlessly
towards the highest rate, having already exceeded the EU average. This partly explains
the stagnating life expectancy among women in the Netherlands (see also section 2.1.1).
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Mortality from breast cancer among Dutch women is relatively high
Breast cancer is a major cause of death among Dutch women. The mortality from breast
cancer among Dutch women is one of the highest in the EU. Spanish and Greek women
have the lowest mortality from breast cancer. As well as Dutch women, Belgian, Dan-
ish, Irish and British women also have a high mortality from breast cancer (figure 2.9).
The difference between the highest and lowest mortality is almost a factor of two, which
suggests that the potential health gain is considerable. However, the related risk factors
would need to be better known and accessible for the purpose of prevention. Currently,
however, breast cancer screening would appear to be the only way of reducing mortali-
ty. A number of countries have recently experienced a stabilization or a slightly declin-
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Figure 2.8: Lung cancer mortality for men in 1996; EU average (EU-15) and selected EU coun-
tries (Source: Eurostat, New Cronos 2001, data processed by RIVM).
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Figure 2.9: Trends in standardised breast cancer mortality over the period 1970-1999, EU aver-
age (EU-15) and selected EU countries (Source: WHO-HFA, 2002).
ing trend in mortality from breast cancer, which is attributed to the effects of breast can-
cer screening. For instance, the recent decline in mortality from breast cancer in Sweden
has been most marked in those regions that were the first to introduce breast cancer
screening (Persson et al., 2001).
Mortality from traffic accidents in the Netherlands is low, and is 
continuing to decline
The Netherlands is one of the top three countries in Europe in terms of traffic safety,
being bettered only by the United Kingdom and Sweden, which have slightly lower traf-
fic-related mortalities. The traffic-related mortality in France and Belgium is approxi-
mately twice as high. The number of traffic fatalities has declined relatively slowly in
the Netherlands since 1989, falling by 27% between 1989 and 1998, whereas there were
larger decreases in Finland (46%), Sweden (40%) and the United Kingdom (36%)
(Eurostat, 2000). The relatively modest decrease in mortality from traffic accidents in
the Netherlands is possibly attributable to the numerous traffic safety measures imple-
mented in the years prior to 1985. Some examples of the measures involved are the law
against driving while intoxicated, the introduction of speed limits, the mandatory use of
seat belts, 30 km/hour zones and the separation of fast and slow traffic categories
(motorway building). In other countries, such measures were chiefly undertaken after
1985 (Davidse, 1999).
The burden of chronic disease in the Netherlands is probably relatively
low
In addition to mortality rates, incidence and prevalence figures to facilitate international
comparisons are also available. However, a summary of international comparative stud-
ies on the incidence and prevalence rates of major diseases goes beyond the scope of
this report. The international differences per disease are covered in the National Com-
pass on Public Health. In general, the international incidence and prevalence patterns of
diseases that are also major causes of death (cardiovascular diseases, stroke, cancer)
show the same picture as mortality. There is little or no good, internationally compara-
ble data on diseases that are less often recorded as a cause of death, such as asthma,
rheumatoid arthritis and diabetes mellitus. We restrict ourselves here to concluding that
the burden of chronic diseases, which occur chiefly at an advanced age, will be relative-
ly low in the Netherlands because of the relatively modest ageing of the population (text
block 2.8).
Large regional differences in diseases and disorders
As well as international differences, there are also differences between regions, which
are of interest because they reflect the differences in the occurrence of health-influenc-
ing factors. There are large differences between regions in the occurrence of and the
mortality from specific diseases and disorders. However, it is no simple matter to identi-
fy a clear general pattern here. Nonetheless, two general aspects can be observed in the
regional patterns. In the first place, a number of diseases occur more often in regions
where many of the residents have a low socio-economic status (SES). This is the case
not only in the major cities (deprived areas) (Van der Lucht & Verkleij, 2001), but also
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in the northeast of the Netherlands and parts of North-Brabant and Limburg. This pat-
tern could also be observed in the healthy life expectancy per municipal medical and
health service region (figure 2.4).
A second pattern that can be observed is that the occurrence of and mortality from a
given disease is higher or lower in a group of adjacent areas. One example of this effect
is the mortality from diseases of the respiratory organs (excluding lung cancer) (figure
2.11), which is higher in the east of the country and South-Limburg. We also see a clus-
tering of areas in the number of hospital admissions for chronic heart failure (East-Bra-
bant, Limburg). These patterns cannot be explained entirely by the distribution of SES
in the Netherlands. It seems that other factors are also involved here, such as regional
differences in socio-cultural factors, environmental factors and aspects of health care
(including hospitals’ and institutions’ admission policies, accessibility and quality).
Not all diseases are equally strongly related to socio-economic status
Many diseases and disorders exhibit a socio-economic gradient. In other words, they
occur relatively more frequently among those with a low socio-economic status than
among those towards the top of this scale. This is apparent from an investigation into
diseases in general practice (Mol et al., 2002). There is a comparable connection
between mortality and SES, but it is not the same for each cause of death (Bos et al.,
2000; Smits et al., 2001). Extreme socio-economic mortality differences among men are
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Text block 2.8: The ageing of the Dutch population has led to compartively little increase in the
burden of disease
While the percentage of elderly people in the
Netherlands has increased steadily during the
past few decades, the degree of ageing of the
population is still relatively low compared with
that in other countries of the European Union (fig-
ure 2.10). The percentage of the population aged
more than 65 years in the Netherlands (13.5% in
1998) is lower than that in any other EU country
with the exception of Ireland. Sweden and Italy
show the most ageing of all EU countries (more
than 17% aged 65+). Because the prevalence of
most chronic diseases is much higher in the 65+
age group than in younger sectors of the popula-
tion, demographic changes can lead to large dif-
ferences in the numbers of cases of chronic dis-
ease (per 100,000 head of population). This is
true of such diseases as rheumatoid arthritis,
dementia, COPD, diabetes mellitus, cardiovascu-
lar diseases and various forms of cancer. The bur-
den of disease and the cost of care will therefore
be strongly determined by demographic trends in
all countries in the future (see also sections 3.2
and 3.5). 
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Figure 2.10: Trends in ageing (percentage of
population over 65 years of age) in selected
EU countries over the period 1980-1998
(Source: WHO-HFA, 2002).
visible, for example, in diseases of the digestive organs (figure 2.12). Among women,
there are large differences in mortality from diseases of the blood, haematopoietic
organs and immune disorders. Within the neoplasm category, the greatest mortality dif-
ferences according to SES are for stomach cancer and neoplasms of the trachea and
lung. Large mortality differences are also evident in diabetes mellitus, myocardial
infarction and chronic heart failure (especially for men) (Smits et al., 2001).
2.1.3 Finally: the provision of information has improved,
but is still not as good as it could be
We are dependent on the data available on the state of health of the Dutch population.
The Netherlands has a wide variety of registrations, surveys and other, usually one-off,
studies that yield data on the health status of the population. The provision of informa-
tion has improved in a number of respects in recent years, and initiatives have been
taken to achieve further improvement. However, a number of significant obstacles
remain.
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Figure 2.11: Regional distribution of two health indicators in the Netherlands after correction
for age and sex (Sources: CBS cause-of-death statistics and LMR; data processed by RIVM).
To start with, data on health and life expectancy is based chiefly on Statistics Nether-
lands (CBS) mortality and health figures, which are obtained from the POLS continuous
health and labour survey. The associated problem areas are the low response and the
under representation of ethnic minority groups. Furthermore, the survey was modified
in 2001, which will give rise to discontinuities in trends. Otherwise, the survey was
improved in a number of important respects, including in the area of questions on the
quality of life.
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Figure 2.12: Association between socio-economic status in Dutch areas (postal code level) and
mortality by ICD-headings. The strength of the association is given as odds ratio’s with the high-
est social status as reference point (Source: Smits et al., 2001).
Secondly: data on the incidence of diseases and disorders was obtained from various
epidemiological studies and care registrations, such as the Second Dutch National Sur-
vey of General Practice into diseases and interventions. However, one major problem
area is that there is still a lack of insight into epidemiological trends. For several dis-
eases (such as neoplasms and a few infectious diseases) national, continuous and valid
databases do exist, but for many diseases they do not. This PHSF again makes extensive
use of a single set of general practice registrations: the Nijmegen Continuous Morbidity
registrations, which are, however, limited in scale and regional in character. In the near
future, considerable progress could be made in this area with relatively modest
resources, by maintaining and continuing the existing infrastructure (the National Infor-
mation Network for Primary Health care, LINH), which was expanded (on a one-off
basis) for the purpose of the Second Dutch National Survey of General Practice. This
will make it possible to establish, within approximately five years, which diseases and
disorders have increased or decreased in scale. Furthermore, there is also a lack of data
on trends in mental disorders, and on mental disorders among young people and mem-
bers of ethnic minorities. This situation could be changed by conducting a follow-up to
NEMESIS.
Thirdly, the calculation of years lived with disability (YLD) and disability-adjusted life-
years (DALY) requires information on the severity of diseases or on the distribution of
the stages (of severity) within diseases, which is absent in almost all registrations. Ideal-
ly, the severity or the quality of life would be recorded as standard for the chronically ill.
An alternative would be to link data on quality of life (as a measure of the severity) with
data on diseases, and initiatives have already been taken in this direction.
A fourth problem area is that in measuring regional differences in health we now have to
rely mainly on data on mortality, hospital admissions and self-reported health (POLS
health and labour). The Local and National Monitor (an initiative of the Municipal Med-
ical and Health Service in the Netherlands (GGD-Nederland), and the National Institute
of Public Health and the Environment (RIVM)) will supply additional, more detailed,
information in the future. We are gaining a deeper insight into socio-economic health
differences. However, it should become so natural to measure socio-economic status in
registrations, including mortality registrations, that we gain more insight into the devel-
opment of the differences in the future. In the meantime, some initiatives have been
taken to set up linking projects, in which existing registrations are enriched with SES
data on an individual level.
Finally, there is almost no information on the mortality and health of ethnic minority
groups, and this is especially so for the elderly among ethnic minorities. This informa-
tion is not recorded systematically anywhere.
Policymakers increasingly stress the value of international benchmarks of health indica-
tors. However, many more improvements are still required in the availability, the quali-
ty and the comparability of international health data if this is to be achieved, for exam-
ple by harmonizing databases. Although the WHO, OECD and Eurostat (European
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Union) have been active in this area for many years and have achieved a great deal,
many countries are still not putting sufficient effort into reporting their data as com-
pletely as possible to these organizations.
2.2 What factors determine our health?
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Hardly any favourable developments in lifestyle and personal risk factors
The number of Dutch people who smoke, drink too much, take too little exercise and
eat unhealthy food, remains disturbingly high. Attributes related to unhealthy behav-
iour such as overweight and high blood pressure are becoming more frequent. The
only favourable development is in the consumption of saturated fats and the associat-
ed high total serum cholesterol level. The unfavourable developments generally apply
equally to young people. In spite of the focus on this group in recent years in terms of
health policy, young people have taken up smoking and drinking and are indulging in
unsafe sex at an increasing rate. Furthermore, the number of overweight young people
is increasing. In contrast, there are a number of favourable trends that can be observed
in lifestyle factors of the elderly.
Like health itself, unhealthy behaviour is also unevenly distributed in the Netherlands
Unhealthy behaviour is more prevalent among groups low on the socio-economic scale,
who are more likely to smoke, drink heavily, and have an unhealthy dietary pattern, in
addition to taking less exercise than the average Dutch person. Furthermore, more
women in low socio-economic groups have taken up smoking in recent years, while in
the total population the percentage of female smokers has remained almost
unchanged. The picture for ethnic minority groups is much more varied; they eat and
drink less than average, but do less well in terms of drug use, safe sex and sporting
activities. Finally, there are also regional differences in healthy behaviour, which often,
but not always, reflect regional socio-economic differences in the Netherlands.
Within the EU, the Netherlands achieves a poor score in terms of smoking and drinking
and a good one in terms of exercise
Compared with the other EU countries, the Netherlands achieves a poor score in terms
of smoking and heavy drinking. The Netherlands does do well in terms of exercise. The
Netherlands is also among the European countries where serious overweight is some-
what less common, but in terms of moderate overweight, the Netherlands is in the mid-
dle bracket. In general, it would appear that differences in lifestyle between EU coun-
tries are becoming smaller, which is most clearly visible in dietary patterns and alcohol
use.
It is chiefly lifestyle factors that contribute to ill health, but environmental factors are
also involved
Smoking is still the major determinant of disease and mortality in the Netherlands and
a major cause of the stagnating extension in life expectancy among women. Almost
15% of all deaths are attributable to this cause. However, other lifestyle factors and
personal risk factors also make a considerable contribution to mortality, with high
blood pressure, serious overweight and too little exercise each adding about 6%. An
From health to determinants of health
Section 2.1 discussed the state of health in the Netherlands. The question that remains is
which factors - or determinants - determine our health? How important is a healthy
lifestyle compared with factors that play a role in an individual’s environment? Are
there any differences between population groups and regions in the Netherlands with
regard to the incidence of determinants? How do we compare with other EU countries?
What contribution do determinants make to health problems and is there anything to be
said about the contribution to the cost of health care? In this section we answer all these
questions, structured according to the determinant groups from the PHSF conceptual
model (see text block 2.9). The objective is to gain the best possible insight into the fac-
tors that determine our health.
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unhealthy lifestyle also accounts for much loss of quality of life, especially heavy drink-
ing and smoking, both of which contribute a loss of more than 8%, chiefly through
alcohol dependence, stroke and coronary heart disease. Finally, smoking, high blood
pressure and serious overweight are important cost items in health care. The costs
attributable to lifestyle factors and personal risk factors are between 5% and 9% of the
total expenditure on health care.
Approximately 2% to 5% of the total burden of disease in the Netherlands is attribut-
able to environmental factors, especially air pollution, noise nuisance, microbiological
food contamination and an unhealthy indoor environment.
Text block 2.9: The relationships between the various determinants of health
The conceptual model of the PHSF, worked out for
the determinants in figure 2.13, distinguishes
three clusters of factors. The first comprises per-
sonal characteristics, including genetic suscepti-
bility to certain diseases and disorders, but also
factors acquired in the course of one’s life, such
as blood pressure and body weight. Psychological
characteristics such as self-esteem and inhibi-
tions also belong in this cluster. The factors in
this cluster are influenced by the exogenous
determinants that form the second cluster. The
latter includes factors from the physical and
social environment on the one hand and lifestyle
factors on the other. The third cluster comprises
the health care and prevention system that influ-
ences the state of health, with or without interac-
tions with personal characteristics and exogenous
determinants. 
Most determinants of health are interrelated,
sometimes in a complex way. Here are a couple of
examples. The development of overweight is
determined both by genetic factors and by the bal-
ance between energy intake through the diet and
energy consumption as a result of physical activi-
ty. The amount of exercise a given individual gets
depends among other things on all kinds of envi-
ronmental factors, such as support from the
social environment and whether the individual’s
work is sedentary in nature. The spending power
(socio-economic status) of the household is also
Lifestyle
Personal factors
Health status
Determinants
Social
environment
Prevention
Exogenous determinants
Genetic
Psychological
Acquired
Healthcare
(somatic)
Physical
environment 
Health protection
Disease prevention
Healthcare
(mental)
Health promotion
Healthcare and prevention
Health policy
Figure 2.13: Conceptual model for PHSF; elabo-
rated for ‘Determinants’ (Source: Ruwaard &
Kramers, 1997).
2.2.1 We are learning ever more about health determinants 
The causes of many diseases and disorders remain unknown. Nonetheless, our knowl-
edge of health determinants is still growing (see table 2.5). In recent years, for example,
we have learned more about the major factors involved in the development of mental
disorders, such as depression. More determinants have also been established for breast
cancer. It is also becoming easier to identify the social environmental factors that con-
tribute to the creation of health problems. Future studies will have to identify the specif-
ic neighbourhood characteristics or combinations of characteristics that are responsible
for the observed health differences between neighbourhoods (see text block 2.3). Table
2.5 shows, moreover, that when diseases develop, a combination of lifestyle factors,
personal risk factors and environmental factors is often involved.
Table 2.5 is restricted to a selection of diseases and determinants, based on the diseases
and disorders in table 2.3. Consequently, a number of diseases and related determinants
(such as drug dependence and drug use) are not included in table 2.5, because they are
not in the top five for incidence, prevalence, mortality and loss of quality of life. For
instance, other than urinary tract infections, there is no mention of the consequences of
unsafe sexual behaviour, such as sexually transmitted diseases and teenage pregnancies.
These lifestyle factors and health consequences are nonetheless covered in this section,
in view of the social importance of these determinants and the existing means of preven-
tion. Although certain diseases in turn form a risk factor for the incidence of other dis-
eases, they too are not included in table 2.5. For example, diabetes mellitus patients
have a greater risk of coronary heart disease, stroke, retinopathy and renal failure, and
those suffering from coronary heart disease have an increased risk of stroke.
Much interest in lifestyle factors and related personal risk factors
While the factors that determine our health are largely personal, such as lifestyle and
personal risk factors, others are present in the social and physical environment (see text
block 2.9). We concentrate on lifestyle factors and personal risk factors in this report
(and in this section) because these are the determinants on which health policy is able to
exercise a direct influence. The task of influencing social and physical environmental
factors belongs largely to other departments. In recent decades, however, much progress
has been made in promoting a healthy environment, one instance being the introduction
of health protection measures in the field of working conditions and environmental fac-
tors. Further health gains can still be made, mainly through influencing the behaviour of
the population or of subgroups. Besides changes on an individual level (such as changes
in knowledge and skills) behavioural change also requires supporting changes to be
made in the environment. We deal with this subject in greater detail in section 2.3.
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(continue text block 2.9)
of importance, since this determines whether one
can afford to participate in sporting activities. In
brief, personal characteristics, lifestyle and envi-
ronmental factors are closely interrelated. The
relationship between the various determinants has
received increased attention in recent years, espe-
cially because this relationship has important
implications for prevention (see text block 2.21).
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2.2.2 Determinants: variation in time and between groups,
regions and countries
Hardly any favourable developments in lifestyle and personal risk factors
Three quarters of the Dutch population eat too much saturated fat and too few vegeta-
bles and fruit, on top of which half the Dutch population takes insufficient exercise. Fur-
thermore, approximately one in three of the Dutch population smokes and approximate-
ly one in ten indulges in unsafe sex (see table 2.6). Hardly any favourable developments
have been observed in the unhealthy behaviour of the Dutch population in recent years.
In general, there has been a continuation or worsening of the situation relative to PHSF
1993 and PHSF 1997. The only exceptions in recent years have been a decrease in the
consumption of saturated fat and an increase in breastfeeding (see also text block 2.14).
The decline in saturated fat consumption is attributable not only to more healthy eating
patterns, but also to the efforts of the food industry to replace saturated and trans-satu-
rated fats with unsaturated vegetable fats in many products. Table 2.6 also shows that
men’s behaviour is generally less healthy than women’s.
The only favourable development in personal risk factors is the strong decline (by one
half) of the percentage of people with high total cholesterol. In contrast, the growth in
the numbers of overweight people is a cause for concern (see table 2.6). The percentage
of the Dutch population in the 20-60 year age range who are overweight (body mass
index ≥ 25) has increased. When the serious overweight (body mass index ≥ 30) are
considered, the percentage even almost doubled from approximately 5% in the late
1970s to approximately 9% in recent years (Sources: Morgen, 1995-1997; Regen-
boog/Doetinchem, 1998 - 2000; data processed by RIVM). Currently, four in every ten
women and five in every ten men are overweight (body mass index ≥ 25). The situation
regarding the other personal risk factors has hardly changed in recent years. The per-
centage of those with high blood pressure has increased slightly, but only among men,
and the percentage of people with a low level of the protecting HDL cholesterol has
remained the same.
There are both favourable and unfavourable developments in environmen-
tal factors
As with lifestyle factors and personal risk factors, the picture for the selected social
environmental factors is largely unfavourable (see table 2.7). It would appear, for
instance, that in 1997 more than three in every ten workers were regularly exposed to
considerable work stress, and the number increased sharply in the second half of the
1990s, stabilizing in 1998. In addition, the existence of feelings of loneliness among
large groups in society, including young adults, can be seen as a gentle hint of a defi-
ciency in social support. There is a lack of insight into how feelings of loneliness devel-
op in society.
For the selected environmental factors (see table 2.7), the following developments can
be observed. A favourable development is the decrease in air pollution (by 20% to 30%
in the past ten years) and industrial noise. The same is true to a smaller extent of traffic
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Table 2.6: Lifestyle and personal risk factors in the Netherlands: current situation (reference year) and
trends a (period).
Determinant Prevalence Trend
Men Women
Lifestyle (≥ 12 years, unless stated otherwise)
Smoking (≥ 15 years) (2000) (current smokers) 37% 29% Unfavourable, decline stagnating 
(1980-2000)
Passive smoking at work and/or home (2000) 40% 20% No information available
Physical inactivity (2001) 56% 54% Constant (1998-2001)
(moderate activity for half an hour or 
more less than five days a week)
Excessive alcohol use b (1997) 14% 2% Unfavourable, slight rise among men 
(three or more glasses a day) (1987-1995)
Heavy alcohol use (1997) 22% 6% Constant
(six glasses or more at least once a week)
Teetotallers (1998) 19% 45% No information available
(zero glasses of alcohol a day)
Drug use c (2001) Unfavourable indication: slight rise 
• soft drugs: cannabis 17% 17% (1997-2001)
• hard drugs d 5% 5%
Sexual behaviour (15-35 years; 2001) No clear trend
(condom use with casual partners)
• sometimes 24% 42%
• never 16% 8%
Insufficient vegetables (1998) 78% 80% Unfavourable, slight rise (1988-1998)
(< 200 grams/day)
Insufficient fruit (juice) (1998) 76% 68% Unfavourable, slight rise (1988-1998)
(< 200 grams/day)
Too much saturated fat (1998)
(> 10 energy per cent) 92% 92% Favourable, slight rise (1988-1998)
Being breastfed (2000) Favourable, rise (1996-2000)
• at birth 75% 75%
• after three months 32% 32%
Personal risk factors (20-60 years) e 
Overweight (1998-2000) Unfavourable trend (1987-1997)
• total (BMI ≥ 25) 48% 36% Rise
• moderate (BMI 25-30) 40% 27% Slight rise
• serious (BMI ≥ 30) 9% 9% Rise
High total cholesterol (1998-2000)
(≥ 6.5 mmol/l) 14% 11% Favourable, sharp fall (1987-1997)
Reduced HDL cholesterol (1998-2000) 19% 4% Constant (1987-1997)
(≥ 6.5 mmol/l)
High blood pressure (1998-2000) 13% 12% Unfavourable for men, slight rise;
(>160/95 mmHg) constant among women
a) for additional information on the prevalence of the determinants and the sources used, please refer to the National Com-
pass on Public Health.
b) alcohol use per capita: eight litres at 100% (2000), stable since the 1990s. Shift in type of drink: more wine, less spirits;
beer consumption unchanged (PGD, 2001).
c) estimates on the basis of surveys in several municipalities with varying urbanization (Abraham et al., 1999).
d) the following hard drugs were considered: cocaine, amphetamines, ecstasy (XTC), hallucinogens (excluding psilocybin
mushrooms), heroin.
e) the source of most recent prevalence figures is ‘Regenboog/Doetinchem, 1998-2000’ and the source of the trend figures
is ‘Morgen, 1987-1997’; data processed by RIVM.
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Table 2.7: Environmental factors in the Netherlands: current situation (reference year) and trends a (period).
Environmental factors Scale of the problem b Trend b
Physical environment
Air pollution (1997) For four out of five residents of the Favourable: average annual
(particulate matter as Netherlands the exposure to particulate concentration of particulate matter
indicator) matter is higher than the standard (140 µg/m3)has fallen (early 1990s-1997) 
Ozone (1997) Number of days with more than the standard No clear trend
8-hour average (110 µg/m3): 18 days
UV radiation(1999) Risk groups with an exposure two to three Unfavourable: UV exposure 6% to
times higher than average: patients under- 7% up (1980-1999)
going UV therapy, sunbed users, outside
workers, sunbathers 
Noise from traffic and Percentage of residents of the Netherlands (1987-1998)
industry (1998) reporting serious nuisance
• road traffic: approximately 27% Almost constant for road traffic
• air traffic: approximately 13% Fairly constant for air traffic
• industry: approximately 5% Favourable: decrease for industry
It is estimated that 11% of residents of the 
Netherlands experience serious nuisance 
from sleep disturbance from traffic and
industrial noise
Noisy neighbours (1998) Indicators for the percentage of people that Nearly constant (1987-1998)
are exposed to excessive noise from their 
neighbours
• approximately 22% of residents of the 
Netherlands report serious nuisance
• approximately 7.5% of adults experience 
serious nuisance through sleep disturbance  
from noisy neighbours
Noise at work (1995) One in five workers in industry and the No information available
building trade is exposed to a noise level that 
may lead to high frequency hearing damage
Pop music (1998-2001) • 2.5% of 25 to 30-year-old men have a No information available
9-10 dB (at 6,000 Hz) hearing loss through 
exposure to music at concerts/discotheques)
• 6.2% of men and women have a 3 dB 
(at 4,000-6,000 Hz) high frequency hearing 
damage through exposure to pop music via 
headphones
Faecal contamination of The contamination in one in three recreation Constant (1993-1995)
fresh swimming water areas with fresh swimming water is above the
in recreation areas gastrointestinal infection increased risk 
(1995) threshold (average concentration higher than 
100/100 mL)
Fungus, dust mite (1997) the exposure to fungus/dust mite is relatively Unfavourable: rise
high in one in five houses because of 
problems  with damp
Radon (1998) Average radon value for the entire housing Unfavourable: rise (50% more
stock: 23 Bq/m3 radon in dwellings in 2000 relative 
to 1987)
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and aircraft noise, which is remarkable, because the most important culprit, traffic, has
increased considerably in the same period. On the other hand, an unfavourable develop-
ment is the increasing pollution of swimming water in recreational areas. The increasing
UV radiation as a result of the damaged ozone layer is also forming a health risk, espe-
cially for those who are exposed to sunlight relatively often, such as outdoor workers
and sunbathers (with two to three times the average UV exposure). For some other envi-
ronmental factors (see table 2.7), the situation is reasonably stable (RIVM, 2002). The
increase in the number of houses with damp problems is unfavourable for the indoor cli-
mate, because it is associated with a relatively high exposure to fungus and dust mites.
The quality of the urban living and working environment can still cause local problems
in connection with the enormous pressure on the limited available space, which has to
be shared among transport, industrial, recreational and residential functions. This causes
a succession of unfavourable factors such as noise, odour, an unhealthy indoor climate,
and particularly an increased risk of disasters involving hazardous substances, explo-
sions, or road, rail and aircraft accidents (computed, or perceived by the public).
An increasing number of young people are indulging in unhealthy 
behaviour
The previous sections presented the determinants for the total population. However,
considerable differences in determinants exist between population groups. For instance,
there is still much unhealthy behaviour, particularly among young people, in spite of the
attention devoted to this group in recent years. This is true, among other things, of
smoking (44% of 15 to 19 year-olds), the consumption of five or more glasses of alco-
hol the last time they went out (39% of secondary school students) and unsafe sex (6%-
9% of secondary school students). Otherwise, there has been an unfavourable trend in
almost all lifestyle factors in the past ten years, with the use of cannabis, for example,
increasing by approximately 30%. The increase occurred mainly in the early 1990s,
with a stabilization appearing to set in during the second part of the 1990s (see table
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(continue table 2.7)
Environmental factors Scale of the problem b Trend b
Social environment
Work stress in work Percentage of employees that are regularly/ Unfavourable: first rise (until 1997)
environment (2000) usually troubled by: Then stabilizing (1997-2000),
• high rate of work: 40% except in the care sector and 
• high time pressure: 35% education  
Perceived loneliness No information available
(1999)
- young adults • 18-24 year old men and women
(19 and 34% respectively)
- adult population • 27% of adults (≥ 18 years)
a) for additional information on the prevalence of determinants and the sources used, please refer to the National Compass
on Public Health.
b) where possible an indication is given of how many people have been exposed, but most often indicators of exposure are
stated (e.g. how many people report serious nuisance, how many locations have a relatively high exposure).
2.8). From an international viewpoint too, the picture of Dutch young people is
unfavourable. The Netherlands occupies sixth position within the EU, with 36% of 15
and 16-year-olds smoking. The highest prevalence of smoking in this age group is in
France (44%). In the United States, conversely, the percentage of young people of this
age who smoke is ‘only’ 17% (Hibell et al., 2000). In the 1990s, smoking increased
among young Europeans (Joossens, 1999). Dutch young people also stand out in alco-
hol use. The percentage of 15 and 16-year-old school students who had consumed alco-
hol ten times or more in the previous month is higher in the Netherlands than in other
European countries (Hibell et al., 2000). As well as unfavourable developments in
healthy behaviour, more young people are becoming overweight (text block 2.10).
The elderly provide good news about healthy behaviour
Unlike young people, behaviour among the elderly is actually more favourable in some
respects than that of the total Dutch population, with the exception of physical exercise
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Text block 2.10: Overweight in young people
An increasing number of young people in the age
range from 3 to 21 years are suffering from over-
weight (body mass index ≥ 25) (Cole & Roede,
1999; Fredriks et al., 2000b). Overweight children
are often stigmatized and are thus also often
plagued by social problems. Moreover, individuals
who were overweight as children are often over-
weight as adults too (Kemper et al., 1999). These
adults are subject to an increased risk of diabetes
mellitus and cardiovascular disease. There are
further indications that the duration of the over-
weight represents an additional risk e.g. of devel-
oping type-2 diabetes mellitus. As a result, over-
weight children may be subject to an increased
risk of developing this disease. 
In 1997, the percentage of overweight children in
the Netherlands varies between 7 and 16%,
depending on age. The prevalence of severe over-
weight (body mass index ≥ 30) varied between
0.5 and 1.6% in boys and between 0.7 and 2.7%
in girls (figure 2.14). The frequency of overweight
also varied strongly from one ethnic group to
another. Children of Turkish and Moroccan origin
have been found to be overweight more often than
children of Dutch origin (Brugman et al., 1995a).
The problem of overweight in children is also
becoming more serious in other European coun-
tries, such as the United Kingdom (Rudolf et al.,
2001). Overweight in children is assuming epi-
demic proportions in America, where it has led to
an increase in the number of new cases of type-2
diabetes mellitus in children (Sinha et al., 2002).
There is reasonable consensus about the impor-
tant role played by good eating habits and exer-
cise in the prevention of overweight. Energy
intake must be adapted to match energy con-
sumption or vice versa, or a combination of these
two measures must be adopted. This must be
taken into account in advisory campaigns aimed
at preventing overweight
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Figure 2.14: Percentage young Dutch people
with serious overweight (body mass index
≥ 30) in 1980 and 1997 by sex and age
(Sources: National Growth Studies (Cole &
Roede,1999; Fredriks et al., 2000a, b)).
and the intake of (saturated) fat (see table 2.8). Furthermore, the behaviour of the elder-
ly has become more healthy in the past ten years.
Conversely, the incidence of overweight, high total cholesterol and high blood pressure
is less favourable among the elderly, partly as a consequence of their more advanced
age. The incidence of overweight and high total cholesterol increases in line with age
until about age 60 for men and 70 for women, after which the percentages decrease,
although they remain substantial: approximately 52% of men above 60 and 40% of
women above 70 are overweight and 15% of men and 27% of women have high total
cholesterol. The incidence of high blood pressure rises (sharply) with age up to approxi-
mately 45% for 60 to 70-year-old men and women and approximately 58% for those
above 70 (Sources: Regenboog and Doetinchem, 1998-2000; data processed by RIVM). 
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Table 2.8: The current situation in healthy behaviour among four specific groups in the Netherlands (in com-
parison with the general population) and the trend in this behaviour in the past decade a (Source: Jansen et
al., 2002).
Determinant Young people The elderly Low SES Ethnic minorities
Smoking
Current Somewhat more More favourable Much less More
favourable favourable favourable b
Trend Unfavourable No change Men: favourable Unknown
Women: unfavourable
Low vegetable and 
fruit consumption
Current Somewhat less More favourable Less favourable More favourable
favourable
Trend Unfavourable Favourable/ Unknown Unknown
unfavourable d
High (saturated) fat intake
Current Somewhat more Somewhat less Less favourable More favourable
favourable favourable
Trend Favourable Favourable Unknown Unknown
Physical inactivity
Current More favourable Less favourable Less favourable Less favourable
Trend No change Favourable No change Unfavourable c
Excessive alcohol use
Current Somewhat more More favourable Unchanged More favourable
favourable
Trend Very unfavourable No change Unfavourable Unknown
Drug use
Current Much less Unknown Unknown
favourable
Trend Unfavourable Unknown Unknown
Unsafe sex
Current Less favourable Less favourable Less favourable
Trend Unfavourable Unknown Unknown
a) when the current situation is judged to be more favourable, this is in comparison with the general population. Nonethe-
less, there could still be an element of an undesirably high level of unhealthy behaviour.
b) varies from one ethnic group to another (sometimes actually less favourable than the total population).
c) based on data on participation in sport.
d) vegetables favourable trend, fruit unfavourable trend.
Finally, the elderly have an unfavourable score for one of the social environmental fac-
tors, namely ‘social support’, measured on the basis of self-experienced loneliness,
which suggests a lack of social support. Approximately one in three elderly men and one
in two elderly women say they have occasionally felt lonely or abandoned, compared
with one in four adults of 18 years and over (Source: POLS health and labour, 1999;
data processed by RIVM).
Lower socio-economic groups achieve a poorer score on major health
determinants
We saw in section 2.1 that people with a low socio-economic status (SES) have a poorer
state of health. We observe the same picture for health determinants: people with a low
socio-economic status (mostly measured according to educational level) exhibit
unhealthy behaviour the most frequently (Jansen et al., 2002). For instance, almost half
of all men in the lowest SES group smoke (compared with 37% in the total male popu-
lation) and the percentage of this group that drink heavily is approximately 14%, com-
pared with 9% in the highest SES group. A number of other lifestyle factors are also less
favourable among the lowest SES group: physical inactivity and the intake of saturated
fat. Accordingly, those with a low SES more often have an unfavourable score for sever-
al lifestyle factors simultaneously.
Furthermore, serious overweight and a low level of protective HDL cholesterol occur
approximately twice as often among those with a low SES than in those at the upper end
of this scale (Sources: Regenboog and Doetinchem, 1998-2000; data processed by
RIVM). Finally, from 1995 to 1997, high blood pressure occurred more often in the low
SES class (11.5%) than in the intermediate (5.8%) and high classes (4.3%).
Growing inequality in health determinants between socio-economic
groups
Trend data for the lower SES groups exist only for smoking, excessive alcohol use and
overweight. While the percentage of smokers in the total population has remained the
same or has declined slightly in the past ten years, during the second half of the 1990s in
particular there was an increase in the prevalence of smoking among women in the
lower SES groups. This increase led to greater socio-economic differences in smoking
behaviour among women. Conversely, the socio-economic differences in excessive
alcohol use have become smaller in recent years, although this is based on an
unfavourable development. The fact is that, over the past ten years, there has been hard-
ly any change in the incidence of excessive alcohol use in the low SES group (Koning-
Dalstra et al., 2000), whereas it has actually risen in the higher SES groups.
The situation with regard to overweight in the low SES group is also unfavourable. The
rising trend in serious overweight is especially pronounced for men with a low SES.
According to recent data for the period from 1998 to 2000, the SES difference in high
blood pressure appears to be declining (Van Leest et al., 2002).
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The picture among members of ethnic minorities is variable
The picture of the risk factors among members of ethnic minorities is clearly different
on a number of points from that of indigenous Dutch people. Some lifestyle factors are
more favourable for the members of ethnic minorities (nutrition, smoking, excessive
alcohol use) while others are less favourable (drug use, safe sex, participation in sport)
relative to people of indigenous origin (see table 2.8 and text block 2.11). There are also
significant differences between different ethnic groups. An accumulation of unhealthy
living habits is especially common among Turkish men over 35 years of age. On the
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Text block 2.11: Unsafe sex: consequences for health and trends
Health consequences of unsafe sex 
Sexual behaviour can influence health in a number
of ways. Here we will only consider the adverse
effects of unsafe sex. Unprotected sexual contact
(intercourse without a condom) increases the risk
of urinary tract infections and sexually transmit-
ted diseases (STD). Moreover, unprotected sexual
contact without any other form of contraception
increases the risk of unwanted pregnancies. 
It has recently been found that STD is once again
on the increase in the Netherlands. The number of
cases diagnosed by municipal medical and health
services and two outpatient clinics in 2001 was
up by about a fifth compared with 2000 (Van de
Laar et al., 2002). This disturbing development
indicates a rise in unsafe sex. 
The numbers of teenage pregnancies and abor-
tions provide an indication of the number of
unwanted pregnancies. Since it is more generally
acceptable in some cultures to get married and
have children young, however, the number of
teenage pregnancies might lead to overestimation
of the number of unwanted pregnancies. The
number of abortions, on the other hand, leads to
underestimation of this variable since not all
unwanted pregnancies lead to abortion. Both the
number of teenage pregnancies and the number
of abortions in the Netherlands have risen in
recent years. The number of teenage mothers has
risen from somewhat more than 2,500 in the mid-
nineties to 3,300 in 2000, of which 73% were
unmarried. The number of abortions per thousand
women of child-bearing age was 5.2 in 1990, and
had risen to 8.0 by 2000. The abortion rate among
women from ethnic minorities is from three to ten
times higher, depending on the country of origin,
than that among women of Dutch origin. The fig-
ure is highest among Antillean women, viz. 86.8.
The main reason for these trends is that the group
at greatest risk of unwanted pregnancies and
abortions in the Netherlands, viz. teenagers and
adult women from ethnic minorities, is increasing
(Garssen & Sprangers, 2001). 
Despite the above-mentioned unfavourable devel-
opments, the abortion rate in the Netherlands is
still low compared with other countries. The fig-
ures in Germany and Belgium are comparable, but
in the rest of Western Europe and America the
abortion rate is two to three times higher (Rade-
makers, 2002). 
Trends in sexual behaviour
The above-mentioned increase in the number of
teenage mothers and abortions indicates less
effective use of contraceptives. This indication is
underlined by the drop in the number of steriliza-
tions and the growing number of women who are
not using any form of contraception (Rademak-
ers, 2002). NISSO (the Dutch Institute for Social
Sexological Research) has been studying safe sex
and condom use in the 15-35-year age group in
the Netherlands since 1987. Within this age
group, the percentage of individuals with varying
partners who always use condoms was lower in
2001 than in previous years (Bakker & Sandfort,
2001). The results of measurements in the com-
ing years will show whether this is a temporary
phenomenon or the start of a new trend. Contra-
ceptive behaviour (use of condoms) within a
steady relationship remained relatively constant
between 1998 and 2001. Positive trends are
observed in the knowledge about safe sex and
STD, the attitude towards condoms and towards
the undertaking of activities to avoid infection
with the AIDS virus. 
Research on a younger age group (school pupils
aged between 12 and 18) showed, however, that
their knowledge of AIDS and STD had not
changed much between 1990 and 1995. Although
their willingness to use condoms had increased,
these young people did not actually use them in
certain situations. As a result, the percentage of
school pupils practising unsafe sex increased
(Brugman et al., 1995b).
other hand, Moroccan women have a relatively healthy lifestyle (Dijkshoorn et al.,
2001).
Regarding personal risk factors, there are indications that members of ethnic minorities
have favourable scores on high total cholesterol, but unfavourable ones on high blood
pressure and overweight. According to a survey of mainly self-reported data, Turkish
people above 35 years of age are relatively frequently overweight and Turkish men are
also more likely to have high blood pressure than indigenous people of the same age.
There were also many overweight Moroccans, especially women. The overweight per-
centage increases with age, rising for Moroccan women to approximately 90%. Moroc-
can men likewise had high blood pressure relatively commonly. Surinamese and Antil-
leans were likewise overweight and had high blood pressure more often than indigenous
Dutch people, here too especially among women (Van Leest et al., 2002).
Regional differences in the incidence of determinants
Healthy and unhealthy ways of living are not uniformly distributed in the Netherlands.
For instance, the percentage of smokers (corrected for age and sex) per region varies
from 27% to 41% (see text block 2.12). With the exception of Groningen, the southern
part of South-Limburg and Eindhoven, the percentage of smokers has increased, espe-
cially in the major cities. This spread is in line with the distribution of socio-economic
status in the Netherlands (see also section 2.1.1: regional differences in healthy life
expectancy). A greater proportion of people with a low socio-economic status live in the
major cities and in the northeast of the Netherlands than elsewhere, which may explain
the higher percentages of smokers. However, this overrepresentation of low socio-eco-
nomic groups in a region has not led as a matter of course to more unhealthy behaviour
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Text block 2.12: More smokers in big cities
The percentage of smokers is above average
(35%) in the four big cities (Amsterdam, Rotter-
dam, The Hague and Utrecht) (see figure 2.15).
There are also more smokers in Groningen, Eind-
hoven and southern South-Limburg. Of these
regions, southern South-Limburg has the highest
percentage of smokers (41.4%). The regions with
a lower percentage of smokers are situated mainly
in the middle and the (south-)west of the country.
There is also an area in the provinces of Drenthe
and Limburg where fewer smokers are found. The
lowest percentage of smokers (26.8%) is found in
the Midden-Holland region. 
Figure 2.15: Smoking: percentage of the Dutch
population (16 years and older) that smoke in the
period 1995-1999, corrected for age and sex by
GGD-region (Source: CBS-POLS, data processed
by RIVM)
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or unhealthy personal risk factors. For example, although the percentage of people who
consider themselves to be overweight is higher than average in the northeast of the
Netherlands, the same does not apply in the major cities.
International comparisons are possible for a number of determinants
It was possible to make international comparisons for a number of lifestyle factors and
personal risk factors using data from projects including MONICA. The percentages of
people with unhealthy behaviour or having an unfavourable risk factor are based on data
from several regions within the countries concerned. A comparison was made for three
lifestyle factors (smoking, excessive alcohol use, physical inactivity) and three personal
risk factors (high blood pressure, high total cholesterol, serious overweight) (see figure
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Text block 2.13: More overweight people reported in the northeast and south
More men appear to be overweight in Rijnmond,
Den Bosch and South-East Drenthe 
Forty-three percent of men in the Netherlands are
overweight (body mass index of 25 or higher),
according to their own report. There are marked
regional differences in the reported male over-
weight percentages (see figure 2.16). South-East
Drenthe (56%), Den Bosch (51%) and Rijnmond
(48%) score higher than the national average
while the regions around Arnhem, Amsterdam and
West-Friesland have the lowest values, ranging
from 32 to 38%.
More women overweight in Drenthe and Gronin-
gen 
Thirty-sex percent of Dutch women are over-
weight (body mass index of 25 or higher), accord-
ing to their own report. Just as in the case of
Dutch men, there are clear regional variations in
the reported figures (see figure 2.16). Values
above the national average are found in Drenthe
(47%) and Groningen (41%), while the lowest
percentages are reported in Leiden (28%) and in
Eindhoven and the North-West of the Veluwe
region (both 29%).
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Figure 2.16: Percentage of the Dutch population older than 20 that report overweight a in the period
1995-1999, corrected for age and sex by GGD-region (Source: CBS-POLS, data processed by RIVM)
a) estimate probably too low, as people are inclined to underestimate their weight
2.17). Use was made predominantly of the prevalence figures for 35 to 65-year-old
adults from various EU countries, and where possible also from Norway, Iceland and
Switzerland. A wider age range was used only for excessive alcohol use and physical
inactivity (18 to 64 years and 15 years and over, respectively). 
Figure 2.17 presents spider graphs on how the Netherlands ‘behaves’ in comparison
with the European average and the most extreme risk profiles in Europe. The outermost
ring of the graph contains the countries with the most unfavourable prevalence for the
determinant concerned. The further away from 0, the more unfavourable the situation.
The innermost ring contains the countries with the most favourable level. The table
below indicates which countries are associated with the points in the graph. The average
was set at one and is referred to as the ‘European pool’. This pool is determined by the
countries for which reliable data is available for the determinant concerned.
Within Europe, the Netherlands achieves a poor score for smoking and
drinking and a good one for exercise
Compared with other countries in Europe, the prevalence of smoking in the Netherlands
stands out unfavourably, with the Netherlands occupying fourth place in Europe. The
difference between men and women, which has existed for some considerable time, is
continuing to decline. The percentage of smokers among women is in Norway and Swe-
den even higher than among men (WHO-HFA, 2000). Women in the Netherlands are
also well on their way to ‘overtaking’ the men. The fact that Dutch women have caught
up with Dutch men in smoking through the 1970s and 1980s has clear consequences for
developments in their life expectancy (see section 2.1).
Besides smoking, the Netherlands also achieves an unfavourable score for excessive
alcohol use among men. Ten percent of Dutch men drink six or more glasses of alcohol
a day, which brings them close to the prevalence among English men (14%), who are
the front runners compared with men in Finland, France, Germany, Sweden and
Switzerland (the ECAS countries). English women also have the highest score in these
countries with four or more glasses of alcohol a day. Among Dutch women, only 1%
drink more than four glasses a day, compared with 6% of women in the United King-
dom. Alcohol consumption has been declining since the 1990s in almost all of Europe.
Only the United Kingdom and Ireland still show a clear upward trend (WHO-HFA,
2002). It can be stated in general that the drinking patterns of the various European
countries are starting to converge in terms of per capita consumption and in terms of
preference for beer, wine or sprits.
In contrast to the unfavourable picture for smoking and excessive alcohol use, the
Netherlands actually compares positively with other European countries in terms of
physical activity. Thirty-eight percent of the Dutch population engages in physical
activity for more than five hours a week. The only countries with a higher percentage
are Sweden, Austria and Finland.
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Food patterns within Europe are converging
The graphs of figure 2.17 do not include the food patterns in the various European coun-
tries. One major reason for this is that there are too few good sources for a broad inter-
national comparison to be made of consumption data for the total population. Neverthe-
less, estimates have been made on the basis of production, import and export figures of
foodstuffs and some nutrients (excluding saturated fat). This trade data shows that veg-
etable and fruit consumption and fibre intake have increased in Southern Europe in the
past twenty years, whereas fat intake, which was traditionally low, has increased. The
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Men Cut-off point Most favourable Least favourable
Smoking current smokers Sweden Belgium
High blood pressure systolic BP ≥ 120 mmHg Denmark Finland
High total cholesterol ≥ 7.8 mmol/l Netherlands Luxembourg
Serious overweight ≥ 30 kg/m2 Netherlands Finland
Alcohol abuse men: ≥ 4 glasses/day Sweden United Kingdom
Physical inactivity 0 hours per week active Finland Belgium
Women Cut-off point Most favourable Least favourable
Smoking current smokers Finland Denmark
High blood pressure systolic BP ≥ 120 mmHg Netherlands Finland
High total cholesterol ≥ 7.8 mmol/l Netherlands Luxembourg
Serious overweight ≥ 30 kg/m2 Denmark Finland
Alcohol abuse women: ≥ 2 glasses/day Sweden United Kingdom
Physical inactivity 0 hours per week active Finland Belgium
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Figure 2.17: Position of the Netherlands in Europe for a number of lifestyle determinants and per-
sonal risk factors. Relatively to the European average, Europe =1.
largest rise can be seen in France. Conversely, fat intake has decreased in Northern and
Western European countries. International comparisons of food consumption among the
elderly in general (Moreiras et al., 1996; De Groot et al., 1991) and among elderly men
in particular (Kromhout et al., 2000) would suggest that this is possibly also true of the
intake of saturated fat, with the consequence that the dietary patterns within Europe,
which historically were highly varied, are starting to converge. A specific aspect of
nutrition which still exhibits large international differences is the percentage of exclu-
sively breastfed infants (see text block 2.14). The Netherlands is one of a group of coun-
tries in which relatively few infants are breastfed.
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Text block 2.14: International comparison of breastfeeding practice
Breastfeeding protects both mother and child
against various diseases
Breastfeeding protects the mother against breast
cancer and possibly also against ovarian cancer
and osteoporosis-related fractures. Moreover,
babies who are breastfed run less risk of acute
middle-ear infections, deficits in cognitive devel-
opment and allergies. The strength of the latter
relationship is currently under review, since some
recent studies (Malcolm et al., 2002) found no
clear correlation. These babies may also run less
risk of food allergies, coeliac disease, infectious
and inflammatory diseases, cot death, auto-
immune diseases and diabetes mellitus. Opinions
in the literature are divided about a number of
protective effects in the medium term (e.g.
against overweight) and the long term (e.g.
against cardiovascular diseases) (Thijs & Anten-
Kools, 2002).
The percentage of Dutch babies receiving moth-
er’s milk rose sharply during the nineties. Seven-
ty-five percent of Dutch mothers breastfed their
child immediately after birth in 2000, as com-
pared with 70% in 1996. About 32% were still
exclusively breastfeeding three months later. Five
years before, the comparable figure was only 17%
(Burgmeijer & Reijneveld, 2001; Lanting et al.,
2002). 
Despite the health benefits involved, the Nether-
lands is low on the EU league table for breast-
feeding
The Netherlands still lags behind other European
countries as far as breastfeeding is concerned,
despite the health benefits and despite the fact
that more and more Dutch mothers are breast-
feeding their babies for ever longer periods of
time (SZB, 2002). The Scandinavian countries in
particular, which are generally comparable with
the Netherlands as regards health status and
health care, score appreciably higher in both fre-
quency and duration of breastfeeding. In 1992, no
fewer than 92% of 3-month-old Norwegian babies
were exclusively breastfed as compared with 32%
in the Netherlands (SZB, 2002). 
In Europe a number of factors influence the deci-
sion as to whether to breastfeed or not. Many of
these factors are interrelated. For example, a
NIPO survey revealed that 84% of Dutch women
who had received a higher education breastfed
their newborn babies as compared with 52% in
the group of women with a lower educational
level. A similar effect has been reported in other
Western European countries, such as Great
Britain (Department of Health, 2001). It has also
been found that single mothers and younger
mothers in European countries are less likely to
breastfeed (Eurodiet, 2000).
Figure 2.18: Percentage of newborn babies being
breastfed at 3 months (both solely breastfed and
in combination with bottle-feeding) in selected
European countries (Source: WHO-HFA, 2002).
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The Netherlands belongs to a group of European countries which have 
relatively few seriously overweight people
Although serious overweight in the Netherlands is becoming increasingly common, the
Netherlands, together with the Scandinavian countries, still appears to belong to the
group of European countries that have a relatively low percentage of seriously over-
weight individuals (see figure 2.17). For instance, a relatively low percentage was found
in the Netherlands (12% among men and 13% among women), just as for the 35 to 65-
year-old residents of selected regions of Denmark (13% among men) and Sweden (12%
among women). Relatively high percentages were actually found for Finnish men
(23%), German men (19%) and for Finnish and Spanish women (both 27%). Otherwise,
the Netherlands is not one of the most favourable countries in terms of moderate over-
weight (body mass index (BMI) 25-30), but is in the average band.
In addition, the Netherlands is one of the more favourable countries in terms of the
prevalence of high total cholesterol. Fewer than 5% of the Dutch population from 35 to
65 years of age have a total cholesterol percentage above 7.8 mmol/l, which puts the
Netherlands at the same level as Italy and France for total cholesterol. The Netherlands
also fares relatively well with respect to high blood pressure, with a significantly lower
prevalence than in countries such as Finland, Germany and Italy.
Data from MONICA and other studies was used for the international comparison in this
section (see appendix 2). This data is based on a few selected regions within a country
and therefore gives no more than a general indication of the overall picture of the inter-
national differences.
2.2.3 Contribution of determinants to burden of disease and
cost of health care
Lifestyle makes a significant contribution to mortality
One way of making the significance of a healthy lifestyle visible is by calculating how
much loss of health can be ascribed to unhealthy behaviour. This can be done using Pop-
ulation Attributable Risk (PAR). The PAR is based on the prevalence of the determinant
in the population and a measure of the strength of the connection between the determi-
nant and the disease, usually the relative risk.
PAR calculations reveal the following. More than 140,000 people died in the Nether-
lands in 2000, of which almost 15% (21,000 people) died from a smoking-related disor-
der (see table 2.9). Lung cancer is one of the major causes, but coronary heart disease,
COPD and stroke make a very significant contribution as well (see figure 2.19). It is
striking that the number of deaths through smoking and alcohol among men is more
than twice as high as among women.
In addition, other lifestyle factors contribute to mortality, including physical inactivity
and an unhealthy diet. Much mortality, including from colon cancer and coronary heart
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disease, can be prevented by promoting a healthy lifestyle. It is difficult to put a precise
figure on the reduction in disease and mortality involved because of the uncertainty con-
cerning the degree to which some determinants protect or promote health. A cautious
estimate is that a dietary pattern characterized by sufficient vegetables and fruit (accord-
ing to the ‘Good Nutrition’ guidelines) yields a reduction of 3,000 deaths from neo-
plasms and more than 5,000 deaths from coronary heart disease (Klerk et al., 1998).
In comparison with PHSF-1997, there are a number of differences in the contribution of
determinants to mortality, which are chiefly attributable to differences in the calcula-
tions and only to a limited extent to changes in the prevalence of the risk factor. The new
calculations use age-dependent relative risks (RRs) for smoking, high blood pressure
and high total cholesterol. As a result, the calculations now produce lower values for
these factors than was the case in the past. Different, more realistic, cut-off points have
been used for excessive alcohol use, excessive saturated fat and too few vegetables and
fruit (see appendix 2). Furthermore, for overweight, additional RRs of three diseases
deemed to have a sufficiently well-established connection with overweight have been
included. Additional RRs have also been included for vegetable and fruit consumption
for certain forms of neoplasms. Otherwise, there is no complete consensus on the latter
RRs (Van Leer et al., 1999).
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Figure 2.19: Contribution of important lifestyle factors and personal risk factors to mortality by
eight causes of death in absolute numbers in 2000 (by sex). Total Dutch mortality in 2000 was
140.000. Dutch population 15.9 million.
Excessive alcohol use is the major determinant for loss of quality of life
Lifestyle factors and personal risk factors not only contribute substantially to mortality,
but also lead to a considerable number of years of ill health and consequently to a loss of
quality of life. In calculating this loss we again made use of Population Attributable
Risk (PAR). Loss of quality of life is expressed in years lived with disability (YLD),
which reflects the incidence and the severity of diseases (see also text block 2.5). The
calculation reveals that smoking is not only the major cause of premature mortality, but
also of much loss of quality of life, mainly through COPD and coronary heart disease.
However, excessive alcohol use is associated even more strongly with loss of quality of
life (see table 2.9), especially through alcohol dependence, stroke and coronary heart
disease. Physical inactivity, hypertension and serious overweight cause coronary heart
disease, stroke and diabetes mellitus, and entail, in addition to mortality and years of life
lost, a relatively large loss of quality of life.
The disability-adjusted life-year (DALY) combines mortality and loss of quality of life
(see also text block 2.5). This identifies smoking as the determinant that is associated
with the greatest loss of health, followed by excessive alcohol use, hypertension and
serious overweight. Otherwise, there are large differences between men and women.
Almost 20% of the total burden of disease among men can be attributed to smoking,
compared with 10% among women. The differences are even greater for excessive alco-
hol use: 12.5% of the burden of disease among men and 2.3% among women.
A ‘male’ lifestyle causes a stagnation of the increase in life expectancy
among Dutch women
Now that the increase in life expectancy among women is stagnating (see section 2.1)
the Netherlands is following in the footsteps of Denmark, where a similar stagnation of
life expectancy was observed in women as long ago as the late 1980s. Further research
pointed to smoking as a major causative factor, but also to a complex of factors that
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Table 2.9: Contribution (in per cent) of eight significant determinants to mortality, loss of quality of life and
burden of disease (disability-adjusted life-year (DALY)) a in the Netherlands.
Mortality b Loss of quality of life c DALY c
Smoking 14.9 8.0 14.7
Nutrition: too much saturated fat 4.9 3.3 4.6
Nutrition: insufficient vegetables and fruit 4.7 1.9 3.9
Physical inactivity 5.7 3.2 4.5
Excessive alcohol use d 1.5 8.6 6.6
Increased systolic blood pressure 6.1 4.5 6.4
Serious overweight 5.7 4.5 5.7
High total cholesterol 1.9 1.8 2.5
a) percentage of loss of quality of life (in years lived with disability (YLD)) and burden of disease (in DALYs) relates only
to the 53 diseases selected for PHSF.
b) the percentage contribution of determinants to mortality deviates somewhat from that presented in PHSF 1997: for an
explanation see the text above figure 2.19.
c) for an explanation of the various health measures: see text block 2.5.
d) excluding accidents.
coincide with an increasing participation of women in the labour market and the
assumption of a more ‘male’ lifestyle in general. Smoking, together with excessive alco-
hol use and high total cholesterol, has a strong influence on the number of years of life
lost, and therefore also on life expectancy, because the associated diseases (lung cancer,
coronary heart disease, disorders resulting from alcohol use) often occur at a young age
(see section 2.1). These developments in women’s lifestyles have led to a sustained
decline in the traditional difference in life expectancy between men and women (Van
der Wilk et al., 2001).
Environmental factors: a contribution of between 2% and 5% to the total
burden of disease
The sections above were concerned mainly with lifestyle factors and personal risk fac-
tors, but environmental factors can also have an impact on people’s health. On the basis
of current knowledge of the health risks of environmental factors, it is estimated that the
burden of disease attributable to the physical environment contributes approximately
2% to 5% of the total burden of disease in the Netherlands, where air pollution, noise,
the indoor environment and microbiological food contamination play a relatively large
part (De Hollander et al., 1999; Melse & De Hollander, 2001). We discuss the contribu-
tion of these factors to loss of health below, as shown in figure 2.20.
The loss of health through particulate matter and ozone is largely associated with respi-
ratory diseases. People with a sensitive respiratory tract use asthma medication more
frequently when they have a higher exposure to particulate matter (Pope et al., 1995;
Katsouyanni, 1996). In the case of people with a highly sensitive respiratory tract, expo-
sure to particulate matter leads to more general practitioner consultations and hospital
admissions, and (in a few cases) results in premature mortality (Verhoeff et al., 1996).
There are indications that particulate matter not only has an impact on people with a
sensitive respiratory tract, but that it also raises the probability (for the entire popula-
tion) of cardiovascular disease and pulmonary disease, and thereby shortens life (Hoek
et al., 2002). Ozone is the most reactive and toxic component of smog. Smog also caus-
es an increase in the severity, duration and frequency of respiratory symptoms among
people with a sensitive respiratory tract, with a corresponding increase in the number of
general practitioner consultations and hospital admissions.
Damp in housing causes a relatively high exposure to dust mite and fungus. For people
with a sensitive respiratory tract, the higher exposure to this environmental factor leads
to asthmatic symptoms and respiratory tract infections. The loss of health through the
radioactive substance radon is largely caused by lung cancer. It is estimated that
between 100 and 1,200 lung cancer cases in the Netherlands annually are caused by
exposure to radon. On average, there are 800 cases a year (Health Council (GR),
2000a). The risk-enhancing effect is especially strong in combination with smoking.
With respect to noise, figure 2.20 shows only the loss of health as a result of stress-relat-
ed symptoms, such as high blood pressure, coronary heart disease and hypertension in
pregnancy. Furthermore, exposure to a high noise load at work or through pop music,
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possibly for a period of years, can cause damage to hearing. Finally, noise can diminish
people’s sense of well-being (noise nuisance) and interfere with their proper functioning
(disturbed sleep, diminished cognitive performance).
The loss of health through microbiological food contamination results from food-relat-
ed infection and intoxication. Chemical food contamination is not included in figure
2.20, because the short-term health consequences are limited and the long-term conse-
quences will not manifest themselves within a human lifetime and/or are impossible to
express quantitatively.
Social environment: the relative contribution to burden of disease was
estimated only for labour 
Little is known about the relative contribution to ill health in the Netherlands of a num-
ber of selected social environmental factors (see table 2.7), such as work stress and lim-
ited social support. However, for the sum of physical and social labour-related factors, it
has been estimated that they are responsible for 7% of the total mortality (Nurminen,
2001). It would appear, moreover, that between 10% and 40% of the Work Incapacity
Benefits (WAO) intake is associated with the labour situation (Gründemann & Nijboer,
1998).
Among the possible consequences of psychosocial factors in the labour situation, such
as work stress and unfavourable labour relations, are generalised stress, burn-out,
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Figure 2.20: Health loss attributable to a selection of environmental factors in DALY’s per year a
for the Netherlands (Source: RIVM/CBS, 2001).
a) estimates of % of DALY’s attributable to environmental factors are made in a different way then for lifestyle factors (see
figure 2.19 and table 2.9). Although a comparison is therefore difficult, it may be assumed that the order of magnitudes
are comparable.
b) all described health effects
c) only premature mortality and hospital admissions
d) only cardiovascular diseases
particulate matter b 1995
particulate matter c 1995
ozone b 1995
ozone c 1995
traffic noise d 1995
airtraffic noise d 1995  
radon 2000
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0 1,000 2,000 3,000 4,000 5,000 6,000
DALY's per year
95%-confidence interval
average
depressive symptoms and cardiovascular diseases. Social support also appears to have
an effect on health. Someone who enjoys some degree of emotional support (for exam-
ple, by being able to talk to others about problems, to feel that they are understood and
have a source of comfort), has a smaller probability of contracting or dying from cardio-
vascular diseases and has a better prognosis in the event of neoplasms. Social integra-
tion, or the existence of social relationships, is also associated with a smaller probability
of contracting or dying from cardiovascular diseases and may have a better prognosis in
the event of neoplasms, as well as a smaller probability of physical impairments (Hem-
ingway & Marmot, 1999; De Boer et al., 1999; Garssen & Goodkin, 1999; Seeman,
2000). A link has also been found between a greater degree of support from social rela-
tionships and a lower heart rate, lower blood pressure, lower total cholesterol, better
immune reactions and fewer stress reactions (Seeman, 2000).
Furthermore, support from social relationships can lead to improved mental health,
because people feel more valued and more help is available in emergencies. Conversely,
little support and much criticism or quarrels are associated with the development and
progress of depression (Finch et al., 1999; Seeman, 1996). A lack of a sense of reciproc-
ity in relationships increases the probability of such things as burn-out, depression and
absence from work through sickness (Buunk & Schaufeli, 2001). Loneliness can be
considered to be a perceived deficiency in social support. A Dutch study has revealed
that less loneliness, more emotional support and more practical support go together with
a smaller probability of mortality among the elderly (Penninx et al., 1997).
It has been established furthermore that unfavourable factors in the immediate living
environment have a negative impact on health (see also text block 2.3), although it is not
known precisely which factors are involved. For instance, it appears that living in a
deprived area in a major city has an independent influence on the state of health. The
probability of dying before the age of 65 in a deprived area is 50% greater than in
wealthier neighbourhoods, which can be explained in part by the social-demographic
composition of the neighbourhoods, but in addition there is an independent effect of liv-
ing in a deprived area. Apparently, the urban deprived area is not only the location but
also the cause of substandard health, and various environmental characteristics may
play a part. A fairly substantial role is probably set aside for the social environment in
the neighbourhood, for example, the quality of the contacts between individual residents
(Van der Lucht & Verkleij, 2001).
Smoking, high blood pressure and overweight are significant cost items
Health care costs can be attributed in part to a number of personal risk factors and
lifestyle factors. In the first place comes the cost of the care that is brought to bear to
eliminate unfavourable levels of certain risk factors, for example, the medicinal treat-
ment of high blood pressure and high total cholesterol. In the second place is the cost of
disorders related to the determinants. It goes without saying that not all costs of, for
example, cardiovascular diseases, can be attributed to high blood pressure and high total
cholesterol. Most diseases and disorders usually have multiple determinants, and, what
is more, these are only partly known or quantifiable. The cost of disease (see section 2.4)
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is therefore partially allocated to determinants, to the extent that the quantitative rela-
tionship between the determinants and the prevalence of disorders is known. Here use is
made of the population attributable risk (PAR) method, which was modified for this
purpose in order to eliminate overlap in the costs (because of the simultaneous presence
of multiple determinants for an individual person).
It was possible to allocate more than 1.5 billion euros of the total cost of care in 1999 to
three personal risk factors: high blood pressure, high total cholesterol and serious over-
weight (see table 2.10), which is equivalent to 4.8% of the total cost of health care in
1999 for people aged 20 and above. It was possible to allocate 6.2% for men, and 3.8%
for women. The most significant component of the cost is related to high blood pressure.
It was possible to allocate an approximately equal amount, almost 1.4 billion euros (or
4.2%), to five lifestyle factors (see table 2.11). Men’s more unhealthy lifestyle is clearly
visible in this table, for all lifestyle factors but particularly for smoking, and alcohol and
drug use. The partial coincidence of personal risk factors with lifestyle factors (for
example: overweight and physical inactivity), made it impossible to sum the figures
from table 2.10 and table 2.11.
The amounts in table 2.10 and table 2.11 should certainly not be used as an answer to
the question ‘how much expense could have been avoided with a properly healthy
lifestyle?’. There are various reasons for this:
• A risk factor (an unhealthy behaviour or an unfavourable personal risk factor) can
often not be eliminated completely.
• People live longer on average as a result of eliminating risk factors by taking up a
healthy lifestyle, so that later in their lives they may succumb to (other) diseases that
also (and possibly even more so) demand care (substitution and postponement of dis-
eases).
• Population attributable risks (PAR) are based on observational investigation and
there is therefore no certainty that the effect of eliminating a risk factor will be equal
to the PAR.
• Prevention also costs money.
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Table 2.10: The cost of health care allocated to three personal risk factors for Dutch men and women in 1999
(millions of euros) (Source: Polder et al., 2002).
Men Women Total
High blood pressure 359.4 352.5 711.9 
Elevated total cholesterol 194.5 122.2 316.7
Serious overweight 257.9 247.4 505.4
Total 811.8 722.1 1533.9
Contribution to the cost of health care of those aged 20 and above (%) 6.2 3.8 4.8
Total health care costs for the Netherlands in 1999. For men: 11.7 and for women: 16.0 billion euros. Total population of the
Netherlands 15.9 million.
On the basis of current knowledge, we conclude that limiting health risks is very impor-
tant in terms of population health status. However, this will yield little or no savings in
the cost of health care. In addition to the cost of prevention as such, the development of
substitute disease may become important. 
2.2.4 Finally: the provision of information needs to be
improved
The current information base is deficient
Various systems exist in the Netherlands for continuously gathering data on health
determinants. Data on the lifestyle factors such as smoking, drinking and exercise comes
mainly from Defacto, the Trimbos-institute, Statistics Netherlands (CBS) and the trend
report on exercise (‘Bewegen’). These figures provide a basis for studying the trends
and breaking them down into socio-economic groups. However, any attempt to study
the interrelationship between risk factors and/or trends in time is hampered by the fact
that different sources and/or methods of data gathering were used. The Second Dutch
National Survey of General Practice does measure these lifestyle factors simultaneously
with personal risk factors and health problems in general practice, but this survey is not
continuous in nature. Available trend data from surveys of drug use (Trimbos-institute,
CEDRO) and sexual behaviour (NISSO, TNO) constitutes only a cautious indication of
the behaviour concerned, because of the generally low and/or selective response and the
likelihood of being given socially acceptable answers. Data on lifestyle among mem-
bers of ethnic minorities originates largely from one-off studies, which provide no
insight into how lifestyle factors are developing over time.
Following the end of the MORGEN project in 1997, the monitoring of personal risk
factors, such as blood pressure and overweight, was continued (to a very limited extent)
by the ‘Regenboog’ (Rainbow) project. The Regenboog project was terminated in 2001
because of the inadequate number of subjects in the study, which caused a gap in the
provision of information on personal risk factors.
PHSF 2002:  HEALTH ON COURSE? 2.2
79
Table 2.11: The cost of health care in the Netherlands allocated to five lifestyle factors according for men and
women in 1999 (millions of euros) (Source: Polder et al., 2002).
Lifestyle factors Men Women Total
Smoking 334.1 174.6 508.7
Physical inactivity 111.0 89.4 200.4
Insufficient vegetables and fruit 86.5 55.0 141.5
Excessive alcohol and/or drugs 225.8 86.2 312.0
Too much saturated fat 126.5 73.7 200.2
Total 884.0 478.8 1362.8
Contribution to the cost of health care of those aged 20 and above (%) 6.8 2.5 4.2
Data on environmental factors originates from a variety of sources. Furthermore, the
lack of data on the percentage of people exposed to environmental factors means that it
is often necessary to resort to indicators, such as self-reported nuisance or locations with
relatively high exposure. Monitors still contain hardly any questions on social environ-
mental factors, partly because little is known about the link between specific environ-
mental factors and health.
New monitor will provide better lifestyle information
Starting in 2003, the Local and National Public Health Monitor, which is an initiative of
GGD Nederland and the RIVM, will be a good information source, especially for
lifestyle factors. This involves coordination with national and international initiatives.
Optionally, data will be gathered on environmental factors and personal risk factors, in
addition to lifestyle factors.
Other examples of broadly-based monitor initiatives of this kind are those for environ-
mental factors, such as the Environmental Balance (Milieubalans) (RIVM, 2002) and
the Environmental Data Compendium (Milieucompendium) (RIVM/Statistics Nether-
lands (CBS), 2001), and for labour-related physical and social environmental factors
(Statistics Netherlands (CBS)-POLS).
There is as much room for improvement in the determinants as there is in the health sta-
tus, in terms of the availability and comparability of international health information.
This is especially true of social environmental factors and personal risk factors, but also
of most lifestyle and environmental factors.
Further research is necessary into health differences in neighbourhoods and
determinants of behaviour
Further research is necessary to establish which specific environmental factors or com-
binations of factors in the immediate living environment contribute to health differences
in neighbourhoods. Likewise, investigation is necessary into the behavioural determi-
nants in the general population and in particular among specific groups such as young
people, the elderly, people with a low socio-economic status and members of ethnic
minorities. Too little is currently known about environmental behavioural determinants
(factors that form a constraint on healthy behaviour) in particular. The same is true of
individual behavioural determinants (knowledge, attitude, self-efficacy). Some exam-
ples of environmental determinants of healthy behaviour are the structure of the neigh-
bourhood or dwelling, social pressure, transport facilities, the availability of other facil-
ities (including those for recreation and care) and safety.
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2.3 What do prevention and care mean for our
health?
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Unhealthy behaviour is the greatest challenge for prevention
Considerable health gains have been achieved in the past with prevention in the broad-
est sense. However, the public sector must continue to strive to maintain these achieve-
ments (for example, through vaccination, health protection and health promotion).
Theoretically, the greatest opportunities for further gains currently lie in the improve-
ment of unhealthy behaviour. However, the prevention of unhealthy behaviour is ham-
pered by a number of obstacles: insufficient embedding of prevention in care; the
approach to unhealthy behaviour is insufficiently integrated; there is too much ad-hoc
project funding and too little structural support for prevention programmes; insuffi-
cient use has been made of local settings (school, neighbourhood, workplace) to devel-
op successful programmes, or of the opportunities to make the surroundings stimulat-
ing for healthy ways of living; there is too little effective communication on health
risks; there is far too little systematic evaluation of the efficacy of preventive interven-
tions. What is required, in brief, is a long-term view and corresponding support.
The quality of cure and care is stagnating through a shortage of innovation and 
investment
Care contributes to better health by being effective, safe and accessible to everyone.
New interventions in this area can still yield health gains. Here too, however, interven-
tions are hampered by a number of obstacles, particularly in the stagnation of substan-
tial care reforms and a considerable gap that has developed recently between the
demand for and the supply of care. In concrete terms, the following points are
involved: an inadequate implementation of successful trial projects on safer or more
integrated care; obstinately long waiting times in some specializations and in the care
sector; shortages of medical personnel and educational facilities; a changing and
increasing demand for care. In principle, there is equal accessibility of care for different
population groups, but deprived groups would appear to require additional care
capacity. All these points need to be addressed in the design of a new care system, from
the perspective of optimum health gain.
In comparison with other countries, the Netherlands presents a variable picture
Some of the data on efficacy, safety and accessibility of prevention and care lends itself
to international comparison. For such preventive activities as breast cancer screening
and vaccination, the Netherlands achieves a favourable score within the EU. However,
the Netherlands achieves an average or below average score for the outcomes of
care/prevention, such as breast cancer survival and perinatal mortality. The frequency
of percutaneous angioplasty, appendix operations and Caesarean sections is average or
below average, which appears to be reasonably adequate. Taking resistance to antibi-
otics as a hallmark of safety, the Netherlands is among the best in Europe. All the above
notwithstanding, the Netherlands has almost the lowest number of doctors per inhabi-
tant in the EU.
2.3.1 Prevention and care for improved health
Prevention and care help, but could things be better?
What lessons can we learn from the successes of prevention and care and where do the
obstacles lie? How should we tackle the job of assessing this? In PHSF 1997 this subject
focused on the efficacy and effectiveness of interventions, which relates to the effect of
an intervention under ideal conditions or in practice. The following questions were
raised: which interventions are effective? Why are some interventions less effective in
practice than we might expect on the basis of the efficacy in ideal conditions? In
answering these questions, a list of obstacles has been identified for both prevention and
care, which revealed that success depends not only on the choice of certain interventions
but also on the associated organizational context. In other words, were the right inter-
ventions applied in the right way at the right time on the right groups of people? And if
not, why not?
These findings led us to opt for a broader perspective in this report than one that is based
strictly on the efficacy of interventions. The underlying assumption is that the objective
of the system of prevention and care is to maintain or improve the state of health of the
population, to reduce undesirable health differences, and to cure and care for people
with diseases or infirmities (see chapter 1). The questions that then arise are as follows:
• What requirements must be imposed on prevention and care in order to best achieve
these objectives? This question relates not only to the efficacy of prevention and
care, but also to other aspects of quality, such as safety and accessibility.
• To what extent have these objectives already been realized? Where can examples of
successful interventions be found and what lessons can be learned from them?
• Where are the obstacles and opportunities for improvement? How can we derive rec-
ommendations for the future?
Prevention: different criteria for categorization
Prevention can be categorized in different ways. This report mainly uses the three tradi-
tional categories: disease prevention, health promotion and health protection (see text
block 2.15 for an explanation and reference to other catagorization schemes). These three
operate overall on different types of determinants and use a variety of methods, which is
indicated clearly in the conceptual model determinants (text block 2.9). Each of these
three types of prevention has its own approach, target groups, opportunities and dilem-
mas. Our expectation of all types of prevention is that they should not only be effective,
but also safe (no undesirable side effects) and accessible (to everyone). These concepts
are mainly used within the framework of care, but are equally applicable to prevention.
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To measure performance, information on prevention and care is needed 
Information on the efficacy, safety and accessibility of prevention and care is fragment-
ed. In order to measure the performance of prevention and care, practical parameters
must be developed and selected through specific studies. In addition, structures must
be developed for regular data gathering, both within the Netherlands and at the inter-
national level (see further chapter 4).
Care: what do we expect of it and what do we call that?
Care can be subdivided into curative care, which focuses on curing (the cure), and nurs-
ing and residential care, which does not generally involve healing (the care). According
to the conceptual model (text block 2.9), care operates primarily to influence health sta-
tus. The terms effective, safe and accessible were mentioned above as essential charac-
teristics of care. These are only some of a series of related concepts, which are often
drawn together under the heading of ‘quality and accessibility of care’ (text block 2.16).
Prevention, cure and care cannot be strictly separated
Prevention, cure and care are generally successive actions in the disease process: pre-
vention takes place before the development, appearance or aggravation of the disease,
followed by cure to heal the disease, and finally care, which is more concerned with
improving or maintaining the quality of life than with healing (see figure 2.38). What is
more, there is a greater emphasis on the collective aspect in prevention, and more on the
individual in cure and care, although it is often impossible to distinguish between them.
Much prevention is embedded in the care system, in a collective sense (for example,
breast cancer screening) or an individual sense (lifestyle advice following myocardial
infarction or depression). The latter situation in particular illustrates that the distinction
between prevention and care is often a difficult one to make, on top of which such a dis-
tinction is also undesirable and counterproductive. A number of the examples presented
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Text block 2.15: Different kinds of prevention
The classical approach to the classification of pre-
vention activities is: 
• Disease prevention: aiming at personal charac-
teristics or latent disease, e.g. using vaccina-
tion, screening or targeted medication;
• Health promotion: aiming at lifestyle factors
and ‘healthy’ environmental characteristics,
e.g. using information campaigns or coordinat-
ed social action;
• Health protection: attempts to prevent exposure
to hazardous (environmental) factors, e.g. by
means of legislation and law enforcement. 
A more methodological classification of preven-
tion activities has been introduced in PHSF 1997
based on five prevention methods (vaccination,
screening, medication, health education and legis-
lation). These five methods can easily be fitted
into the threefold classification given above. In
addition, there is the well-known classification
into primary, secondary and tertiary prevention,
which provides another dimension largely by fol-
lowing the phases of the disease process. Other
classifications are based on disease groups or
target groups (Gunning-Schepers & Jansen,
1997). Finally, in mental health care a distinction
is made between universal, selective, indication-
based and care-based prevention (Bohlmeijer &
Cuijpers, 2001). 
Text block 2.16: What are quality and accessibility of care?
The term quality covers not only the effectiveness
and safety of the measures taken, but also such
concepts as appropriateness (tailoring the care to
the patient’s needs), continuity (effective coupling
of different parts of the care process) and cus-
tomer-friendliness (proper approach to patients
and demand-oriented attitude). These terms show
a certain degree of overlap. The term accessibility
refers mainly to the timely availability of care,
geographical spread and the need to make health
care affordable for everyone. The criterion soli-
darity also applies here. The term effectiveness
(which refers to the need to achieve the above-
mentioned health aims within acceptable cost
restraints) is generally considered to be relevant
as well. This extra dimension is considered in
section 2.5.
below show that coordinated prevention and care, as components of the same process,
are precisely what is needed to yield a considerable health gain (RVZ, 2001a). For
example, an integrated approach incorporating both prevention and care (as well as
other social aspects) can be important when dealing with socio-demographic groups
with health deprivations (Mackenbach & Verkleij, 1997; Van der Lucht & Verkleij, 2001).
A common theme illustrated by examples
The field of prevention, cure and care, and their significance for health, is too broad to
cover here with any pretence of completeness. Furthermore, the availability of good
data on the subject is fairly patchy. We have therefore opted to present examples in this
section that:
• are characteristic of different fields of prevention, cure and care, and
• illustrate recent and relevant developments, or
• show interesting geographical differences.
These examples are described in text blocks 2.17-2.39. We have attempted to identify a
common theme out of these examples.
This section emphasizes that the achievement of a health gain is the central underlying
goal of prevention and care. This means that all the examples examine health outcomes,
or, by way of proxy, process characteristics that have a sufficiently clear or plausible
relationship with health outcomes. Such proxies will often be used where there are prac-
tical difficulties in ascribing certain health outcomes unambiguously to a given inter-
vention, or where it is anticipated that there will be a substantial delay before an effect
on health becomes apparent.
2.3.2 Prevention
Chapter 1 stated that considerable health gains have been achieved in the past 150 years
through what we now refer to as prevention, together with the general development in
prosperity. PHSF 1997 concluded that interventions directed at healthy behaviour still
have considerable potential to achieve health gains at the present time. That report iden-
tified the following points for improvement:
• increased efforts directed at reaching the intended target group;
• more combined intervention strategies;
• more involvement of the medical profession in the implementation of interventions;
• more collaboration between players and authorities;
• better evaluation of programmes and interventions.
The question that we now have to ask is whether any progress has since been made on
these points. We investigated this by means of a number of examples, categorized as
described above into disease prevention, health promotion and health protection. In
general, we can state that although there have been many (often fragmented) initiatives
in recent years, there has been very limited structural investment in prevention, in con-
trast to the considerably increased expenditure on care (see also section 2.4).
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Disease prevention: permanent evaluation remains necessary
The issues of ‘reaching the target group’ and ‘evaluation’ are still as topical as they ever
were (see the examples in text blocks 2.17 and 2.18). Disease prevention in the form of
breast cancer screening illustrates the balancing of positive and negative effects of an
intervention at the population level. While screening gives a chance of earlier and con-
sequently more successful treatment, it also generates an enormous amount of anxiety
during the process, especially in the event of indeterminate and false positive results.
The balance is currently favourable, in spite of recent doubts (text block 2.17).
Another form of disease prevention is the national vaccination programme (NVP), the
health gains of which are due, in particular, to the programme’s continuity (text block
2.18). A more critical attitude to vaccination programmes has also developed recently
outside orthodox-religious or anthroposophic circles. This development indicates that a
different balance is sometimes struck between protection and the probability of disease
on an individual level than the efficacy applicable at the population level. People who
opt out of vaccination will enjoy protection as long as people in their surroundings are
vaccinated. However, in the case of a further decline in coverage, the efficacy of the
national vaccination programme (NVP) may rapidly be undermined. It is therefore
important to view the national vaccination programme (NVP) not only as a success
story from the past, but also as a programme that needs sustained effort to maintain the
health gain that has already been achieved. This must also be communicated clearly to
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Text block 2.17: Screening for breast cancer: efforts continue unabated despite debate
Screening for breast cancer started in the Nether-
lands at the end of the eighties, after the effective-
ness of this procedure had been demonstrated in
international trials. It was claimed that the screen-
ing of women in the age-range 50-70 years with a
coverage of 70% would lead to a drop in deaths
due to breast cancer by about 17%. Danish publi-
cations have however recently cast doubt on the
validity of these trials. The Dutch Gezondheids-
raad (Health Council) concluded in response to
these claims that while the favourable effect of
screening may be lower than initially thought, this
is no reason to stop the screening programme. It
went on to say that the programme should be
subjected to thorough evaluation. It may be noted
that mortality due to breast cancer has shown a
downward trend since screening started in 1988,
despite some fluctuations (estimated reduction of
7-13% in the period 1997-1999 for the 55-74-
year age group). It is assumed that the screening
programme has contributed to this reduction. The
improvement of the 5-year survival rate for breast
cancer has also been attributed in part to screen-
ing (see text block 2.26). The Netherlands com-
pares quite favourably to other EU countries as
regards participation in breast-cancer screening
(see figure 2.21).
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the target group. However, it is necessary to evaluate the current research results criti-
cally in terms of the motives for opting out of vaccination, such as the assumed relation-
ship with increasing allergy. The Netherlands does not have a monopoly on this some-
times irrational resistance to vaccination programmes, as this is also encountered in
other Western countries.
Disease prevention in general practice: a source of dilemmas
It is extremely difficult to give the counterpart of the population approach, which is
known as the high risk approach, a permanent place within the current health care sys-
tem (see the example in text block 2.19). The major problem area is the involvement of
the medical profession. The dilemma is that the additional work stress will be much
more clearly visible than the health yield in the short term. RVZ recently stated that
there is a wide variety of reasons (work stress, funding structure) for why the practice of
care is not structured to incorporate prevention, whereas an improvement in this respect
could yield a considerable health gain. One step in this direction would involve a more
prominent place for prevention in medical education (RVZ, 2001a).
An example of the consequences of this type of prevention is the recent increase in the
application of cholesterol-lowering medicines (text block 2.20). It marks the beginning
of a potentially enormous development, prescribing medicines to individuals or groups
with a given risk profile. This profile can be determined by lifestyle factors, and the
question that arises is how far we should go along this path of ‘compensating’ unhealthy
behaviour with medicines. What is more, in future, such a risk profile can be based on a
genetic profile (predictive medicine; see section 3.3). A question that is asked increas-
ingly often is whether the screening of high risk groups within the care sector should be
imposed because of the general interest (in other words, a public health imperative) or
should it be more a matter of informed individual choice; Marteau & Kinmonth, 2002).
The role of the insurers in possible risk selection is crucial here.
Health promotion needs an integrated approach and continuity
As indicated in section 2.2, a considerable health gain can still be achieved on the point
of promoting healthy behaviour (see also the examples in text blocks 2.21-2.23). At the
same time, however, people seem to be less susceptible to the prevention message. Pre-
vention would be more effective if interventions not only tackled people personally on
their behaviour, but also changed their physical and social environment in such a way as
to support such behaviour (which is known as making the healthy choice the easy
choice). The PHSF theme report ‘Time for healthy living: health promotion for specific
target groups’ (Jansen et al., 2002) gives many practical examples. The key words con-
cerned are support and participation for the target group, empowerment (making people
better able to stand up for themselves) and customization. This last key word refers to a
package of interventions tailored to the situation and target group as an alternative to
dipping into the standard protocols. Other conditions for a successful approach to health
promotion are as follows: an integrated approach, use of multimedia (ICT) and multi-
intervention strategies, utilizing existing networks and infrastructure, and, above all,
continuity: sufficient time for a result, through structural as opposed to project funding.
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Text block 2.18: National Vaccination Programme (NVP) updated but subject to critical review
The National vaccination programme (NVP), intro-
duced in the Netherlands in 1957, has in the inter-
vening period led to the virtual disappearance of
most of the diseases vaccinated against. Coverage
of more than 95% has been achieved for all NVP
diseases. The NVP is currently being updated and
extended, with special reference to expected
health gain, cost-effectiveness and practical feasi-
bility. An additional whooping-cough vaccination
for 4-year-olds was introduced in the autumn of
2001 to prevent recurrence of this disease after
this age. This measure may also reduce the risk of
infection in susceptible infants. Vaccination
against meningitis C was introduced in 2002, in
response to a recent rise in the number of cases
(a nearly fourfold increase in 2001, to 275, with a
mortality rate of roughly 10%) and the recent
availability of a very effective vaccine. In 2003,
hepatitis B vaccination will be added to the pro-
gramme for the children of parents from regions
where this disease is endemic. Another planned
introduction is pneumococcal vaccination in
infants (the vaccination of individuals in the 65+
age group is still under discussion). 
Now that infectious diseases and their complica-
tions are less in the public eye thanks to the suc-
cess of the NVP, greater concern is being
expressed about the side effects of vaccination.
A total of 1,142 reports of suspected side effects
were made in 2000, out of a total of nearly 2.5
million vaccinations. Depending on the type of
vaccine and the nature of the clinical picture
involved, it was estimated that there was an asso-
ciation of 80% on average between the reported
complaint and the vaccination (Vermeer-de Bondt
et al., 2002).
The present average vaccination rate of more than
95% is enough to prevent epidemics. There are
however certain socio-geographic clusters of par-
ents who refuse to have their children vaccinated,
mainly on ideological or religious grounds. There
are certain groups of strict Protestants where the
vaccination coverage is no more than about 30%.
Figure 2.22 shows that the vaccination rate for
MMR (measles, mumps, rubella) in municipalities
with a high proportion of such groups could fall
below 80% (according to the data reported for
1 January 1999), and that the lion’s share of the
reported cases of measles during the epidemic of
June 1999 – May 2000 were concentrated in the
same areas. Of the 3,292 reported cases, 94%
were not vaccinated (Van den Hof et al., 2001).
This confirms the effectiveness of the MMR vac-
cine in protecting against the diseases in ques-
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Figure 2.22: Regional spread of the Dutch measles epidemic 1999-2000 and coverage of mumps,
measles, rubella vaccination (Source: ISIS; IGZ, 2000).
An integrated approach is one of the most important success factors for effective inter-
ventions in the area of a healthy lifestyle and a healthy environment. This involves col-
laboration between various parties, such as different sectors of government policy
(health policy and policy in other sectors, ‘intersectoral policy’), the commercial sector,
interest groups, cultural facilities, local government and, of course, the individuals con-
cerned. Promoting a healthy lifestyle and a healthy environment is definitely not con-
fined to health policy alone. The contribution from all of the above parties also makes it
self-evident that a multimedia and multi-intervention approach should be adopted, and
that existing structures should be used. Local government can help boost all of the
above. Continuity, or great patience, is perhaps the most essential aspect, not only
because the working structure required is complex, but more especially because a sus-
tainable behavioural change can be realized only through long-term investments. Other-
wise, parties with different interests will pass the buck rather than cooperating (see the
alcohol example in text block 2.21).
Settings as a key to health promotion
An integrated approach to health promotion, involving participation and customization,
can be put into practice by approaching people through various ‘settings’, such as at
school, in primary health care, at work and in the neighbourhood (see also text blocks
2.22 and 2.23). This approach was also advocated in a comprehensive report on the ‘The
Evidence of Health Promotion Effectiveness’ (IUHPE, 1999), on the basis of an exten-
sive literature survey. For instance, this report states that in the school health policy, the
presentation of health topics must fit in with the sum of learning objectives, and not be
directly oriented to changing behaviour. Here too, efficacy appears to depend strongly
on the continuity of the programmes. In addition, the report demonstrates convincingly
that behaviour-directed interventions from primary health care are particularly effective
with respect to smoking and alcohol. For other lifestyle factors, the evidence is less
clear (IUHPE, 1999; see also text blocks 2.23 and 2.19).
Furthermore, the IUHPE report mentions the importance of health promotion in the
workplace (GBW), where much health gain can be achieved. In 1998, for example,
almost a quarter of employees stated that work stress had caused them to suffer physical
or psychological symptoms. In addition, one third of the people who end up with a Work
Incapacity Benefit (WAO) suffer from psychological symptoms (see section 2.1). Eval-
uations have shown that stress prevention programmes can lead to a reduction in
absence through sickness and that health promotion in the workplace (GBW) pro-
grammes can have a positive effect on health awareness and healthy behaviour within
companies (see also text block 2.22). On balance, programmes of this type can save
costs. Especially with the current trend towards ever higher productivity, this perhaps
makes the workplace the setting of choice for working preventively on health improve-
ment.
The literature is rather contradictory in terms of the efficacy of community-based inter-
ventions, which in the Dutch translation is often referred to (not entirely correctly) as
the neighbourhood-oriented approach. Analyses of the causes of these contradictions
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(continue text block 2.18)
tion. 
Recently, there has been a tendency to adopt a
more critical attitude towards vaccination, as
reflected in the increased level of debate concern-
ing side effects and the possible adverse long-
term effects of the tendency to vaccinate babies at
an earlier age. There may have been a slight drop
in the national vaccination coverage for babies in
the period 1998-2001, though the overall vaccina-
tion rate is actually better than it was ten years
ago. A local drop of a few percent has, however,
been observed in Amsterdam and Rotterdam
(among both ethnic minority groups and groups
of Dutch origin). It is not yet clear whether this is
mainly a case of postponement to a later date or
whether it represents a decision not to have the
children in question vaccinated at all (IGZ, 2002a;
Van der Wal et al., 2001).
International comparison shows that the vaccina-
tion rate for measles in the Netherlands is rela-
tively high: in 1999, half of the EU countries had a
coverage of less than 90% while three countries
showed a coverage of less than 80% (WHO-HFA,
2002).
Text block 2.19: Cardiovascular disease prevention programme in primary health care stopped
although proven effective 
It was stated in PHSF 1997 that active targeting of
the population group with the highest absolute
risk of cardiovascular disease would provide a
more effective means of preventing this type of
disease than screening the whole population for
blood pressure and cholesterol levels. A pilot pro-
ject along these lines was started in 1998, under
the title ‘Tailored prevention of cardiovascular dis-
ease’, at the primary health care level. About 15%
of all Dutch GPs participated in this project, with
support from preventive medicine professionals.
The project was aimed at the systematic registra-
tion of additional risk factors (in particular blood
pressure and cholesterol level) in patients who
were regarded as being at high risk of developing
cardiovascular disease on the basis of a number
of indications (age, diabetes mellitus, overweight
and family history). This information would pro-
vide a basis for an individual prevention strategy
involving e.g. lifestyle advice or the use of med-
ication to lower the cholesterol level and/or the
blood pressure.
This pilot project was successful: two years after
the start of the project, the number of high-risk
patients (on the basis of age (60+) and other
selected risk factors) for whom a reasonably com-
plete risk profile had been recorded, had
increased appreciably, to about 70% of all partici-
pating patients, and the number of targeted pre-
ventive actions had also increased strongly. Most
of the GPs who participated in the project found
the procedure to be feasible, and appreciated it.
Despite these encouraging results, the Landelijke
Huisartsen Vereniging (National Association of
Dutch GPs) decided to stop the campaign, and
not to implement this approach on a national
scale. The main reasons given were that the work
involved placed an excessive load on GPs, and
that it was insufficiently remunerated.
Text block 2.20: Preventive use of cholesterol-reducing medication: effectiveness versus costs
The medical profession is traditionally reluctant to
prescribe medication for people who do not show
any signs of disease. It was however proposed a
number of years ago that cholesterol-reducing
drugs (statins) should be prescribed for healthy
people with a high risk profile for cardiovascular
disease instead of simply for those with high cho-
lesterol levels (see text block 2.19). This advice
was based on intervention studies which showed
conclusively that cholesterol levels could be
reduced by up to about 30% in this way. On the
basis of these new guidelines, 180,000-360,000
people at high risk of cardiovascular disease
would become eligible for such treatment in the
Netherlands (Gezondheidsraad, 2000b). It was
further advised that the medication should be
combined with a change to a healthier lifestyle. In
practice, however, it is easier to swallow a pill
than to change one’s lifestyle; these drugs could
thus easily be used to compensate for unhealthy
behaviour. If all the smokers in the risk group
were to stop smoking, at least 150,000 fewer peo-
ple would require the treatment (CBO, 1998). The
College voor zorgverzekeringen (CVZ) (Dutch
Health Insurance Funds Council) recently recom-
mended that smoking should not be used as a cri-
terion for reimbursement, but that this topic
should be the subject of widely based discussion
(CVZ, 2002).
Practical effectiveness is a specific problem with
medication of this type: statins only work when
indicate that the approach definitely offers opportunities for success, provided that the
conditions mentioned above are fulfilled (such as participation, customization, an inte-
grated approach, intersectoral action and continuity; Van Assema, 1993; Jansen, 1999)
(see also the example in text block 2.23). The PHSF theme report ‘Health in the cities’
(Van der Lucht & Verkleij, 2001) also deals with this subject extensively, with recom-
mendations such as: ‘take care to provide an integrated approach to health in deprived
areas (living conditions, behaviour, care)’; ‘incorporate health explicitly in the major
cities policy (GSB)’; ‘spread knowledge of the results of intervention projects in the
major cities’.
Evaluation is also an essential part of health promotion
The efficacy of interventions in health promotion is determined by many different fac-
tors, which makes it all the more important for programmes to be set up and executed
according to a plan (Brug et al., 2000). Thorough evaluation is an essential part of this
plan-based approach but such evaluations are still more the exception than the rule,
which is one of the greatest obstacles to gaining an insight into the efficacy of interven-
tions. As a result, we miss opportunities to learn from our experiences. In 2001, the
WHO published a report on evaluation in health promotion, in which it strongly urged
that sufficient financial resources be made available for these evaluations (WHO,
2001b). This report also emphasized the importance of including measures of both
process and outcomes in evaluations, and the importance of training the evaluators.
It is clear for health promotion too that the validity of the points for improvement from
PHSF 1997 is undiminished, and they have since become underpinned even more
securely. In addition to a higher priority for evaluation, these are: attention to the target
group, a multi-intervention approach and intersectoral action. One point of improve-
ment that is new is the emphasis on customization, the local approach and continuity.
Our understanding has therefore improved since PHSF 1997, but we note that there is a
reluctance to proceed with actual implementation. A European study into the implemen-
tation of eight preventive interventions that appeared to be effective and generally
accepted, reveals that, in other countries too, the implementation of the interventions is
often disappointing (ECAHI, 2001). In all trends towards a decentralized and local
approach, powerful support from central government therefore remains essential,
through prioritization, structural funding and continuity in observing the constraints.
Health protection: risk assessment and regulations
Health protection is concerned with averting the health risks of external factors through
collective measures, such as rules (and their enforcement) for environmental pollution,
the safety of food and drinking water, housing and working conditions and traffic safety
(De Hollander, 1993; Gunning-Schepers & Jansen, 1997). Measures taken in this area in
the past have been most effective in yielding health gains. The dilemmas involved here
are different in nature from the other two types of prevention, and they revolve around
the word risk. This concept combines the probability of damage to health with the sever-
ity of the damage.
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Text block 2.21: Prevention of alcohol related problems and smoking: health education supported by
legislation 
It has been found that the most effective way of
preventing excessive alcohol use involves the
combined application of various measures, in par-
ticular health education combined with (legisla-
tive) control of the environment in which alcohol
is consumed. It appears from the literature, both
in the Netherlands and elsewhere, that reducing
the number of sales outlets, raising the statutory
minimum age at which alcoholic drinks may be
purchased, changing the layout of cafés and bars
and in particular raising the price are effective
options (Lemmers, 2000; Van den Broucke,
1998). 
The Drank- en Horecawet (Dutch Alcoholic Bever-
ages and Catering Establishments Act) was
amended in 2000. It has been estimated that the
package of measures originally proposed (raising
the minimum age for the purchase of alcoholic
drinks from 16 to 18 and prohibiting the sale of
alcohol at petrol stations, staff canteens and
snack-bars) would lead to a drop in the average
consumption of alcohol in the Netherlands by
1.5% and hence to a reduction of 1.7% in the
number of excessive drinkers (VWS, 2000).
One measure was dropped from this package, viz.
the raising of the age limit for the purchase of
beverages with a low alcohol content. The age
limit for the purchase of beer and wine remained
at 16, while that for spirits was raised to 18.
Moreover, maintaining the age limit was found to
be difficult in practice, even after the increase in
the stringency of the legal regulations. More than
half of those under the age limit stated that they
could easily get an older friend to buy alcohol for
them (Bieleman et al., 2002). As a result of these
factors, the reduction in alcohol consumption is
doubtless less than calculated above.
Since it was moreover found that most of the
licensees responsible for the sale of alcohol did
not know the regulations, the Keuringsdienst van
Waren (Dutch Inspectorate for Health Protection
and Veterinary Public Health) decided to check
compliance with the new legislation more strictly.
The number of inspectors was increased by 40 to
this end. Licensees are liable to a fine of from 220
to 11,250 euros, or to loss of their licence, in case
of violation (representatives of the catering trade,
on the other hand, argue that it is the consumers
who should be punished). The Platform Verkoop
Alcoholhoudende Dranken voor Thuisverbruik
(Platform for Sale of Alcoholic Beverages for
Home Consumption) has started an information
campaign for supermarket personnel to promote
compliance with the age limits there. An evalua-
tion study will be carried out in 2003 to determine
the extent to which the expected drop in alcohol
consumption has been realized.
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Figure 2.23: Price of a packet of 25 cigarettes in
euro’s in 15 EU countries (Source: EC, 2001).
(continue text block 2.20)
they are taken continuously over a long period. On
the one hand, this demands that the individuals
for whom the medication is prescribed should fol-
low the regime faithfully (not easy if they are basi-
cally healthy), while on the other the effects of the
therapy are by definition not traceable at the indi-
vidual level. The discussion proposed by the CVZ
is all the more urgently needed in view of the high
cost of statins (total costs of use of this medica-
tion in the Netherlands were 255 million euro in
2001; it is not known how much of this total was
accounted for by the costs of the above-men-
tioned prevention programme at primary health-
care level). This treatment can in principle lead to
a reduction in mortality of up to 30% in the high-
risk group, or to a drop in the incidence of coro-
nary heart disease in the general population of 1-
2% (Rutz et al., 2002).
A sizeable academic discipline is occupied with estimating health risks, for example
through exposure to certain pollutants. A large-scale system of (European) regulations is
being drawn up on the strength of the results. These regulations are usually based on
permissible levels, for example a maximum of one death per million people per year
from a given cause (such as a chemical substance). In many cases, however, much
uncertainty surrounds the probability of exposure and the nature or severity of the health
consequences. Moreover, the choice of type of health effect (mortality, morbidity, con-
sequences of nuisance) involved in the assessment is sometimes arbitrary. These uncer-
tainties in the scientific risk estimates generally lead the authorities to err on the side of
caution when establishing standards for acceptable levels.
Apart from the above, standards and rules on protection against risks also have to be
observed and enforced. A prevailing belief that everything is well organized easily leads
to an erosion of inspection and enforcement, as illustrated in the Netherlands by the
recent disasters in Enschede (firework explosion), Volendam (fire in a bar) and
Bovenkarspel (Legionella).
In the case of traffic injuries, in contrast to many other areas, directly demonstrable and
considerable risks are involved (text block 2.24). It would appear that these risks can be
reduced by a combination of regulations and infrastructural measures, together with
improvements in behaviour and enforcement, where the environment (infrastructure)
reinforces behaviour (see also text block 2.21). Unlike most other areas of prevention,
this area has in the Netherlands been the subject of structural investments in safety (by
the Ministry of Transport and Water Management), and this has not been without result.
Risk perception is associated with many factors
As outlined above, there are already considerable uncertainties in the objective assess-
ment of risk. In addition, the perception and judgement of risks by the public also deter-
mines the ultimate picture. This subjective judgement depends on many factors. For
example, health risks are considered to be less acceptable the less they are taken volun-
tarily, or the more they are perceived to be uncontrollable, or are accompanied by mis-
trust of a remote party (industry, government).
On the one hand, public opinion may be swayed by risks that are tiny according to a
quantitative estimate, while on the other hand simply accepting risks that are orders of
magnitude greater. The general picture is that the public is demanding ever more sweep-
ing safety ‘guarantees’ from the government (inspired by the belief that, whatever the
issue, there is always a ‘fix’), while reserving complete freedom to take sometimes con-
siderable risks. This dilemma is also highly visible in traffic safety: we invest millions
in safe roads, but ultimately the limits are determined by individual driving behaviour
(text block 2.24).
These differences in perception are also expressed in the amounts that society is pre-
pared to spend on health measures. Section 2.5 goes into this subject in greater depth
and gives examples of the cost per QALY (Quality-Adjusted Life-Year) gained, which
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Text block 2.22: Health promotion in the workplace: health works! 
More and more companies are adopting a policy
aimed at health promotion in the workplace
(HPW). While 9% of Dutch companies had a HPW
policy in 1996, this figure had risen to 30% by
2002. HPW uses a combined approach to the
worker and the work environment to promote the
health of employees. In most companies, HPW
policy is mainly concerned with smoking (69%),
alcohol consumption (22%), physical activity
(22%) and RSI (19%) (NIPO, 2002). 
The information available about the efficacy of
HPW measures is mainly related to absence
through sickness. A European study showed, for
example, that absence through sickness fell in 18
out of 23 companies that had adopted a combined
approach to this issue. Other effects of a com-
bined HPW policy included improvement in
employees’ problem-solving ability, motivation,
involvement and health awareness. There are also
several examples of cases where investment in
HPW led not only to improved health for employ-
ees but also to a reduction in costs. In one cam-
paign, each euro invested in HPW was found to
yield a profit of 2.5 euros in two years through a
reduction in absenteeism (Vaandrager et al.,
2002).
Text block 2.23: Heartbeat Limburg: sustainable cooperation leads to success
A large-scale regional collaborative campaign
aimed at the prevention of cardiovascular disease
was started up in the Maastricht region of the
Dutch province of Limburg in June 1998 under
the motto ‘Heartbeat Limburg, healthy together’.
The vision underlying this project was that sus-
tainability, collaboration, adequate scope and con-
tent were the necessary conditions for effective
health promotion. Heartbeat Limburg combines a
community approach via the media and other
public channels with direct targeting of the high-
risk group via the medical circuit. 
Within the framework of the community project,
nine local ‘healthy life working groups’ were set
up. These working groups covered four neigh-
bourhoods in Maastricht and five smaller munici-
palities from the surrounding region. Each work-
ing group comprised volunteers from local
organizations and target groups together with a
health education officer, a welfare worker and a
local government officer (from the department of
sport and welfare). They worked together to orga-
nize health promotion activities at neighbourhood
level aimed at the target group selected, such as
‘Food for Health’ guided tours of supermarkets,
lectures on healthy lifestyles or food parties in
participants’ houses with all kinds of games. In
the high-risk project, GPs and cardiologists, in
cooperation with the municipal medical and health
service, trace people who are at high risk of con-
tracting cardiovascular disease. Four health advis-
ers can then offer support for these people in the
achievement of a healthier lifestyle. 
In the period from mid-1998 to mid-2002, the
community project generated more than 430
health promotion activities and the placing of
more than 380 press releases and articles in the
local media. While many of these activities
received support from national health promotion
campaigns run by such bodies as the Dutch
Olympic Committee and the Dutch Sport Federa-
tion, Defacto (Dutch anti-smoking NGO) and
Voedingscentrum/Stuurgroep Goede Voeding (the
Dutch Dietary Centre and Steering Group for a
Healthy Diet), an increasing number of initiatives
were also taken by members of the target groups
themselves. 
A total of more than 3000 patients have joined the
(continue text block 2.21)
Legislation can also support education when it
comes to controlling smoking behaviour. Of the
available options, it seems certain that at least the
price of cigarettes can influence consumption
(Jansen et al., 2002). Figure 2.23 shows the price
of a package of cigarettes (including duty and
VAT) in the 15 EU member states in 2001. The
European Commission wants to reduce the differ-
ences in taxes between the various countries. The
provisions of the new Dutch Tobacco Act include
the prohibition of tobacco advertising, an age
limit of 16 for sales, fines for contravention of this
requirement and an extension of smoke-free envi-
ronments. In particular the first of these measures
is expected to have an appreciable effect. Good
evaluation will be needed to check the precise
results of this package of measures in the Dutch
situation.
can vary by up to five orders of magnitude. For example, on the one hand there are vac-
cination programmes or the mandatory wearing of safety belts (cheap) and on the other
hand there are measures to eliminate Legionella in water pipes or to reduce exposure to
benzene (expensive).
Food safety, another major topic in this context, is the subject of extensive EU regula-
tions. An effect of the rapid globalization of the foodstuffs trade is that contamination
sometimes has large-scale consequences (the dioxin affair), and the effective inspection
of food quality is of undiminished importance. The above-mentioned perception gap is
manifest in the contrast between the often less healthy choice of food (fast food, few
vegetables and fruit, see section 2.2) and the critical attitude towards possible contami-
nation where the calculated risk is minimal. This is complicated even more by the many
sometimes contradictory publications on nutrition and the entanglement of economic
and health interests (hormones in meat, BSE). A PHSF theme report on this subject is
scheduled for 2003.
Health protection policy should take account of both the estimated efficacy of interven-
tions in terms of health gain and the widely differing risk perceptions in society. An
important basis for such a policy would be to make risks of a various nature transparent
and comparable with respect to both the scientific calculations, with their assumptions
and uncertainties, and the crucial elements of public perception.
The living and working environment influences health: intersectoral policy
The environment has already been mentioned above as a stimulating factor for
unhealthy or healthy behaviour and as a setting for enhancing the efficacy of health-pro-
moting activities. What is more, however, the living and working environment itself
may constitute a major determinant of health and well-being, quite aside from the ques-
tion of whether it supports a healthy lifestyle. Policy in the area of housing, education,
working conditions and social security (intersectoral policy; see also above under health
protection) has yielded much health gain and is still of great importance in this regard.
The WHO has recently reiterated (2002) that poverty and its consequences form the
major threat to health. The relevant factors in the Dutch situation are economic position,
social context in the working and living environment, and the often related physical liv-
ing and working environment, which together with a less healthy lifestyle are responsi-
ble for considerable health deficits (Van der Lucht & Verkleij, 2001; RIVM, 2002). The
Socio-economic Differences in Health Programme committee (SEGV-II, 2001) there-
fore recommended, in addition to policy directed specifically at healthy behaviour, that
health differences be reduced through the following measures: educational policy,
income and poverty policy, social policy to reduce the exclusion of chronically ill peo-
ple, improvement of working and housing conditions, incorporation of health in the
major cities policy (GSB) and improvement of the efficacy and accessibility of care for
deprived groups (see also section 2.3.3).
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Text block 2.24: Continued investment in traffic control measures – but behaviour remains the key
factor
The number of victims of traffic accidents in the
Netherlands continues to fall, thanks to massive
investment in traffic infrastructure and vehicle
safety. The Netherlands compares well with other
EU countries in this respect (see section 2.1).
This success is due in part to the joint pressure of
the authorities and consumers on the automotive
industry. Apart from this, massive investment in
traffic accident prevention is set to continue: the
National Traffic and Transport Plan (Dutch abbre-
viation NVVP) envisages spending six billion
euros in order to reduce the annual number of
fatalities to less than 750 by 2010 (Dutch popula-
tion in 2000: 15.9 million), and the number of
injured admitted to hospital per annum to below
14,000 by the same time (this represents reduc-
tions of 30% and 25% respectively). The
approach set out in the NVVP involves regional
analysis of risks and traffic characteristics and the
development of appropriate scenarios, leading to
the formulation of appropriate traffic safety mea-
sures such as infrastructural improvements, leg-
islation and measures to ensure compliance with
this, education and technological measures
(V&W, 2001). Specific possibilities for further
improvement of traffic conditions include adapt-
ing the traffic infrastructure to take account of
more elderly drivers, complete prohibition of the
use of mobile phones while driving, or the use of
‘alcohol sniffer’ locks which do not allow the car
to be started if the driver is over the limit. At the
same time, it is recognized that the lion’s share of
accidents are due to human error, while only 25%
of the six billion euros to be spent within the
framework of the NVVP is earmarked for educa-
tion and traffic monitoring (SWOV, 2001, 2002).
Text block 2.25: Treatment of coronary heart disease: technology reduces mortality
The rapid development of new medical technology
(which can be very expensive) is increasing the
ability of medical care to save and prolong life.
The treatment of coronary heart disease is one
clear example of this trend. For example, an
American study shows that the mortality within 30
days following acute myocardial infarction has
fallen from 27% in 1975 to 17% in 1995 (Heiden-
reich et al., 2001). According to this study, about
70% of this improvement in survival rate can be
ascribed to technological changes and improve-
ments in prevention and treatment possibilities
such as the prescription of aspirin and the intro-
duction of thrombolytic agents and dotter proce-
dures. The remaining 30% is associated with
changes in lifestyle (e.g. smoking habits) and
improvements in diagnostic procedures making it
possible e.g. to recognize mild heart attacks as
such and hence to treat them. Another study cov-
ering 31 different populations from four conti-
nents during the period from the mid-eighties to
the mid-nineties showed that 56 to 72% of the
drop in mortality due to coronary heart disease
could be explained on the basis of the increasing
use of therapies that had proved to be effective
(Tunstall-Pedoe et al., 2000). It may be noted in
this connection that the spectacular improvement
in the survival of patients with coronary heart dis-
ease was partially balanced by the subsequent
death of such patients due to competing causes
such as stroke. 
There are large differences in the extent to which
(continue text block 2.23)
high-risk project via a cardiology out-patients’
clinic and 25 participating GPs’ practices. Prelimi-
nary analysis of the data from 1085 of these sub-
jects yield a favourable impression. Sixty six per-
cent reported having adopted a healthier lifestyle
soon after the provision of the guidance offered
by this campaign, while 87% regarded this guid-
ance as a useful supplement to the support they
were already receiving.
The success factors of the Heartbeat Limburg
campaign are in particular the cooperation (inter-
sectoral, public/private and transmural), the
involvement of the various partners, the creation
of an adequate management platform and sustain-
able financing (the role of the initial main sponsor,
the Dutch Heart Foundation, has in the meantime
been taken over by the municipalities and the
health-care insurer). These success factors give a
clear indication of the reasons why many other
similar initiatives fail. The main new insight gen-
erated by the appraisal of this project is the
importance of good management in such a com-
plex cooperative undertaking (Ruland et al., 2001;
Steenbakkers & Ruland, 2000).
Central theme: effective, safe and accessible prevention
The central theme for all the examples of prevention discussed is the efficacy of preven-
tion and its evaluation. Safety is especially relevant to screening on a population level,
and the balance between health gain and negative effects such as the consequence of
early case-finding and false positive results (text blocks 2.17 and 2.30). The accessibili-
ty or reach of prevention is important in all population programmes: additional effort is
sometimes necessary to extend the reach in all target groups (text blocks 2.17-2.19, 2.22
and 2.23).
Ethical dilemmas in prevention
The health gain that remains to be achieved is linked largely to healthy or unhealthy
behaviour. How prescriptive or coercive should we be with our approach to influencing
behaviour (see Klazinga, 2001)? Are people becoming resistant to the pedantic preven-
tion approach?
These dilemmas can be resolved by promoting the ability of people to make their own
well-informed choices, as well as promoting healthy behaviour. On the one hand, this
approach places demands on the capacity to sift through and assess information. On the
other hand, the government must feel responsible for an effective and balanced package
of information (Verweij, 1999). Such choices are also involved in connection with the
improvements in recognizing genetically determined risks. The fact is that we can also
opt not to know (see also text block 2.30 and section 3.3).
All this demands education and support directed towards empowerment. As people
themselves start to give more direction to their lives (autonomy), they will probably find
more satisfaction and happiness, which in its own right will promote health (De Regt,
2001). Maybe they will then also make more conscious choices on health, not out of a
fear of a particular disease, but more as an expression of an attitude to life.
2.3.3 Health care: cure and care
Alongside prevention and socio-economic developments, medical care has also con-
tributed in the past to extending (healthy) life expectancy, albeit on a more modest scale,
and especially in more recent years (Mackenbach, 1996; Bunker, 2001).
We presented an overview of the efficacy and effectiveness, under ideal conditions and
in practice, of contemporary and new interventions in care for ten major diseases in
PHSF 1997 (Van der Meer & Schouten, 1997). The main conclusions were that the effi-
cacy under ideal conditions of most interventions has already been demonstrated, but
that much less is clear about their efficacy in practice. Obstacles exist in each of the fol-
lowing five steps that have been identified in the individual care process: contact with
the care sector, diagnosis, determining the indication, treatment and patient compliance.
The recommendations were as follows: to spread knowledge on the efficacy and effec-
tiveness of interventions under ideal conditions and in practice; to implement guidelines
and standards on this basis; to evaluate interventions in practice; and to create the asso-
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Text block 2.26: Breast-cancer survival increases by treatment and screening
The effectiveness of methods of treatment for
cancer can be assessed e.g. by considering the
survival rates For example, the 5-year survival
rate for breast cancer showed an average increase
of more than 5% in the EU countries in the period
from 1979 to 1988 (year of diagnosis) (see also
text block 2.17). This increase is ascribed in part
to the effect of screening programmes, since the
drop is correlated with the shift in the time of
diagnosis to an earlier point in the tumour devel-
opment process (Sant et al., 2001). Another con-
tributory factor is the fact that diagnosis has
become more accurate thanks to the use of mam-
mography and the increasing application of MRI
and DNA diagnosis (see section 3.3.2). The major
factor here is that early detection allows treatment
to be given at an earlier stage, thereby increasing
the chances of a successful outcome. There has
also been a rise in the post-operative use of
chemotherapy or hormone therapy in recent years
(see also text block 2.17). Figure 2.25 shows the
5-year survival rate in ten European countries (or,
in most cases, in certain regions within these
countries). The Netherlands occupies an interme-
diate position in this ranking.
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Figure 2.25: Five-year survival rate after breast
cancer in ten EU countries (Source: Eurocare-2;
Berrino et al., 1999. Dutch data collected by IKZ.)
(continue text block 2.25)
effective therapies are used in different places.
For example, figure 2.24 shows the number of
dotter (PTCA) procedures performed per 100,000
head of population in a number of countries in
1999 (these figures are not standardized for age
and gender). The large differences shown in this
figure do not reflect  large differences in the inci-
dence of myocardial infarctions. The use of PTCA
has shown a substantial increase in many coun-
tries, exceeding that of bypass operations. The
increased use of these procedures has been asso-
ciated in various countries with a rise in the sur-
vival rate one year after a myocardial infarction. It
may be noted, however, that survival in the USA is
no greater than that in the more successful EU
countries, despite the threefold greater use of
these procedures in the USA (Jacobzone, 2002).
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Figure 2.24: Number of dotter procedures (PTCA)
per 100,000 inhabitants in selected countries in
1999 (Source: OECD health data; for the Nether-
lands: Prismant, LMR).
ciated support within the framework of quality improvement in care. The interventions
discussed were concerned mainly with the cure (treatment oriented to healing) and to a
much smaller extent with care (residential care, nursing). We again have to ask our-
selves whether we have made any progress in the meantime. As with prevention, we
investigated this subject by reference to examples (text blocks 2.25-2.39).
Innovative interventions in care are helping
The use of more effective interventions has increased, which in some areas has yielded a
health gain (see the examples in text blocks 2.25, 2.26 and 2.29-2.31, for coronary heart
disease, breast cancer, perinatal mortality and care and the use of pharmaceuticals,
respectively; see also Council for Public Health and Health care (RVZ), 2001b).
We mentioned certain initiatives in the above section on prevention, and the desirability
of giving prevention a more prominent place in care. For instance, prevention can sup-
port curative care or help to postpone its use. A strict separation of prevention and care
is therefore not helpful. In other words: preventive interventions must form an explicit
and integrated part of care.
Some researchers think that new interventions and technologies are not being intro-
duced rapidly enough in the Netherlands, partly as a result of organizational obstacles
(Council for Public Health and Health care (RVZ), 2001a, c, d; NYFER, 2002).
Nonetheless, careful consideration is called for in this area. Not all technology that is
new, or effective in trials, actually leads to better care in terms of better health (see the
examples of Van der Meer & Schouten (1997) and text block 2.31). Under conditions of
equal efficacy, renewal must at least lead to a saving in costs. The application of medical
technology assessment (MTA), pharmaco-economic guidelines and post-marketing sur-
veillance must lend satisfactory support to this process. Currently, there is insufficient
coordination and support during MTA investigations (see section 3.3.5).
Measuring the effectiveness of care: outcomes and process parameters
In order to investigate whether the care sector fulfils its primary goal, it is often argued
that health gain should be measured as an assessment criterion for quality, and more
specifically the effectiveness of care (see chapter 1). The awkward question that
remains is: which health outcomes must we measure in order to assess efficacy or suc-
cess of our care interventions in practice (‘performance’, see also chapter 4)? The ques-
tion of whether we wish to use the information on a macro level (comparison of coun-
tries or regions), or on a meso or micro level (comparison of care institutions or
individual care providers) is also important in this regard.
We will deal with the macro level first. There are two trends. On the one hand, the gen-
eral state of health (for example life expectancy) is presented, possibly implicitly, as an
‘outcome’ of the care system (for example in WHO (2000); Ministry of Social Affairs
and Employment, SZW (2000); Council for Public Health and Health care (RVZ)
(2001b)). On the other hand, there is an effort to identify highly specific parameters that
provide valuable information about the performance of the care system, for example,
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Text block 2.27: Variation between primary care practices as an indicator of quality of care
In an ideal health care system, where high-quality
service is accessible to all, any geographical dif-
ferences in the level of care provided would be
slight (after correction for differences in the inci-
dence of the various diseases) assuming that all
health care staff work according to generally
accepted, evidence-based, best practices. In real-
ity, however, differences do occur; the observed
variations between the services provided in dif-
ferent primary care districts can be used as an
indicator of the quality of care.
In New England for example, it was found that for
women reaching the age of 75 the chance of hav-
ing had a hysterectomy varied from 25 to 70% in
neighbouring care districts (Wennberg & Gittel-
sohn, 1982). Comparable differences were later
found in other countries, and for other aspects of
health care such as the probability of being admit-
ted to hospital and the duration of hospitalization;
such differences were also found in the Nether-
lands (Mackenbach, 1990; Van Oers et al., 1997;
Westert, 2002). Local variations in working prac-
tices between different doctors often appear to be
due e.g. to differences in working conditions or in
access to knowledge of the best practices (West-
ert, 1996). Research has shown, moreover, that
the transition from local standards to generally
accepted (or national) standards can be rather dif-
ficult (Lomas et al., 1989). The use of financial
stimuli would seem to be essential if one wishes
to introduce best practices into the health care
system. One good example of advances made in
the Dutch situation is a growing acceptance of the
guidelines laid down by the NHG (Dutch College
of General Practitioners) for the treatment of type
2 diabetes mellitus as a professional standard,
which has led to a reduction in the variation of
care provided to this class of patients (Tacken et
al., 2001). Another example is the reduction in
regional differences in the number of appendec-
tomies in the Netherlands, around a reasonably
stable national average (Figure. 2.26; Westert,
2002). 
Data from seven EU countries (Belgium, Finland,
Ireland, Italy, Luxembourg, Portugal and the
Netherlands) (1998-1999; OECD health data)
shows a variation in the number of appendec-
tomies per 10,000 head of population between 9.5
and 22.4. The Netherlands has the lowest value
with about 9.6, while most other countries show
values of around 15 or higher than 20 (Luxem-
bourg). There is a trend towards a slight decrease
with time in most countries. The differences with-
in Europe are thus greater than within the Nether-
lands. It is difficult to interpret this data without
further research, in view of the fact that the
observed differences and trends cannot be cor-
rected for differences in incidence.
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Figure 2.26: Regional variation (highest, mean
and lowest) in the number of appendectomies per
10,000 head of population in the Netherlands
(corrected for age and gender), in the period from
1980 to 1997 (Source: Prismant, data processed
by RIVM).
cancer survival, avoidable mortality, or the prevention of complications in diabetes mel-
litus. The approach of the OECD (2000a, 2001) goes much further in this direction.
We take the specific approach in this section because the general approach does not pro-
vide sufficient information of value about the current performance of the care sector.
Provisionally, only a limited number of parameters would appear to be in any way suit-
able for, for example, international comparisons (see text block 2.26 (breast cancer sur-
vival) and text block 2.29 (perinatal mortality)). In practice, in the absence of more good
outcome parameters, process characteristics with a sufficiently clear or plausible rela-
tionship with health outcomes are often studied, (see also section 2.3.1 and the text
blocks 2.25 (application of PTCA), 2.27 (practice variation) and 2.34 (antibiotic resis-
tance)).
A large number of outcome or process parameters suggest themselves for comparison
on a meso level (comparison or benchmarking of care institutions). RVZ (RVZ, 2001b)
argues for a ‘care result analysis’ based as much as possible on health outcomes, mea-
suring many highly specific medical parameters. It is precisely this aspect of medical-
technical quality that is missing in recent publications on the comparison of care institu-
tions. We will return to this point later in this section.
The reduction of practice variation and the use of standards: how far
should we go?
An interesting measure for assessing the quality of care is practice variation or inter-
doctor variation, which generally becomes smaller the more that generally accepted
‘best practices’ or standard guidelines are adhered to. There would appear to be a
favourable trend in this respect for appendix operations in the Netherlands (text block
2.27). It is much more difficult to interpret the significance of differences between coun-
tries, because there are probably large variations in disease incidence. The example of
Caesarean sections (text block 2.28) shows quite a different problem: the choice
between what in principle are equally effective ‘treatment’ options can be made on
grounds somewhat removed from health. What does the number of such interventions
then say about the effectiveness of the care?
The general use of standards enhances the quality and efficacy of care, for example, by
discouraging the use of outdated and less satisfactory practices. But how universal are
‘best practices’? ‘Best practices’ have tended to differ between countries both in the past
and more recently (Payer, 1988; Bernstein et al., 2002). In theory, moreover, setting
down ‘best practices’ in guidelines and standards can conflict with a rapid adoption of
new technologies or other care-reforming experiments (see text block 2.33 and Post &
Stokx, 1997). It would appear that the two elements, renewal and standardization, are
not fundamentally incompatible, and it should be possible to combine them in a
demand-oriented approach.
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Text block 2.29: Perinatal mortality as an example of ‘avoidable mortality’: regional and 
international variations
‘Avoidable mortality’ is that part of mortality that
may in principle be prevented by good care
(and/or preventive measures). A high ‘avoidable’
mortality in a particular area provides a signal that
care may be suboptimal there. Hence, variations
in avoidable mortality are sometimes used as an
indicator of the quality or effectiveness of care or
preventive measures (Rutstein et al., 1976). If dif-
ferences are found, further research is required to
point the way to possible improvements. Perinatal
mortality is chosen here by way of illustration,
since this is often used as an indicator of the
quality of (neonatal) preventive and curative care.
Regionally: Significant variations in perinatal mor-
tality were found between the various Dutch
provinces in the period from 1984 to 1994. Zee-
land was the best, with a perinatal mortality equal
to 0.76 of the national average, while Limburg
was the worst, with 1.16 times the national aver-
age. The trends in this mortality also varied, Bra-
bant and Limburg showing a more marked drop
than the other provinces. No relationship was
found between the mortality and various care-
related factors such as the place of delivery or the
presence or absence of specialized neonatal care.
Further, no consistent relationship was found
between mortality and socio-demographic factors
(Treurniet, 1999). 
Internationally (see figure 2.28): Perinatal mortali-
ty has fallen almost everywhere during the past
few decades. This decrease has, however, been
less marked in the Netherlands than in many sur-
rounding countries. I should be noted, however,
that the differences between the various EU coun-
tries have become much smaller. The stagnation
of the figure for the Netherlands is related among
other things to a relatively sharp rise in the risk
factors for a number of perinatal complications,
such as a higher average age of mothers at the
time of delivery, the percentage of first children,
the number of multiple births and the percentage
of children whose mother comes from an ethnic
Text block 2.28: Variation between primary care districts and differences in medical culture: 
caesareans
Some forms of treatment show a more extreme
regional variation than others (see text block 2.27
and Payer, 1988). One striking example is the fre-
quency of caesarean sections, which varies much
more from one country to another than the
regional variations within the Netherlands. In
1997, the number of caesareans per 1,000 births
in the Netherlands varied from about 90 (in south-
ern South-Holland and Overijssel) to about 120
(North-Holland, Drenthe, Zeeland, South-Gelder-
land and North-Limburg). The overall variation of
about 20% is distributed in a fairly arbitrary man-
ner throughout the country (Source: Prismant,
LMR). Within the EU, however, the ‘leaders’ in this
field such as Portugal and Italy show values of
about 300-350 caesareans per 1,000 births, i.e.
three times as many as in the Netherlands (figure
2.27). While differences do exist in the incidence
of risk factors for perinatal complications (where,
it may be remarked, the position in the Nether-
lands is not particularly favourable; see text block
2.29), the variations in the number of caesareans
seems to be mainly due to cultural differences in
the preferences of women and doctors and to dif-
ferent considerations regarding operation plan-
ning and safety. It goes without saying that this
has consequences for the costs of care.
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Figure 2.27 Trends in numbers of caesarean sec-
tions per 1,000 births in six EU countries (Source:
OECD health data, 2001).
Renewal by integrated care
Integrated care, or chain care, is a form of care that arranges for and supervises the best
possible path through the care circuit from the point of view of the individual patient
(see text block 2.33). Another key word here is continuity of care, in which both cure
and care are often involved. Clear improvements can be observed in this area relative to
the traditional approach in strictly separated sectors, in terms of both health and the
most effective use of resources. This shows that demand-oriented care can pay. The
Social and Cultural Planning Office (SCP, 2002) gives several other examples of con-
siderable improvements in both quality and productivity. Why, then, are only isolated
cases involved? Specific initiatives would appear to be necessary, which would be diffi-
cult for the system itself to achieve (given its present operational structure of separate
sectors and subsectors), even though individual care providers may be more than will-
ing to do so.
A safe health care system
Safety is the other side of efficacy: the medical treatment must have no undesirable
adverse effects on health (iatrogenic effects). Nonetheless, effects of this type do occur
in practice. For instance, it has been estimated that ‘adverse events’ in care in the United
States, including medical errors, account for a loss of life expectancy of 6-12 months
(Bunker, 2001). In the Dutch situation, medical errors are said to be involved in approx-
imately one to four deaths per 1,000 hospital admissions (Baan et al., 2001; see also
Treurniet, 1999).
More specific examples can be derived from studies on the undesirable consequences of
medicine use (text block 2.32) or the appearance of resistance as a consequence of the
liberal use of antibiotics (text block 2.34). Trial projects have demonstrated that a target-
ed approach can produce spectacular reductions in adverse effects. Examples are post-
operative wound infections (up to 50% reduction of the risk; Geubbels, 2002) and decu-
bitus ulcer (a reduction in prevalence of 16% in university hospitals and 33% in nursing
homes to less than 5%; Decubitus Ulcer Steering Group 2002). Some of these specific
parameters can be used to compare countries on a macro level (resistance to antibiotics).
The registration of medical errors falls mainly within the scope of the quality systems
on the level of the individual care provider and the institutions. It is also a focal topic for
the Health care Inspectorate. An investigation is currently under way to determine how
inspection can be organized rationally in the Netherlands, to avoid any undesirable con-
sequences of medical action (or its omission) as effectively as possible (Baan et al.,
2001).
An accessible health care system
In the above sections, we discussed the quality of the care process, which we
approached mainly by considering the extent to which medical interventions contribute
to an improvement of the state of health (efficacy and safety). We indicated that achiev-
ing this goal requires that care must also be accessible to everyone. The main factors in
accessibility are the timely availability of care (waiting lists, waiting times), its geo-
graphical spread, and whether it is affordable for everyone. The criterion of solidarity is
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(continue text block 2.29)
minority. Another factor is smoking behaviour
during pregnancy (Achterberg et al., 2001). The
results of an international comparative study into
the role of shortcomings in perinatal care as a
causative factor in perinatal mortality (Vrede-
voogd et al., 2001) indicate that such shortcom-
ings are not found more frequently in the Nether-
lands than in other EU countries: Finland and
Sweden are the only two EU countries where the
situation is better.
Text block 2.30: How far should perinatal care go?
Perinatal mortality in the Netherlands has fallen
during the past few decades. The main reasons
for this are better perinatal care and improve-
ments in living conditions and lifestyle (see text
block 2.29). 
One of the main causes of the improvement in
perinatal care is the increasing availability of
modern facilities derived from advances in med-
ical technology. This improvement is reflected e.g.
in the growing number of premature (and very
premature) babies who are kept alive (sometimes
only for relatively short periods) (WBC-LNR,
1998; Gezondheidsraad, 2000c). It may be noted
that those who survive by this means often suffer
from appreciable problems in later life (e.g. neu-
rological dysfunction, poor social functioning,
high consumption of medical care and poor per-
formance at school) (Theunissen et al., 2000). 
Serious perinatal problems also lead to dilemmas
in the field of medical ethics, related for example
to the question of whether further medical inter-
vention makes any sense in some of such
instances (Gezondheidsraad, 2000c). There are
clear differences in insight between care
providers in various European countries as
regards the limitations to be placed on the use of
intensive care (Rebagliato et al., 2000). Dutch
physicians appear to be more reluctant than many
of their colleagues in other countries to initiate
intensive treatment in a hypothetical case if the
prognosis for the child is very poor (De Leeuw et
al., 2000). Dutch and English physicians appear to
be readier to take the wishes of the parents into
account in such situations. 
Less use is made of the possibilities for prenatal
screening in the Netherlands than in other Euro-
pean countries. In 1998, only 45% of pregnant
women aged 36 or above underwent a floccula-
tion test or amniocentesis. Evidence for Down’s
syndrome was found in 1% of these cases, and
95% of the mothers concerned opted for termina-
tion of the pregnancy (Rutz et al., 2002). The per-
centage taking part in this screening in 1990 was
higher, viz. 56%. This reluctance to undergo
screening may explain why the Netherlands has a
relatively high percentage of newborn children
dying of neural-tube defects compared with other
countries (Achterberg et al., 2001).
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Figure 2.28: Trends in perinatal mortality in
Europe, 1960-1997 (Source: OECD health data,
2001).
also relevant, between rich and poor, between the healthy and the sick, and between
young and old.
The link between accessibility and health outcome is less obvious than it is with effica-
cy. However, inadequate contact with the care sector is one of the reasons why active
interventions can be less effective in practice (Van der Meer & Schouten, 1997). Obtain-
ing direct proof that loss of health results from long waiting times, for example, is no
simple matter. Deaths are merely the tip of the iceberg in this case. The effect will usual-
ly take the form of pain or diminished mobility, for example, and absence from work
while waiting for an operation, or stress through uncertainty about the significance of
symptoms, while waiting for a diagnostic investigation.
A positive point is that the Netherlands has a comparatively extensive package of care
provisions amounting to almost 10% of GDP (or 8% according to the OECD definition).
What is more, accessibility is reasonably uniformly distributed across different popula-
tion groups (text block 2.37). Furthermore, the provisions have a reasonable regional
distribution (although several locations fail to satisfy the accessibility norm for acute
outpatient and emergency care; see Van der Veen et al., 2001; the National Atlas of Pub-
lic Health), and there have been additional initiatives to reach non-Dutch speakers.
Nonetheless, there is a case for investing even more in care for deprived groups in
neighbourhoods, incorporated in an integrated approach to health (text block 2.37, see
also section 2.3.2).
In spite of the above reasons for optimism, the problems with accessibility of care have
recently increased. This is due to deteriorating shortages of capacity in almost all sec-
tors, organizational compartmentalization with (at least until recently) excessively tight
budgets combined with supply control and a changing care demand behaviour. There is
therefore a discrepancy between supply and demand, combined with a rigid structure
(see also SCP, 2002). These problems manifest themselves in the waiting lists (text
block 2.35) and the personnel shortages (text blocks 2.36 and 2.38).
Since 1998, annual budget growth in the care sector has increased from 1.3% to 2.4%,
partly on the basis of the PHSF 1997 forecasts (Post & Stokx, 1997). The government
that took office in July 2002 raised this amount slightly to 2.5%, and made a number of
additional investments (VWS, 2000b). Various analyses have shown that the extra
resources deployed since 1998 have brought about a genuine improvement in produc-
tion, but that, for a variety of reasons, they have not yet led to a reduction in waiting
times.
Accessibility and changing demand for care
The assertive citizen is demanding an increasing number of guarantees from the govern-
ment and others in order to be protected against undesirable risks (see also section
2.3.2). The care client has also changed. Expectations are high and there is less accep-
tance of the fact that the doctor is unable to solve all problems, and this is exacerbated
by the publicity given to numerous success stories about medical breakthroughs. On
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Text block 2.31: medication use: higher expenditure but also more effective
Medication is an important treatment option for
nearly all the 53 diseases dealt with in this report.
The supply of pharmaceuticals in the Netherlands
has grown strongly during the past few decades,
between 25 and 35 new active agents being added
to the list each year (Egberts & Leufkens, 2001).
The costs of pharmaceutical aid (excluding self-
medication and the medication used in hospitals
and nursing homes) show a higher annual rise
than the overall costs of health care, amounting to
10 to 11% per annum in the period from 1998 to
2001. The rising costs are due both to increases
in the price of the medication concerned and to
increases in the amounts consumed. A particular-
ly large rise is seen, for example, in antidepres-
sants, cholesterol-reducing agents (see text block
2.20) and gastric-acid inhibitors. 
Does this mean that pharmaceuticals are making
a greater contribution to the health gain? Broadly
speaking, this is probably so (see e.g. text block
2.26). The detailed picture is more varied, howev-
er. On the one hand, pharmaceuticals are only
licensed for use when their effectiveness has been
demonstrated in clinical trials. On the other, this
does not mean that they are always effective and
safe enough in practice, or that they are better
than existing medicinal products.
We will illustrate this with reference to a few
examples (see also Timmerman & Van den Berg
Jeths, 2001): 
• Antibiotics have been available since the 1940s,
and have made a substantial contribution to the
rise in life expectancy since then. However, the
effectiveness of existing antibiotics is being
reduced by the development of resistant organ-
isms (see also text block 2.34).
• Insulin has saved the life of many patients with
type 1 diabetes mellitus. The many oral antidia-
betic drugs have made a substantial contribu-
tion to delaying the onset of complications in
type 2 diabetes mellitus.
• Opinions are strongly divided as to whether a
new generation of antidepressants, the selec-
tive serotonin reuptake inhibitors (SSRIs) is
more effective than the older tricyclic antide-
pressants (TCAs) (Bijl & Verhoeven, 2002).
Text block 2.32: Adverse effects of the use of pharmaceuticals can be limited 
The use of pharmaceuticals may have undesired
and unintended adverse effects on health as well
as positive effects. Apart from the known and
‘accepted’ side effects of such substances, these
adverse effects can be due to individual variations
in patient characteristics, interaction between var-
ious agents and incorrect use or dosage.
Despite prolonged research during the develop-
ment of pharmaceuticals, it is not always possible
to predict such effects in advance. Good post-
marketing surveillance can however help to deal
with some of these problems (Egberts &
Leufkens, 2001). 
A number of studies of hospitalization or death
due to side effects or undesired effects of medica-
tion have been carried out since the 1980s, espe-
cially in the USA and Australia. It was calculated
in a recent meta-analysis of 64 studies (Beijer &
De Blaey, 2002) that if the findings were extrapo-
lated to the Netherlands this would indicate that
about 8% of all hospitalizations (or a total of
131,000 admissions) could be ascribed to this
cause. The proportion is several times higher in
the elderly, while it is estimated that about 30% of
these cases are avoidable. 
One possible way of improving this situation
involves a more active role for the pharmacist. A
recent study of 142 pharmacies showed that 4.3%
of doctors’ prescriptions were changed by the
pharmacist on such grounds as dosage problems,
risk of interaction with other medication, con-
traindications or double medication. Twenty-two
percent of the changes could have had a clinical
effect (Buurma et al., 2001). The pharmacist can
play a particularly important role in cases of mul-
tiple medication, e.g. in the treatment of heart fail-
ure (Bouvy, 2002).
average, the citizen is better informed on health and new medical technology than in the
past, but has yet to develop a satisfactory care demand behaviour. On top of this comes
the political trend towards demand-driven care and customer orientation. All these ten-
dencies make for a rising demand for care. Okke & Lamberts (2000) identified three
categories of practice in the current ‘post-traditional medicine’: (a) ‘evidence-based’,
(b) non ‘evidence-based’ but still medically justified, and (c) neither of the above two.
The doctor is increasingly expected to act according to (a), but the client is increasingly
demanding (c). If we wish to continue to foster a demand-driven system, we have no
choice but to attempt to channel the flood of medicalized life problems in some way or
other (Kooiker, 2002).
Accessibility and opinions
There is considerable public and political interest, and substantial dissatisfaction, with
deficiencies in the care sector. This trend is not yet clearly visible in care sector public
satisfaction surveys, but the Netherlands achieves no better than an average score with
respect to the accessibility of extramural care (text block 2.39). A relatively recent
Social and Cultural Planning Office (SCP) survey (SCP, 2002) revealed that a signifi-
cant percentage of the Dutch population find the quality of care to be mediocre or poor
(varying according to sector: from over 20% for medical care to more than 60% for care
for the elderly). For all sectors, those who see a deterioration outnumber those who see
an improvement. The main factor behind this assessment seems to be dissatisfaction
with waiting lists. Care users are far more positive, particularly on expertise and cus-
tomer orientation, but not on the continuity of care. Moreover, a majority is not prepared
to pay more for care (SCP, 2002).
A Health care Inspectorate (IGZ) and VWS survey of the causes of the persistent gap
between supply and demand identified rising demand and personnel shortages, in addi-
tion to organizational and financial obstacles (Bon & Van der Maten, 2002). This survey
was based on semi-structured interviews with a large number of care sector employees
(see also text block 2.33). The survey also mentioned an unsatisfactory personnel policy.
These observations are consistent with analyses made by RVZ (2001a). Some respon-
dents in the VWS study even stated that many of the waiting list problems could be
solved rapidly through better logistics and planning. A recent survey by Elsevier among
medical personnel also painted a picture of growing dissatisfaction with the scope for
practicing the profession satisfactorily (Van Leeuwen & Wansink, 2002). The solutions
identified by respondents include improvements to working conditions and more exten-
sive training. They considered the enhancement of market operation through the active
intervention of insurers to be far less important.
The specific place of nursing and residential care
Much of the above is applicable to both cure and care. However, special attention is
appropriate for the care sector, because the ageing of the population and the reprieve
from premature mortality and morbidity is causing a shift from cure to care. Care now
accounts for a very considerable proportion of the total costs in the care sector (section
2.4 and chapter 3).
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Text block 2.34: Antibiotic resistance: strict policy bears fruit in the Netherlands
A total of 2,218 cases of infection by invasive
strains of Staphylococcus aureus were reported in
the Netherlands in 2001. S. aureus is one of the
main causes of infection in hospitals, and can
spread easily. S. aureus infections were originally
treated with ß-lactam antibiotics (including methi-
cillin), but it did not take long for methicillin-
resistant S. aureus (MRSA) strains to develop.
The rise and spread of MRSA is facilitated by poor
hygiene in hospitals and high levels of usage of
antibiotics. 
Data on the prevalence of MRSA in hospitals in
the period from 1999 to 2001 shows large varia-
tions between different European countries, from
less than 3% in the Netherlands and the Scandi-
navian countries to more than 30% in most
Mediterranean countries, England and Ireland.
During this period there was a particularly sharp
rise in the prevalence of MRSA in Germany (from
10 to 18%) and England (from 33 to 45%). Eng-
land thus currently has the doubtful honour of
heading the MRSA league table in Europe. Strict
anti-MRSA measures taken in the Netherlands and
Scandinavia, involving such steps as the active
isolation of infected individuals and appropriate
hygienic measures in hospitals (two aspects of
quality of care) have clearly borne fruit. Neverthe-
less, the Netherlands was not as ‘clean’ in 2001
as it was in 1990: during this period, the number
of cases of MRSA among hospital staff and
patients has roughly tripled, to about 400 (includ-
ing non-invasive infections) (Rutz et al., 2002).
For a related infectious agent, Streptococcus
pneumoniae, which can give rise to meningitis or
bacteraemia as well as to respiratory tract infec-
tions (responsible for 5,100 invasive infections in
the Netherlands in 2001), a clear relationship was
found in ten EU countries between penicillin resis-
tance and the use of ß-lactam antibiotics (includ-
ing penicillin).
The Netherlands scores lowest on both these
counts. Spain uses antibiotics five times as much
as the Netherlands and shows a thirty-fold higher
prevalence of resistance (34%) (EARSS, 2001;
Bronzwaer et al., 2002).
Percentage
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Figure 2.29 Percentage methicillin resistant
Staphylococcus Aureus, 1999-2001 (in Malta:
more than 30%, not visible) (Source: EARSS,
2001)
Text block 2.33: Local examples of care chains for stroke
The term ‘care chain’ (or integrated care) is used
to denote situations where the planning and exe-
cution of care for individual cases extends over
several care sectors. Trials of integrated care for
stroke are under way in various parts of the
Netherlands. One study covering six different
regions showed that the Delft region offered the
best conditions for an effective care chain. It was
further found that this region had the fewest
shortcomings in the care offered, as regards both
content (adequate diagnosis and therapy, rapid
availability of a hospital bed) and organization
(transfer of dossiers, multidisciplinary involve-
ment), which might be thought to have an influ-
ence on recovery. Finally, the study showed that
the patient group in the Delft region was the
healthiest (in terms of limitations on activities of
daily living (ADL) and self-perceived quality of
life). The following elements, among others, were
mentioned as crucial to the success of this pro-
ject: the presence of a specialized stroke unit in
the hospital, early anticipation of the need to
transfer the patient from the hospital to the next
stage in the care chain, which is made ready in
advance (thus reducing the duration of hospital-
ization) and the presence of a transmural nurse
who has contacts with all the institutions involved
and is thus able to prepare and offer guidance for
implementation of a solution tailored to meet the
needs of each patient (Huisman et al., 2001).
In the case of care, the relationship between interventions and health gain is even more
difficult to establish than for cure. The issue is by definition not so much one of healing,
but of improvement (or postponement of deterioration) of quality of life. Measurable
standards do not always exist here and the matter comes down to a perception of what
constitutes a minimum of dignified care. However, some points of departure do exist.
The fact that healthy life expectancy without disabilities exhibits a compression of mor-
bidity that is not reflected in a reduced incidence of disease suggests that people with
impairments are making more effective use of devices (section 2.1). According to the
Social and Cultural Planning Office (SCP) report on individuals with a disability (De
Klerk, 2002), there has been an increase in participation in many forms of leisure-time
activity, especially cultural activities, on the part of those with a disability.
However, with respect to accessibility, the situation in care is at least as great a cause for
concern as in cure. The length of the waiting lists and the capacity shortages in nursing
and residential care persist (text blocks 2.35 and 2.38), in spite of the recent expansion
of capacity. Sometimes acute cases are also involved here, such as the chronic care that
is necessary following a hospital admission for a fractured hip. In this connection, we
would also like to mention the inspiring example of the integrated care for stroke (text
block 2.33).
Initiatives for comparing care institutions
There is a recent trend for comparing the quality of care institutions and providers
through the transparent presentation of quality indicators, to enable consumers and
insurers to make well-informed choices. Such comparisons have recently been pub-
lished by the Consumers’ Association (Sluyters, 2002) and Elseviers Weekly (Van
Leeuwen & Wansink, 2002), in the form of report figures and rankings for a large num-
ber of hospitals in the Netherlands. The assessments were based almost completely on
the opinions and experiences of patients or medical personnel and were mainly con-
cerned with aspects of patient orientation, accessibility or (internal) organization. They
were not based on the measurement of medical-technical quality.
It is likely that, for the time being, consumers will be influenced mainly by patient ori-
entation and accessibility. On the other hand, those in the medical field and insurers
actually do want data to be available on medical-technical quality (outcome or process).
Indicators therefore need to be developed for this very area in the interests of balanced
benchmarking (Council for Public Health and Health care (RVZ), 2001b; see also a
worked example for mental health care: GGZ-Nederland, 2000).
Various authors draw a distinction between indicators for internal use, which are orient-
ed on quality improvement within the organization, and indicators for external use,
which are relevant for consumers, insurers and the Inspectorate (BMG, 2002; Berg &
Schellekens, 2002). The use of ‘internal indicators’ for drawing up ‘public’ league tables
can easily undermine the quality of that data, thereby leading to a failure to achieve the
desired quality improvement. The question is, what are our objectives here? Do we want
to point the finger at the ‘less well performing’ or, conversely, to create a positive stimu-
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Text block 2.35: Waiting lists and waiting times: political hype or sign of a failing system?
Waiting lists have always been a feature of the
health service, and to a certain extent they serve a
useful purpose. However, they have been growing
longer in recent years and people have become
more critical of the delays involved; as a result,
waiting lists have become a social and political
issue (VWS, 2001). Since 1997, records have
been kept of the waiting lists in virtually every
hospital in the country. Records have also been
introduced for some other sectors of the health
care system. Table 2.12 gives an overview of the
results for the period from October to December
2001. 
The table shows that in all cases, more than half
the number of people on the waiting list at a given
point in time have been waiting for longer than is
considered acceptable. This does not mean, how-
ever, that more than half of all patients actually
had to wait so long, since people who receive
treatment quickly may not appear on the waiting
list at all. Most of the waiting in hospitals is for
orthopaedic surgery, general surgery, plastic
surgery and ophthalmological treatment. If the
figures are related to the total numbers of admis-
sions (to give a clearer picture), we see that plas-
tic surgery produces most delays, followed by
orthopaedics. On an annual basis, per 1000 clini-
cal admissions, approximately 700 people are on
the waiting list for plastic surgery at any given
point in time, while the corresponding figure for
orthopaedic treatment is 250. On the (hypotheti-
cal) assumption of equal waiting times for all
patients, this comes down to a waiting time of
about six months for plastic surgery and two
months for orthopaedics (Nienoord-Buré & Talma,
2002). In the care sector, the number of people
waiting without interim care is particularly high
for home care (more than 50%) with large region-
al variations from less than 10 per 1,000 head of
population aged 75 or above in the northern
Dutch provinces to 60 in the central part of the
country. 
What we would really like to know is what per-
centage of the patients treated in a given period
had to wait longer than is acceptable. In the case
of the care for the intellectually disabled, it can be
calculated that 70% of those treated had to wait
longer than the period of 13 weeks which is con-
sidered acceptable. Limitations imposed by the
available data, however, mean that this kind of
calculation cannot be made for most other sec-
tors.
Comparison with previous data for October 1998
and 1999 shows that overall waiting lists and
waiting times for hospitals and for the care sector
have increased or remained stable, despite a rise
in the level of resources available and in produc-
tivity. The care of the intellectually disabled (on a
day-admission and residential basis) is one sector
where waiting lists became shorter in the period
from 1999 to 2001 (VWS, 2001, 2002c). Home
care showed a similar fall between May 2000 and
March 2001, but not thereafter (Taskforce, 2002). 
Table 2.12: Waiting list data in four care sectors (Source: Polder et al., 2002).
Care sector, type Number on the waiting list* Number on the waiting list for
(maximum acceptable waiting time) longer than the standard time
Hospitals, clinical (7 weeks) 74,600 42,700
Hospitals, outpatients (6 weeks) 85,100 43,800
Mental health care, extramural (6 weeks) 16,900 11,200
Care of the disabled, dwelling (13 weeks) 5,000 3,300
Nursing home care (4 weeks after indication) 11,400 9,100
Home-care services (4 weeks after indication) 40,000 29,100
* Dutch population in 2000: 15.9 million.
Text block 2.36: Few physicians per head in the Netherlands; growing shortage in the primary care 
sector
According to the OECD database (2002 edition,
data for 1999), the Netherlands has a very small
number of physicians working in the care sector
compared with the rest of the European Union.
This applies to both GPs and specialists (figure
2.30). While problems exist concerning the com-
parability of such data between countries (it
should be noted that strenuous efforts are being
lus? If we wish to create a stimulus, we will have to exercise great care when selecting
the information for use in a public comparison of institutions. We note that experience in
the United States has shown that the influence of their extensive disclosure of informa-
tion still has a limited effect on the behaviour of the consumer, and that it is no more
powerful than confidential information as a stimulus for quality improvement among
care providers (Geubbels, 2002).
2.3.4 Finally: conclusions and provision of information
Prevention: dilemmas are prompting an integrated approach and 
structural investments
The recommendations of PHSF 1997 for further evaluation of preventive interventions
still apply. Furthermore, the efficacy of many promising prevention initiatives has still
to be properly investigated. Recent experience lends more weight to the necessity of an
integrated approach that is customized for the target group and which incorporates con-
tinuity. The dilemmas have to do with the tension between collective interests and indi-
vidual choice, and the need to view prevention in a long-term perspective, in an era that
focuses on short-term results. If we take the unfavourable trend in the prevalence of risk
factors as a criterion (section 2.2), the success of prevention in recent years has been
modest, in spite of a multitude of initiatives. Therefore, it is high time to translate what
we have learned into integrated action, supported by structural investment, in order to
prevent loss of health in the future. Chapter 4 makes a number of relevant, firm recom-
mendations.
Care: closing the gap between supply and demand by both investment and
innovation
The emphasis on health gain as an objective of care gives direction to renewal in the
care sector, which is necessitated by the widening gap between supply and demand.
Renewed interventions must be more effective (and/or more efficient, see section 2.5)
than existing ones. Integrated care can be more effective and better targeted to demand
than in sectors of segmented care. Safety can be enhanced by better implementation of
‘best practices’, by learning lessons from successful trial projects, by specific registra-
tion in quality systems and a matching model for inspection. In terms of accessibility,
the growth in capacity of medical personnel is lagging behind other countries, and is
even showing signs of stagnation. The solution lies in a combination of additional
investments and the removal of organizational obstacles. Chapter 4 covers this subject
in greater detail.
The provision of information and the measurement of performance
We stated above that the efficacy of care can be measured by outcome or process para-
meters. Similar information is also necessary for the safety and accessibility of care, as
well as for prevention with respect to the same aspects. This information is necessary in
order to compare countries (macro level), or institutions (meso level), over time.
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(continue text block 2.36)
made to resolve these problems), it is very
unlikely that the low score for the Netherlands is
an artefact. It may further be noted that the fig-
ures say nothing about the numbers of FTEs (full-
time equivalents). The relationship between the
total number of physicians working in the care
sector and the number of full-time equivalents is
influenced among other things by the proportion
of woman doctors (many of whom work part-
time). This proportion varies appreciably across
Europe, from less than 30% in Luxembourg,
Switzerland and Italy to more than 50% in Fin-
land. The Netherlands occupies an intermediate
position, with more than 34% (Eurostat New
Cronos, 2002).
The present situation is largely determined by the
long-standing policy of restricting the number of
university students admitted to medical training,
despite the fact that employment surveys have
been indicating for a number of years that short-
ages could be expected in this field (Capaciteit-
sorgaan, 2001). It has recently been announced
that a considerable extension of the number of
medical training places has been planned (VWS,
2002b).
The number of GPs working in the Netherlands
rose by 5.4% between 1996 and 2001, reaching
7,763 (Dutch population in 2000: 15.9 million) as
of 1 January 2001 (Kenens & Hingstman, 2001).
The number of training places has also been
increased. Nevertheless, a growing shortage of
family doctors is to be expected. The reasons for
this include a growing number leaving the profes-
sion, a rise in the proportion of woman doctors
(60% for the 2000/2001 cohort) coupled with an
increasing desire to work part-time (expressed by
both male and female GPs) and a rising demand
for care. The Capaciteitsorgaan (a body set up by
the minister of Public Health, Welfare and Sport
to provide advice about future requirements for
GPs, specialists and dentists) recommended on
the basis of calculations by Nivel that the annual
inflow of new GPs should be raised to 670 by as
early as 2001 (Capaciteitsorgaan, 2001; Van der
Velden & Hingstman, 2001). The Ministry of Pub-
lic Health, Welfare and Sport has recently
announced that it aims to extend the capacity of
training courses for GPs by more than 50%. This
will only bear fruit in the long term, however. In
the meantime, the number of unoccupied prac-
tices is growing: the Dutch Association of GPs
(Dutch abbreviation LHV) estimates that half a
million inhabitants of the Netherlands are already
without a GP (see the Association’s own website,
www.lhv.nl). Nivel is currently carrying out a
study to identify the regions with the greatest
shortage of GPs.
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Figure 2.30: Number of general practitioners and
specialists per 1,000 inhabitants in European
countries, 1999 (Source: OECD health data, 2002).
a) no data for specialists
b) no data for general practitioners
Text block 2.37: Relatively equal access to care for different socio-economic groups in the 
Netherlands
The aim in the Netherlands is to achieve equal
access to health care (for those with a specifically
defined level of health) for all. A longitudinal
study of the use of health care services carried
out in the environs of Eindhoven has shown that
groups with lower socio-economic status (as
determined on the basis of educational level, but
corrected for state of health) make relatively
intensive use of the services of GPs, but relatively
little use of the services of specialists. The
remaining high intensity of use of GPs’ services
can be explained solely on the basis of differences
However, such information is largely unavailable, and even less internationally compa-
rable. From the viewpoint of data gathering, a distinction can be drawn between the effi-
cacy/safety of interventions and the extent to which they are actually applied. As stated
above, the major problem area is the absence of evaluation studies for prevention.
Recent studies are shedding new light on a more flexible evaluation method, involving a
broader range of assessment criteria (WHO, 2001b). A recent initiative, the Quality of
Interventions (QUI) project, sets out to coordinate and improve data on the effects and
the application of prevention projects, on a national basis. For care, data on efficacy
under ideal conditions and in practice is gathered by the Cochrane Collaboration (Van
der Meer & Schouten, 1997). Part of the data on the application of care is maintained in
medical registrations (Prismant). The sector reports issued by the Ministry of Health,
Welfare and Sport (VWS) will make an increasing contribution (for prevention, see
Rutz et al., 2002). Much of the data, for example on personnel and facilities, is difficult
to compare internationally because of differences in the organization of care systems.
However, comparability is being improved within the framework of the ‘system of
health accounts’ (OECD, 2000b).
Chapter 4 presents a framework for measuring performance on a macro level. Its exam-
ple-based contents are evidence of the fragmented nature of the availability of data on
outcomes and relevant process characteristics of prevention and care, which are also
comparable internationally to a certain extent. A great deal of specific data is required at
the diagnosis or treatment level if performance and costs in care and prevention are to be
measured at a meso level. Furthermore, patient-level information on the process through
the entire care system is required to facilitate insights into the effects of chain care. We
deal with this topic in more detail at the end of section 2.4.
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in the tendency to request care. This is in agree-
ment with the results of studies performed in
other countries. Most of the major ethnic-minority
groups in the Netherlands show a similar pattern
of behaviour, though the under-utilization of the
services of specialists is sometimes even greater
(Stronks et al., 2001). When affected by chronic
diseases, members of groups with low socio-eco-
nomic status tend to make less adequate use of
health care services (and to modify their lifestyles
less adequately). The health care given to groups
with lower socio-economic status may also be
less effective (Van der Meer, 1998). An American
study has shown that prejudice and other barriers
to effective consultation can lead to less adequate
care for minority groups (Smedley et al., 2002).
In comparison with other countries, socio-eco-
nomic differences appear to have relatively little
effect on the frequency of surgery in the Nether-
lands, though some under-utilization by lower
socio-economic groups cannot be excluded
(Westert et al., submitted for publication). It has
been suggested on the basis of such data and by
the persistent socio-economic differences in
health (Programmacommissie SEGV-II, 2001) that
a higher level of uptake of health care services by
lower socio-economic groups might be justified. 
A number of trial projects based on this approach
have already been set up. Of these, the local mul-
tidisciplinary and multisectoral health care net-
works in Rotterdam seem to have been particular-
ly successful, largely thanks to the fact that the
services offered were tailored to the needs of the
users by integrating preventative measures with
care and adopting the same preconditions as in
community intervention projects (see also section
2.3.2). In other countries, there is often less
equality in the uptake and availability of care; this
is especially true in the USA (Smedley et al.,
2002; Wagstaff & Van Doorslaer, 1999). In a
league table set up by the Ministry of Social
Affairs and Labour (SZW) in 2000, the Nether-
lands scored well as regards the effect of income
bracket on both health differences and differences
in the accessibility of care.
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Text block 2.38: Capacity problems in nursing and care
In a recent report on dementia by the
Gezondheidsraad (Netherlands Health Council), it
was calculated that an extra 1,300 places per
annum would be needed in nursing homes to deal
with this problem up to 2010. This calculation
was based on data for 2000, when there was
already a shortage of such places. Informal care
(see text block 2.41) does not offer a solution to
this problem, as it runs counter to current labour
market trends, to demographic changes and to
the aim of the Ministry of Economic Affairs to
raise the level of participation in the labour market
(Gezondheidsraad, 2002a). 
The capacity problems in nursing and care are
also mentioned in the evaluation report ‘Zorgen in
de zomer’ (Care in the summer) (IGZ, 2002b),
about care in nursing homes and old people’s
homes. In 2001, indicators of unacceptably low
levels of care were established which were intend-
ed to ‘set alarm bells ringing’. Seventy-one
reports of such unacceptably low levels of care,
passed on via five different channels, were gener-
ated on this basis. The conditions most frequently
reported were: 
• structural departures from personal care plans; 
• consequences of such deviations involving
decubitus, incontinence and mobility; 
• shortages of qualified personnel, in particular
nurses;
• lack of supervision in psychogeriatric wards. 
Another recent report by the ‘Comité Zorg voor
iedereen’ (Care for All Committee) entitled ‘Waar
een rijk land arm in is’ (Islands of deprivation in a
rich country), concerning shortcomings in care
reported by staff in old people’s homes collected
during a one-week survey (Helmer & Palm, 2002)
gives moving and sometimes harrowing anecdotal
evidence of low levels of care similar to those
covered by the above-mentioned IGZ report.
Text block 2.39: WHO survey of ‘Level of prompt attention’
WHO has developed a questionnaire dealing with
the responsiveness of national health systems.
This questionnaire covers seven specific topics,
one of which is ‘prompt attention’. Detailed ques-
tions are asked about the distance travelled to
reach extramural care centres and the promptness
with which the patient gains access to the care
provider. A preliminary publication (Evans, 2002)
gives results for 20 European countries in 2000-
2001. On a scale from 0 to 100, the ‘prompt atten-
tion’ scores range from 25-35 (Italy, France, Swe-
den) to 50-60 (Denmark, Austria, Switzerland,
Ireland). With a score of about 38, the Nether-
lands is in the bottom half of the table. 
This score is appreciably worse than that
achieved by the Netherlands for general satisfac-
tion with the health care system, as expressed in
the Eurobarometer survey. This is based on an
annual review of the answers given to the ques-
tion, ‘Are you very / fairly / not very / not at all
satisfied with our health care system?’ (This is
the formulation of the question put in 1999, which
differs slightly from that used in 1996). More than
70% of respondents in the Netherlands were fairly
to very satisfied in 1996 and 1999 as compared
with less than 30% in Portugal, Italy and Greece
and about 50% in England and Ireland. On the
basis of recent developments, it would not be sur-
prising if the Dutch scores were to show a down-
ward trend. The percentage score for 1999 and
the ranking of the Netherlands among the 15 EU
countries surveyed (table 2.13) do not yet give
any clear evidence of the existence of such a
trend, however. 
NYFER (2002) cites a drop in satisfaction from
7.9 to 6.6 (on a scale of 10) between 1999 and
2001. According to the website of this (restricted-
access) source, this information was derived from
an ‘executive survey’ exploring the responses to
the question ‘does the health infrastructure meets
the needs of society?’
Table 2.13: Percentage of people claiming to be ‘very/fairly satisfied’ with the national health care system. (source:
Eurobarometer, 1999).
Austria 83.4 THE NETHERLANDS 73.2 Ireland 47.7
France 78.2 Luxembourg 71.6 Spain 47.6
Belgium 77.0 Sweden 58.7 Italy 26.3
Denmark 75.8 United Kingdom 55.7 Portugal 24.1
Finland 73.3 Germany 49.9 Greece 18.6
2.4 How much care is used, what is it used for and
by whom?
From health status to health care use
The health status of the population, and particularly ill health, gives rise to a need for
care that leads subsequently to health care use via the balance between demand for care
and care provision. In practice, this is a complicated process involving subjective ele-
ments such as the readiness to complain alongside more objective elements such as
determining the indication and assigning care (text block 2.40). The need for care is
therefore not automatically identical to the demand for care. Expectations of care may
be too high, causing people make excessive demands on care providers. Poor under-
standing can also cause demand to be smaller than the need for care, or may deviate
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Chronic disorders are responsible for a significant part of health care use
Most care is used in connection with chronic disorders, such as intellectual disability,
dementia, stroke and mental disorders, and not with major causes of death such as
neoplasms. The health care use of patients with neoplasms can be high to extremely
high per individual case, but because of the relatively short duration of disease (lung
cancer) or the low incidence (oesophageal cancer), the proportion of neoplasms in the
total cost of care is limited.
Health care use increases rapidly after the sixtieth year of life
As people become older, health care use increases ever more rapidly. This is true for
both men and women, although the average health care use is higher for women than
for men, which is connected not only with the medical care surrounding pregnancy and
birth, but more particularly with women’s higher life expectancy. Otherwise, the gen-
der difference in health care use in the Netherlands has declined slightly since 1994, as
a result of the increase in life expectancy among Dutch men, but also of developments
specific to individual diseases.
Health care use differs from one region to another
With the data available, it is impossible to map out the complete health care use per
region, but sectoral analyses point to striking differences. Health care use in some
regions is proportionally very high, and in others low. It also appears that substitution
between forms of care plays a role. For instance, more home-care services are provided
in regions where the hospital bed occupancy is lower than average. Further investiga-
tion is necessary to identify the precise causes of the differences between regions, ori-
ented to aspects of efficiency and complementarity of provisions, but also in relation to
regional differences in health status.
From an international point of view, the Netherlands is somewhere in the middle
In comparison with surrounding countries, health care use in the Netherlands is at an
average level, which applies both to the scale of health care in terms of gross domestic
product and for the average cost of care per capita. It appears that growth in the cost
of care per capita has been lower than in the surrounding countries in past decades.
from it in some other way. Furthermore, the demand from specific individuals may
deviate from society’s demand for care. Preventive care may be mentioned in this con-
nection, as well as compulsory admissions to mental hospitals, for example.
This section covers health care use in greater detail. Rather than emphasizing the inter-
actions of supply and demand and the process through which care is effected, it address-
es questions such as: how much care is used and how is health care use distributed
across diseases and disorders? Which disorders make the greatest demands on the care
budget and what is the cost per case of disease? What are men’s and women’s share in
the cost of care and how does the cost relate to age? What trends have taken place in
recent years? Are there any regional differences in health care use and how does the
Netherlands perform relative to other countries?
Health care use is extremely heterogeneous and comprises numerous facilities and
activities. Accordingly, in this section, we describe it in terms of cost of care as a unify-
ing measure. High costs point to substantial health care use, whereas low costs indicate
limited health care use, with respect to formal care as it is delivered within the context
of Dutch health care. Informal care is only indirectly involved (text block 2.41).
This section consists mainly of key statistics with a short explanation. More extensive
information can be found in the PHSF theme report Kosten van Ziekten in Nederland
(Cost of Illness in the Netherlands) (Polder et al., 2002) and the associated website
(www.costsofillness.nl).
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Text block 2.40: From health status to health care use
The relationship between health status, the need
for health care and health care use is visualized in
a variety of models and diagrams in the literature.
This variety is related to the care sector for which
models have been developed and to the different
theoretical approaches used to explain health care
use. In the development of the PHSF conceptual
model, it was decided to include only a limited
number of concepts in the ‘Health care use’ block
of the flow diagram.
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Figure 2.31: The conceptual model of PHSF: elabo-
ration of the block ‘Health care use’ (Source:
Ruwaard & Kramers, 1997).
Text block 2.41: Informal care in the Netherlands
(Source: De Boer & De Klerk, 2001) 
About 2.5 million people active in the informal
care sector 
In the Netherlands, caring for those who need it in
one’s own social network on a voluntary, unpaid
basis is still taken for granted. This form of care
is often known as informal care. It is generally
given to the sick or disabled. In the period from
1997 to 1999, more than 20% of the population
aged 16 years or over (about 2.5 million people)
gave such help. This corresponds to about 10% of
the total annual provision of health care, but the
proportion does seem to be falling.
Informal care is generally provided to individuals
with chronic diseases (9%), those with short-term
diseases (15%) and the terminally ill (6%). Some
of the informal carers provided support (mainly in
the form of domestic help but sometimes also
personal care and supervision) to more than one
Health care comprizes almost 10% of the Dutch domestic product
Dutch society expends a considerable proportion of its annual gross domestic product
(GDP) on health care. In 1999, the amount involved was 36 billion euros, which is equal
to 9.6% of GDP, a significant portion of which was for cure provisions such as hospital
care (29.2%), primary health care (3.0%) and medicinal products (10.1%) (see table
2.14). Care sectors such as nursing and residential care (20.7%), care of the disabled
(8.4%) and mental health care (7.1%) represented a substantial part of the total care
budget. The scale of preventive care (3.9%) would appear to be limited, especially con-
sidering that half the amount referred to relates to occupational health care. However,
many preventive activities are also carried out within other health care sectors and are
therefore not identifiable as such in the cost figures.
Table 2.14 is based largely on the 2001 policy document on care from the Ministry of
Health, Welfare and Sport (VWS). Every year, the ministry outlines a coherent picture
of health care in a policy document, which includes developments and policy proposals.
The 1999 policy document refers to a total amount of 32.7 billion euros of care expens-
es, but is nonetheless incomplete. For instance, it did not include dental care for adults,
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person.
Women and individuals in the 45-65 age group
are relatively more active in the informal care sec-
tor, as are persons with a partner who needs such
help and those within easy travelling distance of
the person requiring help. Participation in paid
employment has no influence on whether one pro-
vides informal care or not.
One in ten households receives help from the
informal circuit
About 10% of Dutch households receive informal
care in the course of a year. The recipients are
mainly those with physical disabilities, the elderly
(and very elderly), those living alone and the
elderly living in rural areas. Little is known about
the position of the elderly from ethnic minorities,
but qualitative studies indicate that this group
does make relatively frequent use of this form of
assistance. 
Waiting lists in the care sector place extra load on
informal carers
Long waiting lists for home care and intramural
care place an extra load on informal carers. Infor-
mal carers often pay a high price for the help they
give, in the form of a lack of free time, inability to
meet obligations and fatigue. An overloaded
social network or a shortage of informal aid may
ultimately force those requiring such aid to move
into a home. This is particularly true of elderly
individuals: 37% of the occupants of old people’s
homes and 70% of those in nursing homes (for
somatic complaints) gave the absence of suffi-
cient informal care as the reason for moving to
the home. An effective social network can thus
delay or even prevent the move to a residential
home. 
Forms of support for informal carers 
Since 1997, home-care services have been able to
offer informal care support in cases where a given
person receives both informal care and home
care. This support may take the form of psy-
chosocial guidance, advice, instruction and infor-
mation for the informal carers. Other ways of
lightening the burden on informal carers include
the provision of temporary care to allow the infor-
mal carer to take a break and activity centres for
those requiring care. In June 2001, the Dutch
cabinet created a structural fund of more than ten
million euros for support to informal carers. 
Costs of informal care
In principle, informal carers are not paid. Since
1995, however, individuals with an appropriate
indication can be given a client-linked budget, that
can be used to pay informal carers, but only a
small part of the overall informal care is paid for
in this way. Most informal carers do it out of the
goodness of their hearts. If all informal care were
paid for, the amount involved would at a very
rough estimate be between four and five billion
euros (the total ‘formal’ health care expenditure in
the Netherlands was 36 billion euros in 1999).
self-care pharmaceuticals, spectacles and contact lenses, medical children’s homes and
infant day-care centres, occupational health care and facilities within the framework of
the Services for the Disabled Act (WVG). Altogether, these add up to an additional 3.3
billion euros. Table 2.14 and the remainder of this section do include this additional
amount, bringing the total costs of health care in 1999 to 36.0 billion euros.
As mentioned earlier, we have restricted ourselves here to the costs of health care alone.
However, many diseases cause numerous other expenses, which are referred to as ‘indi-
rect’ and ‘social’ costs. Examples are absence through sickness and the costs of a wide
variety of ailments connected with the disease. These indirect and social costs mean that
the public cost is considerably higher than the cost of care.
Mental disorders demand the most care, followed by cardiovascular 
diseases
More than 82% of the total cost of care can be attributed to diagnostic groups, part of
which can also be attributed to several risk factors (see section 2.2). The pattern for the
17 main groups of ICD-9 is roughly the same for men and women: high costs for mental
disorders, cardiovascular diseases and disorders of the digestive system; low costs for
diseases of the blood, congenital abnormalities and infectious diseases (figure 2.32). A
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Table 2.14: Cost of health care in the Netherlands in 1999. The costs of sectors in millions of euros and share
(per cent) of the total (Source: Polder et al., 2002).
Costs Share
(millions of euros) (%)
Hospital care 10,514 29.2
Primary health care
- primary health care and health centres 1,074 3.0
- dental care 1,029 2.9
- paramedical care 778 2.2
- obstetric and maternity care 260 0.7
- social work (AMW), social and women’s shelters 264 0.7
Medicinal products and medical aids
- medicinal products 3,627 10.1 87 3,627 10.1
- medical aids & devices 1,599 4.4
Mental health care 2,550 7.1
Care of the disabled 3,015 8.4
Nursing and residential care
- nursing homes 2,827 8.0
- residential care homes 2,916 8.2
- home-care services 1,626 4.5
Preventive care 1,406 3.9
Transport 820 2.3
Care insurance administration 1,646 4.6
Total 36,033 100.0
striking observation is the relatively low cost associated with neoplasms (cancer).
Accordingly, it is frequently occurring disorders with an intensive care requirement and
a chronic nature that impose an especially severe burden on the total care budget, rather
than the major causes of death.
Figure 2.32 shows the costs for various health care sectors and parts of sectors. This
also includes costs that are mentioned only partially or not at all in Dutch ministerial
health care policy documents, such as those for spectacles and contact lenses (nervous
system and senses) and for dental care (digestive system). 
Major differences in health care use between individual diseases
The pattern of figure 2.32 can be elaborated according to the disorders selected for
PHSF, both for the total costs and for the average costs per case of disease. This also
indicates that major differences exist between different diseases in terms of health care
use and costs. Diseases that make a great demand on the care budget often demand long-
term and intensive care for large numbers of patients, such as intellectual disability
(7.7% of the total costs), dementia (4.9%) and stroke (2.9%). Conversely, the total costs
2.4 PHSF 2002:  HEALTH ON COURSE?
118
men
4,000 3,000 2,000 1,000
costs (million euro)
diseases of the blood
congenital malformations
perinatal complications 
infectious diseases
cutaneous diseases
endocrine diseases
pregnancy and childbirth
kidneys and urinary tract
 neoplasms
respiratory system
external causes
musculoskeletal system 
nervous and sensory system
 symptoms
digestive system
not disease-related
cardiovascular diseases
not yet attributable
mental disorders
completely within the 'Zorgnota 2001' partly within the 'Zorgnota 2001' not within the 'Zorgnota 2001'  
1,000 2,000 3,000 4,000
women
Figure 2.32: Costs of Healthcare in the Netherlands in 1999 by ICD-chapter and sex with an
indication of the costs that are not or only partially featuring in the official healthcare policy
framework (Zorgnota, 2001) (millions of euro’s ). Total costs in 1999: 36 billion euro’s for 15.9
million Dutchmen. (Source: Polder et al., 2002).
for disorders that demand relatively little (expensive) care, such as eczema (0.3%) and
most infectious diseases, are low. The public cost of diseases which demand substantial
and expensive care, but which occur relatively infrequently, is also low, so total demand
on the care budget remains limited. Examples are decubitus ulcers (0.2%), oesophageal
cancer (0.1%), HIV and AIDS (< 0.1%).
Health care use by women is higher than by men
In the total cost of Dutch health care for 1999, the portion for men was 42%, and that for
women 58%. The difference is caused by the care surrounding pregnancy and birth, and
in particular by the higher life expectancy of women, which causes that the highest age
groups comprise many more women than men (figure 2.33). Furthermore, Dutch
women live more years in ill health than men and they more often live alone. All of
these factors cause that Dutch women make greater demands on health care and that the
average costs are higher for women than for men (see section 2.1).
Apart from these differences, it is the same disorders that generate a high degree of
health care use for both men and women. This is true for total health care use and for
care per disease case. The five disorders with the highest total cost are the same for men
and women, except that the ranking is slightly different (table 2.15). This is also true for
five disorders with the highest average cost per disease case (table 2.16). Slight differ-
ences occur between men and women within the five disorders with the lowest cost.
These differences include work, sport and domestic accidents and urinary tract infec-
tions, with lower and higher average costs per disease case, respectively, for men.
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Figure 2.33: Total costs of Dutch health care (left, millions of euro) and average costs per head
(right, euro) by age and sex in 1994 and 1999.
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Table 2.15: Five disorders with the highest and lowest cost of care for Dutch men and women in 1999 (mil-
lions of euros and portion of the total costs for each sex in per cent) a (Source: Polder et al., 2002).
Disorders with the highest Millions of % Disorders with the lowest Millions of %
total cost of care euros total cost of care euros
Men
Intellectual disability 1,554 10.3 Congenital abnormalities of the 4 <0.1
central nervous system
Coronary heart disease 548 3.9 HIV and AIDS 10 0.1
Dementia 448 3.0 Congenital abnormalities of the 
cardiovascular system 10 0.1
Stroke 417 2.8 Osteoporosis 11 0.1
Work, sport and domestic accidents 368 2.4 Infectious diseases of the 
gastrointestinal tract 13 0.1
Women
Dementia 1,313 6.3 HIV and AIDS 5 <0.1
Intellectual disability 1,226 5.9 Congenital abnormalities of the 
central nervous system 5 <0.1
Work, sport and domestic accidents 704 3.4 Oesophageal cancer 8 <0.1
Stroke 612 2.9 Congenital abnormalities of the 
cardiovascular system 10 <0.1
Coronary heart disease 345 1.6 Meningitis 12 <0.1
a) disorders for which it was impossible or irrelevant to calculate costs per case have been ignored to allow a pure compari-
son with table 2.16. This involved dental abnormalities in particular.
Table 2.16: Five disorders with the highest and lowest average cost of care per disease case for Dutch men
and women in 1999 a,b (Source: Polder et al., 2002).
Disorders with the highest average cost euros c Disorders with the lowest average cost euros c
per case per case
Men
Intellectual disability 26,000 Infections of the gastrointestinal tract 100
Dementia 25,000 Infections of the upper respiratory tract 130
Oesophageal cancer 23,000 Eczema 230
Hip fracture 21,000 Infections of the lower respiratory tract 270
Schizophrenia 14,000 Work, sport and domestic accidents 270
Women
Dementia 33,000 Infections of the gastrointestinal tract 80
Intellectual disability 29,000 Infections of the upper respiratory tract 110
Hip fracture 27,000 Urinary tract infections 120
Oesophageal cancer 21,000 Eczema 210
Schizophrenia 13,000 Infections of the lower respiratory tract 270
a) the cost of collective prevention was not included, because it is unrelated to incident and prevalent cases of disease.
b) the cost was calculated on an annual basis. This means that for disorders with an average duration shorter than one year,
the cost is the total cost, but for chronic disorders the cost is only that of one year. For these disorders, the cost per case
of disease in terms of ‘life-time costs’ are therefore higher or much higher. This is true, for example, of intellectual dis-
ability, dementia and stroke.
c) rounded to 10, 100 or 1,000 euros.
Average health care use per head increases sharply with age
Health care use varies according to age (figure 2.33). The figure on the left confirms the
above-mentioned pattern that the high total cost for Dutch women is attributable mainly
to pregnancy and a higher life expectancy. The pattern for the average cost per resident
is similar for men and women, and is determined completely by age (right hand figure).
The cost per head is relatively high around birth, low and stable during childhood and
adulthood, and rises increasingly sharply from 65 years of age. From the age of 70, the
average cost for women is consistently higher than for men.
Demand for care shifts during life from cure to care
The elderly use so much care that they are the major source of the demand for care with-
in almost all health care facilities and care sectors. However, if we examine the age
groups for their relative share of the various sectors, interesting differences are revealed.
For infants below one year of age, hospital care is by far the largest care sector, and for
the oldest age groups the corresponding sector is nursing and residential care. This shift
in health care use throughout life from cure to care is clearly visible in figure 2.34.
The cost increase is most marked in high age groups
In the period from 1994 to 1999, the cost of health care rose by 4.6% per year. The cost
increase is shown in figure 2.33 according to age and sex. In absolute terms, those age
groups that had high costs in 1994 seem to show the greatest rise. The cost increase in
this period has therefore followed the pattern of the cost distribution. The growth base
of the cost per resident appeared to show no clear age pattern and was roughly equal,
within a wide margin, for all ages.
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Figure 2.34: Share of healthcare sectors in total Dutch health expenditure by age group in 1999
(percentages). (Source: Polder et al., 2002).
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The figure on the left relates to total cost development, including the demographic com-
ponent, which can be deduced from the shift of the cost peak from 45 to 50-year-olds in
1994 to 50 to 55-year-olds in 1999. The figure on the right shows an increasingly pro-
nounced age pattern in the average cost per resident of the Netherlands in this period.
In the period from 1994 to 1999, demographic changes caused costs to rise by 1.1% per
year. It is striking that the cost for men has risen more sharply than that for women
(4.4% as opposed to 3.5%), which means that the difference in health care use between
men and women has declined slightly, particularly in the highest age groups.
Trends in health care use differ per diagnostic group
The developments in health care use and cost differ not only according to age and sex,
they also differ greatly between different diagnostic groups. Table 2.17 shows the five
major ICD groups with the greatest increase in cost and the five with the least increase,
or even a decrease. An investigation of this data reveals that, except for diabetes melli-
tus (endocrine diseases), no characteristic diseases of ageing are mentioned among the
disorders with the greatest cost increase. However, this is partly a result of the heteroge-
neous nature of the ICD chapters. For example, the mental disorders chapter contains
both dementia (a disorder of old age) and intellectual disabilities (which mainly occur
among the younger age groups). Another example concerns disorders of the nervous
system, which include both Parkinson’s disease and epilepsy (table 2.17).
The costs of pregnancy, delivery and childbed and of disorders in the perinatal period
rose considerably in the period from 1994 to 1999, particularly as a result of increased
hospital care. A wide range of factors can be mentioned in this context: the increasing
cost of fertilization treatments, a higher number of births in 1999 and an increase in the
number of multiple births and premature infants. What is more, an increasing number of
first children were born and Dutch women gave birth to their children at a higher aver-
age age (Achterberg & Kramers, 2001).
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Table 2.17: Five disorders (ICD chapters) with the highest and lowest increase in cost for Dutch men and
women in 1994-1999 (Source: Polder et al., 2002).
Men Women
ICD chapters with the greatest Symptoms Pregnancy
cost increase Endocrine diseases Symptoms
Perinatal disorders Perinatal disorders
Infectious diseases Diseases of the blood
Diseases of the blood Endocrine diseases
ICD chapters with the lowest Congenital abnormalities Skin diseases
cost increase Musculoskeletal system Congenital abnormalities
Nervous system and senses Nervous system and senses
Kidneys and urinary tract Musculoskeletal system
Digestive system Digestive system
The increase in health care use for the endocrine disorders diagnostic group is almost
entirely attributable to diabetes mellitus, and is accounted for mainly by higher expendi-
ture on medicinal products. This growth is even larger among men than among women,
especially because they made more frequent use of hospital care. The underlying major
trends in the cost increase for diabetes mellitus are the increase in the number of dia-
betes patients (resulting from better diagnosis, population growth and ageing) and the
increasing number of overweight people (see section 2.1 and 2.2). The more intensive
treatment also plays a role (Herings et al., 2000; Lutterman, 2001).
The costs associated with infectious diseases and parasitic diseases have also increased
by more than the average, somewhat more strongly among men than among women.
This is mainly attributable to diagnostic groups with relatively low costs, such as menin-
gitis and sepsis for both sexes, and HIV/AIDS among women. For HIV/AIDS, the costs
of pharmacotherapy in particular have increased greatly.
Care for disorders of the nervous system underwent only a limited increase in the period
from 1994 to 1999, both among men and women, especially through the declining cost
of epilepsy in hospitals, which is partly the result of a different distribution of registered
diagnoses in the specialist hospitals. It is unclear whether substantial trends are involved
here, or simply changes in the recording of care.
Finally, health care use for disorders of the musculoskeletal system and the digestive
system has increased slightly, which appears to be linked to restrictive measures in den-
tal and paramedical care. However, the nature of the available data means that it cannot
confirm whether these and other developments are genuine trends in health care use.
New insights through regional differences in health care use
Health care use differs not only according to disorder, age and sex, but also according to
region. However, the data currently available does not allow an elaboration of the com-
plete description above according to regional patterns, although it is possible to illus-
trate regional health care use for a number of specific forms of care. Figure 2.35 maps
out admissions and hospital bed occupancy, as well as the use of pharmaceuticals and
home-care services per region. An examination of this figure reveals a number of points.
Firstly, health care use in the Delft region is far lower than average, except for pharma-
ceuticals. Health care use is highest in the Breda region, except for home-care services.
Furthermore, health care use in major cities such as Amsterdam and Rotterdam is also
higher than the average. As a general pattern, it is noticeable that regions with a lower
hospital bed occupancy have a higher than average use of home-care services, and vice
versa. The Twente and North Limburg regions are an exception to this general trend.
We can pose several general questions in response to this overall survey. For example:
does a given region exhibit extensive health care use because the state of health there is
relatively poor, or because of the care provision available? It would appear that the rela-
tively extensive use of hospital facilities and home-care services in the province of Lim-
burg coincides with a relatively low healthy life expectancy (see figure 2.4).
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Figure 2.35: Regional differences in health care utilisation (corrected for age and sex) by AWBZ-
regions. Number of hospital admissions, beddays and hours of home care per 1000 inhabitants in
1999 and prescribed medicines in 2000 (Sources: Polder et al., 2002; Van Batenburg-Eddes 
et al., 2002).
Conversely, however, it is also possible that high health care use leads to a better state of
health. Another question is whether genuine regional differences are involved, or under-
lying factors such as socio-economic differences. Other questions are concerned with
the organization of care. For example, can any conclusions be drawn about the possibil-
ity of substitution between forms of care, purely on the basis of regional differences? Do
the patterns provide any clues about the efficiency and quality of care?
However, the currently available data gives rise to more questions on regional health
care use than can be answered. What is clear, however, is that it is an important field of
research with good prospects for generating new insights. The care maps constitute a
useful instrument in this respect.
The Netherlands occupies a middle position in the proportion of gross
domestic product
Health care use differs between countries, among other things because the demand for
care also comprises a sizeable cultural component. The latter can be seen in terms of
factors such as the use of pharmaceuticals, which is substantially lower in the Nether-
lands than in the surrounding countries. Large international differences also exist in the
supply of care (see text blocks 2.28 and 2.36). For example, Germany has proportional-
ly many more dentists than the Netherlands. Belgium has more pharmacies, but they are
different in nature from those in the Netherlands, which is also true, for example, of
nursing homes in Britain. There are also major differences in the way in which care is
organized and funded. For example, Germans are able to approach a medical specialist
directly, whereas in the Netherlands a referral from a general practitioner is required.
The OECD has made the total cost of care reasonably comparable by correcting for
international differences in the definition and scope of health care. This is why the
amount assumed for the Netherlands is lower than is usual within the Netherlands itself,
and lower than that used in the previous examples in this section. Figure 2.36 shows the
contribution of health care to a number of countries’ gross domestic product since 1975.
The countries have been selected so that the graph shows the entire bandwidth for all
OECD countries and also includes the countries surrounding the Netherlands. The Unit-
ed States has the greatest contribution of health care to GDP, at approximately 13%.
Luxembourg’s contribution of more than 6% is not even half as large. The Netherlands
is in the middle of the spectrum.
The cost of care per inhabitant in the Netherlands is lagging behind that of
other countries
Figure 2.36 shows the scope of health care measured against the prosperity of the coun-
try and not against the state of health or even against the size of the population. This is a
clear disadvantage. It is therefore advisable to examine the cost per capita of the popula-
tion as well (figure 2.37), which reveals two points. Firstly, there were large differences
in the cost per resident in 1998. The United States had by far the highest cost, almost
twice as high as in the Netherlands, despite having the largest group of uninsured people
(who receive little care and generate only modest costs in that country). In Germany,
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France and Luxembourg, the expenses per capita were also higher than in the Nether-
lands, which indicates that in Luxembourg, unlike the United Kingdom, the low contri-
bution of care costs to GDP is not associated with low health care use, but with high
prosperity.
The gradient of the curves in figure 2.37 shows how the costs per resident have devel-
oped in recent decades, relative to the 1998 level. This would appear to indicate that the
Netherlands has undergone the lowest growth. The per capita cost of care in France,
Belgium and Luxembourg has risen significantly faster. The same is also true for the
United Kingdom, in spite of the fact that the level continues to lag behind the Nether-
lands. The fastest rise in the cost per resident has occurred in the United States, where
by 1998 it was more than 90% higher than in the Netherlands, as against a mere 14% in
1975. Note that the above is not directly visible in the graph, which is based on 1998 and
not 1975.
As long as there is no additional information or better comparable data on health care
use in the various countries, we can only guess at the causes of these differences. One of
the causes could be that the Netherlands’ trailing growth figure is related not only to
budgeting and other government policy but also to the fact that the ageing of the popula-
tion in the Netherlands has proceeded more slowly than in other countries. Finally, it has
to be observed that the Dutch government has invested additional funds in care since
1998. Unfortunately, the lack of comparable figures for the other countries means that
none could be included here.
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Figure 2.36: Health care costs as percentage of GDP in seven countries over the period 1975-
1999 (Source: OECD Health Data).
Major patterns in health care use are the same for all developed countries
The OECD has included the distribution of costs over the 17 ICD-9 chapters in the
Health Data database for a number of countries. These figures have not been corrected
for international differences in health care, but were taken directly from the various
cost-of-illness studies. Table 2.18 gives an overview for six countries: Australia, Cana-
da, the Netherlands, Sweden, the United Kingdom and Germany. The above countries
were selected because the reference year of the studies roughly coincided and because
each of them had a background report, which facilitated a better assessment of the com-
parability of the figures.
The table shows that the overall pattern in the distribution of health care use over the
ICD chapters was roughly equal for all countries:
• high costs for mental disorders, cardiovascular diseases, disorders of the digestive
system and the musculoskeletal system;
• low costs for congenital abnormalities, perinatal disorders and infectious diseases.
In spite of this comparable pattern, countries exhibit large differences in terms of major
disorders such as mental disorders, cardiovascular diseases, diseases of the digestive
system and of the musculoskeletal system. What is more, it would appear that several
ICD chapters are missing in the UK figures and that for Canada and the UK the total
costs do not add up to one hundred per cent.
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Figure 2.37: Trend in healthcare expenditure per capita for seven countries over the period
1975-1998 (index: The Netherlands 1998 = 1). Differences with the Netherlands in 1998 were
calculated using dollar exchange rates. (Source: OECD health data, 2001).  
In the absence of standardization, international differences remain 
difficult to interpret
A more detailed study shows that there are three factors that account for differences in
the cost-of-illness figures between countries. Firstly, there are differences in what falls
within the scope of health care in a given country (Van Mosseveld & Van Son, 1998).
Furthermore, most cost-of-illness studies do not include all health care sectors. Second-
ly, the cost contributions per ICD chapter differ as a result of methodological issues and,
thirdly, because of differences in population and treatment practice. Examples of the lat-
ter category are differences in health care use and cost of care as a consequence of inter-
national differences in the state of health and the care requirement, as well as differences
in treatment, where differences in both medical practice and cultural aspects play a role.
A familiar example of a cultural aspect is the specific Dutch preference for giving birth
at home. The large international differences in the number of Caesarean sections should
also be mentioned (see text block 2.28).
The third category is without doubt the most interesting, because it provides an insight
into the efficiency of health care systems. To date, however, the large differences in def-
initions and methods still obstruct analyses of this kind. Standardization is necessary to
gain a better insight into international differences in health care use.
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Table 2.18: Cost of disease by ICD chapters in six countries. Contribution of ICD chapters to the total cost,
with coefficient of variation (Source: Polder et al., 2002).
ICD Chapters AUS a CAN UK GER NETH SWE Coeff.
1993 1993 1993 1994 1994 1991 Var b
Infectious diseases 2.7 1.8 3.7 1.9 1.3 2.0 36%
Neoplasms 6.1 7.3 8.3 5.2 3.9 5.6 26%
Endocrine diseases 3.1 3.0 2.9 3.9 1.9 3.4 23%
Diseases of the blood 0.6 0.6 1.6 0.6 0.3 0.5 71%
Mental disorders 8.4 11.4 14.4 10.9 23.1 18.4 38%
Nervous system and senses 7.4 5.1 3.4 8.4 5.2 5.8 31%
Cardiovascular diseases 11.7 16.7 25.7 12.4 10.5 16.9 36%
Respiratory system 8.0 8.6 9.8 5.2 4.0 7.7 30%
Digestive system 11.8 7.5 8.3 15.9 7.8 4.6 43%
Urinary system 5.3 5.1 6.8 5.0 2.8 3.8 29%
Pregnancy 3.3 4.6 - 2.5 2.6 1.6 38%
Skin diseases 3.0 2.0 3.1 2.3 1.6 2.0 26%
Musculoskeletal system 9.5 5.6 7.3 12.6 6.0 5.4 36%
Congenital abnormalities 0.6 0.7 - 0.4 0.5 1.2 44%
Perinatal disorders 0.8 1.2 - 0.3 0.6 0.6 43%
Symptoms 4.3 4.2 - 4.7 4.8 5.6 13%
External causes 8.3 7.1 - 7.9 4.2 5.6 26%
Unallocated 5.1 1.2 - 0.0 18.8 9.2 111%
Total cost 100.0 93.8 95.3 100.0 100.0 100.0
a) AUS = Australia, CAN = Canada, UK = United Kingdom, GER = Germany, NETH = the Netherlands, SWE = Sweden
b) coefficient of variation = standard deviation / average.
Finally: the provision of information is deficient in a number of respects
The complete description of Dutch health care use draws on virtually all care registra-
tions that are available in the Netherlands, which are numerous. The Netherlands com-
pares favourably in this respect with most other countries, where this type of investiga-
tion tends to be obstructed by the paucity of data. However, it should be noted that the
quality of the Dutch data varies greatly, partly due to sample size, coverage and the
recording method used. In addition, the data involved is usually administrative, and lags
behind practice. For instance, the most important registrations in the field of care of the
disabled still assume complete intramural care, although this is becoming increasingly
uncommon in practice. Little is therefore known about the newer forms of care. Other
registrations also omit various important matters. The Netherlands Medical Registration
System (LMR) encompasses nearly all hospitals, but with respect to the care that they
provide, reliable registrations are restricted to admissions, bed occupancy and opera-
tions. Data on diagnostics, laboratories, specialist units, intensive care, coronary care,
renal dialysis and radiotherapy, for example, is either incomplete or entirely absent.
Another problem is that multiple registrations exist alongside each other in many sec-
tors in the Netherlands. This is true, for example, of mental health care, where outpatient
care, intramural care and outpatient addiction treatment and care each maintain their
own registrations. The nursing home sector even has two competitive registration sys-
tems for the same type of care. This fragmentation encourages inefficiency and a loss of
quality. Otherwise, much progress has been made in mental health care in recent years,
including the introduction of the ZORGIS registration system.
Diagnosis data is indispensable for an epidemiological approach to health care. Howev-
er, a number of care sectors do not record such data, the most important of which are
outpatient care in hospitals, medicinal products and devices, home-care services and
residential care homes. In addition, the data on diagnosis, age and sex is not recorded
simultaneously in a number of registration systems, so that it is impossible to map out
the costs multidimensionally.
A cross-sectional picture of complete health care use can be constructed by combining
the data from a variety of registrations, so as to outline interesting patterns in health care
use. However, an approach of this type provides no insight into the interrelationship
between the care that is provided in the various sectors. It is impossible to determine the
progress of a patient with a given disorder through the care system, although it would be
extremely interesting from the viewpoints of care reform, decompartmentalization and
efficiency. Such analyses require that data from the various registration systems be
linked. To date, the feasibility of such linkage has been hampered by the lack of a
unique number for care purposes and the inadequate recording of other identifying vari-
ables. Privacy aspects are also involved in the use of personal records.
Many care registrations change in the course of time, possibly because they were one-
off registrations for a specific study, or because the purpose of recording or the record-
ing procedures have changed. Such discontinuities in trends have so far hindered the
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creation of a clear picture of the trends in health care use, which means that there is con-
siderable room for improvement in the provision of information for health care
research. The most important focal points are more coherence, linkability, continuity
and filling in the gaps.
2.5 Are the benefits and costs in balance?
Efficiency is more than cost containment
Sections 2.3 and 2.4 discussed the contributions of prevention and care to our health,
health care use and the related costs. We discuss the relationship between health benefits
and cost in greater detail in this section: appropriateness or efficiency. Since as long ago
as the 1980s, ‘efficiency’ has been a key concept in the battle against rising costs in the
care sector in the Netherlands (WRR, 1997). This concerns not only more appropriate
care that is accessible to all, but also care that has to be provided with the lowest possi-
ble use of resources, or at least at acceptable costs (Lapré et al., 1999; Westerhout, 2000;
De Kam & Nypels, 2001).
However, the focus of this debate is not such a black-and-white issue. The definition of
efficiency depends strongly on the context. Efficiency is not a value-free, purely eco-
nomic context. It can play a role in decision-making only if agreement exists on the
‘goal’ itself and all sorts of principles are taken into account. Efficiency is therefore
more than ‘moderation’ alone, and not remotely synonymous with cost containment in
care. The achievement of the goal has the highest priority, although it has to be accom-
panied by an efficient use of resources. For example, a sharp focus on efficiency can
conflict with the principle of equal accessibility. Or, to state the case more clearly: if it
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Efficiency is not a purely economic concept
The concept of efficiency in health care is always accompanied by issues of principle
which deal with fairness, accessibility and solidarity. Efficiency is more than cost con-
tainment. The achievement of public health targets has the highest priority, but the
efficient deployment of resources is important.
Prevention is often less expensive than cure
The cost of each healthy year of life gained varies considerably in health care. Preven-
tive measures in the early stages of the disease chain are often ‘more economical’ than
interventions at the end of the care chain.
Cost-effectiveness is only one of the values
Economic evaluations are a useful aid to making decisions on priorities and allocations
in care and prevention. If cost is the only issue, prevention is not only better than cure,
it is often also considerably less expensive, at least per year of life gained. However,
population health status does not revolve exclusively around cost-effectiveness and
cost containment, but also around solidarity, and the legitimate claim of everyone to
protection, care and residential care.
would be only a matter of efficiency, care budgets would concentrate on investing in
prevention and care for young people. The fact is that young people make up the group
for which the greatest health gain can be achieved at the lowest cost by far, whereas care
for the progressively growing number of elderly people is relatively expensive (section
2.4). Neither does care for the elderly revolve primarily around health gain, but equally
around good residential care and nursing, which is another major public health policy
objective (see chapter 1).
Efficiency in care can also conflict with another principle: solidarity. Is a person who
can be helped only with expensive care, for example, an organ transplant, less entitled to
healing than someone who could be saved with a simple antibiotic? After all, people do
not choose their own afflictions (Bonsel, 2001; Wanless, 2001). In other words, certain-
ly in health care, the concept of efficiency is always accompanied by questions of prin-
ciple surrounding fairness, accessibility and solidarity.
‘Goal’ and ‘moderation’
Efficiency is always linked to a certain goal, which, however, may exist on one of many
levels, or may vary somewhat from the point of view of the different parties. On the
macro level of the national government, the goal is to maintain and improve the health
of the entire Dutch population at the lowest possible social cost (see chapter 1). This
means, for example, that as far as the national government is concerned, non-medical
costs such as lost productivity also count.
On the meso level, the scope of the concept of efficiency is often more limited, and cer-
tain costs and benefits do not enter the equation. For instance, for a commercial medical
expenses insurer in the current situation, efficiency is firstly a favourable ratio of
income from premiums on the one hand to expenditure on care on the other (or, in a
manner of speaking: the legitimate goal is ‘shareholder value’). This means that ‘bad
risks’, such as the elderly with a high probability of chronic disorders, will be avoided
as much as possible, while ‘good risks’, for example athletic young people, will be
attracted by offering them favourable conditions. It goes without saying that the insurer
also benefits from an efficient provision of care, but, by way of example, the same effect
can be realized by discharging patients from hospital sooner into publicly-funded nurs-
ing or residential care (‘partitions between the sources of finance’). For hospital man-
agement, efficiency is related mainly to the production process: the goal is an optimum
bed occupancy, an optimum utilization of specialists, supporting personnel, resources,
equipment and budget, given the capacities of production agreements with the national
government. However, this can give rise to divergent interests even within the hospital.
For instance, ‘wrong beds’ can work to the benefit of management, because patients that
are not being treated are relatively inexpensive, whereas they obstruct the specialist in
accepting new patients for treatment. Finally, the patient does not move on in good time
into residential care, nursing or home-care services.
On the micro level, the consulting physician opts for an intervention (or whether or not
to carry one out). The emphasis here often lies more on the ‘goal’ (health, healing) and
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rather less on the economic side, the ‘moderation’. For instance, the doctor will have
one more diagnostic test carried out in order to be sure, or will prescribe a more expen-
sive medicine, especially if there are no visible cost disadvantages involved. Finally, for
the consumer’s own health (or that of the family), no price is too high, which is a legiti-
mate position, and one that can also be fulfilled thanks to medical expenses insurance.
The finite nature of budgets obviously influences the introduction of an effective tech-
nology, even if the cost of health gain is low. A cost-effective intervention for which a
large number of people are eligible can impose an enormous burden on the available
budget (for example, Taxol or Viagra). On the other hand, a much less cost-effective
intervention will be admitted, because the number of potential users is only small (for
example, ‘orphan medicinal products’ for rare conditions).
The literature often distinguishes four types of efficiency. The focus can be on the tech-
nical efficiency of the process (production), on the utilization of resources - to make
them provide as much value for money as possible (allocative efficiency), on the reduc-
tion of operational costs (transaction), or, more dynamically, on promoting the develop-
ment of more efficient technology (Drummond et al., 1997; Lapré et al., 1999).
In other words, efficiency is a ‘many-headed monster’ where different players place a
different stress on different levels between ‘goal’ and ‘moderation’. In general, efficien-
cy on the micro level of individual interventions can still be considered in a value-free
analytical framework. However, the higher the level of the organization that is under
consideration, the more the publicly supported principles of fairness, reasonableness
and solidarity dominate the assessment of efficiency.
The cost per year of life gained differs greatly within prevention and care
Economic evaluation studies support discussions of efficiency. This has now become a
flourishing branch within the health economy (Drummond et al., 1997; Rutten-van
Mölken et al., 2001; Oostenbrink et al., 2001). Roughly speaking, the idea is to gain
insight into the relationship between the benefits and the cost of care or prevention,
mostly at the (micro) level of interventions and mostly from the perspective of alloca-
tion. If such a study is to be completed satisfactorily, it will of course require transparen-
cy and a certain standardization of the analysis (Drummond et al., 1997; Hutubessy et
al., 2001). Such studies can take one of four forms:
• cost (minimization) analysis, which compares the cost of two or more alternatives;
• cost-effectiveness analysis, in which the monetary cost of two or more alternatives is
compared with the benefits in (clinical) units of health gain, such as a reduction in
symptoms or life-years gained;
• cost-utility analysis, in which monetary cost and benefits are expressed in quality-
adjusted life-years; unlike the previous form, an attempt is made to assess the bene-
fits in ‘health coinage’ that is usable for any condition;
• cost-benefit analysis, in which an attempt is made to express both the cost and the
health benefits in monetary terms.
2.5 PHSF 2002:  HEALTH ON COURSE?
132
Table 2.19 shows a number of estimates of cost-effectiveness of interventions in differ-
ent health care domains. Use was made of a series of databases that have been made
available on Internet by various organizations (HCRA; US Dept. HHS CDC; NHS
EED; the Office of Health Economics HEED; SWOV). In addition, various, sometimes
raw, calculations for the Dutch situation have been included (e.g. Schoon et al., 2000;
De Charro and Oppe, 1998; Puts, 2002; R&M, 2002). When making such comparisons,
account must be taken of considerable uncertainties in the calculation of both the cost
and the benefits. Significant differences in the calculation method can be related to:
• the measurement of the benefits (clinical measures, in life-years, possibly adjusted
for health);
• the costs that are included (medical: personnel, equipment, transport, medicines and
devices, or also social: productivity, cost of care);
• the situation that is used as a reference (no intervention or conservative medical
treatment);
• the time horizon or discount rate.
Furthermore, the efficacy of (medical) technologies can improve rapidly. The statistics
must therefore not be taken too literally. They only provide an indication of the order of
magnitude, purely by way of illustration.
In table 2.19 it is immediately obvious that there is an enormous variation in cost per
quality-adjusted life-year. Disease prevention is often inexpensive, as are health promo-
tion and safety in traffic and at home. Medical treatment covers the entire spectrum
from cost-saving measures (it goes without saying that the prevention of medical and
other costs may be subtracted from the investments) up to life-years gained expensively
through impressive technologies. In addition, some environmental measures are
extremely expensive. Research carried out in the early 1990s showed that, for the Unit-
ed States, limits on benzene emission in the tyre industry cost as much as 20 billion dol-
lars per life-year gained (Tengs et al., 1995). However, it should be noted that the envi-
ronmental measures often have additional benefits in an ecological or sustainability
sense, apart from clean air, soil and water as values in themselves (Davis et al., 2002.)
Can we now conclude from the above that policy in certain domains is ineffective and
that everything should be changed? Researchers from the Harvard Centre for Risk
Analysis in America certainly think so. They claim that a more effective investment of
funds for prevention would yield more than 200,000 life-years annually in the United
States (Tengs et al., 1995). However, this statement is based on the most limited defini-
tion of efficiency, namely pure cost-effectiveness. As commented above, solidarity is a
major aspect of health care, and we consider that everyone should be able to have
expensive treatment paid for. Many environmental risks, however small they may be in
scale and number, are often not accepted by the public because they are involuntary,
because the advantages and disadvantages are not shared fairly or because doubts exist
about whether the technology can be controlled. This is also reflected in Dutch regula-
tions that are based on high levels of protection for the individual citizen (maximum per-
missible risk less than or equal to one in a million), in the first instance regardless of cost.
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People would prefer their food and drinking water to be unadulterated, free of danger-
ous substances or microbes, irrespective of the scale of the health risks involved (Health
Council (GR), 1995, 1996). In other words, like scientists, policymakers and politicians,
the public perceives health, care, risk, and safety on the basis of a rich pallet of values,
standards, feelings, political colour and religious and other convictions. In addition, it
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Table 2.19: Overview of cost-effectiveness calculations for a series of interventions in different population
health status domains.
Costs: euro/QALY a Intervention
< 0 (cost-saving) National Vaccination Programme (NVP) (ZP) b
PKU test, neonatal heel prick (DP)
Screening of pregnant women for syphilis (DP)
Influenza vaccination for chronically ill elderly people (DP)
Smoke detector in the home (DP)
Help with addiction to smoking (HP)
Removal of lead from petrol and paint, stripping lead-based paint coats (HPt)
0-1,000 Mandatory safety belt (HPt)
Disease coping training for asthma (MC)
Screening and treatment of chlamydia (DP)
Practical test for moped and autocycle (low-speed moped) riders (HPt)
1,000-10,000 Chlorination of drinking water (HPt)
Specific vaccinations, e.g. meningococcus C (DP)
Treatment of mild to moderate hypertension with beta blockers and anti-diuretics (DP)
HIV screening of visitors to sexually transmitted disease (STD) clinics (DP)
Surgery and after-care of congenital diaphragmatic hernia (MC)
Influenza vaccination for all elderly people (DP)
Pacemaker (MC)
Cholesterol test and dietary advice (DP)
Bypass operation (MC)
Stroke units (MC)
Viagra (MC)
Mammography population survey (DP)
10,000-100,000 Heart transplant (MC)
Hip replacement for osteo-arthritis (MC)
Statins for patients with coronary heart disease (MC)
Pneumococcal vaccination for the elderly (DP)
Kidney replacing treatments (dialysis) (MC)
Smear and treatment for cervical cancer (DP)
Periodic automobile test (HPt)
Treatment for mild to moderate hypertension with ACE inhibitors, etc. (DP)
Airbags (HPt)
Ban on asbestos in brake blocks (HPt)
Helicopter trauma team (MC)
Lung transplant (MC)
100,000-1,000,000 Reduction of radon in existing dwellings (HPt)
Neurosurgery for malignant brain tumours (MC)
EPO for anaemia in renal dialysis patients (MC)
General measures for controlling Legionella in water distribution systems (HPt)
1,000,000 Measures for reducing industrial benzene emission in the USA (HPt)
Earthquake-proof dwellings in parts of the USA (HPt)
a) QALY: according to quality-adjusted life-year.
b) DP: disease prevention, HPt: health protection, HP: health promotion, MC: medical care.
goes without saying that the budgets available in the different domains are important.
Figures for health benefits and cost form only one of the many aspects that shaped our
assessment of the balance between cost and benefits (Health Council (GR), 1996).
There could also occasionally be an element of diminishing returns. For instance, in col-
lective prevention, such as environmental hygiene, the simple, inexpensive measures
were all taken long ago. New interventions are often relatively expensive. It is therefore
worthwhile for the EU to help East European countries to improve their technology and
to reduce the emission of dangerous substances (each euro invested has a higher return
there than here). In principle, this is even more true for the contribution from the
wealthy West to building up health care in developing countries. Conversely, inexpen-
sive health gain would still appear to be achievable with health promoting measures
directed at individuals. However, individual choice often stands in the way of effective
measures.
Effectiveness of interventions within the course of one disease
In order to scrutinize the costs of different forms of prevention and care (cure and care),
we can also investigate the different phases of one disease (see figure 2.38), where con-
sideration is also given to the distribution of cost (investment) and benefits in time.
Our base is the course of chronic obstructive pulmonary disease (COPD), a group of
chronic, progressive disorders. Approximately 300,000 patients suffer from a form of
COPD In the Netherlands. In the later, more serious, phases especially, these patients
experience a considerable loss of quality of life. A series of effective interventions can
be identified throughout the entire course of disease, starting with different forms
of prevention, medical interventions oriented to healing or improvement, and finally
nursing.
Smoking cigarettes is by far the major cause of COPD. It is therefore possible to achieve
a substantial reduction in the incidence of COPD with programmes aimed at not starting
or at stopping smoking. This is possibly cost-saving, or costs at most a few hundred
euros per life-year gained, according to a combination of the outcomes of several Dutch
studies (Mudde et al., 1996; Mudde & De Vries, 1999; Rutten-van Mölken et al., 1999).
The general practitioner can also detect possible COPD patients at an early stage by, for
example, regularly measuring lung function where symptoms are reported. Through
medication and lifestyle advice, among other means, the general practitioner can then
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Figure 2.38:Scheme depicting the disease process and the role of prevention and healthcare
(Source: Ruwaard & Kramers, 1997).
improve the patient’s quality of life (secondary prevention). The related costs are
approximately 30,000 euros per quality-adjusted life-year (QALY) gained (Van den
Boom et al., 2001). Other forms of (tertiary) prevention, such as support in stopping
smoking, dietary advice (malnutrition may occur in serious COPD) and influenza vacci-
nation, are currently being investigated in the Netherlands (figures are not yet avail-
able). According to data from other countries, for patients with a heart condition help in
stopping smoking is cost-saving or costs at most a few hundred euros per life-year
gained (Brown & Garber, 1998). No Dutch data is (yet) available for medication
(including antibiotics, mucus dissolving agents (NAC), and medicines that improve the
flow of air (bronchodilators)). Studies in other countries often reveal costs in the order
of magnitude of several tens of thousands of euros for each quality-adjusted life-year
(Ruchlin & Dasbach, 2001). Furthermore, medical care can concentrate on improving
the quality of life through what are known as self-management programmes, which
teach patients to ‘manage’ their disease themselves, part of which includes adjusting
their own medication if necessary. Dutch studies are still in progress, but studies in other
countries have shown that a programme of this type is able to save costs with mildly to
moderately ill patients (Gallefosse & Bakke, 2002). For seriously ill patients, there are
programmes for lung rehabilitation (costs per ‘well-year’ on the basis of studies in other
countries, 30,000 to 70,000 euros (Ruchlin & Dasbach, 2001). The main costs here are
oxygen equipment and benefits in quality of life. The most cost-effective solution for
oxygen therapy is determined on an individual basis, and depends, for example, on the
patient’s mobility (Kampelmacher et al., 2001). Studies from other countries show that
for a small group of patients with COPD, as a consequence of a genetically determined
alpha-1 antitrypsin deficiency, treatment costs may differ between 20,000 to a possible
210,000 euros per life-year gained. The large margin is based on uncertainty on the effi-
cacy of the treatment (Hay & Robin, 1991; Alkins & O’Malley, 2000). Finally, surgical
interventions, lung reduction or lung transplantation, are relatively expensive according
to Dutch and foreign studies: estimates varied from 90,000 to 250,000 euros per QALY
(Al et al., 1998; Ruchlin & Dasbach, 2001).
This example appears to bear out the old saying that ‘prevention is better than cure’, or
in any case is less expensive. As always, however, things are rather more complicated in
obdurate practice. Efforts aimed at prevention usually pay off only after a considerable
time (and then by no means for everyone). Furthermore, many prevention measures
have an impact on our cherished freedom of choice regarding lifestyle, which often
make them less attractive. Also, there is no allocation of resources from care to preven-
tion in practice. If patients can be offered an extension to life and an easing of their bur-
den, we will pay a high price, irrespective of a person’s past behaviour. In practice, more
weight is given to accessibility (recall the public dissatisfaction with waiting lists) and
solidarity than to health benefits, in particular where individual patients are concerned.
Undesirable surprises for national health expenditure?
Successful prevention could also have unexpected consequences. Although a high
return in healthy years is to be had for a relatively low price, on a collective level, pre-
vention can also lead to a considerable increase in the cost of care. Successfully deter-
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ring smoking will greatly reduce lung cancer. As an often untreatable disorder, lung can-
cer is relatively inexpensive in terms of care, and furthermore it is fatal usually after a
productive life. The successful prevention of lung cancer therefore causes a consider-
able increase of the inflow into expensive years of old age and care requirement, with
the consequence of possibly higher public cost. A short time ago, a cigarette manufac-
turer caused a stir by cynically presenting the Czech government with a calculation that
smoking ultimately had a favourable effect on the nation’s ledger (see for example
www.tobaccofreekids.org). Savings on pensions, care and residential help for the elder-
ly tipped the balance. Nonetheless, the result of a Dutch study into the costs of smoking
were less clear. Whether smoking saves costs on a macro level also depended on the dis-
count rate, time horizon and whether or not certain social costs were included in the cal-
culation (Barendregt et al., 1997).
What is healthy life worth to us?
Alongside the cost-effectiveness or cost-utility analysis, cost-benefit analysis is a form
of evaluation in which the benefits are often expressed in monetary terms. Efficiency
calculations are made easier by putting cost and benefits under one heading, namely
money. Furthermore, it is easier to include non-health aspects on the benefit side. In
principle, investments in the health domain are compared with investments outside, in
economics, socio-cultural conditions or ecology. Obviously this form of analysis does
not allow us to avoid the almost impossible task of expressing loss of life, life-years, or
burden of disease in money. There are roughly two ways to produce these estimates:
• investigating how health risks that are related to certain risky occupations are
allowed for in the differences in salary, or what extra amount people are prepared to
pay for safer or healthier products (for example, cars with airbags everywhere, or
houses in quieter surroundings);
• posing shrewd questions to find out what people are prepared to pay for one extra
life-year or one year free of disease or disabilities (in the absence of data, costs of
disease or loss of production is also used as a proxy, but these estimation methods are
by their nature relatively unrepresentative of loss of health).
Significant methodological objections are attached to both methods in connection with
the transferability of implicit (behaviour) or explicit (survey) preferences of people
from one circumstance to another, including a series of shortcomings that are character-
istic of all questionnaire-based surveys (Hoevenagel, 1994; Van de Berg & Rutten,
2002; Diener et al., 1998; Klose, 1999; Olsen & Smith, 2001). In terms of the value of a
statistical life, the outcomes of the above-mentioned methods are nevertheless reason-
ably consistent. Americans, Canadians or Europeans give on average in the order of two
million euros for their lives (1.5 to 7 million euros), which is approximately 70,000 to
80,000 euros a year at a discount rate of 3% (which for most of us is considerably more
than our earning capacity, which is another commonly used proxy).
Having completed a thorough analysis of the increase in life expectancy against the
increased cost of health care since 1970, researchers at NYFER conclude that we have
nothing to complain about on a macro level with respect to cost-effectiveness (see also
PHSF 2002:  HEALTH ON COURSE? 2.5
137
chapter 1). For the four years of life expectancy that we have gained in thirty years, we
only pay about 23,000 euros per year extra, on average (NYFER, 2000). It should be
noted that the authors have assumed that a substantial part of these four years is also
directly attributable to the care budget. In the macro-economic view of the researchers,
the question is not whether we spend too much on health care, but whether the money is
spent wisely, for example by giving priority to promising technologies, and improving
the performance in poorly performing sectors (meso and micro levels).
As yet, there has been only a limited application of cost-benefit analysis to the health
care sector (Anell & Norinder, 2000). It was soon evident that expressing mortality and
other loss of health in monetary terms was often ‘a bridge too far’ for policymakers in
the health care sector. They therefore resorted to more abstract measures, such as quali-
ty-adjusted life-years (QALYs). In the environmental domain, however, this kind of
analysis has been of pivotal importance for ten years now. Its application became fash-
ionable in the United States during the Reagan administration. He saw it as a means of
simplifying what he saw as complex and extensive environmental regulation. In the
meantime, the obligation to perform a cost-benefit analysis for new regulations is often
incorporated in law, for example in the Clean Air Act. The EU also stimulates the appli-
cation of this instrument, particularly in the area of air pollution and noise (Dusseldorp
et al., 2001). Economic evaluations are also applied in the Dutch health care sector, for
example when adding care interventions to the package of cover (for example transplant
programmes), or in the introduction of preventive programmes (for example breast can-
cer screening). The submission of a cost-effectiveness dossier for new pharmaceuticals
will become compulsory in 2005 (Van den Berg & Rutten, 2002).
In the early American and European cost-benefit analyses, measures for limiting air pol-
lution achieved conspicuously high scores. These analyses often placed a generous
value on a human life, with amounts varying from 1.5 to approximately 7 million euros
per life lost. Each new case of chronic bronchitis attributable to air pollution was valued
at 100,000 to 300,000 euros (Davis et al., 2002). In more recent studies, however, there
is no longer an exclusive focus on mortality. Instead, an attempt is made to quantify the
years of life lost, taking into account their quality. This usually leads to a considerably
less rosy picture of the relationship between investments and health benefits, in view of
the fact that most ‘modelled’ victims of air pollution are expected to be elderly people in
fragile health and therefore no longer worth the full price (‘harvest effects’). These stud-
ies also place greater relative weight on ecological and sustainability benefits (AHG-
EAHEAP, 1999; Howarth et al., 2001).
If there is no longer an exclusive focus on the value of a statistical life (VOSL), but
more account is taken of duration and quality (VOLY), this bridges the gap to the use of
QALYs or disability-adjusted life-years (DALY)s, as used in cost-utility analyses. For
instance, various attempts have been made to establish the willingness to pay for quali-
ty-adjusted life-years in a credible way (Bleichrodt & Quiggin, 1999). A number of
analyses suggest that, for policymakers, the value of a quality-adjusted life-year is of the
order of 20,000 to 50,000 euros (Melse & De Hollander, 2001). The study by Tengs et
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al. (1995) into the cost-effectiveness of as many as 500 ‘life-saving’ interventions shows
that the distribution’s centre of gravity lies between 10,000 and 100,000 dollars (see
also table 2.19, Tengs et al., 1995).
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3 OUR HEALTH IN THE FUTURE:
PROSPECTS FOR 2020 
Nobody can foretell the future, but that does not make us any less curious, or prevent us
from searching for methods that still allow us a view of the future so that we can antici-
pate developments in our policy. In this chapter we concentrate on assumptions that can
be formulated about the future health status of the population by studying trends in
health-related factors, including the determinants and the autonomous developments
addressed in chapter 1 (see also figure 1.2). We begin by outlining the autonomous
developments up to 2020 under the headings of ‘demographic’, ‘socio-cultural’, ‘eco-
nomic’ and ‘medical technology’ trends. 
3.1 Tomorrow’s world: a brief impression 
Demographic trends
The Dutch population (15.9 million in 2000) will increase by 1.6 million between 2000
and 2020. This trend will be paralleled by a continued rise in the number of elderly peo-
ple. At present, one person in seven is aged 65 or over. This will rise to almost one in
five in 2020. Meanwhile, the percentage of young people (aged 0 - 20) in the population
is declining (Statistics Netherlands, population forecast 2000). 
These forecasts by Statistics Netherlands (CBS) are based on, amongst others, the
assumption that, in future generations, each woman will bear, on average, 1.75 children.
The trend towards starting a family at a later age has come to an end and women will
continue to have their first child at the average age of 29. The annual number of births
will fall from 207,000 in 2000 to 193,000 in 2020. The growth in the (elderly) popula-
tion will push up the number of deaths from 140,000 in 2000 to 174,000 in 2020. 
In 2020, ethnic groups (western and non-western) will account for a quarter of the pop-
ulation, compared with one sixth in 2000. In the next two decades western ethnic groups
will grow in size from around 1.4 million to almost 1.8 million. Non-western ethnic
groups will grow more sharply: from 1.4 million in 2000 to 2.6 million in 2020. Conse-
quently, in 2020 non-western ethnic groups will account for 15% of the population,
compared with 9% in 2000 (Statistics Netherlands, population forecast 2000). 
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The future: both ‘more’ and ‘less’
The next twenty years in the Netherlands will be characterized by ‘more’: more people,
more households, more individual choice, more mobility, more information and com-
munication technology, more diagnostic technology, more therapeutic techniques and
more market forces. However, in some prominent domains the expectations are charac-
terized by ‘less’: notably, less economic growth and less government control. 
The number of households is expected to rise by one million in the next 20 years. This
trend stems from population growth, but also from the fact that households will be
smaller than before. The share of single-person households will rise from 15% to almost
18%. Institutional households (including residential care and nursing homes) will fall
relatively sharply from 1.4% to 0.9%, largely because people will stay longer in their
own homes (Statistics Netherlands, population forecast 2000). 
Socio-cultural trends
Women will continue to close the educational gap between themselves and men. Mean-
while, the educational level of persons between the age of 15 and 65 (the potential
labour force) will improve further. According to forecasts by Statistics Netherlands
(CBS) and the Netherlands Bureau for Economic Policy Analysis (CPB), the share of
the potential labour force with only elementary schooling will fall to around a third in
2020 and the number with higher education will increase to around a quarter. 
Greater freedom of choice will result in smaller households, the independence of house-
hold members, personalized social insurance schemes and employment contracts, more
homes, more cars and increased space consumption. The Social and Cultural Planning
Office (SCP) predicts that this individualization will lead to informalization: more
equality and the end of authority-based relationships (with more problems and conflicts
relating to deference and respect) and traditional social institutions such as the church
and political parties. Business and leisure, work and home will become increasingly
intertwined and people will seek ‘intensification’ by attaching greater importance to the
‘intense and conscious experience’ of work, relationships, sport or leisure activities. The
early 21st century will also see various expressions of hedonism: the reduction of inhibi-
tions by means of drug-taking, group aggression and the aggrandizement of sexuality
and sport. The mass media will respond to this trend and heighten it (Schnabel, 2000). 
In the past few years subjective experience of (in)security has remained fairly stable
(approx. 30% of the population feel unsafe). However, objectively, the situation has
deteriorated in the main cities and in some neighbourhoods. Here, actual crime rates are
higher and often go hand in hand with large problems related to liveability. No signifi-
cant decline is expected in the crime figures in the near future (Maas-de Waal & Van der
Torre, 2000). 
The correlation between educational levels and health is particularly strong. Generally
speaking, people with a higher educational level enjoy better health (see sections 2.1
and 3.2). The downside of the socio-cultural developments outlined above is that more
people will experience stress, loneliness and a lack of social support. Increasing urban-
ization and rapid social change might also add to the emergence of these mental health
problems (Maas & Jansen, 2000). 
Economic and political trends
In the 1990s the economy boomed in the Netherlands. The forecasts that were compiled
before 2001 were also highly optimistic. But 2001 brought an economic downturn,
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which was further exacerbated by the terrorist attacks of 11 September. The upshot was
that the economic growth of most industrial countries – including the Netherlands –
came to a virtual standstill. The CPB analysis for 2003-2006 is based on the expectation
that the economy will recover somewhat and that annual growth will even out at around
2.5% (CPB, 2002). However, these prognoses are constantly being revised downwards.
Given the variability of the economic trends in the past few decades, it is unlikely that
the trough will continue until 2020. 
Technology is progressing rapidly and leading to further growth in the knowledge econ-
omy. Meanwhile, ICT is still triggering changes in products, production methods, mar-
kets, corporate structures and labour patterns. The demarcation lines between communi-
cation, media presentation, advertising and information are fading (Schnabel, 2000). 
Women will increase their participation in the labour market. The size of this increase
depends on many factors, not least childcare facilities, the taxation system, the labour
market and social amenities (CBS/CPB, 1997). At the same time, the participation of
ethnic groups in the labour force will increase from around 7% in 1995 to between 12%
and 16% in 2020. There are no signs of an impending large flow of highly qualified
immigrants from developing countries or Eastern Europe with an educational back-
ground relevant to the Dutch labour market. Though the educational level of the poten-
tial ethnic labour force will improve greatly, the ethnic population will grow to such an
extent that it will be more strongly represented in the lower levels of the labour market.
In 2020 ethnic groups will make up approximately half the workforce in the lower lev-
els of the labour market (people with only an elementary education) as opposed to a
quarter in 1995 (CBS/CPB, 1997). 
Another economic trend expected in the coming years is a decline in the agricultural
land use. This will not, however, be enough to fulfil the requirements of housing, indus-
try, infrastructure, sport & leisure, wildlife and landscape. Over a quarter of the surface
of the Netherlands will be used for a new purpose in the coming decades (Ministry of
Housing, Spatial Planning and the Environment (VROM), 2001). We shall have to find
spatial solutions that will intensify and combine functions. The growing need for recre-
ational space is creating problems, especially in the Randstad (highly urbanized western
part of the Netherlands), where it looks as if there will be an even greater shortage of
green recreational space around the cities. Easily accessible green space is important
and a determining factor for the quality of the living environment (RIVM, 2002). 
The principle of centrally steered social change will be further eroded as the govern-
ment increasingly finds itself dealing with educated and emancipated citizens who have
their own ideas about what is best for them. The national government will increasingly
try to find solutions in market forces and by devolving more powers to local authorities.
Stronger market forces will be reflected; not only in the privatization of government ser-
vices, but also in the structure of the health care sector (e.g. a more prominent role for
private clinics, insurance companies being given a role as coordinators). The govern-
ment will have to rethink many of its policies and tackle dilemmas. The dilemmas it
PHSF 2002:  HEALTH ON COURSE? 3.1
143
faces in terms of law and order include preventive policy versus repressive policy,
supervision versus individual freedom and public-sector versus private-sector responsi-
bility (Maas-de Waal & Van der Torre, 2000). The government will also face some awk-
ward dilemmas when drafting its policy on health and social welfare. We shall return to
this theme in chapter 4. 
Internationalization is cutting across borders, distance and time. Internationalization
brings a stronger influence by the EU, multinationals and NGOs, but also unlimited
tourism and (worker) migration. In this border-free world, national governments are los-
ing their power to multinationals and large NGOs (Herz, 2002). European legislation
and regulations have an ever stronger impact on tobacco and alcohol advertising, food
ingredients and additives, the availability of new drugs and the ground rules for the
health care system (notably in matters of competition and accessibility). Cross-border
health care will increase, but the question is whether it will increase to such an extent
that it will affect health. 
Medical technology trends
Many aspects of health care have progressed enormously in recent decades as a result of
advances in medical technology. On balance, diagnostic technology has so far devel-
oped faster than therapeutic techniques (WRR, 1997) and will probably continue to do
so in the years ahead. However, better and earlier diagnosis means that existing treat-
ments can be more effectively applied in many cases. 
The unravelling of the human genome makes it easier to isolate genetic abnormalities
that cause hereditary disorders, but the therapeutic options are currently lagging behind.
Another important associated trend is the shift from the treatment of diseases to the pre-
vention and treatment of risk factors (Wanless, 2001; Mos et al., 2002). Section 3.3
addresses this subject in detail. 
Tomorrow’s world: possible solutions
In section 3.2 we present some projections and discuss the potential effects of socio-
demographic trends on the future health status. As forecasts are available for these trends
and because they are known to be health-related, it is possible to present these effects in
quantitative terms. We shall then address some major developments in medical technolo-
gy. Here the influence on the health status is described mainly in qualitative terms (sec-
tion 3.3). The aim of this kind of analysis is to determine how the health status in the
Netherlands can change in the future under the influence of ‘autonomous’ developments. 
Section 3.4 presents two analyses of the health status, which are based on developments
in health itself or in health-determining factors, as discussed in chapter 2. The PHSF for
1997 also contains some examples of this type of prospective analysis (Ruwaard &
Kramers, 1997; Van den Berg Jeths, 1997). Given the international perspective of this
PHSF, we are basing the two analyses on health differences in Europe. The first relates
to mortality differences in Western Europe, classified according to cause of death. The
second relates to differences in the prevention of six risk factors. 
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3.2 Socio-demographic projections 
3.2.1 The effects of population growth, ageing and
dejuvenation on the health status
Ageing and dejuvenation
The first question in socio-demographic surveys is: how do population growth, ageing
and dejuvenation affect the health status? According to the CBS forecast of 2000, the
population will grow by 10.3% from 15.9 million in 2000 to 17.5 million in 2020. The
over-65 cohort will grow from 13.6% in 2000 to 18.4% in 2020. The increase will be
sharper for males, mainly because the probabilities of dying are declining faster for men
than for women (see text block 3.2). Men are also subject to ‘double ageing’: the per-
centage of men over the age of 80 is increasing slightly in relation to the percentage of
men over the age of 65. Meantime, the percentage of women over the age of 80 will fall
slightly in relation to the percentage of women over the age of 65. The representation of
the 0-20 cohort in the overall population will drop from over 24% in 2000 to over 22%
in 2020. The expected changes in the Netherlands for six age groups between 2000 and
2020 are shown in figure 3.1. 
Compared with the population forecast of 1996 – which was used as the departure point
for PHSF 1997 –  CBS has not only revised its assumptions on births, deaths and migra-
tion, but has also employed a new forecasting method (see text block 3.1). 
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Population growth and ageing lead to strong increase in chronic diseases 
According to Statistics Netherlands (CBS), male life expectancy will rise from 75.5 in
2000 to 78.0 years in 2020. The increase in female life expectancy will be lower, i.e.
from 80.6 to 81.7 years. The number of patients with a chronic disease will rise by 25-
55% in the next 20 years because of population growth and ageing. The increase will
be higher for men than for women. 
Better education and changes in marital status significantly influence health
The effects of ageing on the health status will be reinforced by shifts in the marital sta-
tus of the population. Conversely, higher levels of education could – at least partly –
cancel out the effects of the ageing population (provided the relationship between
health and all these factors stays the same in the future). The results suggest that,
apart from population growth and ageing, other socio-demographic factors may have
a profound effect on the health status of the population.
Longer life expectancy, especially for men
According to the CBS population forecast, female life expectancy at birth will increase
from 80.6 years in 2000 to 81.7 in 2020. Male life expectancy is expected to rise from
75.5 years in 2000 to 78.0 in 2020. The difference between the life expectancies of men
and women will therefore decrease from over five years in 2000 to slightly less than
four years in 2020 (see text block 3.2). 
Strong rise in disease cases due to population growth and ageing
Changes in the number of new and existing disease cases have been calculated for the
53 selected illnesses and disorders listed in the PHSF. The starting point is the CBS pop-
ulation forecast of 2000 and the assumption that the incidence and prevalence figures
will remain the same for each gender and age group (see chapter 2). The results are clus-
tered according to the degree of change (see table 3.1). 
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Figure 3.1: Changes in the Dutch population size (in percentages) subdivided by age and gender
in 2000-2020 (Source: CBS population forecast 2000, data processed by RIVM). 
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Text block 3.1: CBS population-forecasting method since 2000
CBS reviews its long-term forecast every two
years with the time horizon at 2050. Up to 1998, it
presented a low, medium and high variant, but in
2000 it adopted a new system (De Jong, 2001).
The forecast describes a plausible population
trend on the basis of assumptions about births,
deaths and migration. The uncertainty involved in
making such a forecast is reflected in a probabili-
ty distribution. This system provides an upper and
a lower limit with a probability of two out of three
that the future population will lie somewhere in-
between (67% forecast interval). The lower limit
of the 67% forecast interval for the overall popu-
lation in 2020 is 16.8 million and the upper limit
is 18.1 million (CBS, 2001). This report will make
no further use of these upper and lower limits.
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Text block 3.2: Assumptions about mortality in the CBS population forecast 2000
(Source: Van Hoorn & De Beer, 2001) 
A new element in the CBS population forecast is
an explanatory model for mortality. This model is
based on life expectancy observations for the
entire 20th century and takes account of six
effects: 
1. Smoking. The effect of smoking on male life
expectancy was greatest in the 1970s. This
effect falls to two years in the forecast period
(up to 2050). For women the effect of smoking
on life expectancy was less than one year in
2000. This is expected to increase to two years
in the future.
2. Traffic accidents. The effect of traffic accidents
on life expectancy rose between the 1950s and
the early 1970s and then subsided. For the long
term the CBS sets this effect at zero. In other
words, it will not lead to a deviation from the
life expectancy trend.
3. Rectangularization. The survival curve is
becoming more rectangular: life expectancy at
birth will increase, mainly because more people
out of every 1,000 births will grow old and, to a
lesser extent, because elderly people will be liv-
ing even longer.
4. Antibiotics. It is assumed that since the intro-
duction of antibiotics life expectancy at birth
has consistently been almost 1.5 years higher
than it had been before. 
5. Intrinsic gender-related difference. Life
expectancy at birth is a few years longer for
women than for men. The gender-related differ-
ence is assumed to be a constant three years in
the future.
6. Unforeseen events. World wars and flu epi-
demics have had a negative effect on life
expectancy in the 20th century. It is assumed
that these unforeseen events will not have any
effect on the long-term trend of life expectancy
in the future. 
Finally, in addition to the above six factors the
CBS takes account of a residual trend for the
unexplained aspects of mortality patterns in the
past (an exponential curve). This trend is extend-
ed into the future. The CBS gives a number of rea-
sons for not including any other causes or deter-
minants of mortality (e.g. lifestyle, influence of
medical technology) in the model: either there is
not enough insight into the extent of their effects
on life expectancy, or the effects may be interde-
pendent (a model that includes the effects of
smoking cannot also include smoking-related
causes of death), or no assumptions can be for-
mulated about the future trend (e.g. the effect of
medical breakthroughs). 
Table 3.1: The change in the number of new (i = incidence) and known cases (p = prevalence) of the selected
diseases and disorders in 2020 in the Netherlands compared with 2000 (in percentages) as a result of devel-
opments in the size and composition of the population in terms of age and gender a,b (Source: CBS popula-
tion forecast 2000; data processed by RIVM). 
Change illness/disorder 
-6 - 0% AIDS (i), multiple sclerosis (i), congenital abnormalities of the central nervous system (i),
congenital abnormalities of the cardio-vascular system (i), Down’s syndrome (i), extremely
premature birth (i) 
0 - 5% Intellectual disability (p), asthma (i), constitutional eczema (i), congenital abnormalities of
the central nervous system (p), congenital abnormalities of the cardiovascular system (p),
industrial accidents (i), sport accidents (i), (attempted) suicide (i), violence (i) 
5 - 15% Infections of the gastro-intestinal tract (i), tuberculosis (i), meningitis (i), schizophrenia
(i/p), depression (i/p), anxiety disorders (i/p), multiple sclerosis (p), epilepsy (i), influenza
(i), asthma (p), infections of the upper respiratory tract (i), inflammatory bowel diseases
(i/p), constitutional eczema (p), contact eczema (i/p), neck and back problems (i/p), traffic
accidents (i), domestic accidents (i) 
15 - 25% Breast cancer (i), epilepsy (p), infections of the lower respiratory tract (i), gastric and duo-
denal ulcers (i/p), urinary tract infections (i), rheumatoid arthritis (i) 
As expected, table 3.1 shows only a slight rate of change (-6–15%) in diseases that
affect all age groups or specifically the very young (including many infectious dis-
eases). The growth rate for almost half of the diseases and disorders is between 25% and
60%. This relates particularly to diseases affecting the elderly. The increase therefore
reflects the combination of population growth and ageing. The growth rates are consid-
erably higher for men than for women. In some cases they are double, e.g. for dementia,
Parkinson’s disease, chronic heart failure, strokes and hip fractures (55-70% for men;
not shown in table 3.1). This is partly attributable to the fact that life expectancy for men
will increase more than for women. This data is especially useful when assessing the
required (shifts in) health care capacity (see also section 3.5). 
3.2.2 Effects of trends in martial status, education and
ethnicity on health status 
More widows/widowers, divorcé(e)s and single persons in the future
The second key question in socio-demographic surveys is: how can trends in marital
status and education potentially influence the health status? The number of unmarried
persons will rise sharply from 7 million in 2000 to 8.8 million in 2025. In the Nether-
lands unmarried men outnumber unmarried women by half a million both now and in
the future.  
There will also be more widows/widowers and divorcé(e)s in the future. In 2000 these
groups were more or less even at 800,000. In 2025 there will be almost a million wid-
ows/widowers and some 1.2 million divorcé(e)s. Widows will outnumber widowers and
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Continue table 3.1
Change illness/disorder 
25 - 35% Sepsis (i), breast cancer (p), non-Hodgkin’s lymphoma (p), diabetes mellitus (i), decubitus
ulcers (i/p), rheumatoid arthritis (p), osteoporosis (i/p) 
35 - 45% Oesophageal cancer (p), colorectal cancer (i), non-Hodgkin’s lymphoma (i), skin cancer
(i/p), diabetes mellitus (p), dementia (i/p), Parkinson’s disease (i/p), visual impairment (i),
coronary heart disease (i/p), heart failure (p), stroke (i/p), age-induced and noise-induced
hearing loss (i/p), COPD (i/p), osteo-arthritis (i/p), hip fracture (i) 
45 - 55% Oesophageal cancer (i), stomach cancer (i/p), colorectal cancer (p), lung cancer (i/p), heart
failure (i), visual impairment (p) 
55 - 67% Prostate cancer (i/p), aneurysm of the abdominal aorta (i) 
a) diseases and disorders ordered according to the ICD code. 
b) no demographic projection of STD (i), alcohol or drugs dependency (i/p), mental disorders among children and adoles-
cents (i/p), congenital or early hearing impairments (i/p), dental abnormalities (i/p), Down’s syndrome (p) or health prob-
lems in full-term infants (i/p) due to the absence of suitable age-specific statistics. 
c) a purely demographic projection of the number of cases of illness should be based on an ‘adjusted’ population forecast
which assumes that the age-specific and gender-specific death rates are constant; after all, if incidence and prevalence
are assumed to be constant according to age and gender then this also applies to mortality. 
divorced women will outnumber divorced men. This situation is due to the difference in
life expectancy, as women are, on average, married to men who are two years older. It is
also due to the fact that more men than women remarry after divorce. The difference
between the number of widows and widowers will fall slightly in the future, thus reflect-
ing the smaller difference in life expectancy. The number of married persons will fall
slightly from 7 million in 2000 to 6.8 million in 2025 (no data for 2020). Formal statis-
tics on marital status do not offer a clear picture of actual ‘cohabitation’. For example, in
2000 15% of couples who lived together were unmarried. In 2020 this is expected to rise
to 25%. Data on the trend in marital status has been taken from the CBS household sur-
vey of 2000 (De Jong & Steenhof, 2001). 
Married people have the fewest health problems, followed by persons who have never
been married and widows/widowers; divorcé(e)s have the most health problems. Cou-
ples who live together have fewer health problems than single persons, after corrections
for age, gender and education (Joung & Van Poppel, 1997). Differences in health are
greater for the more subjective variables, such as self-rated health, than for objective
variables, such as the prevalence of chronic diseases. The socio-demographic projection
presented below shows the effects of changes in martial status on public health. 
Higher levels of education
On average, Dutch people with higher levels of education enjoy better health than peo-
ple with lower levels of education (Stronks et al., 1997). This is reflected not only in the
incidence of diseases and disorders but also in the way health status is experienced and
by the existence of long-term disabilities (see also section 2.1). Figure 3.2 shows the
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Figure 3.2: Forecasts of levels of education of the Dutch population aged 15 and over in 1995-
2020 (Source: CBS/CPB, 1997; Herweijer, 2001). 
a) excluding participants in full-time education. 
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further improvement in educational levels both for the potential labour force and for the
elderly in the period 1995-2020. 
Effects of ageing on the health status are heightened by fall in the number
of married people, but mitigated by higher levels of education 
Joung et al. (2001) have presented calculations of the effects of demographic changes in
age, gender, marital status and education on the health status. In other words, they have
added two factors to those of age and gender, which were addressed in section 3.2.1.
Health is measured with three variables: self-rated health, the presence of chronic dis-
eases and the presence of long-term disabilities. The calculation method is explained in
text block 3.3 and the results are shown in table 3.2. 
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Text block 3.3: Method for calculating the influence of demographic trends in age, education and
marital status on the health status
(Source: Joung et al., 2001) 
The calculations are based on the following
sources and assumptions: 
• Data on differences in health, classified accord-
ing to age, gender, marital status and educa-
tion, is taken from the CBS Health Survey, com-
bining data for 1993, 1994 and 1995.
• The CBS 1996 household survey has been used
to estimate the future composition of the popu-
lation in terms of age, gender and marital sta-
tus.
• Use was made of the CBS/CPB forecasts for the
potential labour force (15-65 year-olds who do
not participate in full-time education), supple-
mented by a forecast for the 65-84 age group
(based on the CBS Health Survey 1991-1995,
which assumes that the educational level of age
groups above 65 remains constant).
• Finally, it was assumed that health differences
according to age, marital status and education-
al level are constant throughout the calculation
period. 
Table 3.2: Prevalence statistics per 100 Dutch men and women a in 1996 and 2015, taking account of demo-
graphic trends in age, educational level and marital status (Source: Joung et al., 2001). 
Age Age + level Age +
of education marital status
Self-rated health (less than good)
Men - 1996 21.0
Men - 2015 23.6 21.7 24.0 
Women - 1996 25.3
Women - 2015 27.5 24.8 27.8 
One or more chronic disorders b
Men - 1996 45.0
Men - 2015 48.2 47.5 48.3 
Women - 1996 54.7
Women - 2015 57.2 56.4 57.3 
One or more long-term disabilities
Men - 1996 12.3
Men - 2015 14.7 12.9 15.0 
Women - 1996 18.7
Women - 2015 21.2 18.2 21.5
a) age between 25 and 85. 
b) the question in the CBS Health Survey covers 24 common (groups of) chronic diseases; the actual percentage of people
with at least one chronic disorder is therefore greater.
Table 3.2 first shows the effect of ageing (conform section 3.2.1), but this time the
prevalence is relative and other health variables are presented. The ageing effect is rein-
forced by trends in marital status (though these are nowhere near as strong as ageing). If
educational levels improve as anticipated, the age effect will be largely cancelled out for
men and perhaps even entirely cancelled out for women. 
More people belonging to western and non-western ethnic groups
Besides the above factors, we need to understand the effects of migration on health sta-
tus. It is difficult to accurately forecast migration because social, economic and political
developments on the European and world stage often trigger strong fluctuations in the
annual migration figures. 
The assumptions about migration in the CBS population forecast are specified accord-
ing to country and the type of migration (family unification, asylum seekers, chain
migration, work and study migration and Dutch nationals returning from abroad). These
assumptions result in a declining positive balance from approximately 50,000 in 2000 to
approximately 30,000 in 2020. 
A total of 130,000 immigrants per year has been forecast for the long term, the largest
groups being migrant workers and returning Dutch emigrants. Total emigration amounts
to 100,000 per year and consists mostly of migrant workers returning to their country of
origin and emigrant Dutch nationals (Alders, 2001; CBS, 2001). Table 3.3 shows the
figures for the latest CBS forecast for ethnic groups. 
The ageing trend will also affect the population of non-western ethnic groups. The rep-
resentation of the over-65 age group has trebled from 2% to almost 6% (first and second
generation combined). 
Ethnic groups are currently concentrated in the four major cities. In 2000 over 37% of
the population of Amsterdam, Rotterdam, The Hague and Utrecht consisted of ethnic
groups, two thirds of which were non-western (Van der Lucht & Verkleij, 2001). The
representation of non-western ethnic groups in the population of the four major cities
will about double to almost 40% in 2015 (Huisman & Van Wissen, 1998). 
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Table 3.3: Ethnic groups in 2000 and 2020 (x 1,000) in the Netherlands subdivided into first and second gen-
eration a (Source: CBS forecast for ethnic groups 2000). 
2000 2020
First generation Second generation First generation Second generation
Total non-western 886 523 1,420 1,172 
Total western b 545 822 761 998 
Total 1,431 1,345 2,181 2,170 
a) the first generation consists of persons who were born abroad and with at least one parent who was also born abroad; the
second generation consists of persons who were born in the Netherlands and with at least one parent who was born
abroad. 
b) including Indonesia and Japan. 
Influence of ethnicity on health status unclear
The last PHSF reported that the health status of the various ethnic groups is worse than
that of the indigenous population. However, at that time very little data was available
(Van Wersch et al., 1997). Though a little more information has emerged in recent years,
the picture is still unclear. Chapter 2 of this report contains the latest data on the health
status of ethnic groups. This data indicates that some ethnic groups actually have a high-
er life expectancy than non-ethnic groups. When we look at risk factors, the situation is
variable. The picture for ethnic groups looks better with regard to nutrition, smoking
and alcohol but worse for drug use and participating in sports. High cholesterol levels
are rare among ethnic groups, but high blood pressure and obesity are more common.
Once again, all of these factors vary according to gender and age in the various ethnic
groups. Hence, it is impossible to compile an accurate projection of the effect of trends
in ethnicity on the health status of the population as a whole. 
3.3 Medical technology prospects 
Medical technology is a vast terrain; impossible to see the full picture
What are the most important medical technology developments currently being antici-
pated for prevention and (early) diagnosis, and care and treatment? What is the potential
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More opportunities for prevention
Current preventive technology will be expanded in the future. Genetic profiling will be
increasingly used to identify predispositions for certain diseases and disorders (predic-
tive genetic testing) and to ascertain how a disease is likely to progress. However, pre-
dictive medicine not only paves the way for new types of medical practice, it also cre-
ates new relationships between the medical profession and patients and between the
medical profession and other organizations. In the process, the dividing line between
prevention and care will become blurred. 
Current treatment methods will become more effective
In the next ten years the effects of medical technology on the health status will mainly
take the form of earlier and more accurate diagnoses. This will raise the effectiveness
of existing treatment methods and give the patient a better quality of life. The
patient’s quality of life can also be improved by the developing and upgrading of exist-
ing treatment methods and to a far lesser degree by the emergence of totally new
treatments. 
Improved understanding of genetics will lead to new diagnostic techniques
More insight is being gained all the time into genetically determined diseases. At the
moment treatment options are trailing behind techniques for (early) diagnosis. ICT is
being applied in increasing measure. In the long term (10-20 years and beyond) more
real breakthroughs can be expected in treatment methods, and possibly, better ways
will be found to repair cells, tissue and organs. However, in recent decades experience
has shown that developments often move less quickly than was originally hoped and
anticipated, gene therapy being a case in point. 
influence of these developments on the health status? These questions will be addressed
in this section. 
Medical technology is the umbrella term for a wide range of technologies including
biotechnology, nanotechnology (application of new technology by using minute parti-
cles), telemedicine, imaging techniques, replacement surgery (organ transplants, tissue
transplants or tissue regeneration with the aid of bio-technology), gene therapy, medica-
tion, diagnostics, et cetera. These require not only diverse types of equipment and
instruments but also clinical knowledge and procedures and the right organization and
support systems. This chapter will discuss some major developments in prevention and
(early) diagnosis and in treatment and care. 
3.3.1 Development potential for prevention and (early) 
diagnosis 
Current prevention technologies will be further developed in the future. This section
will discuss three examples of prevention technology: new vaccines, new drugs for pri-
mary prevention and better imaging techniques. It will also focus on new technologies
for (early) diagnosis, which are important in the domain of predictive medicine. 
New vaccines expected for various diseases
The huge advances in biotechnology are playing a crucial role in the development of
new vaccines and, at the same time, adding to the knowledge of immunology and the
micro-organisms that cause infectious diseases (Van Alphen, 2001). 
In some parts of the world vaccines are already being used which have not yet been
introduced in the Netherlands: hepatitis A and B, Varicella zoster (chickenpox) and
pneumococcae. Within ten years vaccines are expected for several other diseases, such
as respiratory syncytial virus (RSV), herpes genitalis, meningococcae B and Helicobac-
ter pylori. Investigations are also being conducted into alternative ways of administer-
ing vaccines (e.g. through nasal sprays and patches) and into new combination vaccines.
In the next few years decisions may be made to include new vaccines in the National
Vaccination Programme (NVP). This will depend on cost-effectiveness amongst other
things (Van der Zeijst et al., 2000). Bacterial mutation has reduced the efficacy of the
current whooping cough vaccine in the NVP and work is underway to improve this 
vaccine. 
Even so, there is at present no prospect of a safe and efficient vaccine for many diseases.
There are many reasons for this, not least the strong mutability of viruses. This is the
main reason why a vaccine against HIV cannot be expected in the short term. Similarly,
a vaccine against the human papilloma virus, which can cause cervical cancer, is not
expected within the next ten years. 
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More drugs for primary prevention
An increasing number of drugs are being produced for primary prevention, with the aim
of (partly) mitigating an unhealthy lifestyle. These drugs, for instance lower blood pres-
sure and cholesterol, support attempts to quit smoking, combat alcoholism and heroin
addiction, and treat low bone mass to prevent osteoporosis (Timmerman & Van den
Berg Jeths, 2001). For a long time, a search has been underway for an anti-obesity drug,
which could be crucial in preventing diabetes mellitus and osteo-arthritis. The current
drugs still have too many adverse side effects (Lutterman, 2001). Articles appear regu-
larly on potential new openings for anti-obesity treatment, such as an intestinal hormone
to suppress the appetite (Batterham et al., 2002). 
Less sharp distinction between medication and nutrition
The distinction between medication and nutrition will become blurred with the produc-
tion of enriched or ‘functional’ foods, ‘novel’ foods and food containing (potential)
medication (nutraceuticals). All of these groups relate to food, the composition of which
has been altered, usually to make it healthier. Typical examples are cholesterol-reducing
margarines and food to which non-absorbable glycerines have been added as a substi-
tute for fat. On average, these foods are more expensive. It is to be expected therefore
that the relatively high cost of these foods will lead to socio-economic differences in
consumption patterns. Assuming that these products have a permanent and measurable
effect on health, these differences in consumption patterns may eventually add to socio-
economic differences in health (Mos et al, 2002). 
Further improvements in imaging techniques
Imaging techniques to facilitate (early) diagnosis are still developing strongly thanks to
the ever widening scope of ICT. In the next few years we can expect to see a mass
changeover to digital imaging and processing. In five or ten years automated image
analysis and computer-supported diagnosis will be firmly established, for example in
the form of three-dimensional images that enable more accurate radiotherapy and ‘real-
time’ imaging (diagnostics and treatment at the same time) to minimize invasive
surgery. 
Echography and magnetic resonance imaging (MRI) will be applied in more and more
domains and will figure more strongly in the overall spectrum of diagnostic techniques
in the years ahead. 
In nuclear medicine positron emission tomography (PET) is proving the most successful
new technique. Because of its added value in locating metastases PET will become
increasingly important this decade. Imaging techniques are developing so fast and in so
many ways that it is impossible to look beyond the next five or ten years (Lembrechts et
al., 2001). 
Is predictive medicine about to take off?
At the start of 2001, the human genome was more or less completely identified (Lander
et al., 2001; Venter et al., 2001). This landmark in bio-medical science triggered a wave
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of optimism about the possibilities for unravelling the causes of disease and about
improved prevention and treatment. This optimism, however, is now being placed in
perspective (Mos et al., 2002). 
Although no-one can say exactly when or to what extent predictive medicine will be
translated into concrete applications, the possibilities for identifying predispositions for
certain diseases and disorders (predictive genetic testing) will increase and it will
become easier to ascertain the progress of a disease (see text block 3.4 for examples).
The downside is that the value of DNA diagnostics may be overestimated because the
role of exogenous factors (gene-gene and gene-environment interactions) is underesti-
mated. What is more, it will take a lot of medical expertise to translate the enormous
volume of complex information into clinically relevant data (Mos et al., 2002). 
Predictive medicine, however, can be described in broader terms than just DNA diag-
nostics: it can also be regarded as ‘all non-symptom-related, risk-oriented health prac-
tices’. Predictive medicine not only introduces new medical practices, but also new rela-
tionships between the medical profession and its patients, and the medical profession
and the government, private insurance companies and other organizations. A brief
account of the ethical and political dilemmas arising from predictive medicine is provid-
ed by Horstman et al. (1999). 
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Text block 3.4: Examples of DNA diagnostics
DNA diagnostics for breast cancer
One of the techniques used in predictive medicine
is DNA chip and micro-array technology. This
technology detects specific DNA fragments, which
confirm a predisposition for a disease or indicate
its progress (Council for Public Health and Health
care (RVZ), 2002). According to expectations, it
will be used in two years’ time to trace gene activ-
ity in breast cancer tissue. Using a set of 70
genes it will be possible to determine with 90%
certainty which mammary tumours will spread
and which will not. This means that women with a
favourable prognosis (30-40%) need not undergo
chemotherapy or hormone treatment (Van ’t Veer
et al., 2002). 
DNA diagnostics in screening programmes
At present, the government is considering the
introduction of screening programmes that make
use of DNA diagnostics, either for the entire pop-
ulation or for specific high-risk groups: 
• A screening programme for colon cancer is still
uncertain as there is still some discussion
about the best strategy (Health Council, 2001).
At present, high-risk groups are already receiv-
ing regular sigmoidscopy/colonoscopy, i.e.
patients with bowel diseases such as colitis
ulcerosa, people who have undergone surgery
for adenomatous polyps, and people with famil-
ial or hereditary forms of colorectal cancer. As
the main genetic abnormalities that underlie the
known hereditary forms of colon cancer have
been identified, DNA diagnostics are already
possible. Thanks to these pre-symptom DNA
diagnostics, only half of the people from fami-
lies with a history of colon cancer now need to
undergo periodic colonoscopies (Bokkel
Huinink & Schornagel, 2001).
• Since the publication of the results and evalua-
tion of an experimental programme for the
detection of familial hypercholesterolemia (FH),
the Minister of Health is pushing for a nation-
wide FH detection programme on the basis of
family history and DNA diagnostics (VWS/GZB,
2001). It is thought that between 35,000 and
40,000 people in the Netherlands are affected
by FH; around 70% of this group are unaware
that they suffer from the disorder. 
3.3.2 New care and treatment options 
In 1997 an increase was reported in ‘half-way technologies’, i.e. medical technologies
that extend life expectancy but cannot provide a complete cure (WRR, 1997). This con-
clusion may also be true of various new methods of treatment, such as new drugs that
could turn cancer into a chronic disease (see text block 3.5). In any event, it is clear that
we may not only expect a wider range of treatment options, but also that these will be
used more often in combination and that the age limits for intervention will rise. This
will have far-reaching consequences for health care costs. Below, we shall present four
examples of potential new methods of treatment: new drugs, gene therapy, stem cell
therapy and tissue engineered medical products. 
More drugs and pharmacotherapy
A study has been conducted on the developments in medication for the 17 diseases and
disorders that occur most often in the population and/or incur the greatest costs. The fol-
lowing general trends emerged (Timmerman & Van den Berg Jeths, 2001):
• New variations will be added to existing categories of medication (applies to almost
all 17 diseases) and entirely new categories of drugs will probably appear. 
• Many patients will receive drug treatment for longer periods as a result of early diag-
nosis and postponement of death.
• The intensity of drug treatment per patient will increase (several types of medication
at the same time; closer supervision). More specific developments for three diseases
are described in text block 3.5. 
Improved administration of medication
Various improvements are also anticipated in the administration of medication (Peters-
Volleberg et al., 2001). New, better and more convenient ways will be found to adminis-
ter medication. These include slow-release anti-depressants, ‘closed-loop’ systems for
glucose regulation, inhalable insulin and better inhalers for asthma/COPD patients. It is
not yet clear whether greater convenience actually improves patient compliance. More
opportunities will also emerge for drug targeting. New forms of administration will be
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Text block 3.5: Three examples of future developments in medication
Cancer: The exponential increase in knowledge of
the biology and biochemistry of cancer cells have
opened up possibilities for new drug categories,
e.g. enzyme blockers and drugs to prevent the
formation of blood vessels in a tumour. These
types of drugs could turn cancer into a chronic ill-
ness (Schornagel et al., 2001). 
Rheumatoid arthritis (RA): The search for
improved therapy for RA is concentrating on the
immune system. Various substances are being
studied to find out how they block inflammation.
Two drugs are now being marketed which belong
to a new category of inflammation blockers: the
TNF alpha-antagonists, etanercept and infliximab.
These are extremely costly. Etanercept costs
e 9,000-13,000 per person per year (Nab &
Breedveld, 2001). 
Cardio-vascular disease: The drug-eluting stent
may play a greater role in the treatment of cardio-
vascular disease. A stent is a tube for keeping an
artery open (often used in combination with bal-
loon angioplasty), to which a medicine has been
attached. For instance, an anti-coagulant may be
gradually released into the surrounding tissue to
prevent further constriction of the arteries (Van
Wijk et al., 2001). 
needed a new generation of drugs, especially for protein-like compounds (e.g. adminis-
tration through liposomes). 
New drugs can further reduce the burden of disease
The present arsenal of drugs contributes to reducing the burden of disease among the
population. The contribution varies according to the disease and its extent is generally
unclear (see section 2.3). New drugs that further reduce the burden of disease may part-
ly or entirely cancel out the effects of population growth and ageing. Below the poten-
tial effects of new drugs on the health status are quantified for seven diseases. The
results are shown in Table 3.4 and the calculation method is explained in text block 3.6.
In the long term the application of genomics may have profound implications for phar-
macotherapy (see text block 3.7). 
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Table 3.4: Number of Years Lived with Disability (YLD) for seven diseases in 2000 and 2020 in the 
Netherlands (Source: De Bruin, 2001). 
Disease  YLD in 2000 YLD in 2020 YLD in 2020 
due to population growth and ageing b with new medication a,b 
Diabetes mellitus 54,200 74,400 67,500 
Schizophrenia 18,200 19,800 18,600 
Chronic heart failure 16,000 22,700 21,000 
Stroke c 64,400 91,600 82,700 
Asthma 14,100 14,700 12,900 
COPD 98,000 133,000 127,000 
Rheumatoid arthritis 45,500 56,700 43,400 
a) including the effects of population growth and ageing. 
b) medium variant of population prospect.
c) including the effect of better drug treatment through temporary admission to a specialized stroke unit.
Text block 3.6: Method for calculating the influence of new drugs on the burden of disease
(Source: De Bruin, 2001)
The influence of new drugs on the incidence of
disease has been calculated as follows: 
• The prevalence of each disease is divided
according to level of severity. A weighting fac-
tor with a value between zero (optimal state of
health) and one (worst state of health) is deter-
mined for each level. This is then used to calcu-
late the YLD in the baseline year 2000. The YLD
is the number of years (corrected for quality of
life) that are spent with a specific disease,
taken at the population level. The prevalence
figures are taken from health care registers and
the data on levels of severity and weighting fac-
tors from Van der Maas & Kramers (1997).
• First the influence of population growth and
ageing on YLD in 2020 is calculated (using the
CBS population forecast from 1998 and the
age-specific distribution of prevalence across
the levels of severity).
• Shifts in prevalence across the levels of severi-
ty are modelled on the basis of new develop-
ments recorded in pharmacotherapy and on the
basis of expert advice. A range of new develop-
ments in pharmacotherapy can often be
observed for each disease. For each develop-
ment a shift is modelled towards less severe
levels; these shifts are added up for all the new
developments for each disease. Bandwidths are
also used when expressing the shifts across
the levels of severity, as there is a high degree
of uncertainty about the health effects of new
drugs (low, medium and high variant).
• The YLD for 2020 is calculated for new drugs,
including the effect of population growth and
ageing.
• When the YLD is calculated no explicit account
is taken of any reduction in or postponement of
mortality (because there are no data for dis-
ease-specific survival rates). Allowance is
made for increasing life expectancy through the
CBS population forecast but this is not specifi-
cally cause-related. 
Promising developments in gene therapy after stagnation?
Developments in molecular biology could pave the way for successful forms of gene
therapy. In gene therapy specific changes are made to genetic material by administering
(therapeutic) DNA. This then brings about a (stable) change in the cellular genome or in
its transcriptional activity. In germ-line gene therapy the changes are introduced in the
sex cells and are hence passed on to subsequent generations. Germ-line treatment of
humans (but not on animals) is subject to a moratorium in the Netherlands. In somatic
gene therapy the patient’s genome is altered within other bodily (somatic) cells to bring
about a long-term therapeutic effect without consequences for further generations (see
also text block 3.8). 
Stem cell therapy – a promising technology but application still uncertain
Damaged cells in tissue can sometimes be replaced with donor cells. Stem cell therapy
is a new form of cell transplant. Bone-marrow transplants are a classic example of this
type of therapy and are already being performed. There are two types of stem cell thera-
py. In somatic stem cell therapy healthy stem cells are removed from a patient. Repro-
duction and (possible) differentiation are then stimulated under laboratory conditions
and the cells are reintroduced into the tissue or organ. But stem cells can also be extract-
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Text block 3.7: The application of genomics in pharmacotherapy
(Source: Leufkens, 2001)
Genomics is expected to have a deep impact on
the way new drugs are developed, used and
assessed. We are now seeing the start of the mas-
sive transformation of the raw data from the
human-genome project, which cynically speaking
amounts to no more than a huge list of ones and
zeros.
Besides determining how greater knowledge of
the human genome will contribute to the develop-
ment of better drugs, we also need to discover the
role that this knowledge can play in improving the
use of existing drugs. The driving idea behind
pharmacogenetics is ‘genetically customized
pharmacotherapy’. Ideally, a drug should not be
prescribed for patients with a genetic profile
which indicates that the drug will not work or that
they will have an increased risk of side effects.
The embedding of genomics in pharmacotherapy
and health care as a whole will raise urgent ques-
tions about privacy and ethics. If patients are
selected because they respond well to a drug and
others are excluded because they do not, this
could lead to ‘orphan patients’ and push up the
costs of pharmacotherapy (individualized treat-
ment almost invariably costs more). Such devel-
opments are not, however, expected in the near
future. 
Text block 3.8: Ups and downs of gene therapy
There are two groups of ‘candidate diseases’ for
gene therapy, namely, ‘hereditary monogenetic’
diseases and ‘acquired’ diseases such as cancer
and cardiovascular disease. Because of technical
and other problems (e.g. administration, which
generally involves the use of modified viruses as
‘packaging’ for the various gene-transfer sys-
tems) the results of somatic gene therapy have
not yet lived up to the initial high expectations.
But despite all the ups and downs of recent years,
gene therapy is now making sure and steady
progress. The most promising applications for the
near future are local injections of viral vectors to
kill tumour cells, immunotherapy with the aid of
DNA vaccinations and the stimulation of blood
vessel formation in cardio-vascular disease (bio-
bypass) (Van Kreijl et al., 2001).
In October 2002, gene therapy met with a new
setback when a young patient developed
leukaemia. An investigation is underway to find
out whether the gene therapy was the cause. In
the meantime, various plans and experiments in
gene therapy have been suspended (De
Volkskrant, 7 October 2002). 
ed from embryonic or foetal tissue. The Embryo Act and the Foetal Tissue Act of 2002
make it possible – under rigorous conditions – to conduct research into stem cells that
have been acquired in this way. The advantage of embryonic stem cells is that they can
be reproduced indefinitely in a culture and can mature into almost any cell type. Possi-
ble applications are pancreas cells for treating diabetes mellitus and brain cells for
Parkinson’s disease. Stem cell therapy is highly promising but still very uncertain
(Gezondheidsraad, 2002b). 
Cautious optimism about Tissue Engineered Medical Products
Tissue engineered medical products (TEMPs) are a new type of medical product that
might be destined for great things in the future. TEMPs consist of human (or possibly
animal) tissue, which coats or permeates a scaffold material. As in stem cell therapy, the
basic principle is to remove healthy cells and stimulate them into reproduction and (pos-
sibly) differentiation under laboratory conditions, usually in combination with the scaf-
fold material. These are then transplanted to the damaged tissue or organ. This proce-
dure can be carried out with either autologous material (from the patient) or allogenic
material (from a donor). Almost every type of tissue and organ is the subject of study at
present. Products made of tissue-engineered skin, bone and cartilage which have been
developed in the Netherlands are expected to be available within five years (Wassenaar
& Geertsma, 2001). The cartilage-engineered products may eventually be used to
replace damaged cartilage, making it possible to postpone or even avoid replacement by
artificial joints. That said, we should not expect a wave of new products in the immedi-
ate future. Although animal testing has borne out theories and hypotheses, efficacy and
– more importantly – durability and safety still need to be proven (Wassenaar & Geerts-
ma, 2001). Elsewhere, people are more optimistic (see text block 3.9). If this optimism
proves founded and it actually becomes possible to replace many tissue types and
organs, TEMPs will have profound implications for the health status in the future. 
Increase in ICT applications
One of the current ICT applications is the Electronic Prescription System (EVS in
Dutch), which generates pharmacotherapy recommendations after the physician has
entered patient data and diagnostic data into the computer. Another ICT application, the
Electronic Patient File (EPD in Dutch), has triggered some discussion. It is conceivable
that in the future each patient will have an electronic medical file and that the informa-
tion exchange between the patient and the care provider and between the care providers
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Text block 3.9: Optimism about TEMPs
In 1997 the Science and Technology Agency of
Japan expressed high expectations of TEMPs
(Mitamura, 1999). It predicted the development of
fully implantable artificial hearts and kidneys, bio-
hybrid endocrine organs (combinations of living
cells and artificial polymers), tissue-engineered
organs (pancreas, liver), retina implants and arti-
ficial muscles before 2020. These predictions are
regarded as highly optimistic by some people.
R&D teams and experts from some German orga-
nizations and research institutes say that the situ-
ation with regard to liver, skin, cartilage, bone,
bone marrow and pancreas tissue looks very
promising in terms of opportunities for further
product development (Marx et al., 1998). 
themselves will take place through the electronic highway (Council for Public Health
and Health care (RVZ), 2001d). 
This brings us to the development of telemedicine and telecare. The Council for Public
Health and Health care (RVZ) estimates that in the next 20 years a much larger part of
the health care budget will be spent on telemedicine (currently only 1%, RVZ, 2001c).
Telemedicine and telecare can improve patient compliance and enhance the efficiency
of the health care process (Vlaskamp et al., 2001). Text block 3.10 provides some exam-
ples of new applications. 
Improvements also expected in existing care and treatment
Up to now we have concentrated on the more spectacular high-tech developments in
health care. However, many technological improvements are also being realized in
existing methods of treatment. The PHSF of 1997 features various examples, such as
better cementing techniques for hip prostheses and better operating techniques for colon
cancer to greatly reduce the risk of metastases (Van der Meer & Schouten, 1997). 
Assistive technology is also important, as it concentrates on making better use of tech-
nology by providing products and services to physically handicapped people so that
they can lead an independent life (see text block 3.11).
Diffusion of medical technology also dependent on organizational and
funding systems
The degree of influence exerted by developments in medical technology on the future
health status not only depends on the nature of the developments themselves but also on
the level of application. This, in turn, depends primarily on how fast new technology is
disseminated, how quickly it is adopted by health care providers and whether the orga-
nizational and funding systems are aware of and open to new developments. 
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Text block 3.10: Some new applications of ICT in health care 
• In the USA and Norway video conferencing (an
electronic home visit) is used for patient and
family counselling. Though the electronic home
visit can also take place by phone, video con-
ferencing is possibly more effective and more
likely to be perceived by the patient as a ‘real’
visit. In addition, the camera provides the care
provider (doctor or nurse) with visual feedback.
• In the USA a highly successful pilot was con-
ducted with a portable unit fitted with a camera,
a screen and some sensors (e.g. sphygmo-
manometer, stethoscope, otoscope). The unit
used the TV cable network. Though this type of
health care is not yet applied in the Netherlands,
there is a strong possibility that it will be used
in the future. Some GPs have already introduced
an electronic consultation. Teleconsultation is
also used for meetings between physicians.
Text block 3.11: Technological improvements in hearing aids
Hearing aids (air-conduction devices) will also
benefit from the use of digital technology to regu-
late phase and control buzzing and background
noise (Van Drongelen et al., 2000). Hearing
impairments are among the more common disor-
ders (see chapter 2) and hearing aids are one of
the most common medical aids. An estimated
400,000 Dutch people wear one. Technological
improvements to hearing aids will also further
improve the quality of life of many people.
3.3.3 Early warning system for developments in medical
technology 
The above developments are only a few examples of the activities taking place in the
vast domain of medical technology. We have said nothing about advances in surgery and
anaesthesia, for instance. The choice of examples has largely been dictated by surveys
in medical technology that were commissioned or conducted by the RIVM in the past
three years. Strictly speaking, early detection and evaluation of medical-technology
developments is the responsibility of the Health Council, with support from initiatives
inside and outside Europe, such as the SBU Alerts of the Swedish Council on Technolo-
gy Assessment in Health care, the Early Warning System of the Danish Centre for Eval-
uation and Health Technology Assessment, and the Emerging Technologies Bulletins of
the Canadian Coordinating Office for Health Technology Assessment. One important
international network is EuroScan, which has been operational since 1998 with partici-
pation by Canada and various Western European countries (Carlsson & Jørgensen,
1998; www.publichealth.bham.ac.uk/euroscan). Other Dutch organizations besides the
Health Council are active in this field as well, such as the Rathenau Institute, which
investigates the political, social and ethical implications of new technologies (Rathenau
Instituut, 1996; Horstman et al., 1999), the Council for Public Health and Health care
(e.g. RVZ, 2001c, 2002), the Advisory Council on Health Research (RGO) and universi-
ty hospitals that participate in research programmes (e.g. clinical trials for new drugs).
In the Netherlands, the early detection and evaluation of developments in medical tech-
nology has been crystallizing in the sector itself, since the government decided in 1995
not to introduce legislation for Medical Technology Assessment (Second Chamber,
1995). 
Early warning systems have three aims: 
1. To identify and assess new medical technology in the domains of prevention, diag-
nostics, cure, care and rehabilitation (including drugs, medical aids, procedures, set-
tings and programmes), which are expected to be relevant to health care policy and
practice within 0-5 years;
2. To classify the technology as supplementary, replacement or totally new in relation to
existing technology;
3. To inform policymakers (in the broadest sense of the word) at an early stage about the
implications of a technology in terms of safety, effectiveness, cost, ethics and health
care organization, with a view to formulating a proactive approach to new medical
technology (Reijmerink & Vos, 2002). 
A fully operational early warning system requires sufficient clarity about the informa-
tion requirements of the various players (government, insurers, health care providers,
patient associations) and proper embedment in the health care system. 
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3.4 Europe as a source of inspiration for forecasts 
3.4.1 European mortality patterns for the Netherlands 
This section analyses the health status by comparing Dutch mortality rates with those in
other European countries. The question is: how would mortality rates and life expectan-
cy in the Netherlands be affected if the highest and/or lowest mortality rates in Western
Europe applied for some major causes of death? 
The mortality rates in Europe show considerable variations for several causes of death
(see section 2.1). Below we present an analysis based on these differences. By selecting
the countries with the highest and lowest mortality rates for some major causes of death
we can calculate a bandwidth of life expectancy that would apply if these levels were
recorded in the Netherlands. Table 3.5 shows the results and the effects on mortality
rates and life expectancy. Text block 3.12 explains the calculation procedure. 
Mortality patterns in the European Union
If the EU mortality pattern for the separate causes of death were to apply to the Nether-
lands, it would result in gains and losses for both men and women. Dutch men have a
lower mortality rate for traffic accidents and suicide in particular, but a higher mortality
rate for smoking-related causes of death, such as for lung cancer and for COPD (but not
for stroke). Reducing male mortality rates for these two causes of death would cause the
largest increase in life expectancy.
The mortality patterns for stomach cancer, cardiovascular diseases, stroke and traffic
accidents among Dutch women compare favourably with the rest of the EU. Life
expectancy would benefit most if the mortality rates for breast cancer matched the EU
average, followed by smoking-related lung cancer and COPD. 
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Scope for significantly higher life expectancy
There are considerable differences in mortality rates across Europe. Significant gains
would be made in life expectancy (6.0 years for men and 3.8 years for women) if the
lowest mortality rates from any EU country were to apply for 14 major causes of death.
If the highest mortality rates in the EU for the same causes of death applied in the
Netherlands, life expectancy would be reduced by 4.6 years for men and 4.1 years for
women. 
An analysis based on European differences in the prevalence of six risk factors
(smoking, excessive use of alcohol, lack of exercise, serious overweight (obesity), hyper-
tension and high overall cholesterol levels) produced a bandwidth of life expectancy of
-2.8 to +1.4 years for men and -3.0 to +1.2 years for women. These shifts in life
expectancy would emerge only after some time, given the time lapse between expo-
sure to these risk factors and their effect on health. 
Life expectancy at birth would improve slightly for Dutch men and women if the mor-
tality rates for the 14 selected causes of death were the same as the EU average. The
increase would be 0.4 years for men and 0.3 years for women. 
Europe’s worst mortality pattern projected onto the Netherlands
Life expectancy at birth falls by 4.6 years for men and 4.1 years for women if Europe’s
worst mortality pattern is projected onto the Netherlands. The strongest contributors to
such a decline are Finland (coronary heart disease and suicide) and Portugal (stomach
cancer, stroke, traffic accidents) for men and Denmark (colon, lung and breast cancer),
Greece (chronic heart failure) and Ireland (coronary heart disease and COPD) for
women. In general, the current mortality rates in other European countries partly reflect
past lifestyles (insofar as is ascertainable). Moreover, it is not known whether and to
what extent health care has influenced the mortality rates in these countries. Many of the
differences in mortality rates are not readily explainable. More elaborate research (e.g.
of the vast bulk of literature) may eventually lead to better insight in this area. 
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Text block 3.12: European mortality patterns for the Netherlands: methodology
The lowest and the highest mortality probabilities
were selected for 14 causes of death from several
countries in Western Europe and then applied to
the Netherlands. These countries were not neces-
sarily the same for men and women for a particu-
lar cause of death.
• 15 countries were chosen: Belgium, Denmark,
Germany, Finland, France, Greece, Ireland,
Italy, Norway, Austria, Portugal, Spain, the
United Kingdom, Sweden and Switzerland. Lux-
embourg and Iceland were not included as sep-
arate countries because of their low popula-
tions and therefore often variable mortality
rates. The mortality figures are taken from
Eurostat’s New Cronos database and relate to
1997, except in the case of Belgium (1995) and
Denmark/Sweden (1996). 
• 14 causes of death were selected. These are
causes from which at least 1,000 people (total
men and women) died in the Netherlands in
2000. It should be mentioned here that over
1,000 people also died of diabetes mellitus,
dementia and domestic accidents, but these
have been left out of the analysis because of
ambiguities and coding changes in the interna-
tional cause-of-death statistics.
• The Eurostat definitions for four causes of
death (lung cancer, chronic heart failure, pneu-
monia and suicide) are broader than those in
the PHSF. The broader definitions have been
applied in the projections for the Netherlands
so that the countries may be compared.
• First the absolute mortality rates for each cause
of death for each country were converted into
relative mortality rates per 100,000 head of the
country’s population in 1997. These relative
figures from all 15 countries were then project-
ed onto the Dutch population in 1997 (accord-
ing to 5-year age intervals and gender). This
made it possible to compare the countries indi-
vidually and with the Dutch situation. Absolute
mortality figures were then calculated for each
cause of death, and the best and worst figures
from the 15 countries were selected for the 14
causes of death (for men and women separate-
ly).
• Finally, the highest and lowest mortality proba-
bilities were entered in a survival table and the
gains and losses were calculated for each
cause of death and for the total life expectancy.
Death from other causes was assumed to be
constant (thus including diabetes mellitus,
dementia and domestic accidents). Gains or
losses in life expectancy for each cause of
death cannot be added up together. The total
gain or loss in life expectancy was calculated
by filling in the combined effect of the 14 caus-
es of death on the mortality probability at 5-
year age intervals.
An analysis was also carried out on the basis of
the mortality probabilities in the EU as a whole.
These were taken directly from Eurostat’s New
Cronos. The set of 15 EU countries is slightly dif-
ferent from the set that was used for the analysis
based on the mortality figures (Norway and
Switzerland are not EU members, Luxembourg
and the Netherlands are). 
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Table 3.5: Effects on mortality and life expectancy if European mortality patterns a,b would apply to the
Netherlands, by gender and for 14 causes of death (Source: CBS cause-of-death statistics and Eurostat New
Cronos, data processed by RIVM). 
Men European Union Worst mortality pattern Best mortality pattern
Cause of death Effect on Effect on Worst Effect on Effect on Most Effect on Effect on
number life country number life favourable number life
of deaths expec- of deaths expec- country of deaths expec-
(in %) tancy (in %) tancy (in %) tancy
(in years) (in years) (in years)
Oesophageal cancer -11 0.01 Ireland 37 -0.05 Greece -73 0.11 
Stomach cancer 9 -0.02 Portugal 120 -0.27 Sweden -35 0.07 
Colon cancer -6 0.02 Ireland 17 -0.08 Greece -56 0.23 
Lung cancer -21 0.23 Belgium 23 -0.39 Sweden -67 0.93 
Prostate cancer -18 0.06 Norway 23 -0.08 Greece -49 0.17 
Non-Hodgkin’s lymphoma -9 0.02 Finland 3 -0.01 Greece -27 0.07 
Coronary heart disease 2 -0.02 Finland 84 -1.48 France -49 1.03 
Chronic heart failure -18 0.16 Greece 34 -0.17 UK -68 0.61 
Stroke 16 -0.12 Portugal 203 -1.31 Norway -42 0.03 
Pneumonia -16 0.03 UK 109 -0.37 Greece -81 0.25 
COPD -27 0.15 Ireland 32 -0.21 Greece -81 0.53 
Traffic accidents 64 -0.20 Portugal 216 -0.58 Sweden -22 0.08 
Suicide 34 -0.08 Finland 208 -0.68 Greece -57 0.17 
Women European Union Worst mortality pattern Best mortality pattern
Cause of death Effect on Effect on Worst Effect on Effect on Most Effect on Effect on
number life country number life favourable number life
of deaths expec- of deaths expec- country of deaths expec-
(in %) tancy (in %) tancy (in %) tancy
(in years) (in years) (in years)
Oesophageal cancer -38 0.02 UK 68 -0.04 Greece -81 0.05 
Stomach cancer 24 -0.03 Portugal 149 -0.18 France -29 0.04 
Colon cancer -9 0.03 Denmark 27 -0.11 Greece -47 0.17 
Lung cancer -25 0.15 Denmark 82 -0.36 Spain -68 0.33 
Breast cancer -24 0.18 Denmark 4 -0.04 Greece -41 0.33 
Non-Hodgkin’s lymphoma -13 0.03 Finland 1 -0.00 Greece -29 0.07 
Coronary heart disease 21 -0.16 Ireland 113 -1.14 France -47 0.63 
Chronic heart failure 0 c 0.04 Greece 125 -0.81 Finland -62 0.52 
Stroke 15 -0.12 Portugal 202 -1.53 France -28 0.30 
Pneumonia -18 0.05 UK 141 -0.54 Greece -82 0.31 
COPD -19 0.07 Ireland 100 -0.32 Greece -78 0.27 
Traffic accidents 29 -0.04 Greece 141 -0.17 UK -25 0.03 
Suicide -9 0.02 Belgium 75 -0.12 Greece -85 0.15 
a) diabetes mellitus, dementia and domestic accidents are not included in the analysis because of ambiguities and changes
in the coding system. These factors may play a role in several causes of death. The effect is untraceable but checks were
performed to ascertain whether wide differences existed between the countries for the category ‘symptoms and other
causes of death’. None were found. 
b) fluctuations may appear in the mortality rates for certain causes of death over the years, so the selection based on 1997
could contain an element of coincidence. This applies especially to pneumonia (e.g. as a result of a flu epidemic or a
severe winter). In 1997 the UK had the highest mortality figures for pneumonia for both men and women. Indeed, the
UK morality rate for pneumonia was higher in 1997 than in previous years. 
c) it is possible to record a zero effect on mortality figures and still have an effect on life expectancy if mortality shifts to
higher age groups. 
Europe’s best mortality pattern projected onto the Netherlands
When Europe’s best mortality pattern is projected onto the Netherlands substantial gains
are realized in life expectancy: 6.0 years for men and 3.8 years for women. What can we
learn from this result? When it comes to well-known and potentially changeable causes
of death we could learn a lot from Sweden about lung cancer among men, from France
about coronary heart disease among men and women, and from the UK about chronic
heart failure among men. Greece has the lowest mortality rates for 7 of the 14 causes of
death for both men and women. We looked into whether this result might be connected
with the coding of the causes of death. If so, we could expect a large other/unknown cat-
egory, but this was not the case. Greece does, however, have the highest mortality rate
for chronic heart failure (for men and women) and for traffic accidents for women. The
low mortality rates for lung cancer among Spanish women is unsurprising, as only 4%
of Spanish women between the age of 45 and 74 smoke. However, as the percentage of
younger women smokers is the same as in the Netherlands, Spain looks set to lose its
lead in this category. Further research into favourable mortality rates in other countries
can also provide openings for policy. 
3.4.2 European risk factor prevalences for the Netherlands
This section determines the health status in the Netherlands, if it were exposed to the
best and worst prevalence of a number of risk factors in other European countries. Six
risk factors will be addressed: smoking, excess use of alcohol, lack of physical exercise,
severe obesity, hypertension and high cholesterol levels. The diseases included in the
model are: oesophageal and lung cancer, diabetes mellitus, myocardial infarction, other
coronary heart diseases, chronic heart failure, stroke and COPD. 
This analysis calculates the effect of the prevalence of the six risk factors on the inci-
dence of new disease cases as well as the bandwidth for life expectancy. Appendix 2
lists the prevalence of the risk factors in the European countries included in this analy-
sis. The calculations were performed using the Chronic Diseases Model of the RIVM.
This is a dynamic model that is suitable for calculating the effects of risk factor preva-
lence on the incidence, prevalence and mortality probabilities for a group of diseases
that are connected with these factors. At the same time, it takes account of demographic
trends (population growth and ageing). Those interested in details about the model may
contact dr R Hoogenveen (rudolf.hoogenveen@rivm.nl). The results reflecting the
effect on the number of new cases of the eight diseases are shown in table 3.6. 
Table 3.7 shows the gains or losses in life expectancy in 2020 when the best and worst
prevalence is projected for each risk factor. As the effects of the different risk factors on
life expectancy are modelled independently of each other, they may be roughly added
together. This produces a gain of 1.4 years and a loss of 2.8 years for men compared
with the reference scenario. For women the gain is 1.2 years and the loss is 3.0 years. In
reality (small) deviations may appear in this sum due to clustering, risk-factor interac-
tion in a single individual, and the fact that other causes of death will replace the one
that is eliminated (although at an older age). 
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What can we learn from Europe?
This analysis shows us that, in theory, the health status could significantly benefit from
risk factor interventions. Again, further research is required to find out why the preva-
lence of these risk factors varies so widely from one EU country to another. This may
open up opportunities for new policy. 
In the analysis that is based on differences in risk factors, the effects on life expectancy
are lower than in the analysis based on mortality differences. This is to be expected, as
far fewer causes of death were included in the risk-factor study. Time also plays a role.
In the past the differences in lifestyle patterns between countries were far greater than
they are today. This is still reflected in the current mortality differences for the causes of
death which correspond with these lifestyle factors. 
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Table 3.6: Effects in 2020 (in percentages compared with the reference scenario a,b on the incidence of new
disease cases in the Netherlands when the best and worst European prevalence levels for six risk factors are
projected onto the Netherlands (Calculation: Chronic Diseases Model RIVM). 
Men Women
Disease Best Worst Best Worst
Oesophageal cancer -15 +22 -23 +38 
Lung cancer -20 +16 -32 +13 
Diabetes mellitus - 6 +24 - 7 +23 
Myocardial infarction -16 +65 -16 +66 
Other coronary heart diseases -14 +51 -15 +50
Chronic heart failure - 7 +37 - 9 +30 
Stroke -15 +41 -16 +68 
COPD -11 +14 -23 + 9 
a) the number of new cases of each illness in 2020 with constant probability of interaction between the risk-factor cate-
gories, e.g. the probability of starting or quitting smoking (calculated from actual smoker data drawn from the population
in the past); this is done to take account of an ‘intrinsic’ age effect for the prevalence of the risk factors (blood pressure
and cholesterol levels rise automatically with age, regardless of lifestyle). 
b) including the effect of population growth and age and gender changes in the population. 
Table 3.7: Effects on life expectancy (in years) in 2020 when the best and worst European prevalence for six
risk factors are projected onto the Netherlands (Calculation: Chronic Diseases Model RIVM b).
Men Women
Risk factor Best Worst Best Worst
Smoking 0.6 -0.5 0.5 -0.3 
Excessive use of alcohol 0.2 -0.1 -a -0.5 
Lack of physical exercise 0.6 -1.4 0.6 -1.6 
Hypertension -a -0.3 -a -0.2 
High overall cholesterol levels -a -0.2 -a -0.1 
Serious overweight -a -0.3 -a -0.3 
a) the Netherlands has the best level or the differences with other countries are too small to emerge in the life expectancy
estimates. 
b) for more information about the Chronic Disease Model: please contact RIVM: dr R Hoogenveen.
Finally, we would like to point out that the Netherlands has the most favourable levels in
Europe for hypertension, high cholesterol and obesity and for excessive alcohol use
among women. However, these levels were last measured a few years ago. At present
the prevalence of risk factors among younger age groups in European countries seems
to be converging, especially for smoking and excessive alcohol use. The improvement
in life expectancy which is calculated on the basis of differences in risk factors will not
emerge for several decades, given the time lapse between the risk factor exposures and
the health effects. 
3.5 Implications for the health care budget 
To recap, population growth and ageing will trigger a sharp rise in diseases and disor-
ders in the future, especially occurring among the elderly. These trends will also push up
the cost of health care and there will be a further shift from cure to care. Developments
in medical technology are also likely to add to the costs. Other cost-related factors are
level of education, marital status and ethnicity (see section 3.20) but account should also
be taken of epidemiological shifts, policy changes, new care-demand patterns and salary
and price developments. 
There is not enough quantitative data available to enable us to estimate the future costs
of health care as caused by all these developments. For this reason the estimate present-
ed below should be seen as a combination of a demographic projection and a trend
extrapolation, which implicitly includes other factors (Polder et al., 2002). The results
are shown in figure 3.3 and the working method is explained in text block 3.13. 
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Figure 3.3: Projection of the development of Dutch health care costs split into components for
the period 2003-2006 (in billions of euros in constant prices from 1999) (Source: Polder et al.,
2002). 
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Between 1994 and1999 shortages in financing were mounting. Extra resources were
made available, especially in 2000-2001, to shorten waiting lists and cut down waiting
times. No allowances were made in our prospects for these additional resources in the
budget. To get rid of waiting lists an annual increase of another 0.6% is needed in the
health care budget for the next four years (Polder et al., 2002). 
The demographic cost projection is different for each disease and disorder. On the basis
of the demographic trends in 2003-2006, the costs associated with intellectual disability
– which topped the league for health care costs in 1999 – will rise by 0.6% per year
compared with an average of 1.2%. Dementia, which is second in the league, will
require an annual increase of 2.1% as a result of demographic trends. On the other hand,
the costs of pregnancy, childbirth and maternity will fall slightly because of the predict-
ed fall in the birth rate (assuming constant costs according to age and gender). 
Recently, in the Netherlands various estimates have been drawn up for health care
expenditure. In a ‘basic scenario’ (expected developments if policy remains unchanged)
CPB and SCP (Dutch Central and Socio Cultural Planning Bureaus) estimate that the
annual rise in costs through volume developments in 2003-2006 will be 2.5%, 1.1% of
which is the result of demographic trends and 1.4% the result of other volume growth
(by all other developments including medical technology). As the influence of medico-
technological developments on health care costs is uncertain, sensitivity analyses have
been performed in which the remaining volume growth in 2003-2006 varies between
1.0 and 1.7% (Folmer et al., 2001). 
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Text block 3.13: Procedure for calculating future health care costs for 2003-2006
(Source: Polder et al., 2002)
The procedure consisted of the following steps: 
• The health care expenditure for 1994-1999 was
corrected for demographic trends and salary
and price developments.
• The ‘residual trend’ thus obtained reflects the
other volume developments (epidemiological
and medical technology developments, plus
changes in demand patterns and the organiza-
tion of the health care); this trend in other vol-
ume developments was projected unchanged
into the future.
• The influence of population growth and ageing
was calculated by applying the profile of the
average costs per head according to age and
gender to the total population in 2003-2006.
These costs were assumed to be constant.
• Salary and price developments have been omit-
ted because of their unpredictability; the results
are therefore in constant prices from 1999. 
In the next period of government the health care
costs, on the basis of demographic trends, will
rise by 1.2% per year. Additional costs arising
from the ‘other developments’ will also be 1.2%
per year. This works out at a total of 2.4% per
year or – in absolute terms – over 3.5 billion
euros (in constant prices from 1999). 
4 MESSAGES FOR POLICY-MAKERS AND
OTHER PARTIES 
Earlier chapters presented new data and insights relating to Dutch public health, care
and prevention. They looked at the past, present and future and drew comparisons both
within the Netherlands and with other countries. The resulting picture will be useful for
the Ministry of Health, Welfare and Sport in developing a vision of health and care for
the medium and long terms. The information is also important for other players: the
Public Health Supervisory Service, local government authorities, other ministries,
patients and consumers, suppliers of prevention and care services, health insurers and
organizations in the field of health research and research programmes. This chapter
returns to the main findings, but they will now be assessed on the basis of the aims of
Dutch public health policy as set out in chapter 1. That basic assumption – the national
public health policy – consists in broad terms of the following two linked lines: 
Maintaining and improving public health. There are three points of special interest here: 
• preventing avoidable disease and mortality; 
• reducing differences in health between socio-economic groups; 
• preserving quality of life (particularly for those with chronic disorders). 
Cure and care for people with diseases and handicaps. Both the cure and the care should be: 
• of high quality (effective, safe and appropriate); 
• available to everyone when needed; 
• provided at an acceptable price. 
This chapter is structured as follows. First of all, section 4.1 describes the main findings.
Section 4.2 provides a broad indication of the significance of the findings for policy and
for the actors involved in that policy. Section 4.3 then discusses a number of difficulties
in society as a whole which may interfere with rational decision-making. Section 4.4
provides a brief review of the availability of relevant data that may be important for
monitoring Dutch health. Finally, this section provides a first indication of a set of
linked indicators that can be used to determine how the Dutch public health system is
performing compared to systems in other countries. This investigation elaborates on the
basic principles of policy, the conceptual framework for public health in chapter 1 and
elements in national and international developments relating to ‘measuring the perfor-
mance of the care system’, as proposed by, for example, WHO and OECD. 
4.1 Important findings 
The Dutch are living longer
Since 1980, life expectancy has increased by 3.1 years for men and by 1.4 years for
women. At birth, our average life expectancy is now 75.5 and 80.6 years respectively.
This increase is primarily the result of a fall in mortality caused by coronary heart dis-
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ease and stroke. In addition, there has been a fall in men in mortality from lung cancer.
The main cause of death remains mortality from coronary heart disease. This disease,
together with mental disorders and chronic lung diseases, also has a considerable
adverse effect on quality of life. Statistics Netherlands (CBS) predicts that life expectan-
cy will continue to increase over the next 20 years. 
We enjoy good health longer
A positive side to the increase in life expectancy is that the years of life which have been
gained in the last decade are mainly spent in good health. The number of healthy years
for men and women was virtually equal at the turn of the millennium: people rate their
health as ‘good’ for about 61 years, there are no physical impairments for more than 70
years, and 68 years are spent in good mental health. Women therefore spend many more
years than men in poor health. Given the fact that there has been no fall in either the
prevalence or the duration of chronic diseases, real improvements are apparently being
made in the social participation of the chronically ill through the use of specific care
facilities such as medical aids or medicines. 
Nevertheless, the Netherlands is gradually becoming ‘just average’ by
European standards.
We are living longer but the Netherlands is falling behind in the European Union. Male
life expectancy is increasing less quickly than in most EU countries. The increase in
female life expectancy is even flattening out to such an extent that we are now below the
EU average. The mortality rate from lung cancer in men is still one of the highest in the
EU. In women, this rate is increasing faster than the European average. Women are also
dying more and more often from chronic obstructive lung diseases (COPD). Both lung
cancer and COPD are largely attributable to cigarette smoking. Perinatal mortality in
the Netherlands is relatively high. The same applies to mortality caused by breast can-
cer, although this figure is now declining. 
If we look at the most favourable national mortality figures within the EU for 14 major
causes of death, there is still room for improvement in life expectancy in the 
Netherlands. The potential improvement is approximately six years for men and four
years for women. It should be pointed out that we would lose four years if we depart
from the least favourable level in the EU for these causes of death. Here, it is certainly
the case that not all the causes of these differences in Europe are known or amenable to
intervention. 
In addition, inequalities in health have proven stubborn.
Health is distributed unevenly in the Netherlands. There are considerable differences
between the poor and the rich, and between different neighbourhoods. Men with the
lowest level of education live 5.0 years less than men with the highest level of educa-
tion. For women, the difference is 2.6 years. On top of that, men and women with the
highest levels of education remain free of physical impairments for almost 10 years
longer. The difference in the number of years people feel healthy is 16 years for men and
14 years for women. Health differences of this size also emerge when comparing
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regions or neighbourhoods. Poorer health in deprived areas is often associated with an
accumulation of unfavourable social and physical environmental factors, in combina-
tion with a less healthy lifestyle. 
On the basis of the available data, it is not easy to determine trends in health differences.
However, there is no indication that there has been any reduction in the existing differ-
ences in the last five years. 
Unhealthy behaviour is the main cause of stagnating health quality
In adults, unhealthy behaviour is the main known cause of stagnating life expectancy.
Personal characteristics associated with unhealthy behaviour, such as overweight and
elevated blood pressure, are on the increase or, at best, persisting at the same,
unfavourable level. On the other hand, the intake of saturated fats is developing
favourably, primarily because of the fact that the food industry has replaced ‘hard’ fats
more and more with vegetable unsaturated fats. In recent years, women have adopted
much of the less healthy behaviour of men. Particularly among young people, the trends
with respect to smoking, excessive alcohol consumption, inadequate consumption of
fruit and vegetables, and inadequate exercise are a source of concern. Severe over-
weight is becoming ever more prevalent at younger and younger ages. On the other
hand, older people have started to adopt healthier behaviour. 
The adverse developments in the lifestyles of young people can be thought of as long-
term investments in ‘poor health’. The same applies more or less to the adult population:
unhealthy behaviour now results in future premature mortality and a loss of quality of
life or, in other words, a reduction in the potential for normal social participation. On the
other hand, the fact that older people are adopting healthier behaviour in certain respects
actually contributes to an increase in healthy life expectancy. In a certain sense, current
developments in healthy life expectancy reflect what has often been a more ‘moderate’
lifestyle among older people in the past. In the long term, the unfavourable lifestyles of
young people at present could result in a further stagnation or even reduction in healthy
life expectancy. 
A significant proportion of total annual mortality in the Netherlands (140,000 deaths in
2000) is linked to behaviour and is therefore, in principle, avoidable. The main con-
tributing factors are: smoking (approximately 15% of annual mortality), too much satu-
rated fat (5%), not enough fruit and vegetables (5%), not enough exercise (6%), high
blood pressure (6%) and severe overweight (6%). A considerable proportion of care use
can be attributed to unhealthy behaviour, overweight and high blood pressure. The asso-
ciated costs account for between 5 and 9% of total expenditure on health care. 
The health effects caused by the physical environment would now appear to be reason-
ably under control in the Netherlands. Rough estimates indicate that the contribution of
environmental factors to the total disease burden in the Netherlands does not exceed
5%. This contribution consists above all of a higher and more severe incidence of health
problems in people with existing disorders, for example as a result of air pollution,
noise, or poor indoor-environment quality. 
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In Europe, the Netherlands does badly in terms of smoking and excessive alcohol con-
sumption. On the other hand, we do relatively well in terms of physical activity. If the
Netherlands was to achieve the most favourable level in Europe for known risk factors,
we would in theory achieve an increase of another 1.4 years of life expectancy for men
and 1.2 years for women. Here also, the ‘influence’ that can be exerted on these factors
is limited, however. 
The accessability of care has been under pressure in recent years due to waiting times
and waiting lists, for example. There are no indications that this is linked to the stagna-
tion in the increase in life expectancy. The latter is primarily the result of unfavourable
changes in lifestyle. It would appear to be obvious that, in certain cases, waiting times in
individual patient care have an adverse effect on the quality of life of the chronically ill. 
Efforts are required to maintain health gains achieved in the past 
In the past, many health gains were achieved through prevention and infrastructure (life
expectancy has doubled since 1850). The fact that infectious diseases are no longer
included in the main diseases and disorders is the result of unremitting efforts: safe
drinking water, sewers, waste disposal and vaccination. Regulations in a wide range of
areas (food, traffic, work, housing, environment and recreation) have prevented, and
continue to prevent, a great deal of damage to health, although this is often difficult to
quantify. However, deregulation has, here and there, resulted in the weakening of an
important aspect of health protection, namely the monitoring of the adequate enforce-
ment and implementation of regulations. A range of serious incidents have made this
clear (the firework disaster in Enschede, the fire in the cafe in Volendam, the Legion-
naire’s disease outbreak in Bovenkarspel. 
New preventive approaches can turn the tide
Considerable health gains can still be achieved through prevention, particularly by
encouraging healthy behaviour. However, the unfavourable trends, both domestic and
international, suggest a certain insensitivity to ‘classic’ forms of health education. Mod-
ern methods are based on a stimulating environment and an integrated approach within
existing ‘settings’ rather than an exclusive emphasis on changing behaviour. This is pos-
sible by granting healthy behaviour a clear position in socio-cultural life as a whole, at
school, in sport and recreation, at work, in neighbourhoods and in traffic. That means
that, alongside the Ministry of Health, Welfare and Sport, other sectors of government,
as well as public and private parties, can contribute to better health. Factual information,
price stimuli, clarity about ‘healthy’ and ‘unhealthy’ products, and the organization of
the workplace and of the built environment can encourage the public to make healthy
choices or discourage unhealthy behaviour. This amounts to: ‘Making the healthy
choice the easy choice’. Support for preventive intervention in the form of legislation
and regulation increases efficacy. 
Other important pre-conditions for successful intervention targeting lifestyles are
approaches catering for specific target groups (young people, ethnic groups, people with
low education), and a long-term vision with the associated continuous support. In other
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words, ‘stamina’ is essential, not only because the required working structures are com-
plex, but above all because lasting changes in behaviour can only be achieved through
long-term investments and ongoing attention. There is still too little evaluation of preven-
tion programmes and too little national follow-up to successful local prevention initiatives. 
Considerable health gains are also possible if prevention is given a more explicit posi-
tion in the provision of health care. Giving prevention a clear place in health care is ben-
eficial for both public health and the efficiency of care. It is often the case that the orga-
nization of the care system (for example, budgeting or the lack of financial stimuli) and
other organizational aspects or workload constitute obstacles. Furthermore, there is gen-
erally not enough emphasis on prevention during medical training. 
In the future, more and different care will be required 
In 1999, Dutch society spent 36 billion euros on health care; that was 9.6% of the gross
domestic product. Most of it was accounted for by cure facilities, such as hospitals
(29%), medicines (10%) and GPs (3%). Care for older people, the chronically ill, and
the disabled (care facilities) accounted for more than 36% of expenditure. Less than 4%
was spent on prevention, half of which related to occupational health care. This does not
include prevention as a part of care provision. Most care use relates to chronic mental
disorders such as intellectual disability and dementia. Older people use more care than
young people. Care use increases more and more rapidly from the sixtieth year of life
onwards in both men and women. 
In the future, the increase in the size and average age of the population will result in a
considerable increase in the number of cases of illness, particularly chronic diseases. If
the trend of recent years continues, the total volume of health care will have to increase
between now and 2006 by 2.4% annually in order to maintain care at the current level.
In addition, there will have to be a further shift of expenditure from cure to care. Half of
the volume growth required in the future will be caused by population growth and the
increasing average age of the population; the other half will be caused by, for example,
developments in medical technology and changes in consumer demand for care. It
should be pointed out that the trend is based on figures from the years in which deficits
actually increased. It is estimated that catching up with the backlogs on waiting lists and
eliminating other difficulties will, in the years to come, require additional investments
of at least 0.6% a year for four years. 
The waiting times and capacity shortages in the areas of nursing and care are already
considerable. Extra resources which have been made available in previous years have
resulted in more production but recent trends do not indicate any reductions as yet in
waiting lists for most sectors. 
Health care use in the Netherlands is average compared to the surrounding countries.
That applies both to the size of the health care system and to the share of gross domestic
product and the average cost of care per capita. The increase in care expenditure per
capita has, in recent decades, lagged behind the surrounding countries. 
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Care is a question of quality as well as quantity.
In the future, what will matter will be not only more care, but also good care. High qual-
ity care means: care that is effective, safe and universally accessible. Care can be more
effective and safer if ‘best practices’ and standards are applied properly and the experi-
ence from pilot projects is implemented on a wide scale. Pilot projects may, for exam-
ple, relate to safer or more integrated care. These improvements in quality can also
result in cost savings. The obstacles to the introduction of these improvements are usu-
ally organizational and financial in nature. 
The timely application of new effective medical technology and the reduction of unnec-
essary inter-physician variation can result in health gains. Nevertheless, the evaluation
of efficacy and safety in practice remains necessary (through ‘medical technology
assessment’, and ‘postmarketing surveillance’). 
Integrated care - the optimization from the patient’s point of view of the transition
through the care circuit - can help to achieve health gains, make practices more patient-
centered, and make more efficient use of resources when compared to the classic
approach based on strictly separated sectors. 
Studies in the United States and Australia indicate that the undesirable negative effects
of medical intervention may result, in general terms, in a considerable loss of health in
the range of a loss of 6-12 months of life expectancy. There has not been any research in
the Netherlands in this area but it is improbable that the Dutch situation will be entirely
different. Pilot projects have shown that specific health risks in care such as bed sores
and wound infections can be considerably reduced if specific attention is paid to the
problem. 
In the Netherlands, there are no indications of socio-economic differences in terms of
access to the required care. It would appear to be the case, however, that people with
lower levels of education make less effective use of care, for example in the case of
chronic diseases. An extensive analysis in the United States (Institute of Medicine) sug-
gests that the quality of care given to non-Western ethnic groups may be less, for exam-
ple because of language problems, cultural differences, subconscious stereotyping and
different ideas about health. Similar causes may also play a role in the Netherlands. 
Prevention is not only better, it is often cheaper
The costs of interventions per healthy year of life gained can vary widely in the diverse
areas of prevention and health care. Some interventions can generate savings, while oth-
ers cost more than e 100,000 per healthy year of life gained. Preventive action at the
start of the disease chain, such as the heel stick, vaccination, or traffic safety measures,
are often more effective than interventions at the end of the care chain such as lung
transplants. So prevention is not only better than cure, it is often more efficient as well.
In other words: investment in prevention is worthwhile, particularly in the long term. 
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In addition to the cost-effectiveness or efficiency of interventions (health per euro
invested), however, there is also the question of solidarity and the legitimate claim of
every Dutch person to protection and care. Since people want to maintain a high level of
personal protection, certain environmental measures can sometimes be costly as well.
Nevertheless, making the link between costs and health gains more explicit may make
decision-making more transparent. 
4.2 Significance of the findings for the various
players 
Central government must invest in prevention to reverse the stagnation in
health status 
Investment in prevention is required in order to break with the pattern of stagnation in
our health status. Central government will have to do this by developing a consistent
policy framework and a long-term vision for health. This should be the basis for ongoing
investment by central government in existing preventive facilities, and provide powerful
encouragement for the development, evaluation and national implementation of new
preventive interventions. Strengthening the position of prevention and intersectoral pol-
icy in the care system should be spearheads here.
• The 2002 PHSF provides central government with a basis for the formulation of
national priorities in the area of collective prevention. In consultation with the other
players, it can link those priorities with quantitative objectives. That enables the
empirical testing of policy progress. At the same time, national objectives can also
encourage and inspire the other players in the development and implementation of
their own policy plans.
• Central government must continue to invest in existing preventive facilities, in order
to consolidate past health gains. This includes keeping the existing system of preven-
tive facilities up to scratch, including inspection and enforcement.
• Encouragement should be provided for the national implementation of new interven-
tions that have proven effective. One way of doing this is through consultations with
other players with a view to disseminating knowledge about these interventions,
establishing partnerships and providing structural financing for national implemen-
tation.
• Central government will have to continue with investments in research that targets
the development, efficacy, implementation and evaluation of preventive interven-
tions with the aim of further strengthening the foundations of prevention policy. 
• The introduction of effective prevention activities in the care system will have to be
encouraged, for example through the elimination of organizational and financial
obstacles, or by actually providing incentives for care suppliers and health insurers.
• Central government can encourage health-driven intersectoral policy by establishing
agreements on the ministerial level between various policy fields about shared objec-
tives. There are opportunities in, for example, the large cities (Ministry of the Interi-
or), sports (Ministry of Health, Welfare and Sport), schools (Ministry of Education,
Culture and Science), employment (Ministry of Social Affairs and Employment),
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road safety (Ministry of Transport, Public Works and Water Management), and hous-
ing and the environment (Ministry of Housing, Spatial Planning and the Environ-
ment).
• Central government can encourage structural collaboration between local govern-
ment and local representatives of care suppliers, health insurers and consumer and
patient organizations. 
Local prevention players should join forces
The actual implementation of collective prevention is largely local. Municipal authori-
ties and municipal health services are important local players, in collaboration with the
local representatives of care suppliers, health insurers and care clients. They should
combine forces and work together on formulating and elaborating a local prevention
policy, with shared local priorities and policy objectives. A national policy framework
can inspire the local parties and provide them with a direction for the elaboration of
local public-health-policy documents and the formulation of local objectives. 
• The local parties can encourage the development, implementation and evaluation of
new interventions in the local setting within the national policy framework. In addi-
tion, they can encourage the implementation of interventions that have proven effec-
tive (after adaptation to local conditions).
• Local forms of intersectoral collaboration must be extended. On the one hand, this
can consist of the further development of national agreements at the ministerial
level; on the other hand, local initiatives elsewhere can serve as a source of inspira-
tion for all levels of government, including the national level. 
• The local parties will have to make a joint appraisal of how preventive interventions
that have proven effective within the care system can be included in the basic pack-
ages of the relevant care suppliers. In addition, they will have to intensify the devel-
opment of new preventive interventions within the care system.
• Joint investment will be required in bilateral risk communications between the gov-
ernment and the public, with the accent being placed on the public’s own responsibil-
ity in this respect. Consumer and patient organizations in particular can make signif-
icant contributions to a balanced approach to risks and risk perception. 
More care, different care and better care are necessary and possible
The 2002 PHSF did not have either the resources or the ambition to cover the full spec-
trum of care. Care was primarily assessed from the point of view of potential health
gains. In this respect, accessibility, efficacy, safety, costs and efficiency are keywords.
In the future, more and different care will be required, particularly as a result of the
increase in the size and average age of the population. Furthermore, there are still
numerous ways in which the quality of care can be improved. Finally, the parties must
make better use of the available options for anchoring prevention in care activities (see
above). 
More and different care can be achieved by: 
• Allowing the annual increase in the care budget to keep pace with demographic
changes, the development of medical technology and other autonomous develop-
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ments. Between now and 2006, an annual increase in the order of at least 2.4 to 3%
would appear to be necessary. An increase of this size is justified in part by the fact
that there was no increase in the budget in the nineties.
• Eliminating capacity shortages by increasing the volume of medical training in asso-
ciation with a long-term vision for the development of capacity in the medical pro-
fessions.
• Implementing the necessary shift from cure to care simultaneous with the necessary
volume growth of total health care. 
Better care can be achieved by: 
• Explicitly including health targets, such as health gains, improvements in the quality
of life and the reduction of inequalities in health, in the formulation of preconditions
for a new care system.
• Improving the quality of care through encouragement of the use of standards and
guidelines, while remaining open-minded in terms of the flexibility required for care
reform.
• Removing financial and organizational obstacles that interfere unnecessarily with
the adoption of effective forms of care reform, integrated care and new technology.
• Determining, within a patient-oriented perspective, whether a limit can be set to the
demand for care that is ‘not medically justified’. 
• Making extra investments in the availability and, in particular, the appropriateness of
care for socially weaker groups.
• Encouraging the development, on the level of institutions or care providers, of meth-
ods for measuring health outcomes or relevant process parameters. Indicators of this
kind may play a role in internal quality improvements, in terms of the external quali-
ty assessment by consumers and insurers on the health care market and in terms of
answering to society and government. 
4.3 Political and policy dilemmas 
Earlier chapters have also identified a number of dilemmas that sometimes appear to be
obstructions to rational policy decisions. This is true for both prevention and care. Some
dilemmas have been with us for quite a while, whereas others will only have practical
significance in the future. To achieve the right societal balance for these dilemmas, it is
important to encourage a political and public debate about them. In brief, the dilemmas
are as follows. 
Prevention is a question of stamina
Prevention demands a long-term vision, enduring attention and investment. The health
benefits of investments are only seen after longer periods of time, and they emerge grad-
ually, without being noticed. For example, successful anti-smoking policy only results
in a reduction in mortality from lung cancer or in the severe disease burden of cardio-
vascular disorders after a few decades. This means that prevention runs a risk of being
the Cinderella of politics, where short-term problems often claim priority. 
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Collective interests versus individual freedom of choice
The Dutch are more assertive, independent, and individualistic than ever. On the one
hand, the public demand maximum safety from the government at any price; on the
other, they reject any restriction on their personal freedom, for example to run consider-
able health risks themselves. Policy therefore has to sail a difficult course between the
collective importance of good public health and respect for individual freedom of
choice. An associated dilemma is the conflict between the collective importance of pub-
lic health and private economic interests (the alcohol and tobacco industries, for exam-
ple). These virtually irreconcilable interests may stand in the way of the establishment
of effective prevention policy. 
Risk: a question of statistics or a question of perception?
There is often little agreement between experts and the public about the odds, nature,
extent or management of health risks. The public appears to disregard the calculations
of risk experts. For a long time, it was thought that communications about risks could
bring the ‘uninformed’ public on the ‘right’ track, but it would appear to be the case that
there has been a failure to understand in full this complex concept that is determined by
its social context: health risk. The government faces the dilemma of, on the one hand,
adopting a rational approach to risks on the basis of scientific calculations of probabili-
ties, the expected amount of damage and the cost-effectiveness of safety measures, and,
on the other, taking into consideration a legitimate perception of risks by the public, that
are based on a wide range of  prevailing standards and values. 
Prevention with prior knowledge
Developments in genetics are providing us with an ever-clearer picture of our personal
risk and treatment profile. That makes it possible to adapt prevention and treatment
accordingly in the future. At the same time, these developments involve all sorts of
moral and ethical dilemmas, above all because the diagnostic possibilities increase
much faster than the treatment options. How do we deal with the right not to know
which diseases we may contract later if there is no possibility of a cure? What do we do
with technology that enables diseases to be diagnosed more reliably and at an earlier
stage than ever before, but which does not generate significant health gains? Do we
allow all tax-payers to pay for expensive medicines that compensate for an unhealthy
individual lifestyle? 
Controlling demand on ‘imperfect’ markets
The principle of demand-driven care and the ‘right to care’ are at odds with a restricting
financial framework that sets limits to the volume of care provision. But even when the
financial structures are less strict, there is a bottom to every purse. Making improve-
ments in this ‘imperfect’ care market results in quite a number of dilemmas: are we sac-
rificing solidarity for efficiency, for example by introducing personal contributions?
Should we extend the basic package of care or will we expect people to take out addi-
tional insurance? Is it helpful here to make a distinction between ‘evidence-based’ med-
icine and problems that are ‘wrongly medicalized’? 
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Flexible standards?
Standards in care improve quality but they can, in theory, act as a brake on timely mod-
ernization and a patient-driven approach. 
Efficiency versus the right to the best care
Investments in preventive measures with the aim of preventing or postponing disease
often result in greater health gains than care at later stages of the disease process: pre-
vention is better than cure, and often cheaper, at least per healthy year of life gained.
There is a dilemma here between the efficient deployment of scarce resources on the
one hand and the right of every Dutch person to the best possible care on the other. 
Measuring performance in care: final judgement or learning opportunity?
Arguments are heard in favour of measuring quality or performance in care in order to
improve the quality of care and to make the options available to consumers and insurers
more transparent. How far should we go in making this information public? Do we want
to use quality measurement to create rankings or to find scapegoats, or do we want to
provide a good learning opportunity to improve quality? 
4.4 PHSF and the provision of information 
The provision of information falls short in some areas
As in previous PHSFs, the PHSF-2002 made use of many registers, population studies,
health surveys and one-off studies. Since PHSF-1997, the provision of information has
improved in some areas and worsened in others (for example, registers of absence from
work through sickness). A number of major difficulties remain in various areas. Sections
2.1 to 2.4 already discussed this in detail. This section returns to the broad outlines. In
order to continue with a monitoring system like the PHSF in the future (including the
National Public Health Compass, the National Atlas of Public health and Cost of 
Illness), it is necessary to have an adequate underlying data collection system that can
generate the required data. That means that continuous investments are required to
maintain and, where necessary, improve the current level of information provision.
Important improvements are desirable in the following areas. 
• Many databases about diseases and determinants lack continuity, national represen-
tativeness and the possibility of regional differentiation. In addition, coordination
between databases is often lacking. As a result, trends in the Dutch population and
regional differences (especially on the level of municipalities, neighbourhoods and
post codes) are difficult to establish. The present development of the Local and
National Public Health Monitor, the continuation of the data infrastructure of the
Second National Study and the continuation of NEMESIS provide good opportuni-
ties for improvements in this respect. 
• There is too little information about socio-economic status, ethnicity, type of house-
hold and other relevant characteristics (such as the severity of the disorder or quality
of life) in registers and studies. Our understanding of socio-economic differences has
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improved but there is still not enough standardization of records of socio-economic
status in registers and studies. As a result, it is difficult to establish a picture of the
trends in these differences. Information about ethnic groups is generally lacking,
especially when it comes to older people in those groups. In addition, many studies
and surveys cover ethnic groups in a limited way, if at all. There are possibilities for
improvement, particularly in the field of operations of Statistics Netherlands. 
• The quality of care registers is very uneven. Coordination between registers are gen-
erally lacking, and linkage between registers is hindered by the absence of a unique
care number. In addition, there is often a lack of diagnosis data and the trend data is
often missing or invalid. This means that the progress of a patient with a certain dis-
ease through the care system cannot be monitored (the care chain) and that it is not
possible to study coordination in care or monitor it over time. There are possibilities
for improvement, for example in the case of Prismant, the manager of a large number
of important care registries. 
• A reasonably complete picture of the quality and accessibility of preventive and care
interventions is not available. The Branch Reports on Prevention, Cure, Care and
Mental health care will in time be able to make an important contribution in this
respect. The national Quality of Interventions project (QUI) will also, in time, pro-
vide a more complete picture of effective preventive interventions. Good coordina-
tion between Branch Reports, the QUI project and PHSF is essential here. 
• Various databases (including those in the public domain) are housed with private
parties and, as a result, accessibility is becoming increasingly difficult or impossible.
• The current efforts to properly monitor developments in the field of medical technol-
ogy are small-scale and fragmented. An integrated overview is lacking. Among poli-
cy-makers, insurers and suppliers, however, there is a demand for information of this
kind since it can benefit the national implementation of new technology. A perma-
nent structure for the monitoring of developments in medical technology could result
in improvements in this respect. 
• The demand for international comparisons (‘benchmarking’) for health and care is on
the increase. In recent years, WHO, OECD and Eurostat have all done a lot to harmo-
nize databases (see text block 4.1), but the availability and comparability of much
information could be greatly improved. The new EU public health programme, that
will be launched in 2003, aims to develop a sustainable ‘monitoring system’ with qual-
itative and quantitative indicators about health, health determinants and health policy
(EU, 2002). This requires the coordinated efforts of the parties involved in data collec-
tion and the supply of data to international bodies. In turn, this requires the unremit-
ting efforts of all the countries that participate in international data collection systems. 
Towards a coordinated framework of health and care indicators 
All the information brought together in earlier chapters is, in principle, relevant for the
policy and for other actors in public health and care. The shortcomings and difficulties
referred to above were also formulated from that point of view. We have shown that this
information is of particular interest for policy if it means we can identify trends over
time, or if we can make comparisons (‘benchmarking’) on the local/regional levels
(municipal authorities, care institutions) or the international level (countries). 
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Recently, various publications have made the link between policy information and spe-
cific policy objectives explicit. Here, a central role is played by the control information
concept (Delnoij et al., 2002). This is the concrete information needed to steer a particu-
lar policy and monitor its effects, including ‘benchmarking’. How can we select and
present the information for the Netherlands about public health and care so that it
becomes control information? The selection has to be based on the areas that policy can
control and that it aims to control. Presentation should take the form of indicators. Indi-
cators here means a number that provides an ‘indication’ (which is as reliable and com-
pact as possible) of the current situation in the relevant area. If we also want to deter-
mine whether quantitative policy objectives are being achieved, well-chosen indicators,
generated regularly by an underlying data collection system, are a powerful tool. 
In the World Health Report 2000 (WHO, 2000), WHO presented and filled in a frame-
work for the analysis and comparison of national ‘health systems’. This framework con-
sists of five indicators for describing a country’s health system. Although the substance
of the report has been widely criticized (Achterberg et al., 2001), the WHO approach
has also been praised for its vision. The OECD has an ongoing programme for supple-
menting and improving the WHO approach (OECD, 2000a, 2001). Others have also
elaborated frameworks of this kind for assessing the performance of the health or care
systems, or the successes achieved by our efforts to improve health (‘health system per-
formance assessment’ or HSPA), both abroad (for example in Canada: CIHI, 1999) and
in the Netherlands (SZW, 2000; Delnoij et al., 2002). In all these cases, there is a coher-
ent framework of performance indicators, for making the best possible assessment of
the condition and performance of the health or health-care systems. 
Text block 4.1 elaborates the framework sketched above and completes it with a number
of indicators selected from the information collected in chapter 2. Two things are
important for establishing a practical, coherent framework of indicators in the future.
First of all, in the years to come, further elaboration of the concept and the translation of
‘control information’ into practical and measurable indicators will be necessary, togeth-
er with broad participation from those involved in policy and the provision of informa-
tion. The indicators defined will then have to be actually measured and calculated on a
regular basis. Here, in broad terms, it will be possible to use the information infrastruc-
ture of the PHSF (National Compass on Public Health, National Atlas of Public Health,
Cost of Illness in the Netherlands study) and the associated partners.
Towards a sustainable information supply: opportunities and recommen-
dations 
A few shortcomings have already been described above, together with a description of
the recent trend for performance indicators. How can the government and other parties
respond best in this area? First of all, it is clear that a good and continuous information
supply is indispensable as support for ‘evidence-based’ policy. That is why central gov-
ernment itself should, more than in the past, develop a long-term vision for information
policy and also be involved in directing the implementation of the policy. This includes
the following elements: 
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• Identification of the fields and subjects for which standard information provision is
required; i.e. the monitoring of quantitative policy objectives.
• Making agreements in consultation with the various parties about the implementa-
tion of data collection; making attempts to improve efficiency here through coordi-
nation and to establish access to relevant sources of information despite private inter-
ests.
• Encouraging that data are collected on the local level, according to local needs, but
also co-ordinated on the national level. 
• Encouraging efforts to make data about health and care more amenable to interna-
tional comparison; in this context, there should be encouragement for active contri-
butions to the design of the European public health programme and for the participa-
tion of Dutch researchers in this programme. 
• Continuing to develop a framework of indicators for measuring performance and
risk in health care and prevention, for ‘benchmarking’ on both the meso-level
(between institutions) and the macro-level (between countries). 
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Text block 4.1: Indicators for monitoring health, determinants and the performance of health (care)
systems; the international context and a detailed example for the Netherlands 
The establishment of public health indicators has
a longer history than the current ‘performance
measurement’ trend. A number of health indica-
tors were established in the eighties as part of the
WHO Health For All (HFA) strategy (WHO regional
office for Europe). These indicators are linked to
HFA targets, which are intended as sources of
inspiration for public health policy in the member
states. In practice, Dutch public health policy has
adopted few of the quantitative HFA targets (Van
de Water & Van Herten, 1996, 1998).
The collection of data on the indicators in the HFA
database has contributed to the potential for inter-
national ‘benchmarking’. Recently, international
comparison has become more important as a
source of inspiration for Dutch health policy and it
has therefore also been one of the leading per-
spectives in this PHSF.
Alongside WHO, the OECD uses a series of indica-
tors for its database that relate primarily to care
facilities and care use, and also publishes Euro-
stat figures about these subjects. Finally, a set of
indicators has been proposed as part of the EU
programme for health monitoring (ECHI, 2001).
At present, this list provides a structuring princi-
ple behind the design of the new EU public health
programme that will be launched in 2003. All
these lists are ‘reasonably complete’ lists of sta-
tistical variables rather than limited sets of control
variables of the kind targeted by the recent trend
of performance measurement. Like PHSF does on
the national level, they provide the context in
which control variables can be selected. 
The indicators listed in the various reports can be
broken down into five categories: health status,
determinants of health, quality and accessibility of
care, health care use and costs, and efficiency.
The health status and determinants categories
include the indicators relating to the health status
of the population and its underlying causes and
the other categories include the indicators for per-
formance in prevention and care. There are differ-
ences in the way in which health status indicators
are used. WHO (WHO, 2000) and a report from
the Ministry of Social Affairs and Employment
(SZW, 2000) both use a general health measure to
assess the performance of the ‘health system’.
The concern here is that general measures of this
kind do not adequately reflect the performance of
the current health system in the broadest sense,
and that they are of even less use for measuring
the performance of the care system. That is why
the frameworks of the OECD, the Canadian report
and Delnoij et al. (OECD, 2000a, 2001; CIHI,
1999; Delnoij et al., 2002) only include health sta-
tus indicators that relate specifically to current
care or prevention activities (for example, avoid-
able mortality). In these approaches, health status
and determinants outside the care system are
items which require monitoring but which have
nothing specific to say about how the system per-
forms. 
Table 4.1 includes a selection of a number of indi-
cators. Where possible, an indication is given of
the situation in the Netherlands as compared to
the other EU countries, and of recent trends in the
Netherlands. It should be emphasized that the
table provides an example of a possible system of
indicators, not a carefully considered selection.
The health status (and health differences) and
determinants categories relate to descriptions of
situations and the other categories relate to the
performance of prevention and care. However,
what are the selection criteria? Health status may
include indicators for the main health problems or
composite indicators such as healthy life
expectancy, as well as indicators for problems
that can clearly be influenced, examples being
traffic deaths and lung cancer mortality. Determi-
nants may include monitoring the determinants of
the main health problems, but also specific fac-
tors that can be influenced, examples being
smoking or exposure to noise. This means that
some status indicators can also be used as per-
formance indicators. In concrete terms, during
the selection of indicators in the example in table
4.1, both criteria were used: the extent of the
health problem and the degree to which it can be
influenced. 
In the quality and accessibility category, the
selection of good indicators is a subject of dis-
cussion on the international level. In the field of
the efficacy of medical activity, both medical out-
come indicators (for example, cancer survival
rates) and process indicators are used when the
link with outcomes is clear enough (see also sec-
tion 2.3). In the area of patient orientation and
accessibility, outcomes are, for example, satisfac-
tion surveys and processes are the factors that
relate to organization and staff. The selection of
indicators in this area was based very much on
the international literature and, for the time being,
the range of relevance and comparable indicators
remains limited. Care use/costs includes only a
few widely-used indicators for care costs. Infor-
mation about care use is, to an increasing extent,
internationally comparable, despite the differ-
ences in how care is organized. In the efficiency
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(continue text block 4.1)
Table 4.1. Example of a system of indicators for health, determinants and performance of prevention and care.
Indicator description Position of the Trend in the Netherlands
Netherlands
Health status and inequalities
Indicators marked (*) may be qualified as performance indicators for prevention and care
Health: life expectancy (m,v) average favourable 
(unfavourable vs. EU-trend)
Health: life expectancy without disabilities ? favourable
Inequalities: socio-economic differences in health life expectancy  ? stable
Mortality: coronary heart disease (m,v) (*) average favourable
Mortality: breast cancer (*) unfavourable favourable
Mortality: lung cancer (m,v) (*) unfavourable favourable (m), unfavourable (w)
Mortality: traffic accidents (m,v) (*) favourable favourable
Burden of disease: prevalence of chronic diseases ? unfavourable: diabetes, mental 
disorders
Participation: % working disability (causes: mental, locomotor) ? ?
Determinants
Indicators marked (*) may be qualified as performance indicators for prevention
Personal risk factors: prevalence of overweight (BMI ≥ 30) (*) favourable unfavourable
Lifestyle: smoking by young people: prevalence (15-19 yrs) (*) unfavourable unfavourable
Lifestyle: smoking prevalence (≥ 15 yrs) (*) unfavourable stable
Lifestyle: alcohol abuse (*) unfavourable unfavourable
Lifestyle: not enough fruit and vegetables (*) unfavourable
Physical environment: noise exposure (*) unfavourable stable
Social environment: work stress (*) ? unfavourable
Quality and accessibility of the healthcare system
Disease prevention: participation breastcancer screening (process) favourable stable
Disease prevention: 5-year survival breastcancer (outcome) average favourable
Disease prevention: vaccination coverage measles (process) favourable unfavourable
Health promotion: price of packet of cigarettes (process) unfavourable ?
Adoption of new technology: PTCA and CABG (process) average ?
Use of protocols: variation in appendix operations (process) favourable favourable
Optimal care: perinatal mortality (outcome) unfavourable favourable
Appropriate use of medication: antibiotic resistance (outcome) favourable stable
Accessibility: volume on waiting lists/waiting times (process) unfavourable stable
Accessibility: responsiveness (WHO survey) (outcome) average ?
Labour market: number of docters/inhabitant (process) low stable
Satisfaction with healthcare (outcome) favourable unfavourable
Healthcare utilisation/Costs
Costs: costs as % of GDP average stable
Utilisation: costs per inhabitant average increasing
Effectiveness
See elucidation in text tekst
category, no selection was made. Macro-selec-
tions (for example in WHO, 2000) such as
‘increase in life expectancy per investment in care’
mean little because life expectancy is still primari-
ly determined by factors from outside the care
system. Micro-selections relating to efficient ways
of achieving health gains (section 2.5) remain
highly fragmented. Process indicators have also
been suggested such as ‘percentage of hands on
the bed’ (percentage of medical staff that are actu-
ally active in patient care; SZW, 2000). Further
discussions are necessary on this topic. 
4.5 PHSF as a national project, now and
in the future 
In order to increase the utility of the PHSF, it was decided to adopt a three-layered
framework for the PHSF 2002: first of all, websites with basic information, secondly a
series of theme reports dealing with specific policy issues and thirdly this summary
report with integrated information (see text block 1.1). This structure constitutes the
next step towards extending the target group of the PHSF from the Ministry of Health,
Welfare and Sport to other players in the area of health and care. The area covered by
the information collection has also been extended. In the PHSF 1993, the emphasis was
on the description of health status and the underlying determinants; in the PHSF 1997,
information was added about prevention and care and, in the PHSF 2002, regional and
international information has been added. The purpose of extending the scope of the
information was to establish benchmarks for the Netherlands in various areas. 
Most of the added value of the PHSF lies in the fact that it brings together the available
knowledge in a conceptual framework. As a result, a clear picture is established of the
links between ill health, its causes and the consequences for health care. Regular updat-
ing of the information makes it possible to identify changes and to compare the perfor-
mance of the Dutch health care system with the surrounding countries on an ongoing
basis. One of the new challenges for the future is therefore to develop the concept of
performance indicators for health care further in accordance with the description intro-
duced in section 4.4. 
Like the previous PHSF-reports, the production of this PHSF is the result of the work of
many individuals. Leading Dutch experts and expertise centres in many areas have
made contributions to the RIVM websites, to the theme reports and to this summary
report. So this third PHSF is once again a national undertaking. 
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Appendix 1: Ranking of diseases and disorders in
the Netherlands according to
mortality, years of life lost, incidence,
prevalence, disease years equivalents
and DALYs
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isa
bi
lit
y
A
sth
m
a
R
he
um
at
oi
d 
ar
th
rit
is
Tu
be
rc
ul
os
is
3,
00
0-
10
,0
00
H
ea
lth
 p
ro
bl
em
s
am
o
n
g 
fu
ll-
te
rm
 n
ew
-
bo
rn
s
Vi
ol
en
ce
A
ne
ur
ys
m
 o
f t
he
ab
do
m
in
al
 ao
rta
Ep
ile
ps
y
Pa
rk
in
so
n’
s 
di
se
as
e
Co
ng
en
ita
l a
no
m
al
ie
s
o
f n
er
vo
us
 sy
ste
m
M
ul
tip
le
 sc
le
ro
sis
A
ID
S
O
cc
up
at
io
na
l a
cc
id
en
ts
D
ow
n’
s 
sy
nd
ro
m
e
In
flu
en
za 1,
00
0-
3,
00
0
St
om
ac
h 
ca
nc
er
A
lc
oh
ol
 in
du
ce
s d
iso
r-
de
rs
Pr
os
ta
te
 c
an
ce
r
O
es
op
ha
gu
s c
an
ce
r
N
on
-H
od
gk
in
 ly
m
-
ph
om
a’
s 
Co
ng
en
ita
l a
no
m
al
ie
s
o
f h
ea
rt 
an
d 
ci
rc
ul
at
o-
ry
 sy
ste
m
Pr
em
at
ur
e 
bi
rth
 an
d
u
n
sp
ec
ifi
ed
 lo
w
 b
irt
h
w
ei
gh
t
Se
ps
is
Sk
in
 ca
nc
er
10
,0
00
-3
0,
00
0
B
re
as
t c
an
ce
r
Su
ic
id
e
CO
PD
Co
lo
re
ct
al
 ca
nc
er
Lo
w
er
 re
sp
ira
to
ry
in
fe
ct
io
ns
R
oa
d 
tra
ffi
c a
cc
id
en
ts
H
ea
rt 
fa
ilu
re
H
om
e 
an
d 
le
isu
re
ac
ci
de
nt
s
D
ia
be
te
s m
el
lit
us
D
em
en
tia
30
,0
00
-1
00
,0
00
Co
ro
na
ry
 h
ea
rt 
di
se
as
e 
Lu
ng
 c
an
ce
r
St
ro
ke
>
 1
00
,0
00
Ta
bl
e 2
: R
an
ki
ng
 o
f d
iso
rde
rs
 b
y t
he
 n
um
be
r o
f p
ote
nti
al 
ye
ar
s o
f li
fe 
los
t in
 th
e N
eth
erl
an
ds
 in
 20
00
 (S
ou
rce
: 
CB
S-
Ca
us
e o
f d
ea
th
 st
at
ist
ic
s/ 
St
at
ist
ic
s o
f u
nn
atu
ra
l c
au
ses
;
pr
o
ce
ss
ed
 b
y R
IV
M
). a
a)
w
ith
in
 ea
ch
 co
lu
m
n 
ite
m
s a
re
 ra
nk
ed
 to
p 
to
 b
ot
to
m
 ac
co
rd
in
g 
to
 n
um
be
r o
f p
ot
en
tia
l y
ea
rs
 o
f l
ife
 lo
st.
 A
n
u
m
be
r o
f d
iso
rd
er
s f
o
r 
w
hi
ch
 th
e n
um
be
r o
f p
ot
en
tia
l y
ea
rs
 o
f l
ife
 lo
st 
is 
ve
ry
 lo
w
 (<
10
0).
 Fo
r
m
o
re
 in
fo
rm
at
io
n 
se
e w
w
w.
n
at
io
na
al
ko
m
pa
s.n
l.
n
o
te
: t
he
 p
op
ul
at
io
n 
of
 th
e N
et
he
rla
nd
s i
n 
th
e y
ea
r 2
00
0:
 1
5.
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Ta
bl
e 3
: R
an
ki
ng
 o
f d
iso
rde
rs
 b
y p
oi
nt
 p
re
va
le
nc
e (
ab
so
lut
e n
um
be
rs)
; s
tan
da
rd
ise
d 
to
 th
e p
op
ul
at
io
n 
in
 th
e N
et
he
rla
nd
s i
n 
20
00
.
 
Th
e i
nfo
rm
ati
on
 ab
ov
e t
he
 sc
ale
 is
 ba
sed
 on
da
ta
 fro
m
 h
ea
lth
 ca
re
 r
ec
o
rd
s, 
wh
ile
 th
at
 b
el
ow
 th
e s
ca
le
 is
 b
as
ed
 o
n 
da
ta
 fo
rm
 ep
ide
mi
olo
gic
al 
po
pu
lat
ion
 st
ud
ies
 a (
So
ur
ce
s:
 s
ee
 N
at
io
na
l P
ub
lic
 H
ea
lth
 C
om
pa
ss
: s
ee
w
w
w
.
n
a
tio
na
al
ko
m
pa
s.n
l).
A
ID
S
O
es
op
ha
gu
s c
an
ce
r
<
 3
,0
00
St
om
ac
h 
ca
nc
er
D
ec
ub
itu
s
3,
00
0-
10
,0
00
Co
ng
en
ita
l a
no
m
al
ie
s
o
f n
er
vo
us
 sy
ste
m
D
ru
g 
de
pe
nd
en
ce
A
lc
oh
ol
 d
ep
en
de
nc
e
Lu
ng
 c
an
ce
r
In
fla
m
m
at
or
y 
 b
ow
el
di
se
as
e 
In
te
st
in
al
 in
fe
ct
io
us
di
se
as
es
 
M
ul
tip
le
 sc
le
ro
sis
N
on
-H
od
gk
in
 ly
m
-
ph
om
a’
s
10
,0
00
-3
0,
00
0
Ep
ile
ps
y
Sc
hi
zo
ph
re
ni
a b
B
re
as
t c
an
ce
r
Ep
ile
ps
y
D
em
en
tia
A
nx
ie
ty
 d
iso
rd
er
s
O
ste
op
or
os
is
Co
lo
re
ct
al
 ca
nc
er
Sk
in
 ca
nc
er
Co
ng
en
ita
l a
no
m
al
ie
s
o
f h
ea
rt 
an
d 
ci
rc
ul
at
o-
ry
 sy
ste
m
Pa
rk
in
so
n’
s 
di
se
as
e
Sc
hi
zo
ph
re
ni
a
Pr
os
ta
te
 c
an
ce
r
30
,0
00
-1
00
,0
00
A
ne
ur
ys
m
 o
f t
he
ab
do
m
in
al
 ao
rta
D
ru
g 
de
pe
nd
en
ce
 c
D
ec
ub
itu
s
Pa
rk
in
so
n’
s 
di
se
as
e
CO
PD
D
ep
re
ss
io
n
A
to
pi
c d
er
m
at
iti
s
St
ro
ke
 d
H
ea
rt 
fa
ilu
re
 
R
he
um
at
oi
d 
ar
th
rit
is
10
0,
00
0-
30
0,
00
0
A
lc
oh
ol
 d
ep
en
de
nc
e c
Co
ro
na
ry
 h
ea
rt 
di
se
as
e
D
em
en
tia
H
ea
rt 
fa
ilu
re
R
he
um
at
oi
d 
ar
th
rit
is 
Vi
su
al
 im
pa
irm
en
ts 
e
St
ro
ke
 d
In
te
lle
ct
ua
l d
isa
bi
lit
y
D
or
so
pa
th
ie
s
A
rth
ro
sis
 f
H
ea
rin
g 
im
pa
irm
en
ts
Co
ro
na
ry
 h
ea
rt 
di
se
as
e
A
sth
m
a 
Vi
su
al
 im
pa
irm
en
ts 
g
D
ia
be
te
s m
el
lit
us
Co
nt
ac
t d
er
m
at
iti
s
30
0,
00
0-
1,
00
0,
00
0
Co
nt
ac
t d
er
m
at
iti
sh
O
ste
oa
rth
ro
sis
D
ia
be
te
s m
el
lit
us
O
ste
op
or
os
is
D
ep
re
ss
io
n 
i
>
 1
,0
00
,0
00
D
or
so
pa
th
ie
s 
H
ea
rin
g 
im
pa
irm
en
ts
A
nx
ie
ty
 d
iso
rd
er
s 
j
a)
w
ith
in
 ea
ch
 co
lu
m
n 
ite
m
s a
re
 ra
nk
ed
 ac
co
rd
in
g 
to
 th
ei
r I
CD
 co
de
s. 
A
n
u
m
be
r o
f d
iso
rd
er
s, 
fo
r w
hi
ch
 p
oi
nt
 p
re
va
le
nc
es
 w
er
e m
iss
in
g 
or
 w
er
e c
on
sid
er
ed
 n
ot
 re
le
va
nt
, a
re
 n
ot
 in
cl
ud
ed
 in
 th
e t
ab
le
.
Th
es
e a
re
 in
fe
ct
io
us
 d
ise
as
es
 ex
cl
ud
in
g A
ID
S,
 b
as
al
 ce
ll 
ca
rc
in
om
a,
 m
en
ta
l d
iso
rd
er
s i
n 
ch
ild
re
n 
an
d 
yo
ut
h,
 D
ow
n’
s 
sy
nd
ro
m
e,
 p
re
m
at
ur
e 
bi
rth
, h
ea
lth
 p
ro
bl
em
s i
n 
fu
ll-
te
rm
 n
ew
-b
or
ns
 an
d 
ac
ut
e
ph
ys
ic
al
 h
ar
m
. F
or
 th
e p
re
va
le
nc
e o
f d
em
en
tia
, s
tro
ke
 an
d 
Pa
rk
in
so
n’
s 
di
se
as
e a
lso
 
b)
da
ta
 fr
om
 n
ur
sin
g 
ho
m
e r
ec
or
ds
 h
av
e b
ee
n 
us
ed
, w
hi
le
 p
sy
ch
ia
tri
c h
os
pi
ta
ls 
pr
ov
id
ed
 ad
di
tio
na
l d
at
a f
or
 th
e p
re
va
le
nc
e o
f s
ch
iz
op
hr
en
ia
. F
or
 m
or
e i
nf
or
m
at
io
n 
ab
ou
t i
nc
id
en
ce
 o
f a
 ce
rta
in
 d
iso
rd
er
se
e 
w
w
w
.
n
at
io
na
al
ko
m
pa
s.n
l. 
b)
re
se
ar
ch
 d
at
a o
nl
y 
av
ai
la
bl
e f
or
 1
8-
65
 y
ea
r o
ld
s. 
O
ve
r 6
4 
ye
ar
,
 th
e s
am
e p
re
va
le
nc
e h
as
 b
ee
n 
as
su
m
ed
 as
 fo
r t
he
 ag
e c
la
ss
 6
0-
64
 y
ea
rs
.
c)
18
-6
5 
ye
ar
 o
ld
s o
nl
y.
d)
pr
ev
al
en
ce
 re
fe
rs
 to
 li
fe
 p
re
va
le
nc
e:
 n
um
be
r o
f p
er
so
ns
 th
at
 ev
er
 h
ad
 a 
str
ok
e.
 
e)
th
e d
at
a o
nl
y 
co
ve
r s
ub
-c
at
eg
or
ie
s o
f m
ac
ul
a d
eg
en
er
at
io
n,
 d
ia
be
tic
 re
tin
op
at
hy
 an
d 
gl
au
co
m
a.
f)
th
e d
at
a o
nl
y 
co
ve
r a
rth
ro
sis
 o
f l
im
bs
. N
ec
k-
 an
d 
ba
ck
 ar
th
ro
sis
 is
 in
cl
ud
ed
 in
 D
or
so
pa
th
ie
s.
g)
th
e d
at
a c
ov
er
 su
b-
ca
te
go
rie
s o
f m
ac
ul
a d
eg
en
er
at
io
n,
 d
ia
be
tic
 re
tin
op
at
hy
,
 g
la
uc
om
a a
nd
 ca
ta
ra
ct
.
h)
th
e d
at
a r
ef
er
 to
 y
ea
r p
re
va
le
nc
e o
f c
on
ta
ct
 d
er
m
at
iti
s o
f h
an
ds
 an
d 
fin
ge
rs
 am
on
g 
20
-6
0 
ye
ar
 o
ld
s. 
Th
is 
gr
ou
p 
is 
co
ns
id
er
ed
 to
 b
e t
he
 h
ig
he
st 
ris
k 
gr
ou
p 
(w
ork
ing
 po
pu
lat
ion
, h
ou
sew
ive
s).
 
i)
da
ta
 fo
r 1
8-
64
 y
ea
r o
ld
s r
ef
er
 to
 d
ep
re
ss
iv
e d
iso
rd
er
 an
d/
or
 d
ys
th
ym
ic
 d
iso
rd
er
 an
d 
fo
r 1
3-
17
 y
ea
r o
ld
s t
o 
de
pr
es
siv
e d
iso
rd
er
 o
n
ly
.
 
Fo
r d
ep
re
ss
iv
e d
iso
rd
er
 in
 o
ve
r 8
5 
ye
ar
 o
ld
s i
t h
as
 b
ee
n 
as
su
m
ed
th
at
 th
e p
re
va
le
nc
e i
s e
qu
al
 to
 th
e p
re
va
le
nc
e i
n 
ag
e c
la
ss
 8
0-
84
 y
ea
rs
.
j)
th
e d
at
a c
ov
er
 1
3 
ye
ar
s o
ld
 an
d 
ov
er
.
 
O
ve
r 8
5 
ye
ar
s, 
pr
ev
al
en
ce
 h
as
 b
ee
n 
as
su
m
ed
 eq
ua
l t
o 
pr
ev
al
en
ce
 in
 ag
e c
la
ss
 7
5-
84
 y
ea
rs
.
n
o
te
: t
he
 p
op
ul
at
io
n 
of
 th
e N
et
he
rla
nd
s i
n 
th
e y
ea
r 2
00
0:
 1
5.
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Ta
bl
e 4
:R
an
ki
ng
 o
f d
iso
rde
rs
 b
y y
ea
r i
nc
id
en
ce
 (a
bs
olu
te 
nu
mb
ers
) b
as
ed
 on
 da
ta 
fro
m
 r
eg
is
tr
ie
s;
 st
an
da
rd
ise
d 
to
 p
op
ul
at
io
n 
in
 th
e N
et
he
rla
nd
s i
n 
20
00
a
  
(So
ur
ce
s:
 s
ee
w
w
w
.
n
a
tio
na
al
ko
m
pa
s.n
l).
a)
w
ith
in
 ea
ch
 co
lu
m
n 
th
e h
ig
he
st 
in
ci
de
nc
e i
s s
ta
te
d 
at
 th
e t
op
. A
n
u
m
be
r o
f d
iso
rd
er
s f
or
 w
hi
ch
 su
ita
bl
e i
nc
id
en
ce
 fi
gu
re
s w
er
e m
iss
in
g 
ha
ve
 n
ot
 b
ee
n 
in
cl
ud
ed
 in
 th
e t
ab
le
. T
he
se
 ar
e i
nt
el
le
ct
ua
l d
is-
ab
ili
ty
,
 m
en
ta
l p
ro
bl
em
s i
n 
ch
ild
re
n 
an
d 
yo
ut
h,
 co
ng
en
ita
l o
f e
ar
ly
-a
cq
ui
re
d 
he
ar
in
g 
im
pa
irm
en
ts,
 (p
ara
)de
nta
l d
iso
rde
rs,
 pr
em
atu
re
 b
irt
h 
an
d 
he
al
th
 p
ro
bl
em
s a
m
on
g 
fu
ll-
te
rm
 n
ew
-b
or
ns
. F
or
 m
or
e
in
fo
rm
at
io
n 
se
e w
w
w.
n
at
io
na
al
ko
m
pa
s.n
l.
b)
da
ta
 re
fe
r t
o 
ba
ct
er
ia
l t
yp
e o
nl
y.
c) 
v
ira
l S
TD
’s 
in
cl
ud
e h
er
pe
s g
en
ita
lis
, h
ep
at
iti
s B
 an
d 
ge
ni
ta
l w
ra
ts.
 B
ac
te
ria
l S
TD
’s 
ar
e 
ch
la
m
yd
ia
 tr
ac
ho
m
at
is
in
fe
ct
io
n,
 sy
ph
ili
s e
n 
go
no
rrh
oe
a.
d) 
pr
em
at
ur
e 
bi
rth
: p
re
gn
an
cy
 sh
or
te
r t
ha
n 
37
 w
ee
ks
; v
er
y 
pr
em
at
ur
e:
 p
re
gn
an
cy
 sh
or
te
r t
ha
n 
32
 w
ee
ks
.
e) 
da
ta
 co
ve
r a
rth
ro
sis
 o
f t
he
 li
m
bs
 o
nl
y. 
N
ec
k-
 an
d 
ba
ck
 ar
th
ro
sis
 is
 in
cl
ud
ed
 in
 D
or
so
pa
th
ie
s.
f) 
th
e d
at
a c
ov
er
 su
b-
ca
te
go
rie
s o
f m
ac
ul
a d
eg
en
er
at
io
n,
 d
ia
be
tic
 re
tin
op
at
hy
,
 g
la
uc
om
a a
nd
 ca
ta
ra
ct
.
M
ul
tip
le
 sc
le
ro
sis
Co
ng
en
ita
l a
no
m
-
al
ie
s o
f n
er
vo
us
sy
ste
m
D
ow
n’
s 
sy
nd
ro
m
e
A
ID
S
<
 1
,0
00
In
fla
m
m
at
or
y 
bo
w
el
di
se
as
es
St
om
ac
h 
ca
nc
er
N
on
-H
od
gk
in
 ly
m
-
ph
om
a’
s
Sc
hi
zo
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re
ni
a
Tu
be
rc
ul
os
is
Co
ng
en
ita
l a
no
m
-
al
ie
s o
f h
ea
rt 
an
d
ci
rc
ul
at
or
y 
sy
ste
m
O
es
op
ha
gu
s c
an
ce
r
M
en
in
gi
tis
 b
1,
00
0-
3,
00
0
Se
ps
is
Lu
ng
 c
an
ce
r
Co
lo
re
ct
al
 ca
nc
er
Ep
ile
ps
y
A
ne
ur
ys
m
 o
f t
he
ab
do
m
in
al
 ao
rta
Pr
os
ta
te
 c
an
ce
r 
D
ec
ub
itu
s
A
lc
oh
ol
 d
ep
en
de
nc
e
D
ru
g 
de
pe
nd
en
ce
Pa
rk
in
so
n’
s 
di
se
as
e
3,
00
0-
10
,0
00
R
he
um
at
oi
d 
ar
th
rit
is
ST
D
’s 
c
Sk
in
 ca
nc
er
Su
ic
id
e(a
tte
mp
t)
D
em
en
tia
O
ste
op
or
os
is
H
ip
 fr
ac
tu
re
Pr
em
at
ur
e 
an
d 
ve
ry
pr
em
at
ur
e 
bi
rth
 d
U
lc
er
s o
f s
to
m
ac
h
an
d 
du
od
en
um
B
re
as
t c
an
ce
r
10
,0
00
-3
0,
00
0
A
rth
ro
sis
e
Vi
su
al
im
pa
irm
en
ts 
f
A
to
pi
c d
er
m
at
iti
s
Co
ro
na
ry
 h
ea
rt 
di
s-
ea
se
D
ia
be
te
s m
el
lit
us
H
ea
rin
g 
im
pa
ir-
m
en
ts
H
ea
rt 
fa
ilu
re
CO
PD
Vi
ol
en
ce
A
nx
ie
ty
 d
iso
rd
er
s
St
ro
ke
30
,0
00
-1
00
,0
00
D
ep
re
ss
io
n
A
sth
m
a
10
0.
00
0-
30
0.
00
0
A
cu
te
 u
rin
ar
y 
tra
ct
–
in
fe
ct
io
ns
Lo
w
er
 re
sp
ira
to
ry
in
fe
ct
io
ns
Sp
or
t i
nju
rie
s
Co
nt
ac
t d
er
m
at
iti
s
In
flu
en
za
 
R
oa
d 
tra
ffi
c a
cc
i-
de
nt
s
O
cc
up
at
io
na
l a
cc
i-
de
nt
s
In
fe
ct
io
us
 in
te
sti
na
l
di
se
as
e
30
0,
00
0-
1.
00
0,
00
0
U
pp
er
 re
sp
ira
to
ry
in
fe
ct
io
ns
H
om
e 
an
d 
le
isu
re
ac
ci
de
nt
s 
D
or
so
pa
th
ie
s
1,
00
0,
00
0
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Ta
bl
e 5
: R
an
ki
ng
 o
f d
iso
rde
rs
 b
by
 d
ise
as
e-
ye
ar
 eq
ui
va
le
nt
s (
los
s o
f q
ua
lity
 of
 lif
e) 
in 
the
 po
pu
lat
ion
 of
 th
e N
eth
erl
an
ds
 in
 20
00
 (S
ou
rce
s 
a
: 
se
e 
w
w
w
.
n
a
tio
na
al
ko
m
pa
s.n
l).
 
a)
M
os
t p
re
va
le
nc
e a
nd
 in
ci
de
nc
e d
at
a a
re
 d
er
iv
ed
 fr
om
 h
ea
lth
 ca
re
 re
co
rd
s; 
da
ta
 o
n 
de
pr
es
sio
n,
 an
xi
et
y 
di
so
rd
er
,
 a
lc
oh
ol
 o
r d
ru
g 
de
pe
nd
en
ce
, a
nd
 in
te
lle
ct
ua
l d
isa
bi
lit
y 
ar
e b
as
ed
 o
n 
po
pu
la
tio
n 
stu
di
es
.
b)
N
o 
di
se
as
e-
ye
ar
 eq
ui
va
le
nt
s h
av
e b
ee
n 
ca
lc
ul
at
ed
 fo
r D
ow
n’
s 
sy
nd
ro
m
e,
 p
re
m
at
ur
e b
irt
h 
an
d 
he
al
th
 p
ro
bl
em
s a
m
on
g 
fu
ll-
te
rm
 n
ew
-
bo
rn
s, 
(pa
ra)
de
nta
l d
iso
rde
rs,
 m
en
tal
 pr
ob
lem
s i
n c
hil
dre
n a
nd
yo
ut
h,
 an
eu
ry
sm
 o
f t
he
 ab
do
m
in
al
 ao
rta
, s
ep
sis
, s
po
rt 
in
jur
ies
, o
ccu
pa
tio
na
l a
cci
de
nts
, v
iol
en
ce,
 su
ici
de
 at
tem
pts
 an
d d
ecu
bit
us.
c)
Fo
r r
oa
d 
tra
ffi
c a
cc
id
en
ts 
an
d 
ho
m
e-
 an
d 
le
isu
re
 ac
ci
de
nt
s o
nl
y 
pe
rm
an
en
t i
nju
rie
s h
av
e b
een
 ta
ke
n i
nto
 ac
co
un
t.  
d)
ST
D
s: 
on
ly
 b
ac
te
ria
l S
TD
’s:
 c
hl
am
yd
ia
 tr
ac
ho
m
at
is,
 g
on
or
rh
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Prevalence data on risk factors in the Netherlands and other European countries have
been used for the calculation of Population Attributable Risks (PARs) in chapter 2, for
the web graphs in chapter 2 and for the forecasting of European prevalence levels of risk
factors in chapter 3. Prevalence data for the Netherlands are presented for age categories
of 25 years and older, the reason being that virtually no incidence and mortality are asso-
ciated with these risk factors under 25 years. To determine which country has the most
favourable/unfavourable prevalence levels, only the highest risk factor levels have been
taken into account (grey in following tables). For methodological reasons (distribution
of population over the various risk factor levels), this has not been done in the case of
alcohol consumption and blood pressure. Here, the two upper risk factor levels have
been used. Risk factor prevalence data for the Netherlands and for selected European
countries are presented, followed by a description of the data sources that have been
used.
Prevalences
Smoking
Smoking prevalence in the Netherlands (% population 25 years and older) for men (m) and women (f)
(Source: StiVoRo, 1999).
Risk classes
never smoked current smoker ex-smoker
age m f m f m f
25-44 44 46 42 37 14 17
45-64 34 52 38 30 28 18
65-74 28 64 31 17 41 19
75+ 33 75 27 11 40 14
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Smoking prevalence in European countries (%  population 35-64 years) (Source: WHO-MONICA, 2002;
Stivoro, 1999).
Risk classes
never smoked current smoker ex-smoker
m f m f m f
Belgium 22 57 46 28 32 15
Luxembourg 23 72 43 18 34 10
Denmark 39 41 44 45 18 15
Finland 38 72 29 15 33 14
France 34 63 27 18 40 19
Germany 34 64 34 22 32 15
Italy 34 62 32 23 34 15
Sweden 44 46 23 29 33 25
Switserland 39 61 31 26 30 14
United Kingdom 38 48 35 33 27 19
Netherlands 36 47 40 34 24 19
Nutrition – saturated fatty acids
Prevalence in the Netherlands (% population 25 years and older) (Source: TNO Voeding, 1998).
Risk classes (% total energy consumed as saturated fat)
< 10.0 10.0-12.5 2.5-15.0 15.0-17.5 ≥ 17.5
age m f m f m f m f m f
25-44 8 8 21 17 32 32 26 25 13 18
45-64 7 7 21 21 26 26 23 27 22 20
65-74 7 8 23 22 23 25 22 27 25 19
75+ 7 8 23 22 23 25 22 27 25 19
Nutrition – fruit and vegetables
Prevalence in the Netherlands (% population 25 years and older) (Source: TNO Voeding, 1998).
Risk classes (grams per day)
< 100 100-200 200-300 300-400 ≥ 400
age m f m f m f m f m f
25-44 17 13 25 24 22 20 16 16 20 27
45-64 13 9 21 19 21 19 17 18 27 35
65-74 12 7 18 17 21 19 18 20 31 38
75+ 12 7 18 17 21 19 18 20 31 38
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Physical activity 
Prevalence in the Netherlands (% population 25 years and older) (Source: Hildebrandt et al., 1999).
Risk classes (hours per week physically active)
inactive moderate recommended
age m f m f m f
25-44 12 10 54 48 33 43
45-64 15 12 47 41 38 47
65-74 16 19 41 35 43 46
75+ 19 27 37 31 45 42
Prevalence in European countries (% population 15 years and older) (Source: IEFS, 1999). 
Risk classes (number of hours physically active)
none < 1 1-3 3-5 ≥ 5
Austria 16 4 18 20 42
Belgium 42 7 18 15 14
Denmark 24 6 16 22 30
Finland 10 5 18 26 41
France 36 7 20 20 16
Germany 31 6 19 19 24
Italy 39 7 20 19 14
Luxembourg 20 8 19 21 30
Sweden 12 4 16 23 45
United Kingdom 24 7 17 25 27
Netherlands 19 6 18 18 38
Alcohol consumption
Prevalence in the Netherlands (% population 25 years and older) (Source: CBS, 1998 data directly
obtained).
Risk classes (number of glasses per day)
0 0 1-3 1 4-5 2-3 ≥ 6 ≥ 4
age m f m f m f m f
25-44 18 55 47 41 18 4 17 0
45-64 19 42 59 50 13 7 9 1
65-74 26 58 67 37 3 4 4 1
75+ 35 79 65 20 0 1 0 0
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Prevalence in European countries (% population 18-64 years) (Source: Leifman, 2002). 
Risk classes (glasses per day)
0 0 1-3 1 4-5 2-3 ≥ 6 ≥ 4
m f m f m f m f
Finland 7 7 82 87 6 4 4 2
France 14 27 69 64 9 7 8 2
Germany 9 19 82 75 7 5 2 1
Italy 12 21 74 67 8 9 6 3
Sweden 9 14 86 84 3 2 3 0
United Kingdom 11 14 62 69 13 11 14 6
Netherlands a 19 45 56 48 15 6 10 1
a) CBS, data of 1998.
Blood pressure
Prevalence in the Netherlands (% population 25 years and older) (Source: Blokstra et al., 1997; Mennen et
al., 1995).
Risk classes (systolice blood pressure mmHg)
< 120 120-140 140-160 ≥ 160 drug use
age m f m f m f m f m f
25-44 39 62 41 20 8 3 1 0 11 15
45-64 21 30 37 27 16 12 5 4 22 27
65-74 11 11 25 23 21 20 11 11 31 34
75+ 10 4 19 14 21 19 12 13 38 50
Prevalence in European countries (% population 35-64 years) (Source: WHO-MONICA, 2002; Blokstra et
al., 1997; Mennen et al., 1995).
Risk classes (systolice blood pressure mmHg)
< 120 120-160 ≥ 160
m f m f m f
Belgium 26 47 71 49 3 4
Luxembourg 23 34 72 57 6 9
Denemark 40 52 55 46 5 3
Finland 11 21 74 65 16 14
France 26 46 66 49 7 5
Germany 17 30 72 60 11 10
Italy 22 32 67 60 11 8
Sweden 26 38 65 54 9 8
Switserland 22 44 72 53 6 4
United Kingdom 23 37 68 56 9 7
Netherlands 39 55 57 42 4 3
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Total cholesterol
Prevalence in the Netherlands (% population 25 years and older) (Source: Blokstra et al., 1997; Mennen et
al., 1995).
Risk classes (total cholesterol mmol/l)
< 5 5.0-6.5 6.5-8.0 ≥ 8.0
age m f m f m f m f
25-44 56 64 37 33 6 3 1 0
45-64 30 29 54 52 14 18 2 2
65-74 36 19 48 45 14 27 2 9
75+ 58 41 33 36 8 16 1 6
Prevalence in European countries (% popualation 35-64 years) (Source: WHO-Monica, 2002; Blokstra et
al., 1997; Mennen et al., 1995).
Risk classes (total cholesterol mmol/l)
< 5.2 5.2-7.8 ≥ 7.8
m f m f m f
Belgium 24 26 69 66 7 8
Luxembourg 13 17 74 68 13 15
Denemark 23 31 72 64 5 4
Finland 23 32 72 64 6 4
France 24 28 72 68 4 4
Germany 20 24 72 70 8 6
Italy 28 31 67 65 5 4
Sweden 31 36 61 57 8 7
Switserland 13 22 74 69 13 9
United Kingdom 23 27 72 66 6 8
Netherlands 35 37 62 60 3 3
Body weight
Prevalence in the Netherlands (% population 25 years and older) (Source: Blokstra et al., 1997; Mennen et
al., 1995).
Risk classes (Quetelet Index)
< 25 25-30 ≥ 30
age m f m f m f
25-44 59 70 33 22 7 8
45-64 35 46 51 38 14 16
65-74 34 36 55 42 12 22
75+ 46 50 46 32 8 18
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Prevalence in European countries (% population 35-64 years) (Source: Leifman, 2002; Blokstra et al., 1997;
Mennen et al., 1995).
Risk classes (Quetelet Index)
< 25 25-30 ≥ 30
m f m f m f
Belgium 35 43 49 37 16 20
Luxembourg 42 49 45 33 14 18
Denemark 46 62 41 26 13 12
Finland 30 42 47 36 23 23
France 37 55 46 28 17 17
Germany 30 45 52 35 18 21
Italy 34 52 51 30 15 18
Sweden 38 56 48 32 14 12
Switserland 36 58 50 29 15 13
United Kingdom 36 48 46 33 18 19
Netherlands 42 54 46 33 12 13
Data sources
Prevalence data for the Netherlands
Smoking
Stivoro-survey: age range 15 years and older, year of data collection 1998 (StiVoRo,
1999).
Nutrition: saturated fatty acids/ fruit and vegetables
Food consumption survey-3: age range 20-65 years, year of data collection 1997-1998
(TNO Voeding, 1998). Data for age categories 65 and older have been extrapolated by
RIVM.
Physical (in)activity
Survey on the Dutch physical activity standard: age range 16-89 years; year of data col-
lection 1998 (Hildebrandt et al., 1999).
Alcohol consumption
Periodiek Onderzoek Leef situatie (‘POLS’; keeping a finger on the pulse in health and
work): age range 20 years and older; year of data collection 1998. Data are directly
obtained from CBS.
Blood pressure, total cholesterol and body weight
MORGEN-project: age range 20-59 years; years of data collection 1993-1997 (Blokstra
et al., 1997); ERGO-research: age range 55 year and older; year of data collection 1990-
1993 (Mennen et al., 1995).
All data have been converted to the age categorisation used by VTV: 25-44, 45-64, 65-
74 and 75 years and older.
Prevalence data for other European countries
Smoking, blood pressure, cholesterol and body weight
MONICA-project: age-range 35-64 years; year of data collection begin/middle 1990s.
In this project, regions in ten European countries are represented (Belgium, Luxem-
bourg, Denmark, Finland, France, Germany, Italy, Sweden, Switzerland and the United
Kingdom). These regions are often not representative for the whole country (WHO-
MONICA, 2002). In order to get just one prevalence figure per country, RIVM calculat-
ed the unweighted average of the regions in each particular country. To determine the
most favourable and unfavourable prevalence levels within Europe, Dutch age range
and cut-off points have been adjusted to those of the MONICA-project. More recent
international comparable data than the data that were used are not readily available.
Physical activity
PAN-EU survey: age range 15 years and older (not sex-specific); year of data collection
1997. In this survey, fourteen countries are represented (Austria, Belgium, Denmark,
Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Portugal, Spain, Swe-
den and the United Kingdom). Greece, Ireland, Portugal and Spain are not included in
the analysis to be consistent with other risk factors, for which data was collected. The
prevalence refers to ‘a typical recent week’ (IEFS, 1999)
Alcohol consumption
ECAS-study: age range 18-64 years; year of data collection: 2000. In the study six
countries are represented (Finland, France, Germany, Italy, Sweden and the United
Kingdom). At the request of RIVM, data for these countries have been converted to the
Dutch criteria of alcohol abuse (Leifman, 2002).
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A
Abortion 66
Absence through sickness 88, 93, 117
Accessibility 13, 15, 24, 27, 37, 44, 51, 81-83, 94,
96, 102, 104, 106, 108, 110, 112, 130-131,
136, 144, 176, 180, 183-184
Accidents 41, 43, 46-47, 50, 58, 62, 74, 95,
119-120, 147, 162-165, 184, 202-203, 205-207
Activities of Daily Living (ADL) 33, 107
Acute physical injuries 45
Ageing 12, 19, 21, 24, 50-51, 106, 122-123, 126,
145-146, 148, 150-151, 157, 165, 167-168
AIDS 34, 46, 48, 66, 117, 119-120, 123, 147,
160-161, 170, 202-207
Air pollution 56, 58-59, 61, 75, 138, 171, 187,
191-192, 195, 197
Alcohol dependence 30, 42-44, 56, 74, 204-207
Alcohol use 55, 58, 60, 63-66, 68-69, 73-75, 91,
167
Aneurysm 148, 202-207
Angina pectoris 47
Antibiotics 21, 81, 102, 105, 107, 136, 147
Antibiotic resistance 100, 107, 184
Antilleans 67
Anxiety disorders 30, 40-44, 46, 48, 147, 202,
204-207
Asthma 41, 43-44, 46, 50, 58, 75, 134, 147,
156-157, 193, 195, 202-207
Autonomous developments 15, 141, 144
Avoidable mortality 100-101, 183
B
Basal cell carcinoma 46, 204
Birth 9, 21, 31-32, 35, 39, 46, 60, 71, 114, 119,
121-122, 128, 146-147, 163, 168-169, 192,
198, 202-207
Blood 10-11, 47, 52, 55-56, 58-60, 64-65, 67-68,
70, 72-75, 77-79, 89, 117, 122, 128, 152,
154, 156, 158, 166, 171, 209, 212, 214-215
Blood pressure 10-11, 47, 55-56, 58-60, 64-65,
67-68, 70, 72-75, 77-79, 89, 152, 154, 166,
171, 209, 212, 214-215
Body Mass Index (BMI) 59, 60, 63, 68, 72,184,
189-190
Body weight 56, 58, 213-215
Bowel disease 202, 204, 206-207
Breast cancer 9, 30, 35, 40-41, 43, 49-50, 57, 71,
81, 83, 85, 97-98, 100, 138, 147-148, 155,
162-164, 170, 184, 197, 202-207
Breastfeeding 58-59, 71, 193
Bronchitis 138
Burden of disease 10, 31, 42-44, 51, 56, 72, 74-76,
137, 157, 184
C
Caesarean sections 81, 100-101, 128
Cardiovascular disease 63, 75, 89, 93, 158
Cardiovascular system 46-47, 120, 147
Care 4-5, 7, 9-17, 19-27, 29-30, 34, 37, 40-42,
44, 46-48, 51, 54, 56, 62, 71-72, 77-84, 86,
88-90, 94-96, 98-138, 142-144, 148,
152-153, 155-161, 163, 167-185, 187-190,
192-198, 200, 204, 206
Care interventions 98, 138, 180
Care of the disabled 109, 116-117, 129
Care process 83, 96, 102, 160
Care, informal 115
Case-finding 96
Cataract 46, 205
Causes of death 10, 20, 26, 30-31, 40, 43, 47-48,
50, 73, 114, 118, 147, 162-166, 170
Central nervous system 120, 147
Cervical cancer 134, 153
Chlamydia 134, 205-207
Cholesterol 55, 58-60, 64-65, 67-68, 70, 72-75,
77-78, 89, 134, 152, 154, 162, 165-167,
213-215
Chronic heart failure (CHF) 40, 43, 47, 51-52, 148,
157, 163-166
Chronic obstructive pulmonary disease (COPD)
9, 30, 32, 35, 40-44, 46, 51, 58, 72, 74, 
135-136, 148, 156-157, 162-166, 170, 188, 
190, 195, 202-207
Client-linked budget 116
Clustering 51, 165
Colorectal cancer 35, 148, 155, 202-207
Common cold 41, 48
Compliance 91, 95-96, 156, 160, 188
Complications 48, 87, 100-101, 105
Congenital 43, 46-47, 117, 120, 122, 127-128, 134,
147-148, 190, 202-207
Constitutional eczema 147
Contact eczema 41, 147
Coronary heart disease 9, 29-31, 35, 40-44, 46-47, 
56-57, 72-75, 91, 95, 98, 120, 134, 148,
163-165, 170, 184, 188, 190, 197,
202-207
Cost of Illness 19-20, 24, 29, 115, 179, 181
Cost-effectiveness 13, 87, 130, 132-134, 137-139,
153, 175, 178, 187-188, 190-191, 194, 196
Cure 11, 13, 15-17, 25-26, 81-84, 96, 98, 102, 
106, 108, 116, 121, 130, 135-136, 156, 161,
167, 169, 173-174, 177-180, 193
D
Decubitus ulcers 12, 119, 148
Dementia 43, 51, 113-114, 118, 120, 122, 148, 
163-164, 168, 173, 202-207
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INDEX
Demographic 15, 22, 26, 51, 113, 122, 141, 148,
150, 165, 167-168, 176, 190
Demography 27
Dental abnormalities 120, 148
Depression 30, 33, 41-44, 46, 48, 57, 77, 83, 147, 
202-207
Determinants 21, 26-27, 44, 56-60, 62, 65, 67-68,
70, 72-74, 77-80, 82, 141, 147, 179-180,
183-185, 188
Diabetes mellitus 27, 30, 41, 43, 46, 48, 50-52, 57, 
63, 71, 74, 89, 99-100, 105, 122-123, 148, 154,
157, 159, 163-166, 188, 193, 196, 202-207
Digestive system 117-118, 122-123, 127-128
Disabilities 9-10, 30, 34, 38, 44-45, 108, 116, 122, 
137, 149-150, 184
Disability-Adjusted Life-Year (DALY) 74
Disease prevention 20, 24, 82-86, 89, 133-134,
184, 188, 192
Domestic accidents 41, 46-47, 119-120, 147,
163-164
Down’s syndrome 103, 147-148, 202-207
Drug dependence 57, 204-206
Drug use 55, 57, 60, 64, 66, 78-79, 152, 187,
191, 212
Drugs 60, 79, 89, 105, 144, 148, 153-154,
156-158, 161, 191
E
Early warning system 161
Ecstasy (XTC) 60
Eczema 41, 119-120, 147
Efficacy 81-82, 85, 88, 90, 93-94, 96, 98, 100,
102, 104, 110, 112, 133, 136, 153, 159, 172,
174-176, 183
Efficiency 11, 13, 15, 17, 22-23, 27, 114, 125,
128-133, 137, 160, 173, 175-176,
178-179, 182-183
Environment 2-4, 11, 14, 20-27, 30, 42, 54, 56-58, 
61-62, 75-77, 80, 86, 88, 91-94, 143,
171-172, 176, 184, 193
Epilepsy 43, 122-123, 147, 202-207
Ethnic minorities 30, 39, 54, 64, 66-67, 79-80, 116
Ethnicity 13, 58, 148, 152, 167, 179
Evidence-based medicine 17, 178
Extramural care 106, 113
F
Familial hypercholesterolaemia (FH) 155, 197
Fat consumption 59
Forecast 141-142, 145-148, 150-151, 157
Fruit 10, 59-60, 64, 70, 73-74, 79, 94, 107, 111,
171, 184, 191, 210, 214
Functional foods 154
Functioning 16, 31, 44, 76, 103, 198
G
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Health on course?   The third Dutch Public Health Status and 
Forecasts (PHSF) report once again contains a large amount of up-to-
date information about public health status, prevention and 
healthcare in the Netherlands. International comparisons and 
regional comparisons within the Netherlands are presented as well. 
Dutch life expectancy has increased over the past decades, but less 
quickly than in most other EU countries. Unhealthy behaviour is the 
major cause underlying this stagnation. A new, powerful, approach 
to prevention may turn the tide, however. Besides the need for 
strengthening prevention the future will bring a demand for more 
care, caused by ageing and population growth. In addition a further 
shift from cure to care will be necessary. Not only more healthcare 
will be needed, but also good quality care: effective, safe and 
accessible to all. 
The 2002 PHSF report aims to be an important source of information 
for the Ministry of Health, Welfare and Sport (VWS), but also for local 
governments, other ministries and many players in the field of Dutch 
public health and healthcare. Besides the ‘Health on course’ 
summary report, our PHSF activities also include publishing a series 
of ‘theme’ reports, about various public health topics, such as ‘Health 
in the larger cities’, and ‘Cost of Illness in the Netherlands’.
Finally, three websites are part of our PHSF activities: The National 
Compass for Public Health and Healthcare 
(www.nationaalkompas.nl), the National Atlas for Public Health and 
Healthcare (www.zorgatlas.nl) and a Cost of Illness website 
(www.costofillness.nl).
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